{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "import warnings\n",
    "warnings.filterwarnings('ignore')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd\n",
    "from tqdm import tqdm\n",
    "import numpy as np\n",
    "import re\n",
    "import matplotlib.pyplot as plt\n",
    "from nltk.stem.porter import *\n",
    "import tensorflow as tf\n",
    "from tensorflow.keras import layers, losses\n",
    "from sklearn.model_selection import train_test_split\n",
    "from keras.models import Model\n",
    "from sklearn.decomposition import NMF\n",
    "from scipy.optimize import minimize\n",
    "from numpy import linalg as LA\n",
    "from nltk.tokenize import word_tokenize\n",
    "from sentence_transformers import SentenceTransformer\n",
    "from collections import Counter"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [],
   "source": [
    "def main_IPC(text):\n",
    "    text = re.sub('\\s+','', text)\n",
    "    text_list = re.split(';|\\|', text)\n",
    "    key_fact = []\n",
    "    for tx in text_list:\n",
    "        try:\n",
    "            temp = re.match('^[A-Z][0-9]+[A-Z]+[0-9]+', tx)[0]\n",
    "            key_fact.append(temp)\n",
    "        except TypeError:\n",
    "            pass\n",
    "    return list(set(key_fact))\n",
    "\n",
    "def IPC_one_row(row, col):\n",
    "    res = {}\n",
    "    for i in col:\n",
    "        if i in row:\n",
    "            res[i] =[1]\n",
    "        else:\n",
    "            res[i] = [0]\n",
    "    return res\n",
    "\n",
    "def IPC_dict(data):\n",
    "    IPC_or = data['IPC']\n",
    "    IPC_data = []\n",
    "    for i in IPC_or:\n",
    "        IPC_data.append(main_IPC(i))\n",
    "    IPC_0 = IPC_data[0]\n",
    "    for i in IPC_data:\n",
    "        IPC_0 = IPC_0 + i\n",
    "    IPC_0 = list(set(IPC_0))\n",
    "    IPC_df = pd.DataFrame(columns=IPC_0)\n",
    "    for row in tqdm(IPC_data):\n",
    "        one_row = pd.DataFrame(IPC_one_row(row, IPC_0))\n",
    "        IPC_df = pd.concat([IPC_df, one_row], ignore_index=True)\n",
    "    IPC_df['Abstract'] = data['Abstract']\n",
    "    IPC_df['ID'] = data['ID']\n",
    "    return IPC_df\n",
    "\n",
    "def IPC_data_cut(IPC_data):\n",
    "    columns = IPC_data.columns[:-2]\n",
    "    col_drop = []\n",
    "    for col in columns:\n",
    "        temp_da = IPC_data[col]\n",
    "        if np.sum(temp_da) < 60:\n",
    "            col_drop.append(col)\n",
    "    IPC_data = IPC_data.drop(col_drop,axis=1)\n",
    "    IPC_data = IPC_data.loc[~(IPC_data.iloc[:,:-2]==0).all(axis=1)]\n",
    "    return IPC_data"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [],
   "source": [
    "data = pd.read_excel('datasets/source data/Biomedical.xlsx')\n",
    "data = data.dropna()\n",
    "data = data.dropna()\n",
    "data = data.sample(frac=1)\n",
    "data = data.reset_index(drop=True)\n",
    "\n",
    "IPC_pro_data = IPC_dict(data)\n",
    "IPC_data = IPC_data_cut(IPC_pro_data)\n",
    "IPC_data[:-50].to_csv('IPC_data_bio_train.csv',index=False)\n",
    "IPC_data[-50:].to_csv('IPC_data_bio_test.csv',index=False)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [],
   "source": [
    "class AnomalyDetector(Model):\n",
    "    def __init__(self):\n",
    "        super(AnomalyDetector, self).__init__()\n",
    "        self.encoder = tf.keras.Sequential([\n",
    "            layers.Dense(512, activation=\"relu\"),\n",
    "            layers.Dense(256, activation=\"relu\"),\n",
    "            layers.Dense(128, activation=\"relu\")])\n",
    "\n",
    "        self.decoder = tf.keras.Sequential([\n",
    "            layers.Dense(128, activation=\"relu\"),\n",
    "            layers.Dense(515, activation=\"relu\"),\n",
    "            layers.Dense(768, activation=\"sigmoid\")])\n",
    "    def call(self, x):\n",
    "        encoded = self.encoder(x)\n",
    "        decoded = self.decoder(encoded)\n",
    "        return decoded"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [],
   "source": [
    "def vectorize(sentences, BERT_model):\n",
    "    return np.array(BERT_model.encode(sentences, show_progress_bar=False))\n",
    "\n",
    "def pre_token(txt_file, stop_words):\n",
    "    txt_pre = re.sub('\\d','', txt_file)\n",
    "    txt_pre = re.sub(r\"[^a-zA-Z]+\", ' ', txt_file)\n",
    "    return [w for w in word_tokenize(txt_pre) if w not in stop_words]\n",
    "\n",
    "def H_i(sent_list):\n",
    "    sent_list = sent_list.astype('float32')\n",
    "    autoencoder = AnomalyDetector()\n",
    "    X_train, X_test = train_test_split(sent_list, test_size=0.33)\n",
    "    autoencoder.compile(optimizer='adam', loss=losses.MeanSquaredError())\n",
    "    autoencoder.fit(X_train, X_train, \n",
    "                    epochs=10,batch_size=512,\n",
    "                    validation_data=(X_test, X_test),\n",
    "                    shuffle=True)\n",
    "    encoded_data = autoencoder.encoder(sent_list).numpy()\n",
    "    decoded_vecs = autoencoder.decoder(encoded_data).numpy()\n",
    "    return np.mean(decoded_vecs, axis=0)\n",
    "\n",
    "def sentences_pre_process(IPC_name, BERT_IPC, IPC_data):\n",
    "    sentens_ID = IPC_data[IPC_data[IPC_name]==1]['ID']\n",
    "    sentences = []\n",
    "    for id in sentens_ID:\n",
    "        temp_vec = BERT_IPC[BERT_IPC['ID']==id].iloc[0,:-1]\n",
    "        sentences.append(temp_vec)\n",
    "    sentences = np.asarray(sentences)\n",
    "    return H_i(sentences)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [],
   "source": [
    "def min_fun(x,y,H):\n",
    "    y = y.reshape(1,-1)\n",
    "    x = x.reshape(1,-1)\n",
    "    return np.sum(np.abs(y - x.dot(H)))\n",
    "\n",
    "def min_transform_unconst(H_out, y, method):\n",
    "    res = minimize(min_fun, x0=np.ones(len(H_out))*0.5, method=method,\n",
    "                   args=(y, H_out))\n",
    "    return res.x\n",
    "\n",
    "def cos_sim(p1, p2):\n",
    "    p1 = np.array(p1).reshape(1,-1)\n",
    "    p2 = np.array(p2).reshape(-1,1)\n",
    "    return p1.dot(p2)/(LA.norm(p1)*LA.norm(p2))\n",
    "\n",
    "\n",
    "def sim_res(p1, rest):\n",
    "    sent_sim_res = []\n",
    "    for one_ex in tqdm(rest):\n",
    "        sent_sim_res.append(cos_sim(p1, one_ex)[0][0])\n",
    "    return np.asarray(sent_sim_res)\n",
    "\n",
    "def tf_idf_one(text, stop_words):\n",
    "    return pre_token(text, stop_words)\n",
    "\n",
    "def tf_idf_df(data, stop_words):\n",
    "    key_data0 = tf_idf_one(data[0], stop_words)\n",
    "    tf_df = dict.fromkeys(key_data0, [1])\n",
    "    tf_df = pd.DataFrame(tf_df)\n",
    "    \n",
    "    for test_d in tqdm(data[1:]):\n",
    "        temp = tf_idf_one(test_d, stop_words)\n",
    "        data = Counter(temp)\n",
    "        temp_df = pd.DataFrame(dict(data), index=[0])\n",
    "        tf_df = pd.concat([tf_df, temp_df])\n",
    "    tf_df = tf_df.fillna(0)\n",
    "    duc_sum = np.asarray(np.sum(tf_df.iloc[:,:-1], axis = 1))\n",
    "    temp_sum = np.asarray(tf_df.astype(bool).sum(axis=0))\n",
    "    df_sum = np.asarray(np.log(len(duc_sum)/temp_sum))\n",
    "\n",
    "    for i in range(len(duc_sum)):\n",
    "        tf_df.iloc[i, :-1] = tf_df.iloc[i, :-1]/duc_sum[i]\n",
    "    for i in range(tf_df.shape[1]):\n",
    "        tf_df.iloc[:, i] = tf_df.iloc[:, i]*df_sum[i]\n",
    "    return tf_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {},
   "outputs": [],
   "source": [
    "def vector_all(IPC_data, BERT_model, stop_words):\n",
    "    sentences = IPC_data['abstract']\n",
    "    BERT_res = []\n",
    "    for i in tqdm(sentences):\n",
    "        temp = pre_token(i, stop_words)\n",
    "        if temp == []:\n",
    "            BERT_res.append(np.zeros(768))\n",
    "        else:\n",
    "            temp_res = (' '.join(np.array(temp)))\n",
    "            temp_res = vectorize(temp_res, BERT_model)\n",
    "            BERT_res.append(temp_res)\n",
    "    BERT_res = np.asarray(BERT_res)\n",
    "    BERT_res = pd.DataFrame(BERT_res)\n",
    "    BERT_res['ID'] = IPC_data['ID']\n",
    "    BERT_res = BERT_res.loc[~(BERT_res.iloc[:,:-1]==0).all(axis=1)]\n",
    "    return BERT_res\n",
    "\n",
    "def pre_pro_all(BERT_IPC, IPC_name, IPC_data):\n",
    "    sentens_ID = IPC_data[IPC_data[IPC_name]==1]['ID']\n",
    "    sentences = []\n",
    "    for id in sentens_ID:\n",
    "        temp_vec = BERT_IPC[BERT_IPC['ID']==id].iloc[0,:-1]\n",
    "        sentences.append(temp_vec)\n",
    "    sentences = np.asarray(sentences)\n",
    "    return np.mean(sentences, axis=0)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Generate BERT meta data"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {},
   "outputs": [],
   "source": [
    "stop_words = open('datasets/stop_words/stop_dict_EN.txt', 'r').read()\n",
    "stop_words = stop_words.split('\\n')\n",
    "IPC_data = pd.read_csv('datasets/IPC_metadata/IPC_data_bio_train.csv')\n",
    "BERT_model = SentenceTransformer('multi-qa-mpnet-base-dot-v1')\n",
    "\n",
    "IPC_all_data = vector_all(IPC_data, BERT_model, stop_words)\n",
    "IPC_all_data.to_csv('BERT_Bio.csv', index=False)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Main algorithm"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "metadata": {},
   "outputs": [],
   "source": [
    "IPC_all_data = pd.read_csv('datasets/BERT_metadata/BERT_Bio.csv')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Epoch 1/10\n",
      "1/1 [==============================] - 1s 1s/step - loss: 0.2952 - val_loss: 0.2913\n",
      "Epoch 2/10\n",
      "1/1 [==============================] - 0s 44ms/step - loss: 0.2910 - val_loss: 0.2809\n",
      "Epoch 3/10\n",
      "1/1 [==============================] - 0s 44ms/step - loss: 0.2807 - val_loss: 0.2588\n",
      "Epoch 4/10\n",
      "1/1 [==============================] - 0s 46ms/step - loss: 0.2585 - val_loss: 0.2198\n",
      "Epoch 5/10\n",
      "1/1 [==============================] - 0s 46ms/step - loss: 0.2196 - val_loss: 0.1642\n",
      "Epoch 6/10\n",
      "1/1 [==============================] - 0s 45ms/step - loss: 0.1640 - val_loss: 0.1067\n",
      "Epoch 7/10\n",
      "1/1 [==============================] - 0s 46ms/step - loss: 0.1065 - val_loss: 0.0697\n",
      "Epoch 8/10\n",
      "1/1 [==============================] - 0s 45ms/step - loss: 0.0696 - val_loss: 0.0556\n",
      "Epoch 9/10\n",
      "1/1 [==============================] - 0s 48ms/step - loss: 0.0555 - val_loss: 0.0520\n",
      "Epoch 10/10\n",
      "1/1 [==============================] - 0s 46ms/step - loss: 0.0520 - val_loss: 0.0511\n",
      "Epoch 1/10\n",
      "1/1 [==============================] - 1s 802ms/step - loss: 0.2963 - val_loss: 0.2924\n",
      "Epoch 2/10\n",
      "1/1 [==============================] - 0s 44ms/step - loss: 0.2926 - val_loss: 0.2835\n",
      "Epoch 3/10\n",
      "1/1 [==============================] - 0s 43ms/step - loss: 0.2836 - val_loss: 0.2634\n",
      "Epoch 4/10\n",
      "1/1 [==============================] - 0s 43ms/step - loss: 0.2636 - val_loss: 0.2268\n",
      "Epoch 5/10\n",
      "1/1 [==============================] - 0s 45ms/step - loss: 0.2272 - val_loss: 0.1723\n",
      "Epoch 6/10\n",
      "1/1 [==============================] - 0s 46ms/step - loss: 0.1729 - val_loss: 0.1120\n",
      "Epoch 7/10\n",
      "1/1 [==============================] - 0s 50ms/step - loss: 0.1128 - val_loss: 0.0701\n",
      "Epoch 8/10\n",
      "1/1 [==============================] - 0s 61ms/step - loss: 0.0710 - val_loss: 0.0547\n",
      "Epoch 9/10\n",
      "1/1 [==============================] - 0s 50ms/step - loss: 0.0553 - val_loss: 0.0518\n",
      "Epoch 10/10\n",
      "1/1 [==============================] - 0s 49ms/step - loss: 0.0522 - val_loss: 0.0513\n",
      "Epoch 1/10\n",
      "1/1 [==============================] - 1s 853ms/step - loss: 0.2954 - val_loss: 0.2911\n",
      "Epoch 2/10\n",
      "1/1 [==============================] - 0s 44ms/step - loss: 0.2903 - val_loss: 0.2771\n",
      "Epoch 3/10\n",
      "1/1 [==============================] - 0s 48ms/step - loss: 0.2760 - val_loss: 0.2486\n",
      "Epoch 4/10\n",
      "1/1 [==============================] - 0s 52ms/step - loss: 0.2471 - val_loss: 0.2025\n",
      "Epoch 5/10\n",
      "1/1 [==============================] - 0s 59ms/step - loss: 0.2007 - val_loss: 0.1436\n",
      "Epoch 6/10\n",
      "1/1 [==============================] - 0s 48ms/step - loss: 0.1418 - val_loss: 0.0905\n",
      "Epoch 7/10\n",
      "1/1 [==============================] - 0s 54ms/step - loss: 0.0889 - val_loss: 0.0610\n",
      "Epoch 8/10\n",
      "1/1 [==============================] - 0s 54ms/step - loss: 0.0600 - val_loss: 0.0517\n",
      "Epoch 9/10\n",
      "1/1 [==============================] - 0s 49ms/step - loss: 0.0510 - val_loss: 0.0501\n",
      "Epoch 10/10\n",
      "1/1 [==============================] - 0s 51ms/step - loss: 0.0494 - val_loss: 0.0499\n",
      "Epoch 1/10\n",
      "1/1 [==============================] - 1s 813ms/step - loss: 0.2956 - val_loss: 0.2936\n",
      "Epoch 2/10\n",
      "1/1 [==============================] - 0s 43ms/step - loss: 0.2924 - val_loss: 0.2857\n",
      "Epoch 3/10\n",
      "1/1 [==============================] - 0s 48ms/step - loss: 0.2841 - val_loss: 0.2672\n",
      "Epoch 4/10\n",
      "1/1 [==============================] - 0s 48ms/step - loss: 0.2654 - val_loss: 0.2338\n",
      "Epoch 5/10\n",
      "1/1 [==============================] - 0s 47ms/step - loss: 0.2316 - val_loss: 0.1837\n",
      "Epoch 6/10\n",
      "1/1 [==============================] - 0s 48ms/step - loss: 0.1813 - val_loss: 0.1247\n",
      "Epoch 7/10\n",
      "1/1 [==============================] - 0s 49ms/step - loss: 0.1224 - val_loss: 0.0783\n",
      "Epoch 8/10\n",
      "1/1 [==============================] - 0s 46ms/step - loss: 0.0764 - val_loss: 0.0573\n",
      "Epoch 9/10\n",
      "1/1 [==============================] - 0s 49ms/step - loss: 0.0558 - val_loss: 0.0519\n",
      "Epoch 10/10\n",
      "1/1 [==============================] - 0s 54ms/step - loss: 0.0505 - val_loss: 0.0513\n",
      "Epoch 1/10\n",
      "1/1 [==============================] - 1s 825ms/step - loss: 0.2952 - val_loss: 0.2915\n",
      "Epoch 2/10\n",
      "1/1 [==============================] - 0s 43ms/step - loss: 0.2913 - val_loss: 0.2832\n",
      "Epoch 3/10\n",
      "1/1 [==============================] - 0s 48ms/step - loss: 0.2830 - val_loss: 0.2655\n",
      "Epoch 4/10\n",
      "1/1 [==============================] - 0s 50ms/step - loss: 0.2652 - val_loss: 0.2335\n",
      "Epoch 5/10\n",
      "1/1 [==============================] - 0s 49ms/step - loss: 0.2332 - val_loss: 0.1846\n",
      "Epoch 6/10\n",
      "1/1 [==============================] - 0s 51ms/step - loss: 0.1844 - val_loss: 0.1259\n",
      "Epoch 7/10\n",
      "1/1 [==============================] - 0s 61ms/step - loss: 0.1257 - val_loss: 0.0782\n",
      "Epoch 8/10\n",
      "1/1 [==============================] - 0s 48ms/step - loss: 0.0779 - val_loss: 0.0561\n",
      "Epoch 9/10\n",
      "1/1 [==============================] - 0s 46ms/step - loss: 0.0559 - val_loss: 0.0507\n",
      "Epoch 10/10\n",
      "1/1 [==============================] - 0s 50ms/step - loss: 0.0506 - val_loss: 0.0501\n",
      "Epoch 1/10\n",
      "1/1 [==============================] - 1s 816ms/step - loss: 0.2965 - val_loss: 0.2913\n",
      "Epoch 2/10\n",
      "1/1 [==============================] - 0s 44ms/step - loss: 0.2913 - val_loss: 0.2782\n",
      "Epoch 3/10\n",
      "1/1 [==============================] - 0s 49ms/step - loss: 0.2782 - val_loss: 0.2523\n",
      "Epoch 4/10\n",
      "1/1 [==============================] - 0s 48ms/step - loss: 0.2525 - val_loss: 0.2100\n",
      "Epoch 5/10\n",
      "1/1 [==============================] - 0s 49ms/step - loss: 0.2104 - val_loss: 0.1536\n",
      "Epoch 6/10\n",
      "1/1 [==============================] - 0s 49ms/step - loss: 0.1541 - val_loss: 0.0987\n",
      "Epoch 7/10\n",
      "1/1 [==============================] - 0s 46ms/step - loss: 0.0992 - val_loss: 0.0652\n",
      "Epoch 8/10\n",
      "1/1 [==============================] - 0s 49ms/step - loss: 0.0653 - val_loss: 0.0531\n",
      "Epoch 9/10\n",
      "1/1 [==============================] - 0s 50ms/step - loss: 0.0530 - val_loss: 0.0503\n",
      "Epoch 10/10\n",
      "1/1 [==============================] - 0s 52ms/step - loss: 0.0501 - val_loss: 0.0498\n",
      "Epoch 1/10\n",
      "1/1 [==============================] - 1s 814ms/step - loss: 0.2953 - val_loss: 0.2910\n",
      "Epoch 2/10\n",
      "1/1 [==============================] - 0s 41ms/step - loss: 0.2920 - val_loss: 0.2824\n",
      "Epoch 3/10\n",
      "1/1 [==============================] - 0s 48ms/step - loss: 0.2829 - val_loss: 0.2636\n",
      "Epoch 4/10\n",
      "1/1 [==============================] - 0s 45ms/step - loss: 0.2631 - val_loss: 0.2299\n",
      "Epoch 5/10\n",
      "1/1 [==============================] - 0s 41ms/step - loss: 0.2281 - val_loss: 0.1802\n",
      "Epoch 6/10\n",
      "1/1 [==============================] - 0s 62ms/step - loss: 0.1769 - val_loss: 0.1231\n",
      "Epoch 7/10\n",
      "1/1 [==============================] - 0s 64ms/step - loss: 0.1196 - val_loss: 0.0788\n",
      "Epoch 8/10\n",
      "1/1 [==============================] - 0s 73ms/step - loss: 0.0769 - val_loss: 0.0580\n",
      "Epoch 9/10\n",
      "1/1 [==============================] - 0s 50ms/step - loss: 0.0579 - val_loss: 0.0517\n",
      "Epoch 10/10\n",
      "1/1 [==============================] - 0s 46ms/step - loss: 0.0523 - val_loss: 0.0506\n",
      "Epoch 1/10\n",
      "1/1 [==============================] - 1s 854ms/step - loss: 0.2948 - val_loss: 0.2898\n",
      "Epoch 2/10\n",
      "1/1 [==============================] - 0s 47ms/step - loss: 0.2900 - val_loss: 0.2773\n",
      "Epoch 3/10\n",
      "1/1 [==============================] - 0s 56ms/step - loss: 0.2774 - val_loss: 0.2512\n",
      "Epoch 4/10\n",
      "1/1 [==============================] - 0s 57ms/step - loss: 0.2511 - val_loss: 0.2073\n",
      "Epoch 5/10\n",
      "1/1 [==============================] - 0s 63ms/step - loss: 0.2069 - val_loss: 0.1490\n",
      "Epoch 6/10\n",
      "1/1 [==============================] - 0s 75ms/step - loss: 0.1484 - val_loss: 0.0940\n",
      "Epoch 7/10\n",
      "1/1 [==============================] - 0s 64ms/step - loss: 0.0936 - val_loss: 0.0626\n",
      "Epoch 8/10\n",
      "1/1 [==============================] - 0s 82ms/step - loss: 0.0626 - val_loss: 0.0522\n",
      "Epoch 9/10\n",
      "1/1 [==============================] - 0s 66ms/step - loss: 0.0524 - val_loss: 0.0497\n",
      "Epoch 10/10\n",
      "1/1 [==============================] - 0s 57ms/step - loss: 0.0500 - val_loss: 0.0494\n",
      "Epoch 1/10\n",
      "1/1 [==============================] - 1s 861ms/step - loss: 0.2948 - val_loss: 0.2897\n",
      "Epoch 2/10\n",
      "1/1 [==============================] - 0s 49ms/step - loss: 0.2902 - val_loss: 0.2778\n",
      "Epoch 3/10\n",
      "1/1 [==============================] - 0s 57ms/step - loss: 0.2782 - val_loss: 0.2530\n",
      "Epoch 4/10\n",
      "1/1 [==============================] - 0s 57ms/step - loss: 0.2531 - val_loss: 0.2106\n",
      "Epoch 5/10\n",
      "1/1 [==============================] - 0s 61ms/step - loss: 0.2103 - val_loss: 0.1529\n",
      "Epoch 6/10\n",
      "1/1 [==============================] - 0s 57ms/step - loss: 0.1525 - val_loss: 0.0977\n",
      "Epoch 7/10\n",
      "1/1 [==============================] - 0s 54ms/step - loss: 0.0974 - val_loss: 0.0653\n",
      "Epoch 8/10\n",
      "1/1 [==============================] - 0s 71ms/step - loss: 0.0655 - val_loss: 0.0535\n",
      "Epoch 9/10\n",
      "1/1 [==============================] - 0s 68ms/step - loss: 0.0539 - val_loss: 0.0501\n",
      "Epoch 10/10\n",
      "1/1 [==============================] - 0s 53ms/step - loss: 0.0506 - val_loss: 0.0493\n",
      "Epoch 1/10\n",
      "1/1 [==============================] - 1s 813ms/step - loss: 0.2957 - val_loss: 0.2922\n",
      "Epoch 2/10\n",
      "1/1 [==============================] - 0s 43ms/step - loss: 0.2919 - val_loss: 0.2830\n",
      "Epoch 3/10\n",
      "1/1 [==============================] - 0s 48ms/step - loss: 0.2827 - val_loss: 0.2637\n",
      "Epoch 4/10\n",
      "1/1 [==============================] - 0s 50ms/step - loss: 0.2633 - val_loss: 0.2297\n",
      "Epoch 5/10\n",
      "1/1 [==============================] - 0s 55ms/step - loss: 0.2293 - val_loss: 0.1796\n",
      "Epoch 6/10\n",
      "1/1 [==============================] - 0s 68ms/step - loss: 0.1792 - val_loss: 0.1223\n",
      "Epoch 7/10\n",
      "1/1 [==============================] - 0s 63ms/step - loss: 0.1219 - val_loss: 0.0784\n",
      "Epoch 8/10\n",
      "1/1 [==============================] - 0s 51ms/step - loss: 0.0780 - val_loss: 0.0585\n",
      "Epoch 9/10\n",
      "1/1 [==============================] - 0s 56ms/step - loss: 0.0580 - val_loss: 0.0533\n",
      "Epoch 10/10\n",
      "1/1 [==============================] - 0s 63ms/step - loss: 0.0528 - val_loss: 0.0523\n",
      "Epoch 1/10\n",
      "1/1 [==============================] - 1s 799ms/step - loss: 0.2940 - val_loss: 0.2905\n",
      "Epoch 2/10\n",
      "1/1 [==============================] - 0s 46ms/step - loss: 0.2903 - val_loss: 0.2814\n",
      "Epoch 3/10\n",
      "1/1 [==============================] - 0s 46ms/step - loss: 0.2812 - val_loss: 0.2628\n",
      "Epoch 4/10\n",
      "1/1 [==============================] - 0s 46ms/step - loss: 0.2622 - val_loss: 0.2300\n",
      "Epoch 5/10\n",
      "1/1 [==============================] - 0s 47ms/step - loss: 0.2288 - val_loss: 0.1808\n",
      "Epoch 6/10\n",
      "1/1 [==============================] - 0s 48ms/step - loss: 0.1789 - val_loss: 0.1227\n",
      "Epoch 7/10\n",
      "1/1 [==============================] - 0s 54ms/step - loss: 0.1208 - val_loss: 0.0767\n",
      "Epoch 8/10\n",
      "1/1 [==============================] - 0s 54ms/step - loss: 0.0756 - val_loss: 0.0556\n",
      "Epoch 9/10\n",
      "1/1 [==============================] - 0s 47ms/step - loss: 0.0551 - val_loss: 0.0499\n",
      "Epoch 10/10\n",
      "1/1 [==============================] - 0s 48ms/step - loss: 0.0497 - val_loss: 0.0489\n",
      "Epoch 1/10\n",
      "1/1 [==============================] - 1s 821ms/step - loss: 0.2955 - val_loss: 0.2909\n",
      "Epoch 2/10\n",
      "1/1 [==============================] - 0s 41ms/step - loss: 0.2909 - val_loss: 0.2799\n",
      "Epoch 3/10\n",
      "1/1 [==============================] - 0s 42ms/step - loss: 0.2798 - val_loss: 0.2570\n",
      "Epoch 4/10\n",
      "1/1 [==============================] - 0s 41ms/step - loss: 0.2567 - val_loss: 0.2177\n",
      "Epoch 5/10\n",
      "1/1 [==============================] - 0s 48ms/step - loss: 0.2172 - val_loss: 0.1628\n",
      "Epoch 6/10\n",
      "1/1 [==============================] - 0s 46ms/step - loss: 0.1625 - val_loss: 0.1064\n",
      "Epoch 7/10\n",
      "1/1 [==============================] - 0s 46ms/step - loss: 0.1064 - val_loss: 0.0695\n",
      "Epoch 8/10\n",
      "1/1 [==============================] - 0s 45ms/step - loss: 0.0696 - val_loss: 0.0556\n",
      "Epoch 9/10\n",
      "1/1 [==============================] - 0s 73ms/step - loss: 0.0557 - val_loss: 0.0524\n",
      "Epoch 10/10\n",
      "1/1 [==============================] - 0s 55ms/step - loss: 0.0525 - val_loss: 0.0512\n",
      "Epoch 1/10\n",
      "1/1 [==============================] - 1s 833ms/step - loss: 0.2951 - val_loss: 0.2908\n",
      "Epoch 2/10\n",
      "1/1 [==============================] - 0s 43ms/step - loss: 0.2911 - val_loss: 0.2798\n",
      "Epoch 3/10\n",
      "1/1 [==============================] - 0s 47ms/step - loss: 0.2804 - val_loss: 0.2571\n",
      "Epoch 4/10\n",
      "1/1 [==============================] - 0s 47ms/step - loss: 0.2581 - val_loss: 0.2186\n",
      "Epoch 5/10\n",
      "1/1 [==============================] - 0s 50ms/step - loss: 0.2201 - val_loss: 0.1652\n",
      "Epoch 6/10\n",
      "1/1 [==============================] - 0s 46ms/step - loss: 0.1669 - val_loss: 0.1091\n",
      "Epoch 7/10\n",
      "1/1 [==============================] - 0s 46ms/step - loss: 0.1106 - val_loss: 0.0701\n",
      "Epoch 8/10\n",
      "1/1 [==============================] - 0s 47ms/step - loss: 0.0711 - val_loss: 0.0546\n",
      "Epoch 9/10\n",
      "1/1 [==============================] - 0s 49ms/step - loss: 0.0551 - val_loss: 0.0512\n",
      "Epoch 10/10\n",
      "1/1 [==============================] - 0s 48ms/step - loss: 0.0516 - val_loss: 0.0510\n",
      "Epoch 1/10\n",
      "1/1 [==============================] - 1s 849ms/step - loss: 0.2956 - val_loss: 0.2908\n",
      "Epoch 2/10\n",
      "1/1 [==============================] - 0s 45ms/step - loss: 0.2901 - val_loss: 0.2769\n",
      "Epoch 3/10\n",
      "1/1 [==============================] - 0s 49ms/step - loss: 0.2755 - val_loss: 0.2488\n",
      "Epoch 4/10\n",
      "1/1 [==============================] - 0s 57ms/step - loss: 0.2465 - val_loss: 0.2028\n",
      "Epoch 5/10\n",
      "1/1 [==============================] - 0s 54ms/step - loss: 0.1993 - val_loss: 0.1434\n",
      "Epoch 6/10\n",
      "1/1 [==============================] - 0s 60ms/step - loss: 0.1391 - val_loss: 0.0896\n",
      "Epoch 7/10\n",
      "1/1 [==============================] - 0s 59ms/step - loss: 0.0859 - val_loss: 0.0607\n",
      "Epoch 8/10\n",
      "1/1 [==============================] - 0s 45ms/step - loss: 0.0585 - val_loss: 0.0521\n",
      "Epoch 9/10\n",
      "1/1 [==============================] - 0s 64ms/step - loss: 0.0508 - val_loss: 0.0506\n",
      "Epoch 10/10\n",
      "1/1 [==============================] - 0s 64ms/step - loss: 0.0498 - val_loss: 0.0504\n",
      "Epoch 1/10\n",
      "1/1 [==============================] - 1s 855ms/step - loss: 0.2952 - val_loss: 0.2919\n",
      "Epoch 2/10\n",
      "1/1 [==============================] - 0s 56ms/step - loss: 0.2911 - val_loss: 0.2816\n",
      "Epoch 3/10\n",
      "1/1 [==============================] - 0s 67ms/step - loss: 0.2804 - val_loss: 0.2597\n",
      "Epoch 4/10\n",
      "1/1 [==============================] - 0s 58ms/step - loss: 0.2581 - val_loss: 0.2222\n",
      "Epoch 5/10\n",
      "1/1 [==============================] - 0s 48ms/step - loss: 0.2200 - val_loss: 0.1686\n",
      "Epoch 6/10\n",
      "1/1 [==============================] - 0s 47ms/step - loss: 0.1661 - val_loss: 0.1111\n",
      "Epoch 7/10\n",
      "1/1 [==============================] - 0s 53ms/step - loss: 0.1088 - val_loss: 0.0706\n",
      "Epoch 8/10\n",
      "1/1 [==============================] - 0s 49ms/step - loss: 0.0692 - val_loss: 0.0545\n",
      "Epoch 9/10\n",
      "1/1 [==============================] - 0s 48ms/step - loss: 0.0537 - val_loss: 0.0515\n",
      "Epoch 10/10\n",
      "1/1 [==============================] - 0s 49ms/step - loss: 0.0508 - val_loss: 0.0513\n",
      "Epoch 1/10\n",
      "1/1 [==============================] - 1s 879ms/step - loss: 0.2949 - val_loss: 0.2916\n",
      "Epoch 2/10\n",
      "1/1 [==============================] - 0s 58ms/step - loss: 0.2918 - val_loss: 0.2839\n",
      "Epoch 3/10\n",
      "1/1 [==============================] - 0s 66ms/step - loss: 0.2840 - val_loss: 0.2665\n",
      "Epoch 4/10\n",
      "1/1 [==============================] - 0s 66ms/step - loss: 0.2666 - val_loss: 0.2348\n",
      "Epoch 5/10\n",
      "1/1 [==============================] - 0s 53ms/step - loss: 0.2350 - val_loss: 0.1863\n",
      "Epoch 6/10\n",
      "1/1 [==============================] - 0s 53ms/step - loss: 0.1866 - val_loss: 0.1277\n",
      "Epoch 7/10\n",
      "1/1 [==============================] - 0s 51ms/step - loss: 0.1282 - val_loss: 0.0793\n",
      "Epoch 8/10\n",
      "1/1 [==============================] - 0s 53ms/step - loss: 0.0797 - val_loss: 0.0562\n",
      "Epoch 9/10\n",
      "1/1 [==============================] - 0s 52ms/step - loss: 0.0566 - val_loss: 0.0503\n",
      "Epoch 10/10\n",
      "1/1 [==============================] - 0s 53ms/step - loss: 0.0507 - val_loss: 0.0491\n",
      "Epoch 1/10\n",
      "1/1 [==============================] - 1s 1s/step - loss: 0.2942 - val_loss: 0.2905\n",
      "Epoch 2/10\n",
      "1/1 [==============================] - 0s 43ms/step - loss: 0.2890 - val_loss: 0.2780\n",
      "Epoch 3/10\n",
      "1/1 [==============================] - 0s 45ms/step - loss: 0.2763 - val_loss: 0.2526\n",
      "Epoch 4/10\n",
      "1/1 [==============================] - 0s 48ms/step - loss: 0.2505 - val_loss: 0.2099\n",
      "Epoch 5/10\n",
      "1/1 [==============================] - 0s 46ms/step - loss: 0.2073 - val_loss: 0.1522\n",
      "Epoch 6/10\n",
      "1/1 [==============================] - 0s 44ms/step - loss: 0.1494 - val_loss: 0.0969\n",
      "Epoch 7/10\n",
      "1/1 [==============================] - 0s 44ms/step - loss: 0.0945 - val_loss: 0.0647\n",
      "Epoch 8/10\n",
      "1/1 [==============================] - 0s 46ms/step - loss: 0.0631 - val_loss: 0.0547\n",
      "Epoch 9/10\n",
      "1/1 [==============================] - 0s 45ms/step - loss: 0.0534 - val_loss: 0.0528\n",
      "Epoch 10/10\n",
      "1/1 [==============================] - 0s 48ms/step - loss: 0.0515 - val_loss: 0.0516\n",
      "Epoch 1/10\n",
      "1/1 [==============================] - 1s 852ms/step - loss: 0.2942 - val_loss: 0.2891\n",
      "Epoch 2/10\n",
      "1/1 [==============================] - 0s 44ms/step - loss: 0.2891 - val_loss: 0.2773\n",
      "Epoch 3/10\n",
      "1/1 [==============================] - 0s 41ms/step - loss: 0.2770 - val_loss: 0.2542\n",
      "Epoch 4/10\n",
      "1/1 [==============================] - 0s 42ms/step - loss: 0.2536 - val_loss: 0.2166\n",
      "Epoch 5/10\n",
      "1/1 [==============================] - 0s 42ms/step - loss: 0.2155 - val_loss: 0.1650\n",
      "Epoch 6/10\n",
      "1/1 [==============================] - 0s 39ms/step - loss: 0.1637 - val_loss: 0.1108\n",
      "Epoch 7/10\n",
      "1/1 [==============================] - 0s 42ms/step - loss: 0.1095 - val_loss: 0.0723\n",
      "Epoch 8/10\n",
      "1/1 [==============================] - 0s 41ms/step - loss: 0.0714 - val_loss: 0.0551\n",
      "Epoch 9/10\n",
      "1/1 [==============================] - 0s 39ms/step - loss: 0.0546 - val_loss: 0.0500\n",
      "Epoch 10/10\n",
      "1/1 [==============================] - 0s 40ms/step - loss: 0.0497 - val_loss: 0.0492\n",
      "Epoch 1/10\n",
      "1/1 [==============================] - 1s 834ms/step - loss: 0.2954 - val_loss: 0.2889\n",
      "Epoch 2/10\n",
      "1/1 [==============================] - 0s 44ms/step - loss: 0.2888 - val_loss: 0.2728\n",
      "Epoch 3/10\n",
      "1/1 [==============================] - 0s 43ms/step - loss: 0.2725 - val_loss: 0.2411\n",
      "Epoch 4/10\n",
      "1/1 [==============================] - 0s 44ms/step - loss: 0.2407 - val_loss: 0.1918\n",
      "Epoch 5/10\n",
      "1/1 [==============================] - 0s 47ms/step - loss: 0.1914 - val_loss: 0.1332\n",
      "Epoch 6/10\n",
      "1/1 [==============================] - 0s 42ms/step - loss: 0.1329 - val_loss: 0.0860\n",
      "Epoch 7/10\n",
      "1/1 [==============================] - 0s 41ms/step - loss: 0.0859 - val_loss: 0.0629\n",
      "Epoch 8/10\n",
      "1/1 [==============================] - 0s 41ms/step - loss: 0.0628 - val_loss: 0.0548\n",
      "Epoch 9/10\n",
      "1/1 [==============================] - 0s 41ms/step - loss: 0.0547 - val_loss: 0.0518\n",
      "Epoch 10/10\n",
      "1/1 [==============================] - 0s 50ms/step - loss: 0.0517 - val_loss: 0.0513\n",
      "Epoch 1/10\n",
      "1/1 [==============================] - 1s 825ms/step - loss: 0.2946 - val_loss: 0.2915\n",
      "Epoch 2/10\n",
      "1/1 [==============================] - 0s 50ms/step - loss: 0.2911 - val_loss: 0.2815\n",
      "Epoch 3/10\n",
      "1/1 [==============================] - 0s 44ms/step - loss: 0.2816 - val_loss: 0.2602\n",
      "Epoch 4/10\n",
      "1/1 [==============================] - 0s 43ms/step - loss: 0.2612 - val_loss: 0.2236\n",
      "Epoch 5/10\n",
      "1/1 [==============================] - 0s 41ms/step - loss: 0.2258 - val_loss: 0.1716\n",
      "Epoch 6/10\n",
      "1/1 [==============================] - 0s 40ms/step - loss: 0.1749 - val_loss: 0.1141\n",
      "Epoch 7/10\n",
      "1/1 [==============================] - 0s 42ms/step - loss: 0.1174 - val_loss: 0.0711\n",
      "Epoch 8/10\n",
      "1/1 [==============================] - 0s 47ms/step - loss: 0.0732 - val_loss: 0.0523\n",
      "Epoch 9/10\n",
      "1/1 [==============================] - 0s 48ms/step - loss: 0.0531 - val_loss: 0.0479\n",
      "Epoch 10/10\n",
      "1/1 [==============================] - 0s 52ms/step - loss: 0.0479 - val_loss: 0.0472\n",
      "Epoch 1/10\n",
      "1/1 [==============================] - 1s 808ms/step - loss: 0.2948 - val_loss: 0.2917\n",
      "Epoch 2/10\n",
      "1/1 [==============================] - 0s 42ms/step - loss: 0.2909 - val_loss: 0.2818\n",
      "Epoch 3/10\n",
      "1/1 [==============================] - 0s 41ms/step - loss: 0.2806 - val_loss: 0.2612\n",
      "Epoch 4/10\n",
      "1/1 [==============================] - 0s 41ms/step - loss: 0.2593 - val_loss: 0.2254\n",
      "Epoch 5/10\n",
      "1/1 [==============================] - 0s 42ms/step - loss: 0.2225 - val_loss: 0.1735\n",
      "Epoch 6/10\n",
      "1/1 [==============================] - 0s 41ms/step - loss: 0.1699 - val_loss: 0.1162\n",
      "Epoch 7/10\n",
      "1/1 [==============================] - 0s 40ms/step - loss: 0.1128 - val_loss: 0.0740\n",
      "Epoch 8/10\n",
      "1/1 [==============================] - 0s 40ms/step - loss: 0.0719 - val_loss: 0.0558\n",
      "Epoch 9/10\n",
      "1/1 [==============================] - 0s 39ms/step - loss: 0.0548 - val_loss: 0.0513\n",
      "Epoch 10/10\n",
      "1/1 [==============================] - 0s 40ms/step - loss: 0.0507 - val_loss: 0.0509\n",
      "Epoch 1/10\n",
      "1/1 [==============================] - 1s 825ms/step - loss: 0.2959 - val_loss: 0.2906\n",
      "Epoch 2/10\n",
      "1/1 [==============================] - 0s 49ms/step - loss: 0.2911 - val_loss: 0.2789\n",
      "Epoch 3/10\n",
      "1/1 [==============================] - 0s 50ms/step - loss: 0.2793 - val_loss: 0.2553\n",
      "Epoch 4/10\n",
      "1/1 [==============================] - 0s 48ms/step - loss: 0.2552 - val_loss: 0.2152\n",
      "Epoch 5/10\n",
      "1/1 [==============================] - 0s 47ms/step - loss: 0.2146 - val_loss: 0.1598\n",
      "Epoch 6/10\n",
      "1/1 [==============================] - 0s 47ms/step - loss: 0.1588 - val_loss: 0.1035\n",
      "Epoch 7/10\n",
      "1/1 [==============================] - 0s 45ms/step - loss: 0.1027 - val_loss: 0.0676\n",
      "Epoch 8/10\n",
      "1/1 [==============================] - 0s 44ms/step - loss: 0.0675 - val_loss: 0.0543\n",
      "Epoch 9/10\n",
      "1/1 [==============================] - 0s 45ms/step - loss: 0.0545 - val_loss: 0.0511\n",
      "Epoch 10/10\n",
      "1/1 [==============================] - 0s 47ms/step - loss: 0.0515 - val_loss: 0.0502\n",
      "Epoch 1/10\n",
      "1/1 [==============================] - 1s 809ms/step - loss: 0.2954 - val_loss: 0.2912\n",
      "Epoch 2/10\n",
      "1/1 [==============================] - 0s 41ms/step - loss: 0.2911 - val_loss: 0.2795\n",
      "Epoch 3/10\n",
      "1/1 [==============================] - 0s 38ms/step - loss: 0.2794 - val_loss: 0.2551\n",
      "Epoch 4/10\n",
      "1/1 [==============================] - 0s 43ms/step - loss: 0.2549 - val_loss: 0.2137\n",
      "Epoch 5/10\n",
      "1/1 [==============================] - 0s 39ms/step - loss: 0.2135 - val_loss: 0.1578\n",
      "Epoch 6/10\n",
      "1/1 [==============================] - 0s 39ms/step - loss: 0.1576 - val_loss: 0.1027\n",
      "Epoch 7/10\n",
      "1/1 [==============================] - 0s 42ms/step - loss: 0.1024 - val_loss: 0.0680\n",
      "Epoch 8/10\n",
      "1/1 [==============================] - 0s 39ms/step - loss: 0.0676 - val_loss: 0.0547\n",
      "Epoch 9/10\n",
      "1/1 [==============================] - 0s 56ms/step - loss: 0.0543 - val_loss: 0.0515\n",
      "Epoch 10/10\n",
      "1/1 [==============================] - 0s 58ms/step - loss: 0.0513 - val_loss: 0.0507\n",
      "Epoch 1/10\n",
      "1/1 [==============================] - 1s 816ms/step - loss: 0.2944 - val_loss: 0.2894\n",
      "Epoch 2/10\n",
      "1/1 [==============================] - 0s 46ms/step - loss: 0.2893 - val_loss: 0.2780\n",
      "Epoch 3/10\n",
      "1/1 [==============================] - 0s 47ms/step - loss: 0.2778 - val_loss: 0.2547\n",
      "Epoch 4/10\n",
      "1/1 [==============================] - 0s 54ms/step - loss: 0.2545 - val_loss: 0.2156\n",
      "Epoch 5/10\n",
      "1/1 [==============================] - 0s 53ms/step - loss: 0.2152 - val_loss: 0.1619\n",
      "Epoch 6/10\n",
      "1/1 [==============================] - 0s 41ms/step - loss: 0.1615 - val_loss: 0.1073\n",
      "Epoch 7/10\n",
      "1/1 [==============================] - 0s 41ms/step - loss: 0.1070 - val_loss: 0.0710\n",
      "Epoch 8/10\n",
      "1/1 [==============================] - 0s 42ms/step - loss: 0.0708 - val_loss: 0.0559\n",
      "Epoch 9/10\n",
      "1/1 [==============================] - 0s 41ms/step - loss: 0.0557 - val_loss: 0.0509\n",
      "Epoch 10/10\n",
      "1/1 [==============================] - 0s 41ms/step - loss: 0.0507 - val_loss: 0.0498\n",
      "Epoch 1/10\n",
      "1/1 [==============================] - 1s 826ms/step - loss: 0.2961 - val_loss: 0.2916\n",
      "Epoch 2/10\n",
      "1/1 [==============================] - 0s 43ms/step - loss: 0.2918 - val_loss: 0.2803\n",
      "Epoch 3/10\n",
      "1/1 [==============================] - 0s 44ms/step - loss: 0.2805 - val_loss: 0.2571\n",
      "Epoch 4/10\n",
      "1/1 [==============================] - 0s 44ms/step - loss: 0.2570 - val_loss: 0.2177\n",
      "Epoch 5/10\n",
      "1/1 [==============================] - 0s 44ms/step - loss: 0.2173 - val_loss: 0.1628\n",
      "Epoch 6/10\n",
      "1/1 [==============================] - 0s 44ms/step - loss: 0.1623 - val_loss: 0.1063\n",
      "Epoch 7/10\n",
      "1/1 [==============================] - 0s 42ms/step - loss: 0.1057 - val_loss: 0.0691\n",
      "Epoch 8/10\n",
      "1/1 [==============================] - 0s 42ms/step - loss: 0.0689 - val_loss: 0.0551\n",
      "Epoch 9/10\n",
      "1/1 [==============================] - 0s 56ms/step - loss: 0.0551 - val_loss: 0.0521\n",
      "Epoch 10/10\n",
      "1/1 [==============================] - 0s 48ms/step - loss: 0.0521 - val_loss: 0.0514\n",
      "Epoch 1/10\n",
      "1/1 [==============================] - 1s 789ms/step - loss: 0.2954 - val_loss: 0.2909\n",
      "Epoch 2/10\n",
      "1/1 [==============================] - 0s 50ms/step - loss: 0.2904 - val_loss: 0.2785\n",
      "Epoch 3/10\n",
      "1/1 [==============================] - 0s 53ms/step - loss: 0.2778 - val_loss: 0.2530\n",
      "Epoch 4/10\n",
      "1/1 [==============================] - 0s 40ms/step - loss: 0.2522 - val_loss: 0.2107\n",
      "Epoch 5/10\n",
      "1/1 [==============================] - 0s 39ms/step - loss: 0.2097 - val_loss: 0.1540\n",
      "Epoch 6/10\n",
      "1/1 [==============================] - 0s 40ms/step - loss: 0.1529 - val_loss: 0.0992\n",
      "Epoch 7/10\n",
      "1/1 [==============================] - 0s 41ms/step - loss: 0.0981 - val_loss: 0.0661\n",
      "Epoch 8/10\n",
      "1/1 [==============================] - 0s 39ms/step - loss: 0.0652 - val_loss: 0.0541\n",
      "Epoch 9/10\n",
      "1/1 [==============================] - 0s 40ms/step - loss: 0.0534 - val_loss: 0.0512\n",
      "Epoch 10/10\n",
      "1/1 [==============================] - 0s 39ms/step - loss: 0.0505 - val_loss: 0.0508\n",
      "Epoch 1/10\n",
      "1/1 [==============================] - 1s 828ms/step - loss: 0.2946 - val_loss: 0.2903\n",
      "Epoch 2/10\n",
      "1/1 [==============================] - 0s 48ms/step - loss: 0.2904 - val_loss: 0.2806\n",
      "Epoch 3/10\n",
      "1/1 [==============================] - 0s 52ms/step - loss: 0.2806 - val_loss: 0.2606\n",
      "Epoch 4/10\n",
      "1/1 [==============================] - 0s 48ms/step - loss: 0.2604 - val_loss: 0.2258\n",
      "Epoch 5/10\n",
      "1/1 [==============================] - 0s 49ms/step - loss: 0.2254 - val_loss: 0.1753\n",
      "Epoch 6/10\n",
      "1/1 [==============================] - 0s 51ms/step - loss: 0.1748 - val_loss: 0.1187\n",
      "Epoch 7/10\n",
      "1/1 [==============================] - 0s 86ms/step - loss: 0.1182 - val_loss: 0.0760\n",
      "Epoch 8/10\n",
      "1/1 [==============================] - 0s 70ms/step - loss: 0.0758 - val_loss: 0.0565\n",
      "Epoch 9/10\n",
      "1/1 [==============================] - 0s 52ms/step - loss: 0.0566 - val_loss: 0.0506\n",
      "Epoch 10/10\n",
      "1/1 [==============================] - 0s 49ms/step - loss: 0.0507 - val_loss: 0.0491\n",
      "Epoch 1/10\n",
      "1/1 [==============================] - 1s 793ms/step - loss: 0.2962 - val_loss: 0.2925\n",
      "Epoch 2/10\n",
      "1/1 [==============================] - 0s 40ms/step - loss: 0.2927 - val_loss: 0.2845\n",
      "Epoch 3/10\n",
      "1/1 [==============================] - 0s 38ms/step - loss: 0.2846 - val_loss: 0.2665\n",
      "Epoch 4/10\n",
      "1/1 [==============================] - 0s 40ms/step - loss: 0.2664 - val_loss: 0.2335\n",
      "Epoch 5/10\n",
      "1/1 [==============================] - 0s 41ms/step - loss: 0.2331 - val_loss: 0.1834\n",
      "Epoch 6/10\n",
      "1/1 [==============================] - 0s 40ms/step - loss: 0.1826 - val_loss: 0.1247\n",
      "Epoch 7/10\n",
      "1/1 [==============================] - 0s 40ms/step - loss: 0.1238 - val_loss: 0.0783\n",
      "Epoch 8/10\n",
      "1/1 [==============================] - 0s 40ms/step - loss: 0.0779 - val_loss: 0.0561\n",
      "Epoch 9/10\n",
      "1/1 [==============================] - 0s 42ms/step - loss: 0.0562 - val_loss: 0.0500\n",
      "Epoch 10/10\n",
      "1/1 [==============================] - 0s 40ms/step - loss: 0.0503 - val_loss: 0.0494\n",
      "Epoch 1/10\n",
      "1/1 [==============================] - 1s 822ms/step - loss: 0.2958 - val_loss: 0.2908\n",
      "Epoch 2/10\n",
      "1/1 [==============================] - 0s 53ms/step - loss: 0.2909 - val_loss: 0.2790\n",
      "Epoch 3/10\n",
      "1/1 [==============================] - 0s 51ms/step - loss: 0.2789 - val_loss: 0.2544\n",
      "Epoch 4/10\n",
      "1/1 [==============================] - 0s 54ms/step - loss: 0.2540 - val_loss: 0.2127\n",
      "Epoch 5/10\n",
      "1/1 [==============================] - 0s 54ms/step - loss: 0.2120 - val_loss: 0.1561\n",
      "Epoch 6/10\n",
      "1/1 [==============================] - 0s 63ms/step - loss: 0.1551 - val_loss: 0.1006\n",
      "Epoch 7/10\n",
      "1/1 [==============================] - 0s 53ms/step - loss: 0.0998 - val_loss: 0.0666\n",
      "Epoch 8/10\n",
      "1/1 [==============================] - 0s 55ms/step - loss: 0.0662 - val_loss: 0.0545\n",
      "Epoch 9/10\n",
      "1/1 [==============================] - 0s 54ms/step - loss: 0.0545 - val_loss: 0.0519\n",
      "Epoch 10/10\n",
      "1/1 [==============================] - 0s 53ms/step - loss: 0.0520 - val_loss: 0.0514\n",
      "Epoch 1/10\n",
      "1/1 [==============================] - 1s 794ms/step - loss: 0.2960 - val_loss: 0.2924\n",
      "Epoch 2/10\n",
      "1/1 [==============================] - 0s 38ms/step - loss: 0.2929 - val_loss: 0.2857\n",
      "Epoch 3/10\n",
      "1/1 [==============================] - 0s 37ms/step - loss: 0.2860 - val_loss: 0.2697\n",
      "Epoch 4/10\n",
      "1/1 [==============================] - 0s 38ms/step - loss: 0.2698 - val_loss: 0.2392\n",
      "Epoch 5/10\n",
      "1/1 [==============================] - 0s 38ms/step - loss: 0.2391 - val_loss: 0.1914\n",
      "Epoch 6/10\n",
      "1/1 [==============================] - 0s 39ms/step - loss: 0.1912 - val_loss: 0.1326\n",
      "Epoch 7/10\n",
      "1/1 [==============================] - 0s 39ms/step - loss: 0.1322 - val_loss: 0.0825\n",
      "Epoch 8/10\n",
      "1/1 [==============================] - 0s 37ms/step - loss: 0.0823 - val_loss: 0.0574\n",
      "Epoch 9/10\n",
      "1/1 [==============================] - 0s 38ms/step - loss: 0.0576 - val_loss: 0.0501\n",
      "Epoch 10/10\n",
      "1/1 [==============================] - 0s 38ms/step - loss: 0.0506 - val_loss: 0.0488\n"
     ]
    }
   ],
   "source": [
    "H_ini_auto = []\n",
    "for cols in IPC_data.columns[:-2]:\n",
    "    col_temp = sentences_pre_process(cols, IPC_all_data, IPC_data)\n",
    "    H_ini_auto.append(col_temp)\n",
    "H_ini_auto = np.asarray(H_ini_auto)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "metadata": {},
   "outputs": [],
   "source": [
    "H_ini_mean = []\n",
    "for cols in IPC_data.columns[:-2]:\n",
    "    col_temp = pre_pro_all(IPC_all_data, cols, IPC_data)\n",
    "    H_ini_mean.append(col_temp)\n",
    "H_ini_mean = np.asarray(H_ini_mean)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "metadata": {},
   "outputs": [],
   "source": [
    "H_ini_mean = np.abs(H_ini_mean)\n",
    "H_ini_auto = np.abs(H_ini_auto)\n",
    "\n",
    "H_ini_mean_store = H_ini_mean.copy()\n",
    "H_ini_auto_store = H_ini_auto.copy()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "metadata": {},
   "outputs": [],
   "source": [
    "W_ini = IPC_data.iloc[:, :-2].to_numpy()\n",
    "W_ini_store = W_ini.copy()\n",
    "A_data = IPC_all_data.iloc[:,:-1].to_numpy()\n",
    "A_data = np.abs(A_data)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "metadata": {},
   "outputs": [],
   "source": [
    "A_data = A_data.astype('float64')\n",
    "W_ini = W_ini.astype('float64')\n",
    "H_ini_mean = H_ini_mean.astype('float64')\n",
    "H_ini_auto = H_ini_auto.astype('float64')\n",
    "\n",
    "A_data = np.ascontiguousarray(A_data)\n",
    "W_ini = np.ascontiguousarray(W_ini)\n",
    "H_ini_mean = np.ascontiguousarray(H_ini_mean)\n",
    "H_ini_auto = np.ascontiguousarray(H_ini_auto)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "metadata": {},
   "outputs": [],
   "source": [
    "NMF_md = NMF(n_components = W_ini.shape[1],init='custom', max_iter=2000)\n",
    "W_out_mean = NMF_md.fit_transform(A_data, W = W_ini, H= H_ini_mean)\n",
    "H_out_mean = NMF_md.components_"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "metadata": {},
   "outputs": [],
   "source": [
    "W_ini = W_ini_store.copy()\n",
    "W_ini = W_ini.astype('float64')\n",
    "W_ini = np.ascontiguousarray(W_ini)\n",
    "\n",
    "NMF_md = NMF(n_components = W_ini.shape[1],init='custom', max_iter=2000)\n",
    "W_out_auto = NMF_md.fit_transform(A_data, W = W_ini, H= H_ini_auto)\n",
    "H_out_auto = NMF_md.components_"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Test process with mean value initial"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "100%|██████████| 50/50 [00:07<00:00,  7.06it/s]\n"
     ]
    }
   ],
   "source": [
    "test_data = pd.read_csv('datasets/IPC_metadata/IPC_data_bio_test.csv')\n",
    "test_data = test_data.iloc[:50,:]\n",
    "sentences = test_data['abstract']\n",
    "token,sent_array = [],[]\n",
    "\n",
    "for i,j in enumerate(sentences):\n",
    "    temp = pre_token(j, stop_words)\n",
    "    token.append(' '.join(np.array(temp)))\n",
    "test_data['token'] = token\n",
    "test_data = test_data.dropna()\n",
    "test_data = test_data.loc[test_data['token']!='',:].reset_index(drop=True)\n",
    "\n",
    "token_list = test_data['token']\n",
    "for sent in tqdm(token_list):\n",
    "    temp = vectorize(sent, BERT_model)\n",
    "    sent_array.append(temp)\n",
    "sent_array = np.asarray(sent_array)\n",
    "sent_BERT = sent_array.copy()\n",
    "sent_array = np.abs(sent_array)\n",
    "sent_array = sent_array.astype('float64')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### TF-IDF"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 35,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "  0%|          | 0/49 [00:00<?, ?it/s]"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "100%|██████████| 49/49 [00:02<00:00, 19.18it/s]\n"
     ]
    }
   ],
   "source": [
    "tf_df = tf_idf_df(test_data['abstract'], stop_words)\n",
    "tf_df = tf_df.fillna(0)\n",
    "tf_df['ID'] = test_data['ID']\n",
    "\n",
    "tf_df_noID = tf_df.drop('ID',axis=1)\n",
    "tf_array = tf_df_noID.to_numpy()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 36,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "100%|██████████| 50/50 [00:00<00:00, 25010.76it/s]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Original:  The present invention relates to a “one-pot process” for preparing intermediate of antibody-drug conjugate. The preparation process provided by the present invention is simple in operation, and needs no such steps like concentration, washing and filtration of the intermediate reaction liquid, disposal of the organic waste liquid, and packaging and storage of the intermediate. The entire reaction system comprises only one separation and purification treatment, saving costs for labor, equipment, venues, raw materials, etc., and greatly reducing the pollution to the environment. In addition, the “one-pot process” for preparing intermediate of antibody-drug conjugate of the present invention produces the intermediate of antibody-drug conjugate with higher yield. The “one-pot process” for preparing intermediate of antibody-drug conjugate provided by the present invention is more suitable for scale-up production.\n",
      "\n",
      "\n",
      "0\n",
      "probability:  0.059326836290766884\n",
      "content:  A preconcentrate comprising a fatty acid oil mixture that contains EPA and DHA, preferably in the form of ethyl ester or triglyceride, and at least one surfactant. The preconcentrates are capable of forming a self-nanoemulsifying drug delivery system, a self-microemulsifying drug delivery system or a self-emulsifying drug delivery system (SNEDDS, SMEDDS or SEDDS) in an aqueous solution. The application is also directed to a food supplement preconcentrate.\n",
      "patent ID US11612579B2\n",
      "\n",
      "\n",
      "1\n",
      "probability:  0.049530510407628035\n",
      "content:  Methods, devices, and medicaments that include a drug are provided for use in the treatment of the prostate by locally administering the drug into the bladder of a patient to achieve a sustained concentration of the drug in urine in the bladder sufficient to produce a therapeutic concentration of the drug in the prostate. The drug may be delivered into the bladder from an intravesical drug delivery device inserted into the bladder, wherein the device continuously releases the drug into the urine in the bladder over an extended period of hours or days.\n",
      "patent ID US20150165177A1\n",
      "\n",
      "\n",
      "2\n",
      "probability:  0.04528104886030397\n",
      "content:  Provided are a recombinant bispecific antibody against CTLA-4 and PDL-1, a nucleic acid molecule for encoding the antibody, a vector and a host cell comprising the nucleic acid molecule, and a method for preparing the antibody. Also provided are a pharmaceutical composition comprising the bispecific antibody, and usage of the bispecific antibody in preparation of the pharmaceutical composition.\n",
      "patent ID US11421029B2\n",
      "\n",
      "\n",
      "3\n",
      "probability:  0.03129627018431071\n",
      "content:  The invention relates to a series of novel compounds containing acryloyl group. In particular, the invention relates to acryloyl group-containing compounds shown in formula (1) and the preparation method thereof, and application of the compounds shown in formula (1) and pharmaceutically acceptable salts thereof in preparation of medicaments for treating, regulating and/or preventing diseases related to physiological conditions related to CRM1 protein.\n",
      "\n",
      "patent ID US11286247B2\n",
      "\n",
      "\n",
      "4\n",
      "probability:  0.027548429581658547\n",
      "content:  Provided herein are poly-1-hydroxymethylethylene hydroxymethyl formal (PHF)-based drug delivery systems. Also disclosed are methods of making antibody-drug conjugates and methods of treatment using these conjugates.\n",
      "patent ID US20200155693A1\n",
      "\n",
      "\n",
      "5\n",
      "probability:  0.02586456314122251\n",
      "content:  A nucleic acid for coding a chimeric antigen receptor protein expressed on the surface of a human T lymphocyte. The chimeric antigen receptor protein comprises an extracellular binding domain, a transmembrane domain and an intracellular signal domain that are orderly connected. The extracellular binding domain comprises a single-chain antibody scFv (EGFR) for specific recognition of 287th to 302th amino acid epitopes of a human epidermal growth factor receptor (EGFR).\n",
      "patent ID US20170159025A1\n",
      "\n",
      "\n",
      "6\n",
      "probability:  0.025452952261595774\n",
      "content:  The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.\n",
      "patent ID US9890219B2\n",
      "\n",
      "\n",
      "7\n",
      "probability:  0.025331295404768795\n",
      "content:  A method of enhancing the growth of an animal is provided. The method includes causing the animal to ingest or absorb an effective amount of a preparation obtainable by a process including, bringing a tyrosinate moiety into contact with an Fe(III)-containing substance, optionally wherein the tyrosinate moiety is tyrosine and it is brought into contact with the Fe(III)-containing substance in the presence of a base, or wherein the tyrosinate moiety is a tyrosine salt and it is brought into contact with an Fe(III)-containing substance. Methods for inhibiting, reducing, or preventing biofilm formation or buildup on a surface; the treatment of, inhibition of growth of, and inhibition of colonization by, bacteria, both in biological and non-biological environments; disinfecting surfaces, potentiating the effects of antibiotics and other anti-microbial agents, and increasing the sensitivity of bacteria and other microorganisms, to anti-microbial agents are also provided.\n",
      "patent ID US20170044197A1\n",
      "\n",
      "\n",
      "8\n",
      "probability:  0.02366905996445854\n",
      "content:  The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) for treatment of pulmonary conditions (e.g. asthma). The HPCs/HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPCs/HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.\n",
      "patent ID US20190142818A1\n",
      "\n",
      "\n",
      "9\n",
      "probability:  0.022257282030207607\n",
      "content:  The present invention relates to a pharmaceutical composition comprising brivaracetam as active ingredient, the invention relates specifically to a prolonged release formulation.\n",
      "patent ID US20120040006A1\n",
      "\n",
      "\n",
      "10\n",
      "probability:  0.022073452746184268\n",
      "content:  An anti-B7-H4 antibody, an antigen-binding fragment thereof and pharmaceutical use thereof. A chimeric antibody and a humanized antibody comprising a CDR region of the anti-B7-H4 antibody, a pharmaceutical composition comprising the anti-B7-H4 antibody and the antigen-binding fragment thereof, and use thereof as an anti-cancer medicament. A humanized anti-B7-H4 antibody and use thereof in the preparation of a medicament for treating diseases or conditions mediated by B7-H4.\n",
      "patent ID US11472882B2\n",
      "\n",
      "\n",
      "11\n",
      "probability:  0.020784340808054406\n",
      "content:  The present invention relates to a method for quantitatively measuring the muscular relaxing activity of a neurotoxin. Specifically, based on an extent of the activity of muscular relaxation of a neurotoxin from bacteria of Clostridium, the present invention relates to a method for quantification of the efficacy (potential and/or diffusion reaction) of a neurotoxin comprising the following steps of: (a) administering a neurotoxin to the hind leg muscle of one of hind legs of a non-human mammal; (b) applying electric stimulus to said non-human mammal; (c) measuring a compound muscle action potential (CMAP) by contraction of said hind leg muscle to which the neurotoxin is administered and/or of the hind leg muscle of the other hind leg to which the neurotoxin is not administered; and (d) taking amplitude data from the compound muscle action potential (CMAP) obtained by the measurement in step (c) and analyzing an extent of a decrease in amplitude to thereby quantify the efficacy of the muscular relaxing activity by the neurotoxin. In contrast to the mouse LD50 currently used as a potential unit of a botulinum toxin which is measurable at a level of only several units, the quantification method of the efficacy of a neurotoxin of the present invention allows for measurement at a level of as low as 0.01 to 1 unit and hence is a method with a high sensitivity, reproducibility and accuracy.\n",
      "patent ID US20090297452A1\n",
      "\n",
      "\n",
      "12\n",
      "probability:  0.019803047501948296\n",
      "content:  The present invention pertains to the field of chemical medicine, particularly to 4-substituted coumarin derivatives and preparation methods and applications thereof. The invention provides 4-substituted coumarin derivatives with a structural formula as shown in Formula I. The invention also provides preparation methods and applications for the above 4-substituted coumarin derivatives. The compounds provided in the invention have strong anti-tumor activity with IC50 for plural tumor cell lines between 0.01-5 nM, and it also performs better to inhibit microtubule polymerization and has diversified biological activities and low toxicity, providing new options for drug-sensitive and drug-resistant tumor cells.\n",
      "\n",
      "patent ID US20180282315A1\n",
      "\n",
      "\n",
      "13\n",
      "probability:  0.019720466026621985\n",
      "content:  The present invention relates to pyrimidine compounds that are useful as anti-proliferative agents. More particularly, the present invention relates to oxygen linked and substituted pyrimidine compounds, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of proliferative disorders. These compounds may be useful as medicaments for the treatment of a number of proliferative disorders including tumors and cancers as well as other disorders or conditions related to or associated with kinases.\n",
      "patent ID US8415338B2\n",
      "\n",
      "\n",
      "14\n",
      "probability:  0.019720466026621985\n",
      "content:  The present invention relates to pyrimidine compounds that are useful as anti-proliferative agents. More particularly, the present invention relates to oxygen linked and substituted pyrimidine compounds, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of proliferative disorders. These compounds may be useful as medicaments for the treatment of a number of proliferative disorders including tumours and cancers as well as other disorders or conditions related to or associated with kinases.\n",
      "patent ID US20090075999A1\n",
      "\n",
      "\n",
      "15\n",
      "probability:  0.01855187873757226\n",
      "content:  Provided is a cassette unit suitable for use with an auto-injector having an electrically powered drive unit. The cassette unit comprises a cassette unit housing defining a housing cavity, a rearward entrance to the cavity and a forward needle projection aperture. The housing cavity may receive a syringe. Axially movable within the barrel of the syringe for forward movement into contact with the syringe plunger, there is a plunger slaving part defining a circumferential wall arranged for frictional sliding relationship with the inner wall of the barrel, a rear drive-receiving face and a front plunger-contacting face. In capping relationship with the rearward entrance of the cassette unit housing there is an end-cap defining a drive rod-receiving opening for receipt of a drive rod for providing forward axial drive to the plunger slaving part. In a pre-use configuration, the plunger slaving part is shaped for releasable engagement with the end-cap.\n",
      "patent ID US20150202374A1\n",
      "\n",
      "\n",
      "16\n",
      "probability:  0.01519225249495734\n",
      "content:  Disclosed in the present invention are a new thiazole compound, particularly a compound represented by formula (I), a pharmaceutical composition thereof and applications thereof in the preparation of drugs for the treatment of diseases related to herpes simplex viruses.\n",
      "patent ID US10647710B2\n",
      "\n",
      "\n",
      "17\n",
      "probability:  0.014564620717603666\n",
      "content:  The present invention relates to methods for the treatment of a bone fracture or bone defect. The invention discloses the effective use of an anti-gremlin-1 antibody to accelerate the healing and bridging of bone tissue in segmental gap defects; and demonstrates that inhibitors of gremlin-1 activity may provide improved therapies for treating or preventing fracture non-union.\n",
      "patent ID US20210107973A1\n",
      "\n",
      "\n",
      "18\n",
      "probability:  0.013355280330617912\n",
      "content:  Formulations and methods of manufacturing formulations for use in colonic evacuation are disclosed herein, in an embodiment, a solid dosage formulation includes an intra-granular fraction intermingled with an extra-granular fraction, wherein the intra-granular fraction includes granules comprising at least one osmotic evacuant agent, at least one antacid, and a first pharmaceutically acceptable excipient component, and wherein the extra-granular fraction includes one or more organic acids, a non-metallic lubricating element, and a second pharmaceutically acceptable excipient component.\n",
      "patent ID US11058671B2\n",
      "\n",
      "\n",
      "19\n",
      "probability:  0.01129551128159319\n",
      "content:  The disclosure is directed to ABC294640, as free base or as salts thereof, in preparing medicines for treating coronavirus infection or preventing diseases caused by coronavirus infection, and a medicine for preventing coronavirus infection or preventing diseases caused by coronavirus infection.\n",
      "patent ID US20220031682A1\n",
      "\n",
      "\n",
      "20\n",
      "probability:  0.011140947892687977\n",
      "content:  The present invention relates to a recombinant fusion protein comprising a fragment of the cardioprotective protein neuregulin-1 (NRG-1) fused to a monoclonal antibody (mAb) backbone and to a method of treating a disease or condition in a subject in need thereof comprising administering a therapeutically effective amount of the recombinant fusion protein or the pharmaceutical composition comprising the recombinant fusion protein disclosed herein.\n",
      "patent ID US11718652B2\n",
      "\n",
      "\n",
      "21\n",
      "probability:  0.010979946783968178\n",
      "content:  Provided herein are poly-1-hydroxymethylethylene hydroxymethyl formal (PHF)-based drug delivery systems. Also disclosed are methods of making antibodydrug conjugates and methods of treatment using these conjugates.\n",
      "patent ID US20190083634A1\n",
      "\n",
      "\n",
      "22\n",
      "probability:  0.010493787743595686\n",
      "content:  Provided are an in vitro fibrosis model, a method of preparing the in vitro model, and use of the in vitro model, the in vitro model including a cell cluster differentiated from mesenchymal cells, wherein the cell cluster exhibits pathological characteristics of fibrosis.\n",
      "patent ID US20200071674A1\n",
      "\n",
      "\n",
      "23\n",
      "probability:  0.010178005588397633\n",
      "content:  The present invention provides a method for generating a functionally modifying antibody to an ion channel comprising immunizing a host with a cyclic peptide comprising at least part of an extracellular sequence of said ion channel.\n",
      "patent ID US9234037B2\n",
      "\n",
      "\n",
      "24\n",
      "probability:  0.010103927127251526\n",
      "content:  Provided herein are a gastric inhibitory polypeptide receptor (GIPR) antibody and its fusion protein with glucagon-like peptide-1 (GLP-1), and a pharmaceutical composition thereof. Also provided herein is a method for using the GIPR antibody and its fusion protein with GLP-1 to treat, prevent or improve one or more symptoms of non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, type 2 diabetes or obesity.\n",
      "patent ID US20210061904A1\n",
      "\n",
      "\n",
      "25\n",
      "probability:  0.008878868341804819\n",
      "content:  The present disclosure provides improved compositions comprising rifabutin, clarithromycin, and clofazimine for use in the treatment of Inflammatory Bowel Diseases. In one instance, the compositions may comprise a formulation of rifabutin, clarithromycin, and clofazimine in a single dosage form, such as a capsule, tablet, etc., with one or more specific excipients.\n",
      "patent ID US9072763B2\n",
      "\n",
      "\n",
      "26\n",
      "probability:  0.00879298539225127\n",
      "content:  Provided are an FGFR4 inhibitor having the structure of formula (I), and a preparation method therefor and the use thereof. The compound has a very strong inhibitory effect on FGFR4 kinase activity and has a very high selectivity, and can be widely used in the preparation of a drug for treating cancers, especially prostate cancer, liver cancer, pancreatic cancer, esophageal carcinomas, gastric cancer, lung cancer, breast cancer, ovarian carcinomas, colon cancer, skin cancer, glioblastomas or rhabdomyosarcomas, and is expected to be developed into a new generation of FGFR4 inhibitor drugs.\n",
      "\n",
      "patent ID US11555036B2\n",
      "\n",
      "\n",
      "27\n",
      "probability:  0.008293842956239054\n",
      "content:  The present invention relates to Rucaparib and/or Talazoparib and/or Veliparib and/or Olaparib, and/or AZD 2461, or a pharmaceutically acceptable salt thereof, for use in the treatment of impaired skin wound healing in a subject, an in vitro method for identifying a subject suffering from impaired skin wound healing to be responsive to the treatment with Rucaparib and/or Talazoparib and/or Veliparib and/or Olaparib and/or AZD 2461, and kits and kits-of-part related thereto.\n",
      "patent ID US11638709B2\n",
      "\n",
      "\n",
      "28\n",
      "probability:  0.00752345632404353\n",
      "content:  The present technology provides methods of preventing or treating vitiligo. The methods provide administering aromatic-cationic peptides in effective amounts to treat or ameliorate melanocyte degeneration such as that found in a subject suffering from, or predisposed to vitiligo. In some embodiments, the methods comprise administering to a subject suffering from, or at risk for vitiligo, an effective amount of an aromatic-cationic peptide to subjects in need thereof. The present technology relates to the treatment, amelioration or prevention of vitiligo in mammals or mammalian cells, through administration of therapeutically effective amounts of aromatic-cationic peptides, such as D-Arg-2′,6′-Dmt-Lys-Phe-NH2.\n",
      "patent ID US20160296589A1\n",
      "\n",
      "\n",
      "29\n",
      "probability:  0.006684704055202041\n",
      "content:  This disclosure provides modified recombinant retroviruses comprisings containing a 2A-peptide or peptide-like coding sequence operably linked to a heterologous polynucleotide. The disclosure further relates to cells and vector expressing or comprising such vectors and methods of using such modified vectors in the treatment of disease and disorders.\n",
      "patent ID US11279949B2\n",
      "\n",
      "\n",
      "30\n",
      "probability:  0.005346780334132783\n",
      "content:  Disclosed is a Tat protein, the amino acid sequence of which is shown as SEQ NO: 1, SEQ NO: 2, SEQ NO: 3 and SEQ NO: 4. The Tat protein of the present invention has been studied and developed and can be a Latent infection of HIV-1 activating potential drug.\n",
      "patent ID US9790255B2\n",
      "\n",
      "\n",
      "31\n",
      "probability:  0.005067717492106131\n",
      "content:  The invention provides methods and compositions for wound treatment and/or blood clot formation, e.g., arresting the flow of blood from an open wound. The methods and compositions provide for promoting and accelerating wound healing and optionally provide for inhibition of microbial infection and/or a local analgesic effect.\n",
      "patent ID US20150079152A1\n",
      "\n",
      "\n",
      "32\n",
      "probability:  0.004952885625913612\n",
      "content:  A sublingual tablet pharmaceutical composition containing edaravone and (+)-2-borneol, and a preparation method thereof. The sublingual tablet pharmaceutical composition includes edaravone, (+)-2-camphanol, an excipient, a filler, a binder, a disintegrant, and a lubricant. The excipient is selected from one or more of mannitol, lactose, dextran, cysteine, glycine, copovidone, and beta-cyclodextrin.\n",
      "patent ID US20200297697A1\n",
      "\n",
      "\n",
      "33\n",
      "probability:  0.004710760724387192\n",
      "content:  A urological medical device having a retrieval string is provided. The retrieval string has a proximal end connected the device and an opposed distal end. In a first embodiment, the retrieval string is configured in an initial confined form which, following a period of deployment in a patient's bladder, changes to an unconfined form in which the distal end of the retrieval string is extendible into the urethra to enable extraction of the device from bladder by pulling the retrieval string. The device may include a bioerodible component which permits the retrieval string to take the unconfined form following degradation of the bioerodible component in vivo. In another embodiment, the retrieval string includes a ferromagnetic material, which can be magnetically captured to facilitate removal of the device from the bladder. The ferromagnetic retrieval string may be buoyant in urine.\n",
      "patent ID US20150088150A1\n",
      "\n",
      "\n",
      "34\n",
      "probability:  0.004013253312387171\n",
      "content:  The present disclosure discloses substituted quinazoline compounds having a capacity to cross the blood-brain barrier. The compound has the structural formula represented by formula (I):\n",
      "\n",
      "The quinazoline compounds, derivatives and pharmaceutically acceptable salts thereof of the present disclosure have the ability to cross the blood-brain barrier and are capable of acting as a drug characteristic of a protein kinase inhibitor, in particular for the expression of a protein through a epidermal growth factor receptor and can be used to treat or prevent disorders associated with abnormal protein kinase activity, such as cancer, cancer with brain metastases, cancer with meningeal metastases, and neuroprotective diseases, and the like.\n",
      "patent ID US20200308140A1\n",
      "\n",
      "\n",
      "35\n",
      "probability:  0.003837797043455303\n",
      "content:  The present invention provides the use of certain compounds to treat peripheral or central pain syndrome and other disorders associated with the T-type calcium ion channels.\n",
      "patent ID US20110053960A1\n",
      "\n",
      "\n",
      "36\n",
      "probability:  0.003719733008392664\n",
      "content:  A medical barrier includes a sheet of unsintered substantially unexpanded hydrophilic polytetraflouroethylene (PTFE) polymer material having a density in a range of about 1.2 gm/cc to about 2.3 gm/cc, and preferably in the range of about 1.45 gm/cc to about 1.55 gm/cc, and having at least one textured surface. In accordance with one embodiment, the sheet has one textured surface and one substantially smooth surface, and has substantially uniform strength in all directions.\n",
      "patent ID US7296998B2\n",
      "\n",
      "\n",
      "37\n",
      "probability:  0.0036323631763786122\n",
      "content:  A sensor can be manufactured by printing a working electrode onto a substrate using aerosol jet printing. Sensing chemistry (e.g., enzyme-based ink that including detection chemistry) also can be printed onto the working electrode using aerosol jet printing. A reference electrode also can be printed on the substrate at a position spaced along the substrate from the working electrode. In certain examples, the substrate can be positioned within a lumen of a skin piercing member of a sensor module.\n",
      "patent ID US20170095187A1\n",
      "\n",
      "\n",
      "38\n",
      "probability:  0.0029550207921312356\n",
      "content:  Disclosed are molecularly targeted and activated kinase inhibitors and use thereof. Specifically, a compound represented by the following formula A or a pharmaceutically acceptable salt thereof, wherein X is a polar and a non-polar uncharged amino acid such as alanine, proline or threonine; A is alanine; N is asparagine; PABC is —NH-phenyl-CH2-O—; and Z is a drug molecule; wherein the lactobionic acid residue, XAN and PABC are linked to each other by an amide bond; PABC is bonded to Z by an ester group, i.e., —OC(O)—.\n",
      "\n",
      "Lacto-XAN-PABC-Z  (Formula A)\n",
      "patent ID US20200140485A1\n",
      "\n",
      "\n",
      "39\n",
      "probability:  0.002894354891042949\n",
      "content:  The invention is directed to a method for preventing cerebral damage in patients having symptoms of atherosclerosis of arteries supplying the brain by administering to the patient a therapeutically effective amount of a composition comprising eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) or a combination thereof.\n",
      "patent ID US8729124B2\n",
      "\n",
      "\n",
      "40\n",
      "probability:  0.0025415448715160505\n",
      "content:  A series of pyrazolo[3,4-d]pyrimidine derivatives that are substituted at the 4-position by a diaza monocyclic, bridged bicyclic or spirocyclic moiety, are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases and malaria; and organ and cell transplant rejection.\n",
      "patent ID USRE48622E1\n",
      "\n",
      "\n",
      "41\n",
      "probability:  0.0022951463859248885\n",
      "content:  Crystalline forms of seletalisib, designated as Form B and Form F and characterized herein, being selective inhibitors of PI3 kinase enzymes, in particular of the human PBKδ isoform, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.\n",
      "patent ID US11059820B2\n",
      "\n",
      "\n",
      "42\n",
      "probability:  0.00178697695236089\n",
      "content:  The present disclosure relates to a sensor including an elongated member including at least a portion that is electrically conductive. The elongated member includes a sensing layer adapted to react with a material desired to be sensed. An insulating layer surrounds the elongated member. The insulating layer defines at least one access opening for allowing the material desired to be sensed to enter an interior region defined between the elongated member and the insulating layer. The insulating layer has an inner transverse cross-sectional profile that is different from an outer transverse cross-sectional profile of the elongated member. The difference in transverse cross-sectional profiles between the elongated member and the insulating layer provides channels at the interior region defined between the insulating layer and the elongated member. The channels extend generally along the length of the elongated member and are sized to allow the material desired to be sensed to move along the length of the sensor.\n",
      "patent ID US8702932B2\n",
      "\n",
      "\n",
      "43\n",
      "probability:  0.0011787333970059738\n",
      "content:  The present invention is directed to a method of controlling and directing cells, for example to stimulate an immune response, inhibit an immune response, direct tissue regeneration or prevent tissue damage for therapeutic activity through the use of heterodimerically-tethered bispecific protein complex of formula A-X:Y-B. Component A may present X on the surface of a cell, may bind a protein (including a marker) expressed on the surface of an effector cell, or A-X is expressed on the surface of an effector cell, whilst B is specific to an epitope on target cell or tissue of interest. X:Y is a heterodimeric-tether which is formed by a binding interaction between X and Y, which together with A and B assists and effects the controlling and directing of the selected cells.\n",
      "patent ID US10954312B2\n",
      "\n",
      "\n",
      "44\n",
      "probability:  0.0004539131966275954\n",
      "content:  The present disclosure provides novel neutralizing antibodies against SARS-COV-2, and the antigen binding fragments thereof. Pharmaceutical composition and kits comprising the same, and the uses thereof are also provided.\n",
      "patent ID US20220073594A1\n",
      "\n",
      "\n",
      "45\n",
      "probability:  0.00033494333296898917\n",
      "content:  A series of substituted 5,6,7,8-tetrahydroimidazo[1,2-α]pyridine derivatives, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.\n",
      "patent ID US20160289228A1\n",
      "\n",
      "\n",
      "46\n",
      "probability:  0.000258928832444574\n",
      "content:  A macrocycle represented by formula (I) and a pharmaceutical composition comprising the macrocycle, or a crystalline form, pharmaceutically acceptable salt, hydrate or solvent compound, stereoisomer, prodrug, or isotopic variant of the macrocycle. The macrocycle and the composition thereof inhibit a protein kinase.\n",
      "patent ID US10543199B2\n",
      "\n",
      "\n",
      "47\n",
      "probability:  0.00021527470259013519\n",
      "content:  The syringe systems disclosed herein provide in part devices for allowing patients with compromised joint strength to more easily administer medicine. Certain exemplary syringe embodiments include a handle forming a handgrip, a syringe barrel that magnifies the dosage marks located on an inner barrel, and a tip cap slidably engageable with the syringe barrel for shielding a needle.\n",
      "patent ID US20180071462A1\n",
      "\n",
      "\n",
      "48\n",
      "probability:  0.0\n",
      "content:  A sterilized cyanoacrylate adhesive composition including a cyanoacrylate composition and a cure speed enhancer, wherein said sterilized cyanoacrylate adhesive composition does not cure upon sterilization, and wherein the composition when cured to form a film on a patient's tissue has water vapor transmission rate from about 950 to about 3000 g/m2/day.\n",
      "patent ID US20140186289A1\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\n"
     ]
    }
   ],
   "source": [
    "results_tf = sim_res(tf_array[0], tf_array)\n",
    "result_sort = np.argsort(results_tf)[::-1]\n",
    "print('Original: ',test_data['abstract'][0])\n",
    "m = 0\n",
    "for i in result_sort[1:]:\n",
    "    print('\\n')\n",
    "    print(m)\n",
    "    m = m+1\n",
    "    print('probability: ', results_tf[i])\n",
    "    print('content: ', test_data['abstract'][i])\n",
    "    print('patent ID', test_data['ID'][i])"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### BERT"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 37,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "100%|██████████| 50/50 [00:00<00:00, 24980.96it/s]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Original:  The present invention relates to a “one-pot process” for preparing intermediate of antibody-drug conjugate. The preparation process provided by the present invention is simple in operation, and needs no such steps like concentration, washing and filtration of the intermediate reaction liquid, disposal of the organic waste liquid, and packaging and storage of the intermediate. The entire reaction system comprises only one separation and purification treatment, saving costs for labor, equipment, venues, raw materials, etc., and greatly reducing the pollution to the environment. In addition, the “one-pot process” for preparing intermediate of antibody-drug conjugate of the present invention produces the intermediate of antibody-drug conjugate with higher yield. The “one-pot process” for preparing intermediate of antibody-drug conjugate provided by the present invention is more suitable for scale-up production.\n",
      "\n",
      "\n",
      "0\n",
      "probability:  0.69053954\n",
      "content:  The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.\n",
      "patent ID US9890219B2\n",
      "\n",
      "\n",
      "1\n",
      "probability:  0.64293087\n",
      "content:  The present invention pertains to the field of chemical medicine, particularly to 4-substituted coumarin derivatives and preparation methods and applications thereof. The invention provides 4-substituted coumarin derivatives with a structural formula as shown in Formula I. The invention also provides preparation methods and applications for the above 4-substituted coumarin derivatives. The compounds provided in the invention have strong anti-tumor activity with IC50 for plural tumor cell lines between 0.01-5 nM, and it also performs better to inhibit microtubule polymerization and has diversified biological activities and low toxicity, providing new options for drug-sensitive and drug-resistant tumor cells.\n",
      "\n",
      "patent ID US20180282315A1\n",
      "\n",
      "\n",
      "2\n",
      "probability:  0.6297618\n",
      "content:  The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) for treatment of pulmonary conditions (e.g. asthma). The HPCs/HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPCs/HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.\n",
      "patent ID US20190142818A1\n",
      "\n",
      "\n",
      "3\n",
      "probability:  0.62855965\n",
      "content:  The invention provides methods and compositions for wound treatment and/or blood clot formation, e.g., arresting the flow of blood from an open wound. The methods and compositions provide for promoting and accelerating wound healing and optionally provide for inhibition of microbial infection and/or a local analgesic effect.\n",
      "patent ID US20150079152A1\n",
      "\n",
      "\n",
      "4\n",
      "probability:  0.61034393\n",
      "content:  The present invention is directed to a method of controlling and directing cells, for example to stimulate an immune response, inhibit an immune response, direct tissue regeneration or prevent tissue damage for therapeutic activity through the use of heterodimerically-tethered bispecific protein complex of formula A-X:Y-B. Component A may present X on the surface of a cell, may bind a protein (including a marker) expressed on the surface of an effector cell, or A-X is expressed on the surface of an effector cell, whilst B is specific to an epitope on target cell or tissue of interest. X:Y is a heterodimeric-tether which is formed by a binding interaction between X and Y, which together with A and B assists and effects the controlling and directing of the selected cells.\n",
      "patent ID US10954312B2\n",
      "\n",
      "\n",
      "5\n",
      "probability:  0.5994077\n",
      "content:  The present invention provides a method for generating a functionally modifying antibody to an ion channel comprising immunizing a host with a cyclic peptide comprising at least part of an extracellular sequence of said ion channel.\n",
      "patent ID US9234037B2\n",
      "\n",
      "\n",
      "6\n",
      "probability:  0.599284\n",
      "content:  The present invention relates to a recombinant fusion protein comprising a fragment of the cardioprotective protein neuregulin-1 (NRG-1) fused to a monoclonal antibody (mAb) backbone and to a method of treating a disease or condition in a subject in need thereof comprising administering a therapeutically effective amount of the recombinant fusion protein or the pharmaceutical composition comprising the recombinant fusion protein disclosed herein.\n",
      "patent ID US11718652B2\n",
      "\n",
      "\n",
      "7\n",
      "probability:  0.5961485\n",
      "content:  The present invention relates to a pharmaceutical composition comprising brivaracetam as active ingredient, the invention relates specifically to a prolonged release formulation.\n",
      "patent ID US20120040006A1\n",
      "\n",
      "\n",
      "8\n",
      "probability:  0.59237856\n",
      "content:  The invention relates to a series of novel compounds containing acryloyl group. In particular, the invention relates to acryloyl group-containing compounds shown in formula (1) and the preparation method thereof, and application of the compounds shown in formula (1) and pharmaceutically acceptable salts thereof in preparation of medicaments for treating, regulating and/or preventing diseases related to physiological conditions related to CRM1 protein.\n",
      "\n",
      "patent ID US11286247B2\n",
      "\n",
      "\n",
      "9\n",
      "probability:  0.5843298\n",
      "content:  The present invention relates to a method for quantitatively measuring the muscular relaxing activity of a neurotoxin. Specifically, based on an extent of the activity of muscular relaxation of a neurotoxin from bacteria of Clostridium, the present invention relates to a method for quantification of the efficacy (potential and/or diffusion reaction) of a neurotoxin comprising the following steps of: (a) administering a neurotoxin to the hind leg muscle of one of hind legs of a non-human mammal; (b) applying electric stimulus to said non-human mammal; (c) measuring a compound muscle action potential (CMAP) by contraction of said hind leg muscle to which the neurotoxin is administered and/or of the hind leg muscle of the other hind leg to which the neurotoxin is not administered; and (d) taking amplitude data from the compound muscle action potential (CMAP) obtained by the measurement in step (c) and analyzing an extent of a decrease in amplitude to thereby quantify the efficacy of the muscular relaxing activity by the neurotoxin. In contrast to the mouse LD50 currently used as a potential unit of a botulinum toxin which is measurable at a level of only several units, the quantification method of the efficacy of a neurotoxin of the present invention allows for measurement at a level of as low as 0.01 to 1 unit and hence is a method with a high sensitivity, reproducibility and accuracy.\n",
      "patent ID US20090297452A1\n",
      "\n",
      "\n",
      "10\n",
      "probability:  0.5721026\n",
      "content:  The invention is directed to a method for preventing cerebral damage in patients having symptoms of atherosclerosis of arteries supplying the brain by administering to the patient a therapeutically effective amount of a composition comprising eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) or a combination thereof.\n",
      "patent ID US8729124B2\n",
      "\n",
      "\n",
      "11\n",
      "probability:  0.5699824\n",
      "content:  A method of enhancing the growth of an animal is provided. The method includes causing the animal to ingest or absorb an effective amount of a preparation obtainable by a process including, bringing a tyrosinate moiety into contact with an Fe(III)-containing substance, optionally wherein the tyrosinate moiety is tyrosine and it is brought into contact with the Fe(III)-containing substance in the presence of a base, or wherein the tyrosinate moiety is a tyrosine salt and it is brought into contact with an Fe(III)-containing substance. Methods for inhibiting, reducing, or preventing biofilm formation or buildup on a surface; the treatment of, inhibition of growth of, and inhibition of colonization by, bacteria, both in biological and non-biological environments; disinfecting surfaces, potentiating the effects of antibiotics and other anti-microbial agents, and increasing the sensitivity of bacteria and other microorganisms, to anti-microbial agents are also provided.\n",
      "patent ID US20170044197A1\n",
      "\n",
      "\n",
      "12\n",
      "probability:  0.56601006\n",
      "content:  The present invention relates to Rucaparib and/or Talazoparib and/or Veliparib and/or Olaparib, and/or AZD 2461, or a pharmaceutically acceptable salt thereof, for use in the treatment of impaired skin wound healing in a subject, an in vitro method for identifying a subject suffering from impaired skin wound healing to be responsive to the treatment with Rucaparib and/or Talazoparib and/or Veliparib and/or Olaparib and/or AZD 2461, and kits and kits-of-part related thereto.\n",
      "patent ID US11638709B2\n",
      "\n",
      "\n",
      "13\n",
      "probability:  0.56442547\n",
      "content:  The present invention relates to methods for the treatment of a bone fracture or bone defect. The invention discloses the effective use of an anti-gremlin-1 antibody to accelerate the healing and bridging of bone tissue in segmental gap defects; and demonstrates that inhibitors of gremlin-1 activity may provide improved therapies for treating or preventing fracture non-union.\n",
      "patent ID US20210107973A1\n",
      "\n",
      "\n",
      "14\n",
      "probability:  0.55173755\n",
      "content:  Disclosed in the present invention are a new thiazole compound, particularly a compound represented by formula (I), a pharmaceutical composition thereof and applications thereof in the preparation of drugs for the treatment of diseases related to herpes simplex viruses.\n",
      "patent ID US10647710B2\n",
      "\n",
      "\n",
      "15\n",
      "probability:  0.5506719\n",
      "content:  The present invention relates to pyrimidine compounds that are useful as anti-proliferative agents. More particularly, the present invention relates to oxygen linked and substituted pyrimidine compounds, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of proliferative disorders. These compounds may be useful as medicaments for the treatment of a number of proliferative disorders including tumours and cancers as well as other disorders or conditions related to or associated with kinases.\n",
      "patent ID US20090075999A1\n",
      "\n",
      "\n",
      "16\n",
      "probability:  0.5445518\n",
      "content:  The present invention relates to pyrimidine compounds that are useful as anti-proliferative agents. More particularly, the present invention relates to oxygen linked and substituted pyrimidine compounds, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of proliferative disorders. These compounds may be useful as medicaments for the treatment of a number of proliferative disorders including tumors and cancers as well as other disorders or conditions related to or associated with kinases.\n",
      "patent ID US8415338B2\n",
      "\n",
      "\n",
      "17\n",
      "probability:  0.5402418\n",
      "content:  Provided are a recombinant bispecific antibody against CTLA-4 and PDL-1, a nucleic acid molecule for encoding the antibody, a vector and a host cell comprising the nucleic acid molecule, and a method for preparing the antibody. Also provided are a pharmaceutical composition comprising the bispecific antibody, and usage of the bispecific antibody in preparation of the pharmaceutical composition.\n",
      "patent ID US11421029B2\n",
      "\n",
      "\n",
      "18\n",
      "probability:  0.52117383\n",
      "content:  Provided herein are poly-1-hydroxymethylethylene hydroxymethyl formal (PHF)-based drug delivery systems. Also disclosed are methods of making antibodydrug conjugates and methods of treatment using these conjugates.\n",
      "patent ID US20190083634A1\n",
      "\n",
      "\n",
      "19\n",
      "probability:  0.5141017\n",
      "content:  Provided herein are poly-1-hydroxymethylethylene hydroxymethyl formal (PHF)-based drug delivery systems. Also disclosed are methods of making antibody-drug conjugates and methods of treatment using these conjugates.\n",
      "patent ID US20200155693A1\n",
      "\n",
      "\n",
      "20\n",
      "probability:  0.5059598\n",
      "content:  An anti-B7-H4 antibody, an antigen-binding fragment thereof and pharmaceutical use thereof. A chimeric antibody and a humanized antibody comprising a CDR region of the anti-B7-H4 antibody, a pharmaceutical composition comprising the anti-B7-H4 antibody and the antigen-binding fragment thereof, and use thereof as an anti-cancer medicament. A humanized anti-B7-H4 antibody and use thereof in the preparation of a medicament for treating diseases or conditions mediated by B7-H4.\n",
      "patent ID US11472882B2\n",
      "\n",
      "\n",
      "21\n",
      "probability:  0.5029487\n",
      "content:  The present disclosure provides novel neutralizing antibodies against SARS-COV-2, and the antigen binding fragments thereof. Pharmaceutical composition and kits comprising the same, and the uses thereof are also provided.\n",
      "patent ID US20220073594A1\n",
      "\n",
      "\n",
      "22\n",
      "probability:  0.4999694\n",
      "content:  A sterilized cyanoacrylate adhesive composition including a cyanoacrylate composition and a cure speed enhancer, wherein said sterilized cyanoacrylate adhesive composition does not cure upon sterilization, and wherein the composition when cured to form a film on a patient's tissue has water vapor transmission rate from about 950 to about 3000 g/m2/day.\n",
      "patent ID US20140186289A1\n",
      "\n",
      "\n",
      "23\n",
      "probability:  0.49149704\n",
      "content:  A macrocycle represented by formula (I) and a pharmaceutical composition comprising the macrocycle, or a crystalline form, pharmaceutically acceptable salt, hydrate or solvent compound, stereoisomer, prodrug, or isotopic variant of the macrocycle. The macrocycle and the composition thereof inhibit a protein kinase.\n",
      "patent ID US10543199B2\n",
      "\n",
      "\n",
      "24\n",
      "probability:  0.46741992\n",
      "content:  Methods, devices, and medicaments that include a drug are provided for use in the treatment of the prostate by locally administering the drug into the bladder of a patient to achieve a sustained concentration of the drug in urine in the bladder sufficient to produce a therapeutic concentration of the drug in the prostate. The drug may be delivered into the bladder from an intravesical drug delivery device inserted into the bladder, wherein the device continuously releases the drug into the urine in the bladder over an extended period of hours or days.\n",
      "patent ID US20150165177A1\n",
      "\n",
      "\n",
      "25\n",
      "probability:  0.46063003\n",
      "content:  A sensor can be manufactured by printing a working electrode onto a substrate using aerosol jet printing. Sensing chemistry (e.g., enzyme-based ink that including detection chemistry) also can be printed onto the working electrode using aerosol jet printing. A reference electrode also can be printed on the substrate at a position spaced along the substrate from the working electrode. In certain examples, the substrate can be positioned within a lumen of a skin piercing member of a sensor module.\n",
      "patent ID US20170095187A1\n",
      "\n",
      "\n",
      "26\n",
      "probability:  0.45535913\n",
      "content:  A preconcentrate comprising a fatty acid oil mixture that contains EPA and DHA, preferably in the form of ethyl ester or triglyceride, and at least one surfactant. The preconcentrates are capable of forming a self-nanoemulsifying drug delivery system, a self-microemulsifying drug delivery system or a self-emulsifying drug delivery system (SNEDDS, SMEDDS or SEDDS) in an aqueous solution. The application is also directed to a food supplement preconcentrate.\n",
      "patent ID US11612579B2\n",
      "\n",
      "\n",
      "27\n",
      "probability:  0.44950607\n",
      "content:  The present technology provides methods of preventing or treating vitiligo. The methods provide administering aromatic-cationic peptides in effective amounts to treat or ameliorate melanocyte degeneration such as that found in a subject suffering from, or predisposed to vitiligo. In some embodiments, the methods comprise administering to a subject suffering from, or at risk for vitiligo, an effective amount of an aromatic-cationic peptide to subjects in need thereof. The present technology relates to the treatment, amelioration or prevention of vitiligo in mammals or mammalian cells, through administration of therapeutically effective amounts of aromatic-cationic peptides, such as D-Arg-2′,6′-Dmt-Lys-Phe-NH2.\n",
      "patent ID US20160296589A1\n",
      "\n",
      "\n",
      "28\n",
      "probability:  0.44784474\n",
      "content:  Formulations and methods of manufacturing formulations for use in colonic evacuation are disclosed herein, in an embodiment, a solid dosage formulation includes an intra-granular fraction intermingled with an extra-granular fraction, wherein the intra-granular fraction includes granules comprising at least one osmotic evacuant agent, at least one antacid, and a first pharmaceutically acceptable excipient component, and wherein the extra-granular fraction includes one or more organic acids, a non-metallic lubricating element, and a second pharmaceutically acceptable excipient component.\n",
      "patent ID US11058671B2\n",
      "\n",
      "\n",
      "29\n",
      "probability:  0.44751927\n",
      "content:  A urological medical device having a retrieval string is provided. The retrieval string has a proximal end connected the device and an opposed distal end. In a first embodiment, the retrieval string is configured in an initial confined form which, following a period of deployment in a patient's bladder, changes to an unconfined form in which the distal end of the retrieval string is extendible into the urethra to enable extraction of the device from bladder by pulling the retrieval string. The device may include a bioerodible component which permits the retrieval string to take the unconfined form following degradation of the bioerodible component in vivo. In another embodiment, the retrieval string includes a ferromagnetic material, which can be magnetically captured to facilitate removal of the device from the bladder. The ferromagnetic retrieval string may be buoyant in urine.\n",
      "patent ID US20150088150A1\n",
      "\n",
      "\n",
      "30\n",
      "probability:  0.4463717\n",
      "content:  Provided herein are a gastric inhibitory polypeptide receptor (GIPR) antibody and its fusion protein with glucagon-like peptide-1 (GLP-1), and a pharmaceutical composition thereof. Also provided herein is a method for using the GIPR antibody and its fusion protein with GLP-1 to treat, prevent or improve one or more symptoms of non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, type 2 diabetes or obesity.\n",
      "patent ID US20210061904A1\n",
      "\n",
      "\n",
      "31\n",
      "probability:  0.44580668\n",
      "content:  The disclosure is directed to ABC294640, as free base or as salts thereof, in preparing medicines for treating coronavirus infection or preventing diseases caused by coronavirus infection, and a medicine for preventing coronavirus infection or preventing diseases caused by coronavirus infection.\n",
      "patent ID US20220031682A1\n",
      "\n",
      "\n",
      "32\n",
      "probability:  0.441269\n",
      "content:  The present disclosure discloses substituted quinazoline compounds having a capacity to cross the blood-brain barrier. The compound has the structural formula represented by formula (I):\n",
      "\n",
      "The quinazoline compounds, derivatives and pharmaceutically acceptable salts thereof of the present disclosure have the ability to cross the blood-brain barrier and are capable of acting as a drug characteristic of a protein kinase inhibitor, in particular for the expression of a protein through a epidermal growth factor receptor and can be used to treat or prevent disorders associated with abnormal protein kinase activity, such as cancer, cancer with brain metastases, cancer with meningeal metastases, and neuroprotective diseases, and the like.\n",
      "patent ID US20200308140A1\n",
      "\n",
      "\n",
      "33\n",
      "probability:  0.44035897\n",
      "content:  The present disclosure provides improved compositions comprising rifabutin, clarithromycin, and clofazimine for use in the treatment of Inflammatory Bowel Diseases. In one instance, the compositions may comprise a formulation of rifabutin, clarithromycin, and clofazimine in a single dosage form, such as a capsule, tablet, etc., with one or more specific excipients.\n",
      "patent ID US9072763B2\n",
      "\n",
      "\n",
      "34\n",
      "probability:  0.43592072\n",
      "content:  Provided is a cassette unit suitable for use with an auto-injector having an electrically powered drive unit. The cassette unit comprises a cassette unit housing defining a housing cavity, a rearward entrance to the cavity and a forward needle projection aperture. The housing cavity may receive a syringe. Axially movable within the barrel of the syringe for forward movement into contact with the syringe plunger, there is a plunger slaving part defining a circumferential wall arranged for frictional sliding relationship with the inner wall of the barrel, a rear drive-receiving face and a front plunger-contacting face. In capping relationship with the rearward entrance of the cassette unit housing there is an end-cap defining a drive rod-receiving opening for receipt of a drive rod for providing forward axial drive to the plunger slaving part. In a pre-use configuration, the plunger slaving part is shaped for releasable engagement with the end-cap.\n",
      "patent ID US20150202374A1\n",
      "\n",
      "\n",
      "35\n",
      "probability:  0.42917496\n",
      "content:  Disclosed are molecularly targeted and activated kinase inhibitors and use thereof. Specifically, a compound represented by the following formula A or a pharmaceutically acceptable salt thereof, wherein X is a polar and a non-polar uncharged amino acid such as alanine, proline or threonine; A is alanine; N is asparagine; PABC is —NH-phenyl-CH2-O—; and Z is a drug molecule; wherein the lactobionic acid residue, XAN and PABC are linked to each other by an amide bond; PABC is bonded to Z by an ester group, i.e., —OC(O)—.\n",
      "\n",
      "Lacto-XAN-PABC-Z  (Formula A)\n",
      "patent ID US20200140485A1\n",
      "\n",
      "\n",
      "36\n",
      "probability:  0.4271825\n",
      "content:  This disclosure provides modified recombinant retroviruses comprisings containing a 2A-peptide or peptide-like coding sequence operably linked to a heterologous polynucleotide. The disclosure further relates to cells and vector expressing or comprising such vectors and methods of using such modified vectors in the treatment of disease and disorders.\n",
      "patent ID US11279949B2\n",
      "\n",
      "\n",
      "37\n",
      "probability:  0.42303404\n",
      "content:  Disclosed is a Tat protein, the amino acid sequence of which is shown as SEQ NO: 1, SEQ NO: 2, SEQ NO: 3 and SEQ NO: 4. The Tat protein of the present invention has been studied and developed and can be a Latent infection of HIV-1 activating potential drug.\n",
      "patent ID US9790255B2\n",
      "\n",
      "\n",
      "38\n",
      "probability:  0.4151248\n",
      "content:  The syringe systems disclosed herein provide in part devices for allowing patients with compromised joint strength to more easily administer medicine. Certain exemplary syringe embodiments include a handle forming a handgrip, a syringe barrel that magnifies the dosage marks located on an inner barrel, and a tip cap slidably engageable with the syringe barrel for shielding a needle.\n",
      "patent ID US20180071462A1\n",
      "\n",
      "\n",
      "39\n",
      "probability:  0.4085534\n",
      "content:  A series of pyrazolo[3,4-d]pyrimidine derivatives that are substituted at the 4-position by a diaza monocyclic, bridged bicyclic or spirocyclic moiety, are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases and malaria; and organ and cell transplant rejection.\n",
      "patent ID USRE48622E1\n",
      "\n",
      "\n",
      "40\n",
      "probability:  0.40632305\n",
      "content:  The present disclosure relates to a sensor including an elongated member including at least a portion that is electrically conductive. The elongated member includes a sensing layer adapted to react with a material desired to be sensed. An insulating layer surrounds the elongated member. The insulating layer defines at least one access opening for allowing the material desired to be sensed to enter an interior region defined between the elongated member and the insulating layer. The insulating layer has an inner transverse cross-sectional profile that is different from an outer transverse cross-sectional profile of the elongated member. The difference in transverse cross-sectional profiles between the elongated member and the insulating layer provides channels at the interior region defined between the insulating layer and the elongated member. The channels extend generally along the length of the elongated member and are sized to allow the material desired to be sensed to move along the length of the sensor.\n",
      "patent ID US8702932B2\n",
      "\n",
      "\n",
      "41\n",
      "probability:  0.40631208\n",
      "content:  A sublingual tablet pharmaceutical composition containing edaravone and (+)-2-borneol, and a preparation method thereof. The sublingual tablet pharmaceutical composition includes edaravone, (+)-2-camphanol, an excipient, a filler, a binder, a disintegrant, and a lubricant. The excipient is selected from one or more of mannitol, lactose, dextran, cysteine, glycine, copovidone, and beta-cyclodextrin.\n",
      "patent ID US20200297697A1\n",
      "\n",
      "\n",
      "42\n",
      "probability:  0.40327948\n",
      "content:  Provided are an in vitro fibrosis model, a method of preparing the in vitro model, and use of the in vitro model, the in vitro model including a cell cluster differentiated from mesenchymal cells, wherein the cell cluster exhibits pathological characteristics of fibrosis.\n",
      "patent ID US20200071674A1\n",
      "\n",
      "\n",
      "43\n",
      "probability:  0.3968706\n",
      "content:  A series of substituted 5,6,7,8-tetrahydroimidazo[1,2-α]pyridine derivatives, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.\n",
      "patent ID US20160289228A1\n",
      "\n",
      "\n",
      "44\n",
      "probability:  0.3780729\n",
      "content:  Provided are an FGFR4 inhibitor having the structure of formula (I), and a preparation method therefor and the use thereof. The compound has a very strong inhibitory effect on FGFR4 kinase activity and has a very high selectivity, and can be widely used in the preparation of a drug for treating cancers, especially prostate cancer, liver cancer, pancreatic cancer, esophageal carcinomas, gastric cancer, lung cancer, breast cancer, ovarian carcinomas, colon cancer, skin cancer, glioblastomas or rhabdomyosarcomas, and is expected to be developed into a new generation of FGFR4 inhibitor drugs.\n",
      "\n",
      "patent ID US11555036B2\n",
      "\n",
      "\n",
      "45\n",
      "probability:  0.37463626\n",
      "content:  Crystalline forms of seletalisib, designated as Form B and Form F and characterized herein, being selective inhibitors of PI3 kinase enzymes, in particular of the human PBKδ isoform, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.\n",
      "patent ID US11059820B2\n",
      "\n",
      "\n",
      "46\n",
      "probability:  0.3610869\n",
      "content:  A nucleic acid for coding a chimeric antigen receptor protein expressed on the surface of a human T lymphocyte. The chimeric antigen receptor protein comprises an extracellular binding domain, a transmembrane domain and an intracellular signal domain that are orderly connected. The extracellular binding domain comprises a single-chain antibody scFv (EGFR) for specific recognition of 287th to 302th amino acid epitopes of a human epidermal growth factor receptor (EGFR).\n",
      "patent ID US20170159025A1\n",
      "\n",
      "\n",
      "47\n",
      "probability:  0.35960788\n",
      "content:  A medical barrier includes a sheet of unsintered substantially unexpanded hydrophilic polytetraflouroethylene (PTFE) polymer material having a density in a range of about 1.2 gm/cc to about 2.3 gm/cc, and preferably in the range of about 1.45 gm/cc to about 1.55 gm/cc, and having at least one textured surface. In accordance with one embodiment, the sheet has one textured surface and one substantially smooth surface, and has substantially uniform strength in all directions.\n",
      "patent ID US7296998B2\n",
      "\n",
      "\n",
      "48\n",
      "probability:  0.3583087\n",
      "content:  The present invention provides the use of certain compounds to treat peripheral or central pain syndrome and other disorders associated with the T-type calcium ion channels.\n",
      "patent ID US20110053960A1\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\n"
     ]
    }
   ],
   "source": [
    "results_BERT = sim_res(sent_BERT[0], sent_BERT)\n",
    "result_sort_BERT = np.argsort(results_BERT)[::-1]\n",
    "print('Original: ',test_data['abstract'][0])\n",
    "m = 0\n",
    "for i in result_sort_BERT[1:]:\n",
    "    print('\\n')\n",
    "    print(m)\n",
    "    m = m+1\n",
    "    print('probability: ', results_BERT[i])\n",
    "    print('content: ', test_data['abstract'][i])\n",
    "    print('patent ID', test_data['ID'][i])"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Minimize solver (Auto-encoding)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 38,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "100%|██████████| 50/50 [00:48<00:00,  1.03it/s]\n"
     ]
    }
   ],
   "source": [
    "sent_uncons_LB = []\n",
    "for one_abs in tqdm(sent_array):\n",
    "    one_res = min_transform_unconst(H_out_mean, one_abs, 'L-BFGS-B')\n",
    "    one_scale = one_res\n",
    "    sent_uncons_LB.append(one_scale)\n",
    "sent_uncons_LB = np.asarray(sent_uncons_LB)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 39,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "100%|██████████| 50/50 [01:47<00:00,  2.15s/it]\n"
     ]
    }
   ],
   "source": [
    "sent_uncons_CG = []\n",
    "for one_abs in tqdm(sent_array):\n",
    "    one_res = min_transform_unconst(H_out_mean, one_abs, 'CG')\n",
    "    one_scale = one_res\n",
    "    sent_uncons_CG.append(one_scale)\n",
    "sent_uncons_CG = np.asarray(sent_uncons_CG)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "100%|██████████| 50/50 [00:00<00:00, 50003.62it/s]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Original:  The present invention relates to a “one-pot process” for preparing intermediate of antibody-drug conjugate. The preparation process provided by the present invention is simple in operation, and needs no such steps like concentration, washing and filtration of the intermediate reaction liquid, disposal of the organic waste liquid, and packaging and storage of the intermediate. The entire reaction system comprises only one separation and purification treatment, saving costs for labor, equipment, venues, raw materials, etc., and greatly reducing the pollution to the environment. In addition, the “one-pot process” for preparing intermediate of antibody-drug conjugate of the present invention produces the intermediate of antibody-drug conjugate with higher yield. The “one-pot process” for preparing intermediate of antibody-drug conjugate provided by the present invention is more suitable for scale-up production.\n",
      "\n",
      "\n",
      "0\n",
      "probability:  0.6134541428492318\n",
      "content:  The invention provides methods and compositions for wound treatment and/or blood clot formation, e.g., arresting the flow of blood from an open wound. The methods and compositions provide for promoting and accelerating wound healing and optionally provide for inhibition of microbial infection and/or a local analgesic effect.\n",
      "patent ID US20150079152A1\n",
      "\n",
      "\n",
      "1\n",
      "probability:  0.5353578510006934\n",
      "content:  A sensor can be manufactured by printing a working electrode onto a substrate using aerosol jet printing. Sensing chemistry (e.g., enzyme-based ink that including detection chemistry) also can be printed onto the working electrode using aerosol jet printing. A reference electrode also can be printed on the substrate at a position spaced along the substrate from the working electrode. In certain examples, the substrate can be positioned within a lumen of a skin piercing member of a sensor module.\n",
      "patent ID US20170095187A1\n",
      "\n",
      "\n",
      "2\n",
      "probability:  0.5240888852578035\n",
      "content:  The present invention relates to a pharmaceutical composition comprising brivaracetam as active ingredient, the invention relates specifically to a prolonged release formulation.\n",
      "patent ID US20120040006A1\n",
      "\n",
      "\n",
      "3\n",
      "probability:  0.5037993467190014\n",
      "content:  A urological medical device having a retrieval string is provided. The retrieval string has a proximal end connected the device and an opposed distal end. In a first embodiment, the retrieval string is configured in an initial confined form which, following a period of deployment in a patient's bladder, changes to an unconfined form in which the distal end of the retrieval string is extendible into the urethra to enable extraction of the device from bladder by pulling the retrieval string. The device may include a bioerodible component which permits the retrieval string to take the unconfined form following degradation of the bioerodible component in vivo. In another embodiment, the retrieval string includes a ferromagnetic material, which can be magnetically captured to facilitate removal of the device from the bladder. The ferromagnetic retrieval string may be buoyant in urine.\n",
      "patent ID US20150088150A1\n",
      "\n",
      "\n",
      "4\n",
      "probability:  0.49873330467864796\n",
      "content:  The present invention relates to a method for quantitatively measuring the muscular relaxing activity of a neurotoxin. Specifically, based on an extent of the activity of muscular relaxation of a neurotoxin from bacteria of Clostridium, the present invention relates to a method for quantification of the efficacy (potential and/or diffusion reaction) of a neurotoxin comprising the following steps of: (a) administering a neurotoxin to the hind leg muscle of one of hind legs of a non-human mammal; (b) applying electric stimulus to said non-human mammal; (c) measuring a compound muscle action potential (CMAP) by contraction of said hind leg muscle to which the neurotoxin is administered and/or of the hind leg muscle of the other hind leg to which the neurotoxin is not administered; and (d) taking amplitude data from the compound muscle action potential (CMAP) obtained by the measurement in step (c) and analyzing an extent of a decrease in amplitude to thereby quantify the efficacy of the muscular relaxing activity by the neurotoxin. In contrast to the mouse LD50 currently used as a potential unit of a botulinum toxin which is measurable at a level of only several units, the quantification method of the efficacy of a neurotoxin of the present invention allows for measurement at a level of as low as 0.01 to 1 unit and hence is a method with a high sensitivity, reproducibility and accuracy.\n",
      "patent ID US20090297452A1\n",
      "\n",
      "\n",
      "5\n",
      "probability:  0.4890668578284013\n",
      "content:  A medical barrier includes a sheet of unsintered substantially unexpanded hydrophilic polytetraflouroethylene (PTFE) polymer material having a density in a range of about 1.2 gm/cc to about 2.3 gm/cc, and preferably in the range of about 1.45 gm/cc to about 1.55 gm/cc, and having at least one textured surface. In accordance with one embodiment, the sheet has one textured surface and one substantially smooth surface, and has substantially uniform strength in all directions.\n",
      "patent ID US7296998B2\n",
      "\n",
      "\n",
      "6\n",
      "probability:  0.4872315265425977\n",
      "content:  The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) for treatment of pulmonary conditions (e.g. asthma). The HPCs/HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPCs/HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.\n",
      "patent ID US20190142818A1\n",
      "\n",
      "\n",
      "7\n",
      "probability:  0.47749709142718133\n",
      "content:  The present invention provides a method for generating a functionally modifying antibody to an ion channel comprising immunizing a host with a cyclic peptide comprising at least part of an extracellular sequence of said ion channel.\n",
      "patent ID US9234037B2\n",
      "\n",
      "\n",
      "8\n",
      "probability:  0.4686222563418514\n",
      "content:  A sterilized cyanoacrylate adhesive composition including a cyanoacrylate composition and a cure speed enhancer, wherein said sterilized cyanoacrylate adhesive composition does not cure upon sterilization, and wherein the composition when cured to form a film on a patient's tissue has water vapor transmission rate from about 950 to about 3000 g/m2/day.\n",
      "patent ID US20140186289A1\n",
      "\n",
      "\n",
      "9\n",
      "probability:  0.46388520135957745\n",
      "content:  The present disclosure provides novel neutralizing antibodies against SARS-COV-2, and the antigen binding fragments thereof. Pharmaceutical composition and kits comprising the same, and the uses thereof are also provided.\n",
      "patent ID US20220073594A1\n",
      "\n",
      "\n",
      "10\n",
      "probability:  0.45458020668550814\n",
      "content:  Formulations and methods of manufacturing formulations for use in colonic evacuation are disclosed herein, in an embodiment, a solid dosage formulation includes an intra-granular fraction intermingled with an extra-granular fraction, wherein the intra-granular fraction includes granules comprising at least one osmotic evacuant agent, at least one antacid, and a first pharmaceutically acceptable excipient component, and wherein the extra-granular fraction includes one or more organic acids, a non-metallic lubricating element, and a second pharmaceutically acceptable excipient component.\n",
      "patent ID US11058671B2\n",
      "\n",
      "\n",
      "11\n",
      "probability:  0.438103583473303\n",
      "content:  The present invention is directed to a method of controlling and directing cells, for example to stimulate an immune response, inhibit an immune response, direct tissue regeneration or prevent tissue damage for therapeutic activity through the use of heterodimerically-tethered bispecific protein complex of formula A-X:Y-B. Component A may present X on the surface of a cell, may bind a protein (including a marker) expressed on the surface of an effector cell, or A-X is expressed on the surface of an effector cell, whilst B is specific to an epitope on target cell or tissue of interest. X:Y is a heterodimeric-tether which is formed by a binding interaction between X and Y, which together with A and B assists and effects the controlling and directing of the selected cells.\n",
      "patent ID US10954312B2\n",
      "\n",
      "\n",
      "12\n",
      "probability:  0.4373489550534217\n",
      "content:  A sublingual tablet pharmaceutical composition containing edaravone and (+)-2-borneol, and a preparation method thereof. The sublingual tablet pharmaceutical composition includes edaravone, (+)-2-camphanol, an excipient, a filler, a binder, a disintegrant, and a lubricant. The excipient is selected from one or more of mannitol, lactose, dextran, cysteine, glycine, copovidone, and beta-cyclodextrin.\n",
      "patent ID US20200297697A1\n",
      "\n",
      "\n",
      "13\n",
      "probability:  0.427103279230312\n",
      "content:  A macrocycle represented by formula (I) and a pharmaceutical composition comprising the macrocycle, or a crystalline form, pharmaceutically acceptable salt, hydrate or solvent compound, stereoisomer, prodrug, or isotopic variant of the macrocycle. The macrocycle and the composition thereof inhibit a protein kinase.\n",
      "patent ID US10543199B2\n",
      "\n",
      "\n",
      "14\n",
      "probability:  0.4164584135193624\n",
      "content:  The present disclosure provides improved compositions comprising rifabutin, clarithromycin, and clofazimine for use in the treatment of Inflammatory Bowel Diseases. In one instance, the compositions may comprise a formulation of rifabutin, clarithromycin, and clofazimine in a single dosage form, such as a capsule, tablet, etc., with one or more specific excipients.\n",
      "patent ID US9072763B2\n",
      "\n",
      "\n",
      "15\n",
      "probability:  0.40995293455122067\n",
      "content:  The present disclosure relates to a sensor including an elongated member including at least a portion that is electrically conductive. The elongated member includes a sensing layer adapted to react with a material desired to be sensed. An insulating layer surrounds the elongated member. The insulating layer defines at least one access opening for allowing the material desired to be sensed to enter an interior region defined between the elongated member and the insulating layer. The insulating layer has an inner transverse cross-sectional profile that is different from an outer transverse cross-sectional profile of the elongated member. The difference in transverse cross-sectional profiles between the elongated member and the insulating layer provides channels at the interior region defined between the insulating layer and the elongated member. The channels extend generally along the length of the elongated member and are sized to allow the material desired to be sensed to move along the length of the sensor.\n",
      "patent ID US8702932B2\n",
      "\n",
      "\n",
      "16\n",
      "probability:  0.40478866373932954\n",
      "content:  The invention is directed to a method for preventing cerebral damage in patients having symptoms of atherosclerosis of arteries supplying the brain by administering to the patient a therapeutically effective amount of a composition comprising eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) or a combination thereof.\n",
      "patent ID US8729124B2\n",
      "\n",
      "\n",
      "17\n",
      "probability:  0.40070721808351084\n",
      "content:  Crystalline forms of seletalisib, designated as Form B and Form F and characterized herein, being selective inhibitors of PI3 kinase enzymes, in particular of the human PBKδ isoform, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.\n",
      "patent ID US11059820B2\n",
      "\n",
      "\n",
      "18\n",
      "probability:  0.3909638384529456\n",
      "content:  This disclosure provides modified recombinant retroviruses comprisings containing a 2A-peptide or peptide-like coding sequence operably linked to a heterologous polynucleotide. The disclosure further relates to cells and vector expressing or comprising such vectors and methods of using such modified vectors in the treatment of disease and disorders.\n",
      "patent ID US11279949B2\n",
      "\n",
      "\n",
      "19\n",
      "probability:  0.36846747520158374\n",
      "content:  A preconcentrate comprising a fatty acid oil mixture that contains EPA and DHA, preferably in the form of ethyl ester or triglyceride, and at least one surfactant. The preconcentrates are capable of forming a self-nanoemulsifying drug delivery system, a self-microemulsifying drug delivery system or a self-emulsifying drug delivery system (SNEDDS, SMEDDS or SEDDS) in an aqueous solution. The application is also directed to a food supplement preconcentrate.\n",
      "patent ID US11612579B2\n",
      "\n",
      "\n",
      "20\n",
      "probability:  0.3540305783137737\n",
      "content:  An anti-B7-H4 antibody, an antigen-binding fragment thereof and pharmaceutical use thereof. A chimeric antibody and a humanized antibody comprising a CDR region of the anti-B7-H4 antibody, a pharmaceutical composition comprising the anti-B7-H4 antibody and the antigen-binding fragment thereof, and use thereof as an anti-cancer medicament. A humanized anti-B7-H4 antibody and use thereof in the preparation of a medicament for treating diseases or conditions mediated by B7-H4.\n",
      "patent ID US11472882B2\n",
      "\n",
      "\n",
      "21\n",
      "probability:  0.3440118600687335\n",
      "content:  The present invention relates to a recombinant fusion protein comprising a fragment of the cardioprotective protein neuregulin-1 (NRG-1) fused to a monoclonal antibody (mAb) backbone and to a method of treating a disease or condition in a subject in need thereof comprising administering a therapeutically effective amount of the recombinant fusion protein or the pharmaceutical composition comprising the recombinant fusion protein disclosed herein.\n",
      "patent ID US11718652B2\n",
      "\n",
      "\n",
      "22\n",
      "probability:  0.34374080283989755\n",
      "content:  The present invention pertains to the field of chemical medicine, particularly to 4-substituted coumarin derivatives and preparation methods and applications thereof. The invention provides 4-substituted coumarin derivatives with a structural formula as shown in Formula I. The invention also provides preparation methods and applications for the above 4-substituted coumarin derivatives. The compounds provided in the invention have strong anti-tumor activity with IC50 for plural tumor cell lines between 0.01-5 nM, and it also performs better to inhibit microtubule polymerization and has diversified biological activities and low toxicity, providing new options for drug-sensitive and drug-resistant tumor cells.\n",
      "\n",
      "patent ID US20180282315A1\n",
      "\n",
      "\n",
      "23\n",
      "probability:  0.3247457601875402\n",
      "content:  Disclosed in the present invention are a new thiazole compound, particularly a compound represented by formula (I), a pharmaceutical composition thereof and applications thereof in the preparation of drugs for the treatment of diseases related to herpes simplex viruses.\n",
      "patent ID US10647710B2\n",
      "\n",
      "\n",
      "24\n",
      "probability:  0.32348348461259113\n",
      "content:  Methods, devices, and medicaments that include a drug are provided for use in the treatment of the prostate by locally administering the drug into the bladder of a patient to achieve a sustained concentration of the drug in urine in the bladder sufficient to produce a therapeutic concentration of the drug in the prostate. The drug may be delivered into the bladder from an intravesical drug delivery device inserted into the bladder, wherein the device continuously releases the drug into the urine in the bladder over an extended period of hours or days.\n",
      "patent ID US20150165177A1\n",
      "\n",
      "\n",
      "25\n",
      "probability:  0.3067650483824003\n",
      "content:  Provided are a recombinant bispecific antibody against CTLA-4 and PDL-1, a nucleic acid molecule for encoding the antibody, a vector and a host cell comprising the nucleic acid molecule, and a method for preparing the antibody. Also provided are a pharmaceutical composition comprising the bispecific antibody, and usage of the bispecific antibody in preparation of the pharmaceutical composition.\n",
      "patent ID US11421029B2\n",
      "\n",
      "\n",
      "26\n",
      "probability:  0.30607452186499073\n",
      "content:  The present invention relates to methods for the treatment of a bone fracture or bone defect. The invention discloses the effective use of an anti-gremlin-1 antibody to accelerate the healing and bridging of bone tissue in segmental gap defects; and demonstrates that inhibitors of gremlin-1 activity may provide improved therapies for treating or preventing fracture non-union.\n",
      "patent ID US20210107973A1\n",
      "\n",
      "\n",
      "27\n",
      "probability:  0.3030870189026716\n",
      "content:  The present invention relates to pyrimidine compounds that are useful as anti-proliferative agents. More particularly, the present invention relates to oxygen linked and substituted pyrimidine compounds, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of proliferative disorders. These compounds may be useful as medicaments for the treatment of a number of proliferative disorders including tumours and cancers as well as other disorders or conditions related to or associated with kinases.\n",
      "patent ID US20090075999A1\n",
      "\n",
      "\n",
      "28\n",
      "probability:  0.30245747536159684\n",
      "content:  Provided herein are poly-1-hydroxymethylethylene hydroxymethyl formal (PHF)-based drug delivery systems. Also disclosed are methods of making antibodydrug conjugates and methods of treatment using these conjugates.\n",
      "patent ID US20190083634A1\n",
      "\n",
      "\n",
      "29\n",
      "probability:  0.2991541956194405\n",
      "content:  The invention relates to a series of novel compounds containing acryloyl group. In particular, the invention relates to acryloyl group-containing compounds shown in formula (1) and the preparation method thereof, and application of the compounds shown in formula (1) and pharmaceutically acceptable salts thereof in preparation of medicaments for treating, regulating and/or preventing diseases related to physiological conditions related to CRM1 protein.\n",
      "\n",
      "patent ID US11286247B2\n",
      "\n",
      "\n",
      "30\n",
      "probability:  0.2969961706185794\n",
      "content:  The present invention relates to Rucaparib and/or Talazoparib and/or Veliparib and/or Olaparib, and/or AZD 2461, or a pharmaceutically acceptable salt thereof, for use in the treatment of impaired skin wound healing in a subject, an in vitro method for identifying a subject suffering from impaired skin wound healing to be responsive to the treatment with Rucaparib and/or Talazoparib and/or Veliparib and/or Olaparib and/or AZD 2461, and kits and kits-of-part related thereto.\n",
      "patent ID US11638709B2\n",
      "\n",
      "\n",
      "31\n",
      "probability:  0.2862172075842267\n",
      "content:  A method of enhancing the growth of an animal is provided. The method includes causing the animal to ingest or absorb an effective amount of a preparation obtainable by a process including, bringing a tyrosinate moiety into contact with an Fe(III)-containing substance, optionally wherein the tyrosinate moiety is tyrosine and it is brought into contact with the Fe(III)-containing substance in the presence of a base, or wherein the tyrosinate moiety is a tyrosine salt and it is brought into contact with an Fe(III)-containing substance. Methods for inhibiting, reducing, or preventing biofilm formation or buildup on a surface; the treatment of, inhibition of growth of, and inhibition of colonization by, bacteria, both in biological and non-biological environments; disinfecting surfaces, potentiating the effects of antibiotics and other anti-microbial agents, and increasing the sensitivity of bacteria and other microorganisms, to anti-microbial agents are also provided.\n",
      "patent ID US20170044197A1\n",
      "\n",
      "\n",
      "32\n",
      "probability:  0.27776408868185465\n",
      "content:  Provided herein are a gastric inhibitory polypeptide receptor (GIPR) antibody and its fusion protein with glucagon-like peptide-1 (GLP-1), and a pharmaceutical composition thereof. Also provided herein is a method for using the GIPR antibody and its fusion protein with GLP-1 to treat, prevent or improve one or more symptoms of non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, type 2 diabetes or obesity.\n",
      "patent ID US20210061904A1\n",
      "\n",
      "\n",
      "33\n",
      "probability:  0.26261793252383947\n",
      "content:  Provided herein are poly-1-hydroxymethylethylene hydroxymethyl formal (PHF)-based drug delivery systems. Also disclosed are methods of making antibody-drug conjugates and methods of treatment using these conjugates.\n",
      "patent ID US20200155693A1\n",
      "\n",
      "\n",
      "34\n",
      "probability:  0.23051852661949737\n",
      "content:  The present invention relates to pyrimidine compounds that are useful as anti-proliferative agents. More particularly, the present invention relates to oxygen linked and substituted pyrimidine compounds, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of proliferative disorders. These compounds may be useful as medicaments for the treatment of a number of proliferative disorders including tumors and cancers as well as other disorders or conditions related to or associated with kinases.\n",
      "patent ID US8415338B2\n",
      "\n",
      "\n",
      "35\n",
      "probability:  0.2287568535236206\n",
      "content:  The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.\n",
      "patent ID US9890219B2\n",
      "\n",
      "\n",
      "36\n",
      "probability:  0.22406652431584795\n",
      "content:  A nucleic acid for coding a chimeric antigen receptor protein expressed on the surface of a human T lymphocyte. The chimeric antigen receptor protein comprises an extracellular binding domain, a transmembrane domain and an intracellular signal domain that are orderly connected. The extracellular binding domain comprises a single-chain antibody scFv (EGFR) for specific recognition of 287th to 302th amino acid epitopes of a human epidermal growth factor receptor (EGFR).\n",
      "patent ID US20170159025A1\n",
      "\n",
      "\n",
      "37\n",
      "probability:  0.21388625061801844\n",
      "content:  The present technology provides methods of preventing or treating vitiligo. The methods provide administering aromatic-cationic peptides in effective amounts to treat or ameliorate melanocyte degeneration such as that found in a subject suffering from, or predisposed to vitiligo. In some embodiments, the methods comprise administering to a subject suffering from, or at risk for vitiligo, an effective amount of an aromatic-cationic peptide to subjects in need thereof. The present technology relates to the treatment, amelioration or prevention of vitiligo in mammals or mammalian cells, through administration of therapeutically effective amounts of aromatic-cationic peptides, such as D-Arg-2′,6′-Dmt-Lys-Phe-NH2.\n",
      "patent ID US20160296589A1\n",
      "\n",
      "\n",
      "38\n",
      "probability:  0.192795283803782\n",
      "content:  Provided are an in vitro fibrosis model, a method of preparing the in vitro model, and use of the in vitro model, the in vitro model including a cell cluster differentiated from mesenchymal cells, wherein the cell cluster exhibits pathological characteristics of fibrosis.\n",
      "patent ID US20200071674A1\n",
      "\n",
      "\n",
      "39\n",
      "probability:  0.17777380779433183\n",
      "content:  The syringe systems disclosed herein provide in part devices for allowing patients with compromised joint strength to more easily administer medicine. Certain exemplary syringe embodiments include a handle forming a handgrip, a syringe barrel that magnifies the dosage marks located on an inner barrel, and a tip cap slidably engageable with the syringe barrel for shielding a needle.\n",
      "patent ID US20180071462A1\n",
      "\n",
      "\n",
      "40\n",
      "probability:  0.17470364602061847\n",
      "content:  Disclosed are molecularly targeted and activated kinase inhibitors and use thereof. Specifically, a compound represented by the following formula A or a pharmaceutically acceptable salt thereof, wherein X is a polar and a non-polar uncharged amino acid such as alanine, proline or threonine; A is alanine; N is asparagine; PABC is —NH-phenyl-CH2-O—; and Z is a drug molecule; wherein the lactobionic acid residue, XAN and PABC are linked to each other by an amide bond; PABC is bonded to Z by an ester group, i.e., —OC(O)—.\n",
      "\n",
      "Lacto-XAN-PABC-Z  (Formula A)\n",
      "patent ID US20200140485A1\n",
      "\n",
      "\n",
      "41\n",
      "probability:  0.15816926726143704\n",
      "content:  Disclosed is a Tat protein, the amino acid sequence of which is shown as SEQ NO: 1, SEQ NO: 2, SEQ NO: 3 and SEQ NO: 4. The Tat protein of the present invention has been studied and developed and can be a Latent infection of HIV-1 activating potential drug.\n",
      "patent ID US9790255B2\n",
      "\n",
      "\n",
      "42\n",
      "probability:  0.1101691866083962\n",
      "content:  A series of pyrazolo[3,4-d]pyrimidine derivatives that are substituted at the 4-position by a diaza monocyclic, bridged bicyclic or spirocyclic moiety, are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases and malaria; and organ and cell transplant rejection.\n",
      "patent ID USRE48622E1\n",
      "\n",
      "\n",
      "43\n",
      "probability:  0.10105071914184964\n",
      "content:  Provided are an FGFR4 inhibitor having the structure of formula (I), and a preparation method therefor and the use thereof. The compound has a very strong inhibitory effect on FGFR4 kinase activity and has a very high selectivity, and can be widely used in the preparation of a drug for treating cancers, especially prostate cancer, liver cancer, pancreatic cancer, esophageal carcinomas, gastric cancer, lung cancer, breast cancer, ovarian carcinomas, colon cancer, skin cancer, glioblastomas or rhabdomyosarcomas, and is expected to be developed into a new generation of FGFR4 inhibitor drugs.\n",
      "\n",
      "patent ID US11555036B2\n",
      "\n",
      "\n",
      "44\n",
      "probability:  0.09821342011423717\n",
      "content:  The disclosure is directed to ABC294640, as free base or as salts thereof, in preparing medicines for treating coronavirus infection or preventing diseases caused by coronavirus infection, and a medicine for preventing coronavirus infection or preventing diseases caused by coronavirus infection.\n",
      "patent ID US20220031682A1\n",
      "\n",
      "\n",
      "45\n",
      "probability:  0.060795252766926176\n",
      "content:  The present invention provides the use of certain compounds to treat peripheral or central pain syndrome and other disorders associated with the T-type calcium ion channels.\n",
      "patent ID US20110053960A1\n",
      "\n",
      "\n",
      "46\n",
      "probability:  0.05830922274831354\n",
      "content:  Provided is a cassette unit suitable for use with an auto-injector having an electrically powered drive unit. The cassette unit comprises a cassette unit housing defining a housing cavity, a rearward entrance to the cavity and a forward needle projection aperture. The housing cavity may receive a syringe. Axially movable within the barrel of the syringe for forward movement into contact with the syringe plunger, there is a plunger slaving part defining a circumferential wall arranged for frictional sliding relationship with the inner wall of the barrel, a rear drive-receiving face and a front plunger-contacting face. In capping relationship with the rearward entrance of the cassette unit housing there is an end-cap defining a drive rod-receiving opening for receipt of a drive rod for providing forward axial drive to the plunger slaving part. In a pre-use configuration, the plunger slaving part is shaped for releasable engagement with the end-cap.\n",
      "patent ID US20150202374A1\n",
      "\n",
      "\n",
      "47\n",
      "probability:  0.048523522512312275\n",
      "content:  The present disclosure discloses substituted quinazoline compounds having a capacity to cross the blood-brain barrier. The compound has the structural formula represented by formula (I):\n",
      "\n",
      "The quinazoline compounds, derivatives and pharmaceutically acceptable salts thereof of the present disclosure have the ability to cross the blood-brain barrier and are capable of acting as a drug characteristic of a protein kinase inhibitor, in particular for the expression of a protein through a epidermal growth factor receptor and can be used to treat or prevent disorders associated with abnormal protein kinase activity, such as cancer, cancer with brain metastases, cancer with meningeal metastases, and neuroprotective diseases, and the like.\n",
      "patent ID US20200308140A1\n",
      "\n",
      "\n",
      "48\n",
      "probability:  0.014725801524123864\n",
      "content:  A series of substituted 5,6,7,8-tetrahydroimidazo[1,2-α]pyridine derivatives, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.\n",
      "patent ID US20160289228A1\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\n"
     ]
    }
   ],
   "source": [
    "results_LB = sim_res(sent_uncons_LB[0], sent_uncons_LB)\n",
    "results_LB = np.abs(results_LB)\n",
    "result_sort_LB = np.argsort(results_LB)[::-1]\n",
    "print('Original: ',test_data['abstract'][0])\n",
    "m = 0\n",
    "for i in result_sort_LB[1:]:\n",
    "    print('\\n')\n",
    "    print(m)\n",
    "    m = m+1\n",
    "    print('probability: ', results_LB[i])\n",
    "    print('content: ', test_data['abstract'][i])\n",
    "    print('patent ID', test_data['ID'][i])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 43,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "100%|██████████| 50/50 [00:00<00:00, 46655.22it/s]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Original:  The present invention relates to a “one-pot process” for preparing intermediate of antibody-drug conjugate. The preparation process provided by the present invention is simple in operation, and needs no such steps like concentration, washing and filtration of the intermediate reaction liquid, disposal of the organic waste liquid, and packaging and storage of the intermediate. The entire reaction system comprises only one separation and purification treatment, saving costs for labor, equipment, venues, raw materials, etc., and greatly reducing the pollution to the environment. In addition, the “one-pot process” for preparing intermediate of antibody-drug conjugate of the present invention produces the intermediate of antibody-drug conjugate with higher yield. The “one-pot process” for preparing intermediate of antibody-drug conjugate provided by the present invention is more suitable for scale-up production.\n",
      "\n",
      "\n",
      "0\n",
      "probability:  0.6730880824061102\n",
      "content:  The invention provides methods and compositions for wound treatment and/or blood clot formation, e.g., arresting the flow of blood from an open wound. The methods and compositions provide for promoting and accelerating wound healing and optionally provide for inhibition of microbial infection and/or a local analgesic effect.\n",
      "patent ID US20150079152A1\n",
      "\n",
      "\n",
      "1\n",
      "probability:  0.6214961311829537\n",
      "content:  A sterilized cyanoacrylate adhesive composition including a cyanoacrylate composition and a cure speed enhancer, wherein said sterilized cyanoacrylate adhesive composition does not cure upon sterilization, and wherein the composition when cured to form a film on a patient's tissue has water vapor transmission rate from about 950 to about 3000 g/m2/day.\n",
      "patent ID US20140186289A1\n",
      "\n",
      "\n",
      "2\n",
      "probability:  0.60190256144198\n",
      "content:  The present invention relates to a pharmaceutical composition comprising brivaracetam as active ingredient, the invention relates specifically to a prolonged release formulation.\n",
      "patent ID US20120040006A1\n",
      "\n",
      "\n",
      "3\n",
      "probability:  0.5816318795726599\n",
      "content:  The present invention provides a method for generating a functionally modifying antibody to an ion channel comprising immunizing a host with a cyclic peptide comprising at least part of an extracellular sequence of said ion channel.\n",
      "patent ID US9234037B2\n",
      "\n",
      "\n",
      "4\n",
      "probability:  0.5527885053725924\n",
      "content:  A sensor can be manufactured by printing a working electrode onto a substrate using aerosol jet printing. Sensing chemistry (e.g., enzyme-based ink that including detection chemistry) also can be printed onto the working electrode using aerosol jet printing. A reference electrode also can be printed on the substrate at a position spaced along the substrate from the working electrode. In certain examples, the substrate can be positioned within a lumen of a skin piercing member of a sensor module.\n",
      "patent ID US20170095187A1\n",
      "\n",
      "\n",
      "5\n",
      "probability:  0.5410098337255396\n",
      "content:  Crystalline forms of seletalisib, designated as Form B and Form F and characterized herein, being selective inhibitors of PI3 kinase enzymes, in particular of the human PBKδ isoform, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.\n",
      "patent ID US11059820B2\n",
      "\n",
      "\n",
      "6\n",
      "probability:  0.5407492795816004\n",
      "content:  The present invention is directed to a method of controlling and directing cells, for example to stimulate an immune response, inhibit an immune response, direct tissue regeneration or prevent tissue damage for therapeutic activity through the use of heterodimerically-tethered bispecific protein complex of formula A-X:Y-B. Component A may present X on the surface of a cell, may bind a protein (including a marker) expressed on the surface of an effector cell, or A-X is expressed on the surface of an effector cell, whilst B is specific to an epitope on target cell or tissue of interest. X:Y is a heterodimeric-tether which is formed by a binding interaction between X and Y, which together with A and B assists and effects the controlling and directing of the selected cells.\n",
      "patent ID US10954312B2\n",
      "\n",
      "\n",
      "7\n",
      "probability:  0.5377584663090885\n",
      "content:  A medical barrier includes a sheet of unsintered substantially unexpanded hydrophilic polytetraflouroethylene (PTFE) polymer material having a density in a range of about 1.2 gm/cc to about 2.3 gm/cc, and preferably in the range of about 1.45 gm/cc to about 1.55 gm/cc, and having at least one textured surface. In accordance with one embodiment, the sheet has one textured surface and one substantially smooth surface, and has substantially uniform strength in all directions.\n",
      "patent ID US7296998B2\n",
      "\n",
      "\n",
      "8\n",
      "probability:  0.5333277194864661\n",
      "content:  The present invention relates to a method for quantitatively measuring the muscular relaxing activity of a neurotoxin. Specifically, based on an extent of the activity of muscular relaxation of a neurotoxin from bacteria of Clostridium, the present invention relates to a method for quantification of the efficacy (potential and/or diffusion reaction) of a neurotoxin comprising the following steps of: (a) administering a neurotoxin to the hind leg muscle of one of hind legs of a non-human mammal; (b) applying electric stimulus to said non-human mammal; (c) measuring a compound muscle action potential (CMAP) by contraction of said hind leg muscle to which the neurotoxin is administered and/or of the hind leg muscle of the other hind leg to which the neurotoxin is not administered; and (d) taking amplitude data from the compound muscle action potential (CMAP) obtained by the measurement in step (c) and analyzing an extent of a decrease in amplitude to thereby quantify the efficacy of the muscular relaxing activity by the neurotoxin. In contrast to the mouse LD50 currently used as a potential unit of a botulinum toxin which is measurable at a level of only several units, the quantification method of the efficacy of a neurotoxin of the present invention allows for measurement at a level of as low as 0.01 to 1 unit and hence is a method with a high sensitivity, reproducibility and accuracy.\n",
      "patent ID US20090297452A1\n",
      "\n",
      "\n",
      "9\n",
      "probability:  0.5138887279386296\n",
      "content:  A sublingual tablet pharmaceutical composition containing edaravone and (+)-2-borneol, and a preparation method thereof. The sublingual tablet pharmaceutical composition includes edaravone, (+)-2-camphanol, an excipient, a filler, a binder, a disintegrant, and a lubricant. The excipient is selected from one or more of mannitol, lactose, dextran, cysteine, glycine, copovidone, and beta-cyclodextrin.\n",
      "patent ID US20200297697A1\n",
      "\n",
      "\n",
      "10\n",
      "probability:  0.5094530532358438\n",
      "content:  A urological medical device having a retrieval string is provided. The retrieval string has a proximal end connected the device and an opposed distal end. In a first embodiment, the retrieval string is configured in an initial confined form which, following a period of deployment in a patient's bladder, changes to an unconfined form in which the distal end of the retrieval string is extendible into the urethra to enable extraction of the device from bladder by pulling the retrieval string. The device may include a bioerodible component which permits the retrieval string to take the unconfined form following degradation of the bioerodible component in vivo. In another embodiment, the retrieval string includes a ferromagnetic material, which can be magnetically captured to facilitate removal of the device from the bladder. The ferromagnetic retrieval string may be buoyant in urine.\n",
      "patent ID US20150088150A1\n",
      "\n",
      "\n",
      "11\n",
      "probability:  0.5072931153939811\n",
      "content:  The present disclosure provides novel neutralizing antibodies against SARS-COV-2, and the antigen binding fragments thereof. Pharmaceutical composition and kits comprising the same, and the uses thereof are also provided.\n",
      "patent ID US20220073594A1\n",
      "\n",
      "\n",
      "12\n",
      "probability:  0.4880442541963808\n",
      "content:  Formulations and methods of manufacturing formulations for use in colonic evacuation are disclosed herein, in an embodiment, a solid dosage formulation includes an intra-granular fraction intermingled with an extra-granular fraction, wherein the intra-granular fraction includes granules comprising at least one osmotic evacuant agent, at least one antacid, and a first pharmaceutically acceptable excipient component, and wherein the extra-granular fraction includes one or more organic acids, a non-metallic lubricating element, and a second pharmaceutically acceptable excipient component.\n",
      "patent ID US11058671B2\n",
      "\n",
      "\n",
      "13\n",
      "probability:  0.4827542678442135\n",
      "content:  The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) for treatment of pulmonary conditions (e.g. asthma). The HPCs/HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPCs/HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.\n",
      "patent ID US20190142818A1\n",
      "\n",
      "\n",
      "14\n",
      "probability:  0.4797523602250734\n",
      "content:  The invention is directed to a method for preventing cerebral damage in patients having symptoms of atherosclerosis of arteries supplying the brain by administering to the patient a therapeutically effective amount of a composition comprising eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) or a combination thereof.\n",
      "patent ID US8729124B2\n",
      "\n",
      "\n",
      "15\n",
      "probability:  0.4775031364817903\n",
      "content:  The present disclosure provides improved compositions comprising rifabutin, clarithromycin, and clofazimine for use in the treatment of Inflammatory Bowel Diseases. In one instance, the compositions may comprise a formulation of rifabutin, clarithromycin, and clofazimine in a single dosage form, such as a capsule, tablet, etc., with one or more specific excipients.\n",
      "patent ID US9072763B2\n",
      "\n",
      "\n",
      "16\n",
      "probability:  0.4759839004589312\n",
      "content:  A macrocycle represented by formula (I) and a pharmaceutical composition comprising the macrocycle, or a crystalline form, pharmaceutically acceptable salt, hydrate or solvent compound, stereoisomer, prodrug, or isotopic variant of the macrocycle. The macrocycle and the composition thereof inhibit a protein kinase.\n",
      "patent ID US10543199B2\n",
      "\n",
      "\n",
      "17\n",
      "probability:  0.4544810962945733\n",
      "content:  The present invention relates to Rucaparib and/or Talazoparib and/or Veliparib and/or Olaparib, and/or AZD 2461, or a pharmaceutically acceptable salt thereof, for use in the treatment of impaired skin wound healing in a subject, an in vitro method for identifying a subject suffering from impaired skin wound healing to be responsive to the treatment with Rucaparib and/or Talazoparib and/or Veliparib and/or Olaparib and/or AZD 2461, and kits and kits-of-part related thereto.\n",
      "patent ID US11638709B2\n",
      "\n",
      "\n",
      "18\n",
      "probability:  0.44688853132703654\n",
      "content:  Disclosed in the present invention are a new thiazole compound, particularly a compound represented by formula (I), a pharmaceutical composition thereof and applications thereof in the preparation of drugs for the treatment of diseases related to herpes simplex viruses.\n",
      "patent ID US10647710B2\n",
      "\n",
      "\n",
      "19\n",
      "probability:  0.44654434779854785\n",
      "content:  The present disclosure relates to a sensor including an elongated member including at least a portion that is electrically conductive. The elongated member includes a sensing layer adapted to react with a material desired to be sensed. An insulating layer surrounds the elongated member. The insulating layer defines at least one access opening for allowing the material desired to be sensed to enter an interior region defined between the elongated member and the insulating layer. The insulating layer has an inner transverse cross-sectional profile that is different from an outer transverse cross-sectional profile of the elongated member. The difference in transverse cross-sectional profiles between the elongated member and the insulating layer provides channels at the interior region defined between the insulating layer and the elongated member. The channels extend generally along the length of the elongated member and are sized to allow the material desired to be sensed to move along the length of the sensor.\n",
      "patent ID US8702932B2\n",
      "\n",
      "\n",
      "20\n",
      "probability:  0.43938674108625925\n",
      "content:  A preconcentrate comprising a fatty acid oil mixture that contains EPA and DHA, preferably in the form of ethyl ester or triglyceride, and at least one surfactant. The preconcentrates are capable of forming a self-nanoemulsifying drug delivery system, a self-microemulsifying drug delivery system or a self-emulsifying drug delivery system (SNEDDS, SMEDDS or SEDDS) in an aqueous solution. The application is also directed to a food supplement preconcentrate.\n",
      "patent ID US11612579B2\n",
      "\n",
      "\n",
      "21\n",
      "probability:  0.4362829329897514\n",
      "content:  The present invention pertains to the field of chemical medicine, particularly to 4-substituted coumarin derivatives and preparation methods and applications thereof. The invention provides 4-substituted coumarin derivatives with a structural formula as shown in Formula I. The invention also provides preparation methods and applications for the above 4-substituted coumarin derivatives. The compounds provided in the invention have strong anti-tumor activity with IC50 for plural tumor cell lines between 0.01-5 nM, and it also performs better to inhibit microtubule polymerization and has diversified biological activities and low toxicity, providing new options for drug-sensitive and drug-resistant tumor cells.\n",
      "\n",
      "patent ID US20180282315A1\n",
      "\n",
      "\n",
      "22\n",
      "probability:  0.4096266503424193\n",
      "content:  This disclosure provides modified recombinant retroviruses comprisings containing a 2A-peptide or peptide-like coding sequence operably linked to a heterologous polynucleotide. The disclosure further relates to cells and vector expressing or comprising such vectors and methods of using such modified vectors in the treatment of disease and disorders.\n",
      "patent ID US11279949B2\n",
      "\n",
      "\n",
      "23\n",
      "probability:  0.39935291213425794\n",
      "content:  The present invention relates to a recombinant fusion protein comprising a fragment of the cardioprotective protein neuregulin-1 (NRG-1) fused to a monoclonal antibody (mAb) backbone and to a method of treating a disease or condition in a subject in need thereof comprising administering a therapeutically effective amount of the recombinant fusion protein or the pharmaceutical composition comprising the recombinant fusion protein disclosed herein.\n",
      "patent ID US11718652B2\n",
      "\n",
      "\n",
      "24\n",
      "probability:  0.39884559619927523\n",
      "content:  Provided are an in vitro fibrosis model, a method of preparing the in vitro model, and use of the in vitro model, the in vitro model including a cell cluster differentiated from mesenchymal cells, wherein the cell cluster exhibits pathological characteristics of fibrosis.\n",
      "patent ID US20200071674A1\n",
      "\n",
      "\n",
      "25\n",
      "probability:  0.3890873930747391\n",
      "content:  An anti-B7-H4 antibody, an antigen-binding fragment thereof and pharmaceutical use thereof. A chimeric antibody and a humanized antibody comprising a CDR region of the anti-B7-H4 antibody, a pharmaceutical composition comprising the anti-B7-H4 antibody and the antigen-binding fragment thereof, and use thereof as an anti-cancer medicament. A humanized anti-B7-H4 antibody and use thereof in the preparation of a medicament for treating diseases or conditions mediated by B7-H4.\n",
      "patent ID US11472882B2\n",
      "\n",
      "\n",
      "26\n",
      "probability:  0.38653001196309333\n",
      "content:  A method of enhancing the growth of an animal is provided. The method includes causing the animal to ingest or absorb an effective amount of a preparation obtainable by a process including, bringing a tyrosinate moiety into contact with an Fe(III)-containing substance, optionally wherein the tyrosinate moiety is tyrosine and it is brought into contact with the Fe(III)-containing substance in the presence of a base, or wherein the tyrosinate moiety is a tyrosine salt and it is brought into contact with an Fe(III)-containing substance. Methods for inhibiting, reducing, or preventing biofilm formation or buildup on a surface; the treatment of, inhibition of growth of, and inhibition of colonization by, bacteria, both in biological and non-biological environments; disinfecting surfaces, potentiating the effects of antibiotics and other anti-microbial agents, and increasing the sensitivity of bacteria and other microorganisms, to anti-microbial agents are also provided.\n",
      "patent ID US20170044197A1\n",
      "\n",
      "\n",
      "27\n",
      "probability:  0.3602600085330179\n",
      "content:  The present invention relates to methods for the treatment of a bone fracture or bone defect. The invention discloses the effective use of an anti-gremlin-1 antibody to accelerate the healing and bridging of bone tissue in segmental gap defects; and demonstrates that inhibitors of gremlin-1 activity may provide improved therapies for treating or preventing fracture non-union.\n",
      "patent ID US20210107973A1\n",
      "\n",
      "\n",
      "28\n",
      "probability:  0.34798907277588764\n",
      "content:  The present invention relates to pyrimidine compounds that are useful as anti-proliferative agents. More particularly, the present invention relates to oxygen linked and substituted pyrimidine compounds, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of proliferative disorders. These compounds may be useful as medicaments for the treatment of a number of proliferative disorders including tumours and cancers as well as other disorders or conditions related to or associated with kinases.\n",
      "patent ID US20090075999A1\n",
      "\n",
      "\n",
      "29\n",
      "probability:  0.34725316878325985\n",
      "content:  The invention relates to a series of novel compounds containing acryloyl group. In particular, the invention relates to acryloyl group-containing compounds shown in formula (1) and the preparation method thereof, and application of the compounds shown in formula (1) and pharmaceutically acceptable salts thereof in preparation of medicaments for treating, regulating and/or preventing diseases related to physiological conditions related to CRM1 protein.\n",
      "\n",
      "patent ID US11286247B2\n",
      "\n",
      "\n",
      "30\n",
      "probability:  0.3470083703745951\n",
      "content:  Provided herein are poly-1-hydroxymethylethylene hydroxymethyl formal (PHF)-based drug delivery systems. Also disclosed are methods of making antibodydrug conjugates and methods of treatment using these conjugates.\n",
      "patent ID US20190083634A1\n",
      "\n",
      "\n",
      "31\n",
      "probability:  0.34348599804006125\n",
      "content:  Provided are a recombinant bispecific antibody against CTLA-4 and PDL-1, a nucleic acid molecule for encoding the antibody, a vector and a host cell comprising the nucleic acid molecule, and a method for preparing the antibody. Also provided are a pharmaceutical composition comprising the bispecific antibody, and usage of the bispecific antibody in preparation of the pharmaceutical composition.\n",
      "patent ID US11421029B2\n",
      "\n",
      "\n",
      "32\n",
      "probability:  0.33346879038144217\n",
      "content:  The present invention relates to pyrimidine compounds that are useful as anti-proliferative agents. More particularly, the present invention relates to oxygen linked and substituted pyrimidine compounds, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of proliferative disorders. These compounds may be useful as medicaments for the treatment of a number of proliferative disorders including tumors and cancers as well as other disorders or conditions related to or associated with kinases.\n",
      "patent ID US8415338B2\n",
      "\n",
      "\n",
      "33\n",
      "probability:  0.32723972103198823\n",
      "content:  Provided herein are poly-1-hydroxymethylethylene hydroxymethyl formal (PHF)-based drug delivery systems. Also disclosed are methods of making antibody-drug conjugates and methods of treatment using these conjugates.\n",
      "patent ID US20200155693A1\n",
      "\n",
      "\n",
      "34\n",
      "probability:  0.31091284671887215\n",
      "content:  Provided herein are a gastric inhibitory polypeptide receptor (GIPR) antibody and its fusion protein with glucagon-like peptide-1 (GLP-1), and a pharmaceutical composition thereof. Also provided herein is a method for using the GIPR antibody and its fusion protein with GLP-1 to treat, prevent or improve one or more symptoms of non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, type 2 diabetes or obesity.\n",
      "patent ID US20210061904A1\n",
      "\n",
      "\n",
      "35\n",
      "probability:  0.3058624563775315\n",
      "content:  Methods, devices, and medicaments that include a drug are provided for use in the treatment of the prostate by locally administering the drug into the bladder of a patient to achieve a sustained concentration of the drug in urine in the bladder sufficient to produce a therapeutic concentration of the drug in the prostate. The drug may be delivered into the bladder from an intravesical drug delivery device inserted into the bladder, wherein the device continuously releases the drug into the urine in the bladder over an extended period of hours or days.\n",
      "patent ID US20150165177A1\n",
      "\n",
      "\n",
      "36\n",
      "probability:  0.29490896177060083\n",
      "content:  A nucleic acid for coding a chimeric antigen receptor protein expressed on the surface of a human T lymphocyte. The chimeric antigen receptor protein comprises an extracellular binding domain, a transmembrane domain and an intracellular signal domain that are orderly connected. The extracellular binding domain comprises a single-chain antibody scFv (EGFR) for specific recognition of 287th to 302th amino acid epitopes of a human epidermal growth factor receptor (EGFR).\n",
      "patent ID US20170159025A1\n",
      "\n",
      "\n",
      "37\n",
      "probability:  0.28558399942771345\n",
      "content:  Disclosed is a Tat protein, the amino acid sequence of which is shown as SEQ NO: 1, SEQ NO: 2, SEQ NO: 3 and SEQ NO: 4. The Tat protein of the present invention has been studied and developed and can be a Latent infection of HIV-1 activating potential drug.\n",
      "patent ID US9790255B2\n",
      "\n",
      "\n",
      "38\n",
      "probability:  0.27048379581831183\n",
      "content:  The present technology provides methods of preventing or treating vitiligo. The methods provide administering aromatic-cationic peptides in effective amounts to treat or ameliorate melanocyte degeneration such as that found in a subject suffering from, or predisposed to vitiligo. In some embodiments, the methods comprise administering to a subject suffering from, or at risk for vitiligo, an effective amount of an aromatic-cationic peptide to subjects in need thereof. The present technology relates to the treatment, amelioration or prevention of vitiligo in mammals or mammalian cells, through administration of therapeutically effective amounts of aromatic-cationic peptides, such as D-Arg-2′,6′-Dmt-Lys-Phe-NH2.\n",
      "patent ID US20160296589A1\n",
      "\n",
      "\n",
      "39\n",
      "probability:  0.24053029378531565\n",
      "content:  Disclosed are molecularly targeted and activated kinase inhibitors and use thereof. Specifically, a compound represented by the following formula A or a pharmaceutically acceptable salt thereof, wherein X is a polar and a non-polar uncharged amino acid such as alanine, proline or threonine; A is alanine; N is asparagine; PABC is —NH-phenyl-CH2-O—; and Z is a drug molecule; wherein the lactobionic acid residue, XAN and PABC are linked to each other by an amide bond; PABC is bonded to Z by an ester group, i.e., —OC(O)—.\n",
      "\n",
      "Lacto-XAN-PABC-Z  (Formula A)\n",
      "patent ID US20200140485A1\n",
      "\n",
      "\n",
      "40\n",
      "probability:  0.23774309089996967\n",
      "content:  The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.\n",
      "patent ID US9890219B2\n",
      "\n",
      "\n",
      "41\n",
      "probability:  0.2300356708715283\n",
      "content:  The syringe systems disclosed herein provide in part devices for allowing patients with compromised joint strength to more easily administer medicine. Certain exemplary syringe embodiments include a handle forming a handgrip, a syringe barrel that magnifies the dosage marks located on an inner barrel, and a tip cap slidably engageable with the syringe barrel for shielding a needle.\n",
      "patent ID US20180071462A1\n",
      "\n",
      "\n",
      "42\n",
      "probability:  0.16717429065960923\n",
      "content:  A series of pyrazolo[3,4-d]pyrimidine derivatives that are substituted at the 4-position by a diaza monocyclic, bridged bicyclic or spirocyclic moiety, are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases and malaria; and organ and cell transplant rejection.\n",
      "patent ID USRE48622E1\n",
      "\n",
      "\n",
      "43\n",
      "probability:  0.15701057027434331\n",
      "content:  Provided are an FGFR4 inhibitor having the structure of formula (I), and a preparation method therefor and the use thereof. The compound has a very strong inhibitory effect on FGFR4 kinase activity and has a very high selectivity, and can be widely used in the preparation of a drug for treating cancers, especially prostate cancer, liver cancer, pancreatic cancer, esophageal carcinomas, gastric cancer, lung cancer, breast cancer, ovarian carcinomas, colon cancer, skin cancer, glioblastomas or rhabdomyosarcomas, and is expected to be developed into a new generation of FGFR4 inhibitor drugs.\n",
      "\n",
      "patent ID US11555036B2\n",
      "\n",
      "\n",
      "44\n",
      "probability:  0.1459562176918733\n",
      "content:  A series of substituted 5,6,7,8-tetrahydroimidazo[1,2-α]pyridine derivatives, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.\n",
      "patent ID US20160289228A1\n",
      "\n",
      "\n",
      "45\n",
      "probability:  0.11389736082786209\n",
      "content:  The present invention provides the use of certain compounds to treat peripheral or central pain syndrome and other disorders associated with the T-type calcium ion channels.\n",
      "patent ID US20110053960A1\n",
      "\n",
      "\n",
      "46\n",
      "probability:  0.0728822419619831\n",
      "content:  The present disclosure discloses substituted quinazoline compounds having a capacity to cross the blood-brain barrier. The compound has the structural formula represented by formula (I):\n",
      "\n",
      "The quinazoline compounds, derivatives and pharmaceutically acceptable salts thereof of the present disclosure have the ability to cross the blood-brain barrier and are capable of acting as a drug characteristic of a protein kinase inhibitor, in particular for the expression of a protein through a epidermal growth factor receptor and can be used to treat or prevent disorders associated with abnormal protein kinase activity, such as cancer, cancer with brain metastases, cancer with meningeal metastases, and neuroprotective diseases, and the like.\n",
      "patent ID US20200308140A1\n",
      "\n",
      "\n",
      "47\n",
      "probability:  0.022859972235273338\n",
      "content:  The disclosure is directed to ABC294640, as free base or as salts thereof, in preparing medicines for treating coronavirus infection or preventing diseases caused by coronavirus infection, and a medicine for preventing coronavirus infection or preventing diseases caused by coronavirus infection.\n",
      "patent ID US20220031682A1\n",
      "\n",
      "\n",
      "48\n",
      "probability:  0.006326683514124909\n",
      "content:  Provided is a cassette unit suitable for use with an auto-injector having an electrically powered drive unit. The cassette unit comprises a cassette unit housing defining a housing cavity, a rearward entrance to the cavity and a forward needle projection aperture. The housing cavity may receive a syringe. Axially movable within the barrel of the syringe for forward movement into contact with the syringe plunger, there is a plunger slaving part defining a circumferential wall arranged for frictional sliding relationship with the inner wall of the barrel, a rear drive-receiving face and a front plunger-contacting face. In capping relationship with the rearward entrance of the cassette unit housing there is an end-cap defining a drive rod-receiving opening for receipt of a drive rod for providing forward axial drive to the plunger slaving part. In a pre-use configuration, the plunger slaving part is shaped for releasable engagement with the end-cap.\n",
      "patent ID US20150202374A1\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\n"
     ]
    }
   ],
   "source": [
    "results_CG = sim_res(sent_uncons_CG[0], sent_uncons_CG)\n",
    "results_CG = np.abs(results_CG)\n",
    "result_sort_CG = np.argsort(results_CG)[::-1]\n",
    "print('Original: ',test_data['abstract'][0])\n",
    "m = 0\n",
    "for i in result_sort_CG[1:]:\n",
    "    print('\\n')\n",
    "    print(m)\n",
    "    m = m+1\n",
    "    print('probability: ', results_CG[i])\n",
    "    print('content: ', test_data['abstract'][i])\n",
    "    print('patent ID', test_data['ID'][i])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 42,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<matplotlib.legend.Legend at 0x16794a9df40>"
      ]
     },
     "execution_count": 42,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "iVBORw0KGgoAAAANSUhEUgAABNYAAAIyCAYAAAAHcEcRAAAAOXRFWHRTb2Z0d2FyZQBNYXRwbG90bGliIHZlcnNpb24zLjguMCwgaHR0cHM6Ly9tYXRwbG90bGliLm9yZy81sbWrAAAACXBIWXMAAA9hAAAPYQGoP6dpAAEAAElEQVR4nOzdd3hT5dsH8G+SpmnTTemilJa9ZW9ZMqqyBZlSKFtAlAoCDkpRQEUQUPihyHIBgoDK3jJkKYJsWQVltIzukXneP/omku6madb5fq6rF+TknOfcJyenPblzP88jEQRBABEREREREREREZWI1NYBEBEREREREREROSIm1oiIiIiIiIiIiMzAxBoREREREREREZEZmFgjIiIiIiIiIiIyAxNrREREREREREREZmBijYiIiIiIiIiIyAxMrBEREREREREREZmBiTUiIiIiIiIiIiIzMLFGRERERERERERkBibWiCxAIpFg1qxZtg6jUBERERg+fLhF28x93GvWrIFEIkF8fLxF99OhQwd06NDBom06ovj4eEgkEqxZs8Yu9j1r1ixIJBKr7D/3e+DQoUOQSCTYtGmTVfY/fPhwREREWGVfREREVDKGe5JHjx7ZOpQyxfsR67P1PTA5BibWyOncuHEDY8eORZUqVeDm5gZvb2+0adMGixcvRlZWlq3Ds7jz58+jX79+CA8Ph5ubG0JDQ9GlSxd89tlntg6tzNy7dw+zZs3C2bNnLdqu4Y+k4UculyMiIgKTJk1CcnKyRfdlKTt27LD7pO7TyurcWYI9x0ZE5EwMX8QZftzc3FCjRg1MnDgRCQkJJW5v7ty52Lp1q+UDzcf333+PRYsWFXv9iIgIdO/e3WTZ08culUpRoUIFdO3aFYcOHcqzvU6nw+rVq9GhQweUK1cOCoUCERERiI6Oxu+//17KoyFzbdmyBS+88ALKly8PV1dXVKhQAf3798eBAwdsHZpVleW1p9fr8fXXX6NLly4oX7485HI5AgMD0bVrV3z55ZdQqVRlsl8ic7jYOgAiS9q+fTtefvllKBQKREVFoV69elCr1Th69CimTp2Kixcv4ssvv7T4frOysuDiYv3L6bfffkPHjh1RqVIljB49GsHBwfjnn39w4sQJLF68GK+99ppx3atXr0IqtWwu3VrHvWfPHpPH9+7dQ1xcHCIiItCwYUOL7+9///sfPD09kZGRgf379+Ozzz7DmTNncPToUYvvq7R27NiBpUuX2iS59u6772L69Okl2sbcc5f7PVAWCottxYoV0Ov1ZR4DEZGYzJ49G5UrV0Z2djaOHj2K//3vf9ixYwcuXLgApVJZ7Hbmzp2Lfv36oXfv3mUX7P/7/vvvceHCBbzxxhulaqdLly6IioqCIAi4desWli1bhueeew7bt2/HCy+8ACDnPuull17Crl270K5dO7z99tsoV64c4uPj8cMPP2Dt2rW4c+cOKlasaIEjo+IQBAEjRozAmjVr0KhRI8TExCA4OBj379/Hli1b0KlTJxw7dgytW7cuk/3b2/1IWV17WVlZ6NOnD3bv3o3WrVtjypQpCAoKwpMnT/Drr79i/PjxOHnyJFauXGnR/RaXOffA5NyYWCOncevWLQwcOBDh4eE4cOAAQkJCjM9NmDAB169fx/bt28tk325ubmXSblHmzJkDHx8fnD59Gr6+vibPJSYmmjxWKBQW339ZH3dmZiaUSiVcXV3LdD+59evXD+XLlwcAjB07FgMHDsSGDRtw6tQpNG/e3Kqx2DMXF5cyT6za6j2Qm1wut+n+iYic0QsvvICmTZsCAEaNGgV/f38sXLgQP/30EwYNGmTj6MpWjRo18Morrxgf9+nTB8888wwWLVpkTKxNnToVu3btwqeffponkRcbG4tPP/3UmiGbJTs7G66urhb/ctdWFixYgDVr1uCNN97AwoULTboDvvPOO/jmm2/K9N5ILPcjkydPxu7du7Fo0SK8/vrrJs+9+eabuHbtGvbu3VtoG1qtFnq9vkzuIa1xD0yOxTl+wxEB+Pjjj5Geno6VK1eaJNUMqlWrZvKLWavV4v3330fVqlWNZfVvv/12nrLi33//HZGRkShfvjzc3d1RuXJljBgxwmSd3GONGboUXr9+HcOHD4evry98fHwQHR2NzMzMPLF9++23aNKkCdzd3VGuXDkMHDgQ//zzT5HHfOPGDdStWzdPUg0AAgMDTR7nHmPN0A3j6NGjmDRpEgICAuDr64uxY8dCrVYjOTkZUVFR8PPzg5+fH9566y0IglDocefnp59+Qrdu3VChQgUoFApUrVoV77//PnQ6ncl6HTp0QL169fDHH3+gXbt2UCqVePvtt43PGcbXOnToEJo1awYAiI6ONnalWLNmDWJjYyGXy/Hw4cM8cYwZMwa+vr7Izs4uNN78tG3bFkDO6/20kydP4vnnn4ePjw+USiXat2+PY8eOmayTlpaGN954AxEREVAoFAgMDESXLl1w5swZ4zoFjX9X1Nhyw4cPx9KlSwGYdisxWL9+PZo0aQIvLy94e3ujfv36WLx4cZHHm5ycjOHDh8PHxwe+vr4YNmxYvl1h8xtfYu/evXj22Wfh6+sLT09P1KxZ03geCzt3huMtznvgaTqdDm+//TaCg4Ph4eGBnj175rl2ivP6FhVbfmOaZGRk4M0330RYWBgUCgVq1qyJTz75JN/rZOLEidi6dSvq1asHhUKBunXrYteuXXliIiISs+eeew5AzpelAPDJJ5+gdevW8Pf3h7u7O5o0aZJnbE2JRIKMjAysXbvW+Lv76d/5d+/exYgRIxAUFGT8/btq1SqTNgzjdv7www+YM2cOKlasCDc3N3Tq1AnXr183rtehQwds374dt2/fNu7LUuNd1a9fH+XLlzce+7///osvvvgCXbp0ybc6TiaTYcqUKUVWq3322WeoW7culEol/Pz80LRpU3z//fcm69y9excjR4403qtVrlwZr776KtRqtXGdmzdv4uWXX0a5cuWgVCrRsmXLPF9YG17H9evX491330VoaCiUSiVSU1MBWO6+qTCPHj1C//794e3tDX9/f7z++usm937t27dHgwYN8t22Zs2aiIyMLLDtrKwszJs3D7Vq1cInn3yS7xhbQ4cONfkStiSvW1HvPyDv/Yhh29zdiAsal3fjxo2oU6cO3NzcUK9ePWzZsiXfexxrXXv5+eeff/DVV1/h+eefz5NUM6hevTrGjx+f53g/+eQTLFq0yPj57tKlS1Cr1Zg5cyaaNGkCHx8feHh4oG3btjh48GCedktzDwwU7zOd4X730qVL6NixI5RKJUJDQ/Hxxx8X+dqQ/WKalZzGL7/8gipVqhS79HrUqFFYu3Yt+vXrhzfffBMnT57EvHnzcPnyZWzZsgVATtVX165dERAQgOnTp8PX1xfx8fHYvHlzsfbRv39/VK5cGfPmzcOZM2fw1VdfITAwEB999JFxnTlz5uC9995D//79MWrUKDx8+BCfffYZ2rVrhz///DPfpJlBeHg4jh8/jgsXLqBevXrFiim31157DcHBwYiLi8OJEyfw5ZdfwtfXF7/99hsqVaqEuXPnYseOHZg/fz7q1auHqKioErW/Zs0aeHp6IiYmBp6enjhw4ABmzpyJ1NRUzJ8/32Tdx48f44UXXsDAgQPxyiuvICgoKE97tWvXxuzZszFz5kyMGTPGmPRq3bo1nn32WcyePRsbNmzAxIkTjduo1Wps2rQJffv2NavKzjAZg5+fn3HZgQMH8MILL6BJkyaIjY2FVCrF6tWr8dxzz+HIkSPGm6px48Zh06ZNmDhxIurUqYPHjx/j6NGjuHz5Mho3blziWJ42duxY3Lt3D3v37sU333xj8tzevXsxaNAgdOrUyfh+u3z5Mo4dO1bgTQqQ08WhV69eOHr0KMaNG4fatWtjy5YtGDZsWJHxXLx4Ed27d8czzzyD2bNnQ6FQ4Pr168ab5sLOnUFx3gNPmzNnDiQSCaZNm4bExEQsWrQInTt3xtmzZ+Hu7l5kzAbFie1pgiCgZ8+eOHjwIEaOHImGDRti9+7dmDp1Ku7evZuniuDo0aPYvHkzxo8fDy8vLyxZsgR9+/bFnTt34O/vX+w4iYicmeELLMPvxcWLF6Nnz54YMmQI1Go11q9fj5dffhnbtm1Dt27dAADffPMNRo0ahebNm2PMmDEAgKpVqwIAEhIS0LJlS+MXHAEBAdi5cydGjhyJ1NTUPAmrDz/8EFKpFFOmTEFKSgo+/vhjDBkyBCdPngSQU5GUkpKCf//91/h73tPT0yLHnpSUhKSkJFSrVg0AsHPnTmi1WgwdOtTsNlesWIFJkyahX79+xgTTX3/9hZMnT2Lw4MEAcoZBaN68OZKTkzFmzBjUqlULd+/exaZNm5CZmQlXV1ckJCSgdevWyMzMxKRJk+Dv74+1a9eiZ8+e2LRpE/r06WOy3/fffx+urq6YMmUKVCoVXF1drXbf1L9/f0RERGDevHk4ceIElixZgqSkJHz99dcAchJfo0ePznPvfPr0afz999949913C2z76NGjePLkCd544w3IZLIiYynp61bU+6+0tm/fjgEDBqB+/fqYN28ekpKSMHLkSISGhuZZ19rX3tN27twJnU5nUtFZXKtXr0Z2djbGjBkDhUKBcuXKITU1FV999RUGDRqE0aNHIy0tDStXrkRkZCROnTplHP6jNPfAQMk+0yUlJeH555/HSy+9hP79+2PTpk2YNm0a6tevb6xYJQcjEDmBlJQUAYDQq1evYq1/9uxZAYAwatQok+VTpkwRAAgHDhwQBEEQtmzZIgAQTp8+XWh7AITY2Fjj49jYWAGAMGLECJP1+vTpI/j7+xsfx8fHCzKZTJgzZ47JeufPnxdcXFzyLM9tz549gkwmE2QymdCqVSvhrbfeEnbv3i2o1eo864aHhwvDhg0zPl69erUAQIiMjBT0er1xeatWrQSJRCKMGzfOuEyr1QoVK1YU2rdvX+hxG9q8deuWcVlmZmaeWMaOHSsolUohOzvbuKx9+/YCAGH58uV51m/fvr3Jvk+fPi0AEFavXp1n3VatWgktWrQwWbZ582YBgHDw4ME86z/NcN6uXr0qPHz4UIiPjxdWrVoluLu7CwEBAUJGRoYgCIKg1+uF6tWr53ntMjMzhcqVKwtdunQxLvPx8REmTJhQ6H5zn5uCjvvWrVt5jnvChAlCfr/KX3/9dcHb21vQarWF7ju3rVu3CgCEjz/+2LhMq9UKbdu2zbNvw+tl8OmnnwoAhIcPHxbYfmHnriTvgYMHDwoAhNDQUCE1NdW4/IcffhAACIsXLzYuK+7rW1hsw4YNE8LDw42PDa/TBx98YLJev379BIlEIly/ft24DIDg6upqsuzcuXMCAOGzzz7Lsy8iImdnuF/Yt2+f8PDhQ+Gff/4R1q9fL/j7+wvu7u7Cv//+KwhC3nsItVot1KtXT3juuedMlnt4eOT7e37kyJFCSEiI8OjRI5PlAwcOFHx8fIztG/6m1K5dW1CpVMb1Fi9eLAAQzp8/b1zWrVs3k78HRQkPDxe6detmsgyAMHLkSOHhw4dCYmKicPLkSaFTp04CAGHBggWCIAjC5MmTBQDCn3/+Wex95darVy+hbt26ha4TFRUlSKXSfO91Dfc4b7zxhgBAOHLkiPG5tLQ0oXLlykJERISg0+kEQfjvdaxSpYrJubP0fVN+DPckPXv2NFk+fvx4AYBw7tw5QRAEITk5WXBzcxOmTZtmst6kSZMEDw8PIT09vcB9GN4PW7ZsKVZMJX3divP+y30/Ytg29z1ufveM9evXFypWrCikpaUZlx06dEgAkOc9ba1rLz+G9/7Zs2dNlqtUKuHhw4fGn6fbNhyvt7e3kJiYaLKdVqs1eV0FQRCSkpKEoKAgk89qpbkHLslnOsP97tdff21ybMHBwULfvn0LfF3IvrErKDkFQ4m5l5dXsdbfsWMHACAmJsZk+ZtvvgkAxhJtwzcL27Ztg0ajKXFc48aNM3nctm1bPH782Bjv5s2bodfr0b9/fzx69Mj4ExwcjOrVq+dbovy0Ll264Pjx4+jZsyfOnTuHjz/+GJGRkQgNDcXPP/9crBhHjhxpUsrcokULCIKAkSNHGpfJZDI0bdoUN2/eLO6hGz1dNZSWloZHjx6hbdu2yMzMxJUrV0zWVSgUiI6OLvE+nhYVFYWTJ0+adNv87rvvEBYWhvbt2xerjZo1ayIgIAAREREYMWIEqlWrhp07dxoHUj579iyuXbuGwYMH4/Hjx8bzlpGRgU6dOuHw4cPGgWV9fX1x8uRJ3Lt3r1THVVK+vr7IyMgocvyJ3Hbs2AEXFxe8+uqrxmUymcxkIozC9gnkdP81d2Ddkr4HoqKiTK77fv36ISQkxHiNl5UdO3ZAJpNh0qRJJsvffPNNCIKAnTt3mizv3Lmz8VtcAHjmmWfg7e1t1jVFROQsOnfujICAAISFhWHgwIHw9PTEli1bjBU0T99DJCUlISUlBW3bti1Wt0BBEPDjjz+iR48eEATB5D4rMjISKSkpedqJjo42GY/JUL1cFr+rV65ciYCAAAQGBqJFixY4duwYYmJijJU8Jb23zY+vry/+/fdfnD59Ot/n9Xo9tm7dih49ehjHunua4f5wx44daN68OZ599lnjc56enhgzZgzi4+Nx6dIlk+2GDRtmcu6sed80YcIEk8eG+xfDfYGPjw969eqFdevWGYdu0Ol02LBhA3r37g0PD48C2zbn80ZJXreyfP/du3cP58+fR1RUlEmVZfv27VG/fv0861v72nua4XXOXQ26Y8cOBAQEGH/Cw8PzbNu3b18EBASYLJPJZMbXVa/X48mTJ9BqtWjatKlJHKW5By7pZzpPT0+TijxXV1c0b96c94UOjIk1cgre3t4AchI3xXH79m1IpVJjub1BcHAwfH19cfv2bQA5f2z69u2LuLg4lC9fHr169cLq1auLPb1zpUqVTB4buhImJSUBAK5duwZBEFC9enWTPxQBAQG4fPlyngkI8tOsWTNs3rwZSUlJOHXqFGbMmIG0tDT069cvzx/s4sTo4+MDAAgLC8uz3BB3SVy8eBF9+vSBj48PvL29ERAQYPxDkpKSYrJuaGhoqQcYHTBgABQKBb777jvjPrZt24YhQ4bkOxZCfn788Ufs3bsX33//PVq2bInExESTG4xr164ByLlxzH3evvrqK6hUKuOxffzxx7hw4QLCwsLQvHlzzJo1yyp/NMePH48aNWrghRdeQMWKFTFixIhijel1+/ZthISE5LmZqVmzZpHbDhgwAG3atMGoUaMQFBSEgQMH4ocffihRkq2k74Hq1aubPJZIJKhWrZqx+25ZuX37NipUqJDn5rp27drG55+W+zoDcn4fmHNNERE5i6VLl2Lv3r04ePAgLl26hJs3b5qMcbVt2za0bNkSbm5uKFeuHAICAvC///0vz/1Dfh4+fIjk5GR8+eWXef5WG77AyX2fVdR9myX16tULe/fuxb59+3Dy5Ek8evQICxYsMA7yX9J72/xMmzYNnp6eaN68OapXr44JEyaYjGn28OFDpKamFjmcyO3bt/O9Dyjob17lypVNHlvzvin3fUHVqlUhlUpN7guioqJw584dHDlyBACwb98+JCQkFNnt1pzPGyV53cry/WfYV+7PPgUts/a19zTDvVV6errJ8jZt2mDv3r3Yu3cvunbtmu+2ud97BmvXrsUzzzwDNzc3+Pv7IyAgANu3bzc5ntLcA5f0M13FihXzfC7hfaFj4xhr5BS8vb1RoUIFXLhwoUTbFZVokUgk2LRpE06cOIFffvkFu3fvxogRI7BgwQKcOHGiyHE1Chp/wfANmV6vh0Qiwc6dO/NdtyTjdri6uqJZs2Zo1qwZatSogejoaGzcuBGxsbFmxZjfckPcxZWcnIz27dvD29sbs2fPRtWqVeHm5oYzZ85g2rRpeRIuJRkTqyB+fn7o3r07vvvuO8ycORObNm2CSqUq0TgN7dq1M84K2qNHD9SvXx9DhgzBH3/8AalUaox7/vz5xnEZcjOcu/79+6Nt27bYsmUL9uzZg/nz5+Ojjz7C5s2bjWMoFPQ+1Ol0xRrDIz+BgYE4e/Ysdu/ejZ07d2Lnzp1YvXo1oqKisHbtWrPaLIq7uzsOHz6MgwcPYvv27di1axc2bNiA5557Dnv27CnWsVjiPZBbWby+JVXU7wIiIjFq3rx5vpVSAHDkyBH07NkT7dq1w7JlyxASEgK5XI7Vq1fnGXw/P4a/1a+88kqBYyQ988wzJo+t+bu6YsWK6Ny5c4HP16pVCwBw/vz5Au81ilK7dm1cvXoV27Ztw65du/Djjz9i2bJlmDlzJuLi4sxqszhy/y239H1TSeR3DxAZGYmgoCB8++23aNeuHb799lsEBwcXej4A03PSu3fvEsdSFHPef4Xd45jLFtfe0wyv84ULF0wmmggICDCeo2+//TbfbfO7j/z2228xfPhw9O7dG1OnTkVgYCBkMhnmzZuXZ2Iyc5X0Mx3vC50PE2vkNLp3744vv/wSx48fR6tWrQpdNzw8HHq9HteuXTN+awTkDLSZnJycp7S4ZcuWaNmyJebMmYPvv/8eQ4YMwfr16zFq1KhSxVy1alUIgoDKlSujRo0apWrraYab1Pv371usTXMcOnQIjx8/xubNm9GuXTvjcsOMV+YqKiEaFRWFXr164fTp0/juu+/QqFEj1K1b16x9eXp6IjY2FtHR0fjhhx8wcOBAY5c+b2/vIm/CACAkJATjx4/H+PHjkZiYiMaNG2POnDnGG0Q/P798Zxy6ffs2qlSpUmjbhb0Wrq6u6NGjB3r06AG9Xo/x48fjiy++wHvvvZfvt5NAzrWxf/9+pKenm9wEXL16tcjjBACpVIpOnTqhU6dOWLhwIebOnYt33nkHBw8eROfOnYtdNVhchm/BDQRBwPXr101u2Ir7+pYktvDwcOzbtw9paWkmVWuG7s35dU8gIqLi+/HHH+Hm5obdu3dDoVAYl69evTrPuvn9/g4ICICXlxd0Ol2x/lYXl6X/jhXkhRdegEwmw7fffluqCQw8PDwwYMAADBgwAGq1Gi+99BLmzJmDGTNmICAgAN7e3kV+MR0eHp7vfUBx/+ZZ+r6pMNeuXTOpWrp+/Tr0er3JrJcymQyDBw/GmjVr8NFHH2Hr1q0YPXp0kV+2Pfvss/Dz88O6devw9ttvF7l+aV+34jBUteW+z8ldDWfYV+5ZRvNbZutrz/De/+677zBkyJASb5/bpk2bUKVKFWzevNkk3tzFB6W5By6rz3TkONgVlJzGW2+9BQ8PD4waNQoJCQl5nr9x4wYWL14MAHjxxRcBAIsWLTJZZ+HChQBgnO0mKSkpzzcHhm/aitsdtDAvvfQSZDIZ4uLi8uxHEAQ8fvy40O0PHjyY7zcbhnEkilO6XJYMNxxPx6hWq7Fs2bJStWsY/yK/ZAmQ8we5fPny+Oijj/Drr7+aNavQ04YMGYKKFSsaZ9ds0qQJqlatik8++SRPmTqQUwIP5HxbmLtkPjAwEBUqVDB5/1StWhUnTpwwmdZ+27Zteabnzk9Br0Xu945UKjUmmwp777744ovQarX43//+Z1ym0+nw2WefFRnLkydP8izLfb0Ude5K6uuvvzbpkrFp0ybcv3/f5Oa7uK9vSWJ78cUXodPp8Pnnn5ss//TTTyGRSDijExFRKclkMkgkEpPKm/j4eGzdujXPuh4eHnl+d8tkMvTt2xc//vhjvokjw9/qkvLw8ChWd7jSCgsLw+jRo7Fnz558/wbr9XosWLAA//77b4Ft5L4XcHV1RZ06dSAIAjQaDaRSKXr37o1ffvkFv//+e57tDfdvL774Ik6dOoXjx48bn8vIyMCXX36JiIgI1KlTp9BjsfR9U2GWLl1q8tjw2uX+uzx06FAkJSVh7NixSE9PL9a9olKpxLRp03D58mVMmzYt33vwb7/9FqdOnQJQ+tetOMLDwyGTyXD48GGT5bnvtStUqIB69erh66+/NjkHv/76K86fP2+yrq2vvUqVKmHEiBHYuXNnnvssg5JUduX3eeTkyZMm5wUo3T1waT/TkeNjxRo5japVq+L777/HgAEDULt2bURFRaFevXpQq9X47bffsHHjRgwfPhwA0KBBAwwbNgxffvmlsbviqVOnsHbtWvTu3RsdO3YEkNMff9myZejTpw+qVq2KtLQ0rFixAt7e3sbkXGlj/uCDDzBjxgzEx8ejd+/e8PLywq1bt7BlyxaMGTMGU6ZMKXD71157DZmZmejTpw9q1aplPNYNGzYgIiKi1BMBlFbr1q3h5+eHYcOGYdKkSZBIJPjmm29KXeZctWpV+Pr6Yvny5fDy8oKHhwdatGhh/IZSLpdj4MCB+PzzzyGTyTBo0KBS7U8ul+P111/H1KlTsWvXLjz//PP46quv8MILL6Bu3bqIjo5GaGgo7t69i4MHD8Lb2xu//PIL0tLSULFiRfTr1w8NGjSAp6cn9u3bh9OnT2PBggXG9keNGoVNmzbh+eefR//+/XHjxg18++23JoPdF6RJkyYAgEmTJiEyMhIymQwDBw7EqFGj8OTJEzz33HOoWLEibt++jc8++wwNGzY0qdLMrUePHmjTpg2mT5+O+Ph41KlTB5s3by7Wh4jZs2fj8OHD6NatG8LDw5GYmIhly5ahYsWKxoF7izp3JVWuXDk8++yziI6ORkJCAhYtWoRq1aph9OjRxnWK+/qWJLYePXqgY8eOeOeddxAfH48GDRpgz549+Omnn/DGG28U69wREVHBunXrhoULF+L555/H4MGDkZiYiKVLl6JatWr466+/TNZt0qQJ9u3bh4ULF6JChQqoXLkyWrRogQ8//BAHDx5EixYtMHr0aNSpUwdPnjzBmTNnsG/fvny/ECpKkyZNsGHDBsTExKBZs2bw9PREjx49LHXYJhYsWIAbN25g0qRJ2Lx5M7p37w4/Pz/cuXMHGzduxJUrVzBw4MACt+/atSuCg4PRpk0bBAUF4fLly/j888/RrVs3Y7X13LlzsWfPHrRv3x5jxoxB7dq1cf/+fWzcuBFHjx6Fr68vpk+fjnXr1uGFF17ApEmTUK5cOaxduxa3bt3Cjz/+aBwXriBSqdSi902FuXXrFnr27Innn38ex48fx7fffovBgwebdCkEgEaNGqFevXrYuHEjateujcaNGxer/alTp+LixYtYsGABDh48iH79+iE4OBgPHjzA1q1bcerUKfz2228AUOrXrTh8fHzw8ssv47PPPoNEIkHVqlWxbdu2fMcwmzt3Lnr16oU2bdogOjoaSUlJ+Pzzz1GvXj2TZJs9XHuLFi3CrVu38Nprr2H9+vXo0aMHAgMD8ejRIxw7dgy//PJLsQsIunfvjs2bN6NPnz7o1q0bbt26heXLl6NOnTomx12ae+DSfqYjJ2CFmUeJrOrvv/8WRo8eLURERAiurq6Cl5eX0KZNG+Gzzz4TsrOzjetpNBohLi5OqFy5siCXy4WwsDBhxowZJuucOXNGGDRokFCpUiVBoVAIgYGBQvfu3YXff//dZJ8AhNjYWONjwxTMDx8+NFnPML38rVu3TJb/+OOPwrPPPit4eHgIHh4eQq1atYQJEyYIV69eLfRYd+7cKYwYMUKoVauW4OnpKbi6ugrVqlUTXnvtNSEhIcFk3fDwcJPpsA2x5J5evaDYhw0bJnh4eBR63Pkd37Fjx4SWLVsK7u7uQoUKFYS33npL2L17d56pwdu3b1/glPDt27cX2rdvb7Lsp59+EurUqSO4uLjkmQJbEATh1KlTAgCha9eu+baZn4KOXRAEISUlRfDx8TGJ488//xReeuklwd/fX1AoFEJ4eLjQv39/Yf/+/YIg5EydPXXqVKFBgwaCl5eX4OHhITRo0EBYtmxZnvYXLFgghIaGCgqFQmjTpo3w+++/5znu/KZO12q1wmuvvSYEBAQIEonEOPX3pk2bhK5duwqBgYGCq6urUKlSJWHs2LHC/fv3i3wdHj9+LAwdOlTw9vYWfHx8hKFDhwp//vlnkVON79+/X+jVq5dQoUIFwdXVVahQoYIwaNAg4e+//zZpv6BzV5L3gGF6+XXr1gkzZswQAgMDBXd3d6Fbt27C7du3zXp9C4st9/T2giAIaWlpwuTJk4UKFSoIcrlcqF69ujB//nxBr9ebrAdAmDBhQp6Ycl+TRERiUdA9SG4rV64UqlevLigUCqFWrVrC6tWr8/ztEQRBuHLlitCuXTvB3d1dAGDyuzUhIUGYMGGCEBYWJsjlciE4OFjo1KmT8OWXXxrXMfxN2bhxo0m7+f3dTU9PFwYPHiz4+voKAPL8bcgtPDxc6Natm8mygv4u5Eer1QpfffWV0LZtW8HHx0eQy+VCeHi4EB0dLfz555+FbvvFF18I7dq1M96nVK1aVZg6daqQkpJist7t27eFqKgoISAgQFAoFEKVKlWECRMmCCqVyrjOjRs3hH79+gm+vr6Cm5ub0Lx5c2Hbtm0m7RT0OhpY8r4pN8P74tKlS0K/fv0ELy8vwc/PT5g4caKQlZWV7zYff/yxAECYO3duke3nZrjPKleunODi4iKEhIQIAwYMEA4dOmSyXmlet/zef/ndjzx8+FDo27evoFQqBT8/P2Hs2LHChQsX8r0/Xr9+vVCrVi1BoVAI9erVE37++Wehb9++Qq1atUzWs9a1VxitViusXr1aeO6554yvc/ny5YVOnToJy5cvNzmvhtdq/vz5edrR6/XC3LlzhfDwcEGhUAiNGjUStm3blu9rae49sEFxPtMVdL+bXzzkOCSCwBHyiMj5nDt3Dg0bNsTXX39dqrFJiIiIiMj5LF68GJMnT0Z8fHy+s3fbo6FDh+L48eP5jpVmroYNGyIgIAB79+61WJtEYsMx1ojIKa1YsQKenp546aWXbB0KEREREdkRQRCwcuVKtG/f3mGSakDOxGSGmetLSqPRQKvVmiw7dOgQzp07hw4dOlggOiLx4hhrRORUfvnlF1y6dAlffvklJk6caByQnoiIiIjELSMjAz///DMOHjyI8+fP46effrJ1SMXy119/YevWrTh8+DCmTp1qVht3795F586d8corr6BChQq4cuUKli9fjuDgYIwbN87CEROJC7uCEpFTiYiIQEJCAiIjI/HNN98YB+clIiIiInGLj49H5cqV4evri/Hjx2POnDm2DqlYZs2ahc8++wzdunXDsmXL4OnpWeI2UlJSMGbMGBw7dgwPHz6Eh4cHOnXqhA8//JCTLhGVEhNrREREREREREREZuAYa0RERERERERERGZgYo2IiIiIiIiIiMgMnLwAgF6vx7179+Dl5QWJRGLrcIiIiMhBCIKAtLQ0VKhQAVIpv6+0R7zPIyIiInMU9z6PiTUA9+7dQ1hYmK3DICIiIgf1zz//oGLFirYOg/LB+zwiIiIqjaLu85hYA4yzBt66dQvlypWzcTRkaRqNBnv27EHXrl0hl8ttHQ5ZEM+tc+P5dV7OdG5TU1MRFhbGGYjtmOHc/PPPP/D29rZxNEREROQoinufx8QaYOwW4OXlxRsuJ6TRaKBUKuHt7e3wH+DIFM+tc+P5dV7OeG7ZxdB+Gc6Nt7c37/OIiIioxIq6z+NgIERERERERERERGZgYo2IiIiIiIiIiMgMTKwRERERERERERGZgWOsEREREZHo6XQ6aDQaW4dB5BTkcjlkMpmtwyAisgom1oiIiIhItARBwIMHD5CcnGzrUIiciq+vL4KDgzm5CxE5PSbWiIiIiEi0DEm1wMBAKJVKJgGISkkQBGRmZiIxMREAEBISYuOIiIjKFhNrRERERCRKOp3OmFTz9/e3dThETsPd3R0AkJiYiMDAQHYLJSKnxskLiIiIiEiUDGOqKZVKG0dC5HwM1xXHLiQiZ2e3ibWlS5ciIiICbm5uaNGiBU6dOlXguh06dIBEIsnz061bNytGTERERESOiN0/iSyP1xURiYVdJtY2bNiAmJgYxMbG4syZM2jQoAEiIyON/fRz27x5M+7fv2/8uXDhAmQyGV5++WUrR05ERERERERERGJhl4m1hQsXYvTo0YiOjkadOnWwfPlyKJVKrFq1Kt/1y5Urh+DgYOPP3r17oVQqmVgjIiIiIiIiIqIyY3eTF6jVavzxxx+YMWOGcZlUKkXnzp1x/PjxYrWxcuVKDBw4EB4eHvk+r1KpoFKpjI9TU1MB5PT/5xgAzsdwTnlunQ/PrXPj+XVeznRuneEYyPEU1cUuNjYWs2bNsk4wuUgkEmzZsgW9e/cu830NHz4cycnJ2Lp1q8XbjoiIwBtvvIE33njD4m0TEZFzsbvE2qNHj6DT6RAUFGSyPCgoCFeuXCly+1OnTuHChQtYuXJlgevMmzcPcXFxeZYfPHiQg9c6sb1799o6BCojPLfOjefXeTnDuc3MzLR1CCRC9+/fN/5/w4YNmDlzJq5evWpc5unpWaL21Go1XF1dLRYfERGRmNhdYq20Vq5cifr166N58+YFrjNjxgzExMQYH6empiIsLAwdO3bkVOtOSKPRYO/evejSpQvkcrmtwyEL4rl1bjy/zsuZzq2h6p3ImoKDg43/9/HxgUQiMS67ceMGxo4dixMnTiAjIwO1a9fGvHnz0LlzZ+M2ERERGDlyJK5du4atW7fipZdewpo1a7BixQrMnj0bjx8/RmRkJNq2bYvZs2cjOTnZuO1PP/2EuLg4XLp0CRUqVMCwYcPwzjvvwMXFBREREQCAPn36AADCw8MRHx+fJ/74+HhUrlwZ69atw5IlS3DmzBlUq1YNS5cuRfv27QEAOp0OY8aMwYEDB/DgwQNUqlQJ48ePx+uvvw4AmDVrFtauXQvgvwq+gwcPokOHDvjnn3/w5ptvYs+ePZBKpWjbti0WL15sjM9Q6fbss89iwYIFUKvVGDhwIBYtWgS5XI4OHTrg9u3bmDx5MiZPngwAEAShlGeNiIicld0l1sqXLw+ZTIaEhAST5QkJCSY3EfnJyMjA+vXrMXv27ELXUygUUCgUeZbL5XKHv8GngvH8Oi+eW+fG8+u8nOHcOnr8VLBMtbbE27jKpHCR5QxhrNXpodbpIZVI4CaXFdmu0tUyt+Xp6el48cUXMWfOHCgUCnz99dfo0aMHrl69ikqVKhnX++STTzBz5kzExsYCAI4dO4Zx48bho48+Qs+ePbFv3z689957Jm0fOXIEUVFRWLJkCdq2bYsbN25gzJgxAHK6n54+fRqBgYFYvXo1nn/+echkMhRm6tSpWLRoEerUqYOFCxeiR48euHXrFvz9/aHX61GxYkVs3LgR/v7++O233zBmzBiEhISgf//+mDJlCi5fvozU1FSsXr0aQM64yxqNBpGRkWjVqhWOHDkCFxcXfPDBB3j++efx119/GSvzDh48iJCQEBw8eBDXr1/HgAED0LBhQ4wePRqbN29GgwYNMGbMGIwePdoi54XI4aU9AH5fDTSNBrwK/1xOJDZ2l1hzdXVFkyZNsH//fuPYDHq9Hvv378fEiRML3Xbjxo1QqVR45ZVXrBApERERETmrOjN3l3ibpYMbo9szIQCA3RcTMOH7M2hRuRw2jG1lXOfZjw7iSYY6z7bxH3YzP9inNGjQAA0aNDA+fv/997Flyxb8/PPPJvfSzz33HN58803j43feeQcvvPACpkyZAgCoUaMGfvvtN2zbts24TlxcHKZPn45hw4YBAKpUqYL3338fb731FmJjYxEQEAAA8PX1LfILcQCYOHEi+vbtCwD43//+h127dmHlypV46623IJfLTYZuqVy5Mo4fP44ffvgB/fv3h6enJ9zd3aFSqUz29e2330Kv1+Orr74yVrKtXr0avr6+OHToELp27QoA8PPzw+effw6ZTIZatWqhW7du2L9/P0aPHo1y5cpBJpPBy8urWMdBJAppD4BfPwRqvsDEGlEudpdYA4CYmBgMGzYMTZs2RfPmzbFo0SJkZGQgOjoaABAVFYXQ0FDMmzfPZLuVK1eid+/e7M7ppMz55hgANBotVLqc7eVC4YP95sdS3yATERERlbX09HTMmjUL27dvx/3796HVapGVlYU7d+6YrNe0aVOTx1evXjV24TRo3ry5SWLt3LlzOHbsGObMmWNcptPpkJ2djczMzBKPVdyq1X8JRxcXFzRt2hSXL182Llu6dClWrVqFO3fuICsrC2q1Gg0bNiy0zXPnzuH69evw8vIyWZ6dnY0bN24YH9etW9ekoi4kJATnz58vUfxERESAnSbWBgwYgIcPH2LmzJl48OABGjZsiF27dhknNLhz5w6kUqnJNlevXsXRo0exZ88eW4RMVmDON8f/ccFbpw6YtaWlvkEmIiIix3FpdmSJt3GV/Xd/Glk3CJdmR0KaawbPo9M6ljq2wkyZMgV79+7FJ598gmrVqsHd3R39+vWDWm1aJefh4VHittPT0xEXF4eXXnopz3Nubm5mx5yf9evXY8qUKViwYAFatWoFLy8vzJ8/HydPniwyxiZNmuC7777L85yhog7I241bIpFAr9dbJngiZ5H2IOcHAO6fM/0XyKlcY/UakX0m1oCc0vCCun4eOnQoz7KaNWtyUFEiIiIisojSVqy7PDXemiXbLcqxY8cwfPhwY/VZenp6vhMI5FazZk2cPn3aZFnux40bN8bVq1dRrVq1AtuRy+XQ6XTFivXEiRNo164dAECr1eKPP/4w3v8fO3YMrVu3xvjx443rP11xBuQMIZN7X40bN8aGDRsQGBgIb2/vYsWRn/zaJhKd31fndP982i+T/vt/++lAxxnWjYnIDtltYo0ot+J+c/wwTYUL/6YAAFRaHWI2/gUAWNC3LtxcXeHvpcAzFX3KLE4iIiIiW6levTo2b96MHj16QCKR4L333itWJdZrr72Gdu3aGScROHDgAHbu3GkcpwwAZs6cie7du6NSpUro168fpFIpzp07hwsXLuCDDz4AkDPj6P79+9GmTRsoFAr4+fkVuM+lS5eievXqqF27Nj799FMkJSVhxIgRxuP4+uuvsXv3blSuXBnffPMNTp8+jcqVKxu3j4iIwO7du3H16lX4+/vDx8cHQ4YMwfz589GrVy/Mnj0bFStWxO3bt7F582a89dZbqFixYrFex4iICBw+fBgDBw6EQqFA+fLli7UdkVNpGp0zphqQU6n2yySgxxIg5P/HcWS1GhEAIO/XaER2SunqUqwfvQAo5LKcH5f/xs5QuEihkMug0wvFbovjqxEREZEjWbhwIfz8/NC6dWv06NEDkZGRaNy4cZHbtWnTBsuXL8fChQvRoEED7Nq1C5MnTzbp4hkZGYlt27Zhz549aNasGVq2bIlPP/0U4eHhxnUWLFiAvXv3IiwsDI0aNSp0nx9++CE+/PBDNGjQAEePHsXPP/9sTGCNHTsWL730EgYMGIAWLVrg8ePHJtVrADB69GjUrFkTTZs2RUBAAI4dOwalUonDhw+jUqVKeOmll1C7dm2MHDkS2dnZJapgmz17NuLj41G1alWTLqREouIVDFRomPNjSKaFNPhvGRNrRAAAicD+k0hNTYWPjw8ePXrEiQ+cwPl/U5CQmg0AUGl0mLDuTwDA5wPqw02hAAB0qBmQb/cMciwajQY7duzAiy++mGesFHJ8PL/Oy5nOreEeIiUlpVTdzqjsFHaOsrOzcevWLVSuXNniY4Q5g9GjR+PKlSs4cuSIRduNj49H5cqV8eeffxY5GQE5Ll5fTubeWeDL9sCYX3OSakQiUNz7PJbjkNNJU2mKXCdDpYOPkok1IiIiIoNPPvkEXbp0gYeHB3bu3Im1a9di2bJltg6LiOyBV3DOmGqsUiPKg4k1cio6vYAsddEDzaapNPBROnaVBBEREZElnTp1Ch9//DHS0tJQpUoVLFmyBKNGjbJ1WERkD7yCOVEBUQGYWCOnkp6tRXE6N6dmaYGCx9IlIiIiEp0ffvjBKvuJiIgAR6MhIiJnwb5w5FRSs4vuBgoAacVcj4iIiIiIiIioIEyskVMpbmItQ62FXs9vSomIiIiIiIjIfOwKSk4lJat4iTW9HkjL1nKcNSIryFRrzdpOo9FCpcvZXi5ISrSt0pV/3oiIiIiIqOzxkwc5DY1Oj0xV0RMXGKRkcQIDImuoM3N3KbZ2wVunDpR4q/gPu5Vin0RERERERMXDrqDkNFKLWa1mUNzqNiIiIiIiIiKi/LBijZxGcgkTZclZ6jKKhIiedml2ZKHPn/snGU/STa9HlVaHmI1/AQAW9K0LN1dX43O+HnI0qsRpfYmIiIiIyPZYsUZOIzmzZIkylUaPLHXxu44SkXmUri6F/ggCoJDLTH9cZMbtFS5Sk+f0QtFtEhGJ3aFDhyCRSJCcnGzRdocPH47evXtbtM2yNmvWLDRs2LBUbcTHx0MikeDs2bMAyu71JSIix8PEGjkFvV4wq2tnUgmTcURkWXq9gCxNyRLcKo0eWp2+jCIiImtYunQpIiIi4ObmhhYtWuDUqVOFrr9o0SLUrFkT7u7uCAsLw+TJk5GdnW2laO2PRCIp9GfWrFm2DtFiLJEUmzJlCvbv31+qNsLCwnD//n3Uq1evVO1YS+5EoCWtWbMGvr6+Fm+XiMhRMbFGTiElSwO9GZ+zmVgjsq1MjQ6CUPLtMlhtSuSwNmzYgJiYGMTGxuLMmTNo0KABIiMjkZiYmO/633//PaZPn47Y2FhcvnwZK1euxIYNG/D2229bOfJiSHsAHJyX828Zun//vvFn0aJF8Pb2Nlk2ZcqUMt2/o/H09IS/v3+p2pDJZAgODoaLi+WqotVq3ocSETkDJtbIKTwxM0H2JIM3NES2lKnSmred2rztiMj2Fi5ciNGjRyM6Ohp16tTB8uXLoVQqsWrVqnzX/+2339CmTRsMHjwYERER6Nq1KwYNGlRklZtNpD0Afv2wzBNrwcHBxh8fHx9IJBKTZZ6ensZ1//jjDzRt2hRKpRKtW7fG1atXTdr66aef0LhxY7i5uaFKlSqIi4uDVlv837F6vR7z5s1D5cqV4e7ujgYNGmDTpk3G53U6HUaOHGl8vmbNmli8eLFJG4cOHULz5s3h4eEBX19ftGnTBrdv38aaNWsQFxeHc+fOGavx1qxZk28cBbUB5K16M3RnnTt3LoKCguDr64vZs2dDq9Vi6tSpKFeuHCpWrIjVq1cbtymqAuzx48cYNGgQQkNDoVQqUb9+faxbt85knQ4dOmDixIl44403UL58eURG5j8GqSG+uLg4BAQEwNvbG+PGjTNJxO3atQvPPvssfH194e/vj+7du+PGjRvG5ytXrgwAaNSoESQSCTp06GB87quvvkLt2rXh5uaGWrVqYdmyZXmOc/PmzejYsSOUSiUaNGiA48ePG1/n6OhopKSkOGWFJBGROTgQDTmFJDMTZCqNHplqLcdkIrKRdDMTaxlmbkdEtqVWq/HHH39gxowZxmVSqRSdO3c2fnDPrXXr1vj2229x6tQpNG/eHDdv3sSOHTswdOjQfNdXqVRQqVTGx6mpqQAAjUYDjcZ02AiNRgNBEKDX66E3p/Q9N0GAFIBeEGBWKb0ZDHHnjt/w+J133sH8+fMREBCA8ePHY8SIEThy5AgA4MiRI4iKisKiRYvQtm1b3LhxA+PGjYMgCJg5c2a++xMEwfiaAcDcuXPx3XffYdmyZahevToOHz6MV155Bf7+/mjfvj20Wi1CQ0OxYcMG+Pv747fffsO4ceMQFBSE/v37Q6vVonfv3hg1ahS+++47qNVqnDp1CoIg4OWXX8b58+exe/du7NmzBwDg4+OT51gLa0Ov10P4/9Jow3aCIODAgQMIDQ3FoUOHcOzYMYwePRrHjh1Du3btcPz4cfzwww8YO3YsOnXqhIoVK5q8zk+/Xwz/z8zMROPGjTF16lR4e3sb36OVK1dG8+bNjbGuXbsW48aNM56D/N53giBg//79UCgUOHDgAOLj4zFy5EiUK1cOH3zwAQAgLS0Nb7zxBp555hmkp6cjNjYWffr0wZkzZyCVSnHixAm0bNkSe/bsQd26deHq6gq9Xo/vvvsOM2fOxJIlS9CoUSP8+eefGDt2LNzd3TFs2DCT983HH3+M6tWr491338WgQYPw999/o2XLlvj000+NFaRATkVgfsdheO01Gg1kMlme54mI7F3u+4aCMJtADk+j05s1vprB43Q1lOV4KRDZQqaZXTozVOwKSuSIHj16BJ1Oh6CgIJPlQUFBuHLlSr7bDB48GI8ePcKzzz4LQRCg1Woxbty4AruCzps3D3FxcXmW79mzB0ql0mSZi4sLgoODkZ6ebna3PElGAqQZOd1YZYkXoASQfesEdBnpAAC9RyAEj6BCWiid7OxsCIJgTCAaZGZmAgBmzJiBRo0aAQAmTpyIAQMGIDExEW5uboiNjcXrr7+OPn36AADKly+P6dOnY9asWXjjjTfy3Z9Go4FWq0VqaipUKhXmzZuHLVu2GJNHL730Eg4dOoSlS5ca9xsTE2PcvkePHjh8+DDWrVuH559/HklJSUhJSUHHjh0REBAAAMZ4NBoN5HI5JBKJ8dzllyAtrA1DnDqdziTJ6uvri/fffx9SqRT9+vXDxx9/jLS0NEyYMAEAMH78eHz00UfYu3cv+vbti/T0nPOZkZGB1NRU4+ublpYGqVQKLy8vjB492hhTVFQUtm/fju+++w61atUCkJMArFKlCt555x3jernP29PH/emnn0KpVCIsLMzYHXrKlCmQSqXo0qWLcf3AwEAsWrQI1apVw6lTp1CnTh24u7sDANzc3IyvXWpqKmJjYzF79mx07twZANC5c2e8+uqr+N///oc+ffoYj3P8+PFo27YtgJwx6lq1aoWzZ8+iRo0acP3/mboN7er1+nyPQ61WIysrC4cPHy5RFSQRkb0w/K4vCrMJ5PCSMtRmjdFk8DhDjbByyqJXJCKLY8UaERXl0KFDmDt3LpYtW4YWLVrg+vXreP311/H+++/jvffey7P+jBkzTBI5qampCAsLQ9euXeHt7W2ybnZ2Nv755x94enrCzc3NrPgkZ5ZBcvgjk2XKfdON/xfaTYPQYXruzSzGzc0NEokkz7EZkh4tW7Y0Ple1alUAOccdGBiIixcv4uTJk1i4cKFxO51Oh+zsbLi4uORJRAKAXC6Hi4sLvL29cfHiRWRmZuKll14yWUetVqNRo0bG/S5btgyrV6/GnTt3kJWVBbVajYYNG8Lb2xve3t4YNmwY+vbti86dO6Nz5854+eWXERISAgBQKBSQyWR5ju9pJW1DLpejXr16JgPwh4SEoG7duib78ff3R3p6Ory9vY3daz08PODt7W18bby8vODt7Q2dTod58+Zh48aNuHv3LtRqNVQqlfEYgZxEbrNmzQo9FkN8DRs2RHBwsHFZx44d8eabbyIlJQXh4eG4du0aYmNjcerUKTx69MhYMfbkyZN84wVykoK3bt3CpEmTTBKnWq0WPj4+Jts1b97cuF316tUB5HzA9Pb2LvA9l1t2djbc3d3Rrl07s68vIiJbyu9Lg/wwsUYO71F66cZJS8pQQ68XIJVKLBQRERWHIAhmj5WWpdFBpxcg43VL5FDKly8PmUyGhIQEk+UJCQkmSYSnvffeexg6dChGjRoFAKhfvz4yMjIwZswYvPPOO5BKTYcMVigUUCgUedqRy+WQy+Umy3Q6HSQSCaRSaZ52iq3ZCKDWizn/v38O+GUS0GMJENIAACDxCobE3LaLwRB37vgNjxUKhfH/T3fHk0qlSE9PR1xcXJ7EGJCTmMvvNTGMqyWVSo3f5G/fvh2hoaEm6xn2u379ekydOhULFixAq1at4OXlhfnz5+PkyZPG9tesWYPXX38du3btwg8//ID33nsPe/fuRcuWLSGRSPI9vtxK0oZEIoGrq6tJmwUtEwTB5P1h+H/uxx9//DGWLFmCRYsWoX79+vDw8MAbb7wBjUZj0qanp2eRx5LfMefeX69evRAeHo4VK1agQoUK0Ov1qFevHrRabb7xAf9VXqxYsQItWrQw2adMJjNZt7D3TUHvudykUikkEkm+1x4RkSMo7u8uJtbI4T3OUBW9UiF0egFJmWr4e+a9CSeispOp1pk9BJEgABlqLbzdeKNO5EhcXV3RpEkT7N+/H7179waQ041s//79mDhxYr7bZGZm5vkAb/igL5SmZN1SvIJzfp4W0gCo0NAm4ZRE48aNcfXqVVSrVs2s7evUqQOFQoE7d+6gffv2+a5z7NgxtG7dGuPHjzcue3qQfYNGjRqhUaNGmDFjBlq1aoXvv/8eLVu2hKurK3S64nX/L6gNazh27Bh69eqFV155BUDO+/rvv/9GnTp1zGrv3LlzyMrKMnbpPHHiBDw9PREWFobHjx/j6tWrWLFihbG75tGjR022N3TXfPq1CwoKQoUKFXDz5k0MGTLErLgMbRf3nBARiQETa+TQ0rI1UGlKPzjwo3Qm1oisrbTdOTNUTKwROaKYmBgMGzYMTZs2RfPmzbFo0SJkZGQgOjoaQM7YVKGhoZg3bx6AnDG5Fi5ciEaNGhm7gr733nvo0aMHB0QvpZkzZ6J79+6oVKkS+vXrB6lUinPnzuHChQvGQfIL4+XlhSlTpmDy5MnQ6/V49tlnkZKSgmPHjhm7Z1avXh1ff/01du/ejcqVK+Obb77B6dOnjbNW3rp1C19++SV69uyJChUq4OrVq7h27RqioqIAABEREbh16xbOnj2LihUrwsvLK09FYlFtWEP16tWxadMm/Pbbb/Dz88PChQuRkJBgdmJNrVZj5MiRePfddxEfH4/Y2FhMnDgRUqkUfn5+8Pf3x5dffomQkBDcuXMH06ebdjcODAyEu7s7du3ahYoVK8LNzQ0+Pj6Ii4vDpEmT4OPjg+effx4qlQq///47kpKSTLpQFyYiIgLp6enYv38/GjRoAKVSmW+3YSIisWBijRzaw7TSVasZPEpXoSa8LNIWERWPueOrGXCcNSLHNGDAADx8+BAzZ87EgwcP0LBhQ+zatcs4ocGdO3dMKtTeffddSCQSvPvuu7h79y4CAgLQo0cPzJkzx1aHUDCvYKD99LwVbHYqMjIS27Ztw+zZs/HRRx9BLpejVq1axm63xfH+++8jICAA8+bNw82bN+Hr64vGjRsbJ5cYO3Ys/vzzTwwYMAASiQSDBg3C+PHjsXPnTgA5XU6vXLmCtWvX4vHjxwgJCcGECRMwduxYAEDfvn2xefNmdOzYEcnJyVi9ejWGDx9uEkNRbVjDu+++i5s3byIyMhJKpRJjxoxB7969kZKSYlZ7nTp1QvXq1dGuXTuoVCoMGjQIs2bNAgBjF9tJkyahXr16qFmzJpYsWYIOHToYt3dxccGSJUswe/ZszJw5E23btsWhQ4cwatQoKJVKzJ8/H1OnToWHhwfq169f4GQV+WndujXGjRuHAQMG4PHjx4iNjTXGRkQkRhLBLmrobSs1NRU+Pj549OgR/P39bR0OlcDJm4+Rll3wh2uVRocJ6/4EAHw+oD7c8hlzxaBFlXLwYvWLQ9FoNNixYwdefPFFjt3hgP76NxmJqfknx4tz7fp7uqJRJb8yjZHKhjNdu4Z7iJSUlCIH8ibbKOwcZWdn49atW6hcuTIHVye7MXz4cCQnJ2Pr1q22DqVUeH0RkaMr7n1e2Y2kSlTGsjW6QpNqJWWp6jciKp70Ul6/pa14IyIiIiIiKi0m1shhWToRlsjEGpHVaHV6ZKpLN/CxSqOHWlv6MRaJiIiIiIjMxTHWyGElpmVbtL30bC2y1Dq4u3IgZKKylqGyzGxi6Sotyrm4WqQtIiIie7BmzRpbh0BERCXAijVySGqtHsmZGou3a+lkHRHlLzXbMtdvmoXaISIiIiIiMgcTa+SQEtOyURbTbrA7KJF1WGp8REuOs0hERERERFRSTKyRQyqrBFhKpgbZGst0USOigllq4gEm1oiIiIiIyJaYWCOHo9bqkZShLrP2E1LZHZSoLOn1AtJVlunCmanWQqcvg/JVIiIiIiKiYmBijRxOWXUDNUhIZXdQorKUodZCb6HJPAWB46wREREREZHtMLFGDqesE1+pWRpkqdkdlKispFq4+ya7gxIRERERka0wsUYORaXVITmz7LqBGrA7KFHZsXSFmaVmGCUiciaHDh2CRCJBcnKyrUOxC7NmzULDhg1L1UZ8fDwkEgnOnj0LgK8xERHlYGKNHEpiqqpMu4EaMLFGVHZSsyxbYWbp9oiIzKHT63D6wWnsuLkDpx+chk5fdtXvEomk0J9Zs2aV2b5twRJJsSlTpmD//v2laiMsLAz3799HvXr1StWOteROBFrSmjVr4Ovra/F2iYgckYutAyAqCWslvNKytchQaeGh4CVCZEmWnLjAIEOlhVanh4uM3xURkW3su70PH576EAmZCcZlQcogTG8+HZ3DO1t8f/fv3zf+f8OGDZg5cyauXr1qXObp6Ynff//d4vt1ZJ6envD09CxVGzKZDMHBwRaKKIdarYarq6tF2yQiIuvipxByGNkaHZIzrdfli1VrRJaXprLcxAUm7XKcNSKykX239yHmUIxJUg0AEjMTEXMoBvtu77P4PoODg40/Pj4+kEgkJsueTiD98ccfaNq0KZRKJVq3bm2SgAOAn376CY0bN4abmxuqVKmCuLg4aLUF/04dPnw4evfujblz5yIoKAi+vr6YPXs2tFotpk6dinLlyqFixYpYvXq1yXbnz5/Hc889B3d3d/j7+2PMmDFIT083Pn/o0CE0b94cHh4e8PX1RZs2bXD79m2sWbMGcXFxOHfunLEib82aNfnGVlAbQN6qN3OOo6gKsMePH2PQoEEIDQ2FUqlE/fr1sW7dOpN1OnTogIkTJ+KNN95A+fLlERkZWejrHBcXh4CAAHh7e2PcuHFQq/8bEmXXrl149tln4evrC39/f3Tv3h03btwwPl+5cmUAQKNGjSCRSNChQwfjc1999RVq164NNzc31KpVC8uWLctznJs3b0bHjh2hVCrRoEEDHD9+3Pg6R0dHIyUlxWmrJImISoKJNXIY1k50cXZQIstLzSqb5DjHWSMiW9Dpdfjw1IcQkHecCsOyj059VKbdQovyzjvvYMGCBfj999/h4uKCESNGGJ87cuQIoqKi8Prrr+PSpUv44osvsGbNGsyZM6fQNg8cOIB79+7h8OHDWLhwIWJjY9G9e3f4+fnh5MmTGDduHMaOHYt///0XAJCRkYHIyEj4+fnh9OnT2LhxI/bt24eJEycCALRaLXr37o327dvjr7/+wvHjxzFmzBhIJBIMGDAAb775JurWrYv79+/j/v37GDBgQJ6YCmvDUsdRlOzsbDRp0gTbt2/HhQsXMGbMGAwdOhSnTp0yWW/t2rVwdXXFsWPHsHz58gLb279/Py5fvoxDhw5h3bp12Lx5M+Li4ozPZ2RkICYmBr///jv2798PqVSKPn36QP//32AZ9rtv3z7cv38fmzdvBgB89913mDlzJubMmYPLly9j7ty5eO+997B27VqT/b/zzjuYMmUKzp49ixo1amDQoEHQarVo3bo1Fi1aBG9vb+M5mTJlSrFeIyIiZ8R+buQwrJ3oylBpka7SwpPdQYksJqWMEmtl1S4RUWHOJJ7JU6n2NAECHmQ+wJnEM2gW3MyKkf1nzpw5aN++PQBg+vTp6NatG7Kzs+Hm5oa4uDhMnz4dw4YNAwBUqVIF77//Pt566y3ExsYW2Ga5cuWwZMkSSKVS1KxZEx9//DEyMzPx9ttvAwBmzJiBDz/8EEePHsXAgQPx/fffIzs7G19//TU8PDwAAJ9//jl69OiBjz76CHK5HCkpKejevTuqVq0KAKhdu7Zxf56ennBxcSm0G2ZqamqhbVjiOIoSGhpqkmB67bXXsHv3bvzwww9o3ry5cXn16tXx8ccfF9meq6srVq1aBaVSibp162L27NmYOnUq3n//fUilUvTt29dk/VWrViEgIACXLl1CvXr1EBAQAADw9/c3ee1iY2OxYMECvPTSSwByKtsMiVXDewHIGZeuW7duAIC4uDjUrVsX169fR61atUwqJYmIxI4Va+QQstS6Mqt0KQy7gxJZVllVlnECAyKyhYeZDy26Xll45plnjP8PCQkBACQmJgIAzp07h9mzZxvHH/P09MTo0aNx//59ZGZmFthm3bp1IZX+9zEiKCgI9evXNz6WyWTw9/c37ufy5cto0KCBMakGAG3atIFer8fVq1dRrlw5DB8+HJGRkejRowcWL15sMo5ccZjTRkmPoyg6nQ7vv/8+6tevj3LlysHT0xO7d+/GnTt3TNZr0qRJsdpr0KABlEql8XGrVq2Qnp6Of/75BwBw7do1DBo0CFWqVIG3tzciIiIAIM/+npaRkYEbN25g5MiRJuf9gw8+MOlGChT+3iEiov8wsUYOwVYJLibWiCxHo9MjU1U23aGyNTpka2zX1YqIxClAGWDR9cqCXC43/t/QLdLQVTA9PR1xcXE4e/as8ef8+fO4du0a3NzcitWmod38lulLMKjm6tWrcfz4cbRu3RobNmxAjRo1cOLEiWJvb04blj6O+fPnY/HixZg2bRoOHjyIs2fPIjIy0mRcNAAmCcbS6NGjB548eYIVK1bg5MmTOHnyJADk2d/TDOParVixwuS8X7hwIc9rVdh7h4iI/sM+buQQEtNsM95ZpkqHtGwNvNzkRa9MRIUq6+6aqVkauMllZboPIqKnNQ5sjCBlEBIzE/MdZ00CCYKUQWgc2NgG0RWtcePGuHr1KqpVq1am+6lduzbWrFmDjIwMY1Lp2LFjxi6YBo0aNUKjRo0wY8YMtGrVCt9//z1atmwJV1dX6HTF+/KkoDas4dixY+jVqxdeeeUVADlJqL///ht16tQxq71z584hKysL7u7uAIATJ07A09MTYWFhePz4Ma5evYoVK1agbdu2AICjR4+abG+YbfTp1y4oKAgVKlTAzZs3MWTIELPiMrRd3HNCROTsWLFGds9W3UANbJXUI3I2ZZ1Y4zhrRGRtMqkM05tPB5CTRHua4fG05tMgk9pn0n/mzJn4+uuvERcXh4sXL+Ly5ctYv3493n33XYvuZ8iQIXBzc8OwYcNw4cIFHDx4EK+99hqGDh2KoKAg3Lp1CzNmzMDx48dx+/Zt7NmzB9euXTOOkRYREYFbt27h7NmzePToEVSqvPdmRbVhDdWrV8fevXvx22+/4fLlyxg7diwSEgoeg68oarUaI0eOxKVLl7Bjxw7ExsZi4sSJkEql8PPzg7+/P7788ktcv34dBw4cQExMjMn2gYGBcHd3x65du5CQkICUlBQAOeOlzZs3D0uWLMHff/+N8+fPY/Xq1Vi4cGGxY4uIiEB6ejr279+PR48eFdp1mIjI2TGxRnbvoY0TW4mcHZTIIphYIyJn1Dm8MxZ2WIhAZaDJ8iBlEBZ2WIjO4Z1tFFnRIiMjsW3bNuzZswfNmjVDy5Yt8emnnyI8PNyi+1Eqldi9ezeePHmCZs2aoV+/fujUqRM+//xz4/NXrlxB3759UaNGDYwZMwYTJkzA2LFjAQB9+/bF888/j44dOyIgIADr1q3Ldx+FtWEN7777Lho3bozIyEh06NABwcHB6N27t9ntderUCdWrV0e7du0wYMAA9OzZE7NmzQIASKVSrF+/Hn/88Qfq1auHyZMnY/78+Sbbu7i4YMmSJfjiiy9QoUIF9OrVCwAwatQofPXVV1i9ejXq16+P9u3bY82aNahcuXKxY2vdujXGjRuHAQMGICAgoFiTMRAROSuJIAh569ZFJjU1FT4+Pnj06BH8/f1tHQ7l8nv8EyRnmveBWaXRYcK6PwEAnw+oDzeFwqx2Wlfzh9KVPaftjUajwY4dO/Diiy/mGROF7IsgCDj090PodMX7k2POtSuVAh1qBEIqlRS5LllGptq8SSM0Gg12796DyMiuZl279vT72HAPkZKSAm9vb1uHQ/ko7BxlZ2fj1q1bqFy5cqFjihWHTq/DmcQzeJj5EAHKADQObGy3lWpk/4YPH47k5GRs3brV1qGYzZLXFxGRLRT3Ps9+7kyJ8qHS6sxOqllSYqoKEeV5uRCZK12lLXZSzVx6PZCWrYWPkklWa6kzc3cptnbBW6cOmLVl/IfdSrFforIhk8rQLLiZrcMgIiIiK2NXULJrj9ILntXImh6lszsoUWlYq5tmcpZ9/M4gIiIiIiJxYAkO2bVHdjJxQHKmBmqtHq4uzEUTmcNalaccZ826Ls2OLHKde8nZuHo/1fhYpdUhZuNfAIAFfevC7f9nrQOARpX84OvBikMiojVr1tg6BCIiKiYm1shu6fUCnmTYT/XJ4wwVQnzcbR0GkUOyWsWaHXQdF5PijXUmQCHPf5wphYvU5Dk9BLsaP42IiIiIqCgsvyG7lZSphk5vP3NrPLaTbqlEjiZbo0OWWmeVfam1erMH1KeykaEq/rnPtNL7hCg3zuVFZHm8rohILOwysbZ06VJERETAzc0NLVq0wKlTpwpdPzk5GRMmTEBISAgUCgVq1KiBHTt2WClaKiuP7ahaDcgZZ403CEQlZ+3umaxasy8ZquInOkuyLpElGGalzczMtHEkRM7HcF1x5nYicnZ2199iw4YNiImJwfLly9GiRQssWrQIkZGRuHr1KgIDA/Osr1ar0aVLFwQGBmLTpk0IDQ3F7du34evra/3gyaLsrUJMqxOQmq2FjztvDohKwtqJruRMDSr4stu2PdDrBWRpil+FVpLqNiJLkMlk8PX1RWJiIgBAqVRCIpHYOCoixyYIAjIzM5GYmAhfX1/IZPkPB0BE5CzsLrG2cOFCjB49GtHR0QCA5cuXY/v27Vi1ahWmT5+eZ/1Vq1bhyZMn+O2334zfhkRERFgzZCoDKq3OLisXnmSomVgjKqGkTOsmyZOtvD8qWKZGh5IU+mZrdNDq9HCR2WVBPTmp4OBgADAm14jIMnx9fY3XFxGRM7OrxJparcYff/yBGTNmGJdJpVJ07twZx48fz3ebn3/+Ga1atcKECRPw008/ISAgAIMHD8a0adMK/HZEpVJBpfpvtsnU1JzZyjQaDTQadiGyBw9TVRB0pU+sCXrdU//Xl7rNx2mZqOjjWvSKZBWG65XXrf3S6PRIy8gu8XaluXYzsrTIyMqGqwu/Ibe1lIy8v8uLOrcpmdnwdnOcLzD4+8fxSSQShISEIDAwkOeTyELkcjkr1YhINOwqsfbo0SPodDoEBQWZLA8KCsKVK1fy3ebmzZs4cOAAhgwZgh07duD69esYP348NBoNYmNj891m3rx5iIuLy7P84MGDUCqVpT8Qshs5vYpy3uZZt89BX8q/75kA7v5V2qjI0vbu3WvrEMjCSnvt7rtp8ZDIQoo6t0cd7NxxbC7nIZPJmAggIiKiErOrxJo59Ho9AgMD8eWXX0Imk6FJkya4e/cu5s+fX2BibcaMGYiJiTE+Tk1NRVhYGDp27Ah/f39rhU6FOB3/BBnZpa9Yk2l1wKnzAAD38AZwcy19FUSTyn7wUjhONYUz02g02Lt3L7p06cKBce3UzYfpuPO45ImH0l67oX5KVA/yLPF+ybIu3E3BozSVybKizm3FckpUC3Scc2eoeiciIiIicbKrxFr58uUhk8mQkJBgsjwhIaHA/vkhISF5So1r166NBw8eQK1Ww9U1b7c9hUIBhUKRZ7lcLueHczug1emRqQEkstK/PSX6/wYglkilFmkzQw2U8+T7xJ7w2rVfqWrBrOuutNduqlrP94QdyNTm/V1e1LnN0jnWDHKOFCsRERERWZ5djQ7s6uqKJk2aYP/+/cZler0e+/fvR6tWrfLdpk2bNrh+/Tr0er1x2d9//42QkJB8k2pk/1ItUKlWllKyOP4KUXFodXqk2uh6Sc/WQqPTF70ilRmtTo8sdcln+Uyz878BRERERERPs6vEGgDExMRgxYoVWLt2LS5fvoxXX30VGRkZxllCo6KiTCY3ePXVV/HkyRO8/vrr+Pvvv7F9+3bMnTsXEyZMsNUhUCnZ6oN4caVm23d8RPYiJUtTohkhLc3as5GSqXQzZ3bWaPXI1pQ8IUdEREREZAt21RUUAAYMGICHDx9i5syZePDgARo2bIhdu3YZJzS4c+cOpNL/8oFhYWHYvXs3Jk+ejGeeeQahoaF4/fXXMW3aNFsdApWSuR/GrCVTpYNOL0AmlRS9MpGIJWXaNgmdnKlBoJebTWMQs9JUnqWrtHCTcxB5IiIiIrJ/dpdYA4CJEydi4sSJ+T536NChPMtatWqFEydOlHFUZC2OUBGWnq2Fj5Lj6hAVJtnGFWNJGaxYs6XSJNbSsrUo75l3LFQiIiIiIntjd11BSdz0esGsMXmsLV1t31V1RLam0ws2T5KnqzjOmi2V5vzb+5AAREREREQGTKyRXcnS6Gw6JlNxZdp5d1UiW0vJ0kBv45yWIOR0ByXr0+sFZJTi9yQnMCAiIiIiR8HEGtmVDAepBMt0gKo6Iluyl4kDbN0dVazSVNpSfUmSrdFBpeXvWSIiIiKyf0yskV3JVjtGty0m1ogKZy8JLVtPoCBWlujKyao1IiIiInIETKyRXcnSOEbCKpuVFEQF0usFpNjJGFlp2RpoOc6a1Vni/NvLe4iIiIiIqDBMrJFdyXaQxJpOJ3BQdKIC2MP4agaCACQzQWN1lpi4ghMYEBEREZEjYGKN7IragZJVaq3jxEpkTU/spBuoQVKGfcXj7DQ6PTJVpf+ShBVrREREROQImFgju+JIySpHipXImuxlfDUDjrNmXZaqNNPqBGQ6yIQ2RERERCReTKyRXXGkijV2BSXKy57GVzPgOGvWZcmut8lMihIRERGRnWNijeyGIAjQ6QRbh1FsGr3jxEpkLfY0vpoBx1mzLksmVu0tSUtERERElBsTa2Q3tA6WqGIFDFFeSXbWDdTA3rqnOitBsGzFIivWiIiIiMjeMbFGdkPnaIk1B4uXyBrsdTwze43L2aSptBatPM5QadntnoiIiIjsGhNrZDf0gmMlqgQHi5eorOn1gsUGrre01CyNwyXvHVFKGSQwWbVGRERERPaMiTWyG472odfBwiUqc6nZ9pu8EgR2B7WGsugKnJLF80ZERERE9ouJNbIb9vlxvGCOVmFHVNbsvbKI3UHLXlm8B3jeiIiIiMieMbFGdsPR8lSOFi9RWbPXiQsMWPlUtjJUWqi1lh8Pjd14iYiIiMieMbFGZCaJxNYRENkPQRCQbKfjqxmkZGmgZ4KmzJRVYpXdeImIiIjInjGxRnaDiSoix2Xp2SDLgl6fMw4clY2y7ArM7qBEREREZK+YWCO74Wh5NYnDRUxUdpIzHCPxwQRN2SnLrsCsWCMiIiIie8XEGtkNiYOVrEkdK1yiMpXsIOOXMUFTNjJUWqg0lh9fzSAlSwOtruzaJyIiIiIyFxNrZDdkDpZYc7REIFFZcpRKsOQsDQTOPGJxTzLKNmEpCLD7MfyIiIiISJyYWCO74Wh5KlasEeXIVGuhKYPZIMuCTicgXaW1dRhOxxozwiaVcfKOiIiIiMgcTKyR3ZA5WKbK0eIlKiuOUq1mUJaD7IuRIAhlXrEGlH1VHBERERGROZhYI7vhaF1BmVgjypHiYImqFHYptKg0lRZaK8wIm5athdpBKiOJiIiISDyYWCO7IZVKHKo7KBNrRDkcZeICA1asWdaTdOudf2t0OSUiIiIiKgkm1siuOFKyypFiJSoraq0emSqdrcMokWyNDtkax4rZnj2xYrKL3UGJiIiIyN4wsUZ2xUXqOG9JR+u6SlQWHLVbpaPGbW90egHJTKwRERERkYg5ThaDRMGB8moOlQQkKiuOmqBy1LjtTXKmGnorDnuWpdYhU81ZXYmIiIjIfjAzQHbFkZJVMhkr1ohSsx0zQZXKxJpF2KKCjFVrRERERGRPHCeLQaLg4kDJKheOsUYiJwiCw1Z+pWZroNeX/UyWzu6xDZJcj604WQIRERERUVGYWCO74kjjlnHyAhK7DLUOOp1jJqf0eiBNxS6FpaHS6pCebf3XMClTDUFwzPcdERERETkfJtbIrjhSsooVayR2jt6d0tHjt7WkDNu8flqdgNQsJkWJiIiIyD4wsUZ2xVG6gkqlgMSBquuIyoKjjq9m4Ojx29rjDJUo901ERERE9DQm1siuOEpXUKmDxElUlhy9asjR47c1W04iwAkMiIiIiMheMLFGdkXqIN0rHWn2UqKyoNcLSFc5dsVXhkoLrU5v6zAcUlq2BiqN7V67lCwNNDx3RERERGQHmB0gu+I4FWu2joDIttLVWuidIK+RzgkMzGLrijFBAJJYtUZEREREdoCJNbIrjtLF0lEq64jKSpoNZoMsC85yHNb22A6SWvYQA5lv6dKliIiIgJubG1q0aIFTp04Vun5ycjImTJiAkJAQKBQK1KhRAzt27LBStEREREQFc7F1AERPc5C8msMkAInKSpqTDPzPCQxKTqcXkJxp+6SWravmyHwbNmxATEwMli9fjhYtWmDRokWIjIzE1atXERgYmGd9tVqNLl26IDAwEJs2bUJoaChu374NX19f6wdPRERElAsTa2RXHKUSjHk1EjtnqfRyluOwpuRMtV10A85S65Cp1kLpylsZR7Nw4UKMHj0a0dHRAIDly5dj+/btWLVqFaZPn55n/VWrVuHJkyf47bffIJfLAQARERHWDJmIiIioQLwbJTID82okZoIgOM3YZJlqLfR6wWGS+vbAnirFHqeroSzHWxlHolar8ccff2DGjBnGZVKpFJ07d8bx48fz3ebnn39Gq1atMGHCBPz0008ICAjA4MGDMW3aNMhksjzrq1QqqFQq4+PU1FQAgEajgUbDKlUiIiIqnuLeN/BulOwKP9oS2b9sjR46nWDrMCxCrwcyNTp4KvjnsLjsaWyzJxlqhJVT2joMKoFHjx5Bp9MhKCjIZHlQUBCuXLmS7zY3b97EgQMHMGTIEOzYsQPXr1/H+PHjodFoEBsbm2f9efPmIS4uLs/yPXv2QKnk+4WIiIiKJzMzs1jr8ZME2RXn+KhO5NzSVM5V8ZGerWVirZhUWh3S7aj77JNMNQRBgIT9852aXq9HYGAgvvzyS8hkMjRp0gR3797F/Pnz802szZgxAzExMcbHqampCAsLQ9euXeHt7W3N0ImIiMiBGarei8JPEmRXBMExUmuOESVR2bCnxIolpKs0ANxsHYZDsKduoACg0wlIydLAV+lq61ComMqXLw+ZTIaEhAST5QkJCQgODs53m5CQEMjlcpNun7Vr18aDBw+gVqvh6mp6/hUKBRQKRZ525HK5cYw2IiIioqIU975BWsZxEJWIg+TVoNc7SKBEZSBDpbN1CBaV7mTHU5Yep9tXYg2wr66pVDRXV1c0adIE+/fvNy7T6/XYv38/WrVqle82bdq0wfXr16F/ataMv//+GyEhIXmSakRERETWxsQa2RW9g2TWdA4SJ1FZcJaJCwwynOx4ylJSpv0lsZKYWHM4MTExWLFiBdauXYvLly/j1VdfRUZGhnGW0KioKJPJDV599VU8efIEr7/+Ov7++29s374dc+fOxYQJE2x1CERERERG7ApKdkXnIJVgT31pTiQqgiAgS+NciagstQ46vQAZZwYtVIZKC5XG/n75pWRpoNXp4SLjd4WOYsCAAXj48CFmzpyJBw8eoGHDhti1a5dxQoM7d+5AKv3vfIaFhWH37t2YPHkynnnmGYSGhuL111/HtGnTbHUIREREREZMrJFd0TpIYk3LzBqJVKZa55SJ5Qy1Ft5uHHupMPY2vpqBIABJmRoEeOUdU4vs18SJEzFx4sR8nzt06FCeZa1atcKJEyfKOCoiIiKikuPXu2RXNDrH+MSu1QkOM9ECkSVlqJ2rWs0gk+OsFcleE2uAfXZRJSIiIiJxYGKN7IpW5zjJKkepriOypCy1cyagMp00YWgpgiDgiR0nr+w56UdEREREzo2JNbIragepWAMAtdZxYiWyFGebEdQg00kThpaSmq2Fzo6/+EjP1vJ3MhERERHZhN0m1pYuXYqIiAi4ubmhRYsWOHXqVIHrrlmzBhKJxOTHzc3NitGSpdjjwNgFUfFDHImQs01cYMDEWuEcYeZNdgclIiIiIluwy8Tahg0bEBMTg9jYWJw5cwYNGjRAZGQkEhMTC9zG29sb9+/fN/7cvn3bihGTJQiCAJXWcT7cZmscJ1YiS3HWBBS7ghbOnruBGjCxRkRERES2YJeJtYULF2L06NGIjo5GnTp1sHz5ciiVSqxatarAbSQSCYKDg40/hinbyXGotHo40nwATKyR2Oj1gkNVlZaEVic4zOQp1qbXC0jJ0tg6jCIlZdh/jERERETkfFxsHUBuarUaf/zxB2bMmGFcJpVK0blzZxw/frzA7dLT0xEeHg69Xo/GjRtj7ty5qFu3br7rqlQqqFQq4+PU1FQAgEajgUbDG3NbSctUQ9BZtmpE0Oue+r/eou2nZ6mg0Sgs1h6VnOF65XVrHZlqrcWv0YKU5bVbkLSsbHgp5GW+H0eTmqWBVm25a6yszm16phYZWdlwdZFZpL3i4u8fIiIiInGzu8Tao0ePoNPp8lScBQUF4cqVK/luU7NmTaxatQrPPPMMUlJS8Mknn6B169a4ePEiKlasmGf9efPmIS4uLs/ygwcPQqlUWuZAyC7kjLOe8zbPun0Oegt+3roF4NaflmuPzLd3715bh0AWVpbXbkGO3Cz7fVDZntt9NjiHmZmZ1t8pEREREdkNu0usmaNVq1Zo1aqV8XHr1q1Ru3ZtfPHFF3j//ffzrD9jxgzExMQYH6empiIsLAwdO3aEv7+/VWKmvK4npuPfJ5b9gCLT6oBT5wEA7uEN4OZquWoUF5kEz1YPsFh7VHIajQZ79+5Fly5dIJez0qis3U3KwrWENKvsqyyv3YJUDfREWDl+uZLb+bspeJymKnrFYirLcxvqp0T1IE+LtVcchqp3RxUfH4+9e/fCzc0Nffr0gaendV8/IiIiIkdnd4m18uXLQyaTISEhwWR5QkICgoODi9WGXC5Ho0aNcP369XyfVygUUCjyduGTy+X8cG5DWTpAIiv4LakyY0wztV7y1P8B6VOPi0shz7+cQgdAByncCnierIfXrnVooSr0GrUkyVPXqkQqtcp+tZDyfZSLIAhIVekt+vqX5blNU+utfg4d5T0zd+5crFixAmfOnIGfnx8A4NChQ+jevTuysrIAAO+//z5OnDiBcuXK2TJUIiIiIodid4k1V1dXNGnSBPv370fv3r0BAHq9Hvv378fEiROL1YZOp8P58+fx4osvlmGkZGnp2YWPszNhXen6Xb7540WztvsqqmmBz6WrtEyskWg4+4Qdzn585shQ66DVOc6sMukqLbQ6PVxkdjk3k01t3boVERERxqQaAEybNg16vR5xcXF48OABli1bhkWLFmH27Nk2jJSIiIjIsdjlnWdMTAxWrFiBtWvX4vLly3j11VeRkZGB6OhoAEBUVJTJ5AazZ8/Gnj17cPPmTZw5cwavvPIKbt++jVGjRtnqEKiEVFod1FrHm5EvrYhkIJEzUWmdO/GU7aQznpZGcqba1iGUiCDAIWYwtYX4+HjUqVPH+PjevXs4ffo0JkyYgHfffReff/45OnXqhC1bttgwSiIiIiLHY3cVawAwYMAAPHz4EDNnzsSDBw/QsGFD7Nq1yzihwZ07dyCV/pcTTEpKwujRo/HgwQP4+fmhSZMm+O2330xuIMm+pWYVnaBaOqhRidtVaXWI2fgXAGBB37pwc3UtcRuFScvmBzgSD5WTJ56cPXFojuRMx/sdl5ylgb8nZ2zOLTU1Fb6+vsbHhw8fhkQiQY8ePYzLGjdujOXLl9sgOiIiIiLHZZeJNQCYOHFigV0/Dx06ZPL4008/xaeffmqFqKispBYjQVXQWGfFpXCRlrqN3FgZQWKicsCq0pJQa/UQBAESScnHYnRWqQ74O46/l/MXFBSE27dvGx/v3bsXCoUCLVq0MC7Lzs7m+5+IiIiohOw2sUbi4qgfhFQaPbI1Oo6zRk5Pq9NDp3ecsbbMIQiAWqeHwoXXM5CTaMxUO14VX2qWhgnSfDRr1gw//fQTtm3bBjc3N2zYsAEdO3Y0mczp1q1bqFChgg2jJCIiInI8djnGGomLIAgOm1gDHDcpSFQSzl6tZiCW4ywOR/3dptUJyHDAhGBZe/vtt6HVatGrVy9ERkYiOzsbb7/9tvF5lUqFw4cPm1SwEREREVHRWLFGNpem0kLnQLPO5ZaUqUaQt5utwyAqU444uYg5xHKcxVGcLvr2KjVLA08Fb3Ge1rhxY5w4cQLffPMNAKB///5o3ry58fk///wTHTt2xODBg20VIhEREZFD4l0n2VxyhuN+eAOAJAePn6g4NDpxJJzEcpzF4YjjqxmkZmtQAe62DsPuNGjQAA0aNMj3uZYtW3JGUCIiIiIzsCso2dyTTLWtQyiVDJWWswmS0xNLF0lWrP0nNbvo2ZrtVXFmmhaz9PR0nDlzBkeOHLF1KEREREQOj4k1silBEJDk4Ik1AEjOdNzKDqLiEEsll1iOsyjZGh00DpxkTFdpoHfyyTbMER8fj169esHPzw/NmjVDx44djc8dO3YMderUyTPzOhEREREVjok1sqnULMceX83gcbrjJweJCqNxguu0ONRacRxnURx5fDUA0OuBDDWr1p52584dtGzZEjt27ECvXr3QqlUrCMJ/7/cWLVrg0aNHWLdunQ2jJCIiInI8TKyRTTl6N1ADZ6i6IyqMWCq5tHpxHGdR0hy4G6iBMxyDJcXGxiIpKQm//vorNm3ahC5dupg87+LigrZt2+LYsWM2ipCIiIjIMTGxRjb1JENl6xAsIkutQyarI8iJaUXSrU4slXlFcYaklDMcgyXt3r0bffr0QevWrQtcJzw8HHfv3rViVERERESOj4k1shmtTu9UY5OxOyg5M61YKtZEcpxFSXeCpFS6yvGPwZKePHmCiIiIQtcRBAEqlXN84UVERERkLUyskc0kZWogOFFxyJMMJtbIeYmlkksslXmF0ej0yNY4/kzHTKyZCgoKwrVr1wpd5/z586hUqZKVIiIiIiJyDkyskc04WyLqSabaZCBoImeiE0nCiYk1IMNJElIarXMkCC2lS5cu2LZtG/766698nz9y5AgOHDiAF1980cqRERERETk2JtbIZh47yfhqBjqdgNQs5/hASpSbWAb114nkOAvjTJVezpIktIR3330X7u7uaNeuHebMmYPr168DAHbu3In33nsPzz//PMqXL4+pU6faOFIiIiIix+Ji6wBInLI1OmSqnK+S4HGGCj5Kua3DILI4sVSs6fWAXi9AKpXYOhSbyVQ7z+/mTLUO/rYOwk5ERERg9+7dGDhwIN577z1IJBIIgoDu3btDEARUqlQJmzZtQkhIiK1DJSIiInIoTKyRTThbN1CDpEznPC4SN71ecKrxEIuiEwRIId7EmjNVrDnTsVhCixYtcO3aNfzyyy84efIknjx5Am9vb7Ro0QK9evWCq6urrUMkIiIicjhMrJFNOGtiLSVLA51egEzE1S7kfHRiyqohpzpPLrN1FLbjTN0nM9XOcyylNXv2bFSuXBlDhw5Fnz590KdPH1uHREREROQUOMYa2YSzVnbp9UCykx4biZdYuoEa6EWWSHyaTi9ApXGeceYynHDIAXN98MEHOH/+vK3DICIiInI6TKyR1WWpdU71wS23pEyNrUMgsiixJZrElkh8mrNVeKm1emh1zvv3piQqVaqE5ORkW4dBRERE5HSYWCOrS85y7oqulCwm1si5iC3RJOaJQbOcaOICg0yN8x2TOQYOHIhdu3YhJSXF1qEQERERORUm1sjqkp28ois1SwNBZBU+5NxEllcTXYXe05xpRlADZ0wWmuO9997DM888g+eeew7bt29HYmKirUMiIiIicgqcvICsLtXJK7p0egHpKi283OS2DoXIIsSWKBZzYi3LCau7mFjLoVQqAeRczz179ixwPYlEAq3WuboEExEREZUlJtbIqvR6ARlONoZPflKzmVgj5yG2PJPIDteEUybWnPCYzNG2bVtIJJyxmoiIiMjSmFgjq0pXa0UxflF6tvMnD0k8xFbBJbbjfVq2E1Z3MbGW49ChQ7YOgYiIiMgpcYw1sqoMlTgSTukq5+7uSuIitjHWxJpXEwQB2VrnS0I5Y7KQiIiIiOwHK9bIqsSSWMtQ8YMcOQ9BZJ0jxZpYU+v0TllRrNI64UGV0t27d3H27FmkpqbC29sbDRs2RGhoqK3DIiIiInJITKyRVTnjjHP5UWv10Or0cJGxKJSIHEO2xjkTUDq9ALVWD1cX/j6+fv06Xn31VRw4cCDPc506dcKyZctQrVo1G0RGRERE5LiYWCOrEtPsbFkaHbyYWCNnILIKLrFV6BmonHgsMpVWJ/rE2j///INnn30WiYmJqFWrFtq1a4eQkBA8ePAAhw8fxr59+9C2bVucOnUKYWFhtg6XiIiIyGEwsUZWJaYuOSqtHl62DoLIAsSWZhJrV1Bn/v2crdHDy83WUdhWXFwcEhMTsWzZMowdOzbPDKFffPEFXn31VcyePRsrVqywUZREREREjoeJNbIaQRCg0TnvB7fc1E78IZWInI8zJ9bUIvrbU5Ddu3ejR48eGDduXL7Pjx07Fjt27MDOnTutHBkRERGRYxN3vwiyKq1eEFUliFYnooMlIoencsIZQQ2cuZtrcSUmJqJevXqFrlOvXj08fPjQShEREREROQcm1shqdHpxJZo0zji9HhE5LWeuWHPmYyuugIAAXLp0qdB1Ll26hICAACtFREREROQcmFgjq9GLqVwNOV1fiYgchTN3X3fmYyuuyMhI/Pzzz1i5cmW+z69atQq//PILnn/+eStHRkREROTYOMYaWY3Y8kxiO15yXpKiV3EqErEd8P9z5jEwnfnYiis2Nha//PILxowZg0WLFqF9+/YICgpCQkICDh8+jIsXL6J8+fKIjY21dahEREREDoWJNbIasX1YzT3jGpHDEtlbWSK2A0ZOha0zV3U587EVV6VKlXDs2DGMHTsWhw4dwsWLF02e79ixI/73v/8hLCzMRhESEREROSYm1shqpCJLNInscInIgTn75DKcFTRH9erVceDAAfzzzz84e/YsUlNT4e3tjYYNGzKhRkRERGQmJtbIamRScWWa5FIOYUjOQWwVXGJMijt7V0mtToAgCKwk/n9hYWFMpBERERFZCD/5k9W4SCWi+sDqIhPRwZJTE1lOXFS/pww0WicuV/t/Yq9a+/fff/Hzzz8jOTk53+eTkpLw888/4+7du9YNjIiIiMjBMbFGViORSODqIp63nEJEx0rOTWxVPmKr0APEkXTS6Jw/eViYDz74ANHR0XB3d8/3eaVSiREjRmDevHlWjoyIiIjIsfGTP1mVm1xm6xCsRiGiYyXnJrY0k8jyiAAArd75E2taESQPC3PgwAF07doVCoUi3+cVCgW6du2Kffv2WTkyIiIiIsfGxBpZlbuIkk1KER0rOTfRTTxi6wBsQCuCai6xV6zdvXsXERERha4THh7OrqBEREREJcTEGlmV0lUcySZ3VxmkYhuYipyWRGR/KcQ20Qrg/JMXAOKoyiuMq6srUlNTC10nNTVVdF2/iYiIiEpLZB+XyNY83cQxEa2nQhzHSeIguoo1kR0vAGj1zl/NJYaqvMLUr18fv/zyC1QqVb7PZ2dn4+eff0b9+vWtHBkRERGRY2NijazK201u6xCswkskCUQSB7EVcInteAGxVKyJO7EWHR2Nf//9Fz179sTNmzdNnrtx4wZ69eqFe/fuYdSoUTaKkIiIiMgx8dM/WZWbXAaFXAqVxrk/xPm4iyOBSOLAijXnpxNB0knskxdER0djx44d+PHHH1GrVi1UrlwZoaGhuHv3Lm7dugWtVosBAwYgOjra1qESERERORRWrJHV+bq72jqEMiWRAN5MrJETEVueSSa2A4Y4qrnEcIxF+eGHH7BkyRJUq1YN165dw6FDh3Dt2jXUqFEDS5cuxbp162wdIhEREZHDMTux9uqrr+LPP/+0ZCwkEn4ezp108nKTQy5jzpqch/gq1mwdgfWJYfwxMVTlFUUikWDixIm4dOkS0tLS8O+//yItLQ0XLlzAq6++auvwiIiIiByS2Z/+v/jiCzRt2hRNmzbFF198gbS0NEvGRU7M30Nh6xDKVDkP567II/ERWwWXGGcFFcOMmaxYM+Xh4YEKFSrAw8PD1qEQEREROTSzE2v79u1D//79cfHiRYwfPx4VKlTAyJEjceLECUvGR07I3VUGpUJm6zDKTICncycOSXykIks0iS2RCAAiyKtBJ4aDLMQ///yDAwcOIDMz07hMr9fjo48+Qps2bdC5c2ds377dhhESEREROSazE2vPPfcc1q1bh3v37mHhwoWoXLkyVq9ejTZt2qBevXpYsmQJkpKSLBkrORFnTT7JXaTwduecIOR8xFTFJbZEIiCSijURdHctzHvvvYeXX34Zcvl/wzHMmTMHM2bMwPHjx3HgwAH07t0bp0+ftmGURERERI6n1ANB+fn54fXXX8dff/2F48ePY8SIEfjnn38wefJkhIaG4pVXXsGvv/5qiVjJiQR6udk6hDIR6KUQ5YyC5PzEkmwSUwLxaWIYf0wMx1iYY8eOoXPnzsbEmiAI+Pzzz1GrVi3cuXMHp06dgoeHB+bPn2/jSImIiIgci0VHWG/RogVWrFiBn376CSEhIcjOzsb333+P5557DnXr1sXGjRuL3dbSpUsREREBNzc3tGjRAqdOnSrWduvXr4dEIkHv3r3NPAqyBh+lHG5y5+sOGujlnJV4RGLpHimWBOLT9HoBgghyTjoxHGQhEhMTER4ebnx89uxZPHz4EK+99hoqVqyIpk2bsmKNiIiIyAwWS6ylpqZi2bJlaNy4MTp16oR79+6hbdu2+Oqrr/Dqq6/in3/+wcCBA/Hxxx8X2daGDRsQExOD2NhYnDlzBg0aNEBkZCQSExML3S4+Ph5TpkxB27ZtLXVYVIaCfZwrCaWQSzlxATktqUgmuhVLAvFpYkk4ib1iTa/XQ/9Ul99Dhw5BIpHgueeeMy4LDQ3FgwcPbBEeERERkcMq9UelI0eOYNiwYQgJCcHEiRMRHx+P1157DRcvXsSvv/6KESNG4PPPP8eNGzdQr149fPbZZ0W2uXDhQowePRrR0dGoU6cOli9fDqVSiVWrVhW4jU6nw5AhQxAXF4cqVaqU9rDICoJ93G0dgkUFebuxGyg5LReRZNbE2BVULAknsRxnQSpVqmRS/b9161aEhISgZs2axmUPHjyAr6+vDaIjIiIiclxmj7L+ySefYOXKlfj7778hCAJatmyJsWPHYsCAAXBzyzt+VkBAAPr164dZs2YV2q5arcYff/yBGTNmGJdJpVJ07twZx48fL3C72bNnIzAwECNHjsSRI0cK3YdKpYJKpTI+Tk1NBQBoNBpoNJpCtyXLUUgBT1cJ0rLK7jUX9Lqn/q+HoNOW2b4CPV34/rEyw+vN173sSQRtmV4/uVnz2n2aRJCI7v2kVovj3AoAVCq1xbv7Osr7pW/fvpgzZw769esHNzc3HD16FBMnTjRZ59KlS/xykoiIiKiEzE6svfXWW/D29sa4ceMwbtw41K9fv8htmjRpgqioqELXefToEXQ6HYKCgkyWBwUF4cqVK/luc/ToUaxcuRJnz54tVuzz5s1DXFxcnuUHDx6EUqksVhvkGFQ6wPA2z7p9DvoyHNbt15tl1zYVbu/evbYOgSzMmtfu0zIB7LhonX2Jla3OLQDsKoPf05mZmZZvtAxMmTIFe/bswebNmwEAzzzzjMmXnbdv38apU6cwffp0G0VIRERE5JjMTqytWLECgwYNKlEi6sUXX8SLL75o7i7zlZaWhqFDh2LFihUoX758sbaZMWMGYmJijI9TU1MRFhaGjh07wt/f36LxUeG0Oj2O33wMna5suujItDrg1HkAgHt4A7i5ystkP7VCvBHs45wzndozjUaDvXv3okuXLsaZ7qhsXLqXisTUbKvtz1rXbm7+XgrUD/Wxyr7sRUqWGn/eTrba/mx1bgGgdTV/uLpYNpNnqHq3d97e3jhx4gQuXLgAAKhduzZkMtPXYvPmzWjatKktwiMiIiJyWGYn1uRyOa5fv45nnnmmwHUuXLiAM2fOFFml9rTy5ctDJpMhISHBZHlCQgKCg4PzrH/jxg3Ex8ejR48exmWGwXldXFxw9epVVK1a1WQbhUIBhSLvwPlyuZwfzq1MLgdC/DxxNymrTNqX6P/r8iORSiGRmf2WL5CLTIIK5TxFOTaTveC1W/bkcjkkMut1F7TGtZsfVxG+lyQqvdVeX8B25xYApDI55BaekdrR3i/16tXLd3l4eLjJrKFEREREVDxmj0YdHR2NrVu3FrrOTz/9hOjo6BK16+rqiiZNmmD//v3GZXq9Hvv370erVq3yrF+rVi2cP38eZ8+eNf707NkTHTt2xNmzZxEWFlai/ZP1VfRz7EkMKvi6M6lGTs9FJo73uBivZTGN6S+WGVCJiIiIyHrM/ppYKMbNqU6ng9SMmeRiYmIwbNgwNG3aFM2bN8eiRYuQkZFhTNJFRUUhNDQU8+bNg5ubW55vXw0zWhX0rSzZFy83Ofw8XJGUobZ1KGYJ8+O4fOT8xJJwchHJcT5NL6Jkk5iOlYiIiIiso0z7X/z5558oV65cibcbMGAAHj58iJkzZ+LBgwdo2LAhdu3aZZzQ4M6dO2Yl7Mh+hZVzd8jEWoCXAu6uVhx5m8hGxJJwEksC8WliSjbpxVSeR0RERERWUaLE2nPPPWfyeM2aNTh06FCe9XQ6Hf7991/Ex8ejf//+ZgU2ceLEPNPAG+S3z9xxkWMJ8FRA6SpDplpn61BKpFI5VquROLjIxPFlhlwkx/k0nYiSTWI6Vnu3dOlSzJ8/Hw8ePECDBg3w2WefoXnz5kVut379egwaNAi9evUqckgSIiIiImsoUWLt6YSWRCJBfHw84uPj86wnlUpRrlw5vPzyy1i0aFEpQyQxkEgkCCunxNUHabYOpdi83XO6sBKJASvWnJeICtZENZ6cPduwYQNiYmKwfPlytGjRAosWLUJkZCSuXr2KwMDAAreLj4/HlClT0LZtWytGS0RERFS4En01r9frjT+CIGDWrFkmyww/Wq0WiYmJWL9+vbH7JlFRKvi6Q+7iONUi4f6sViPxEEtiTSyTNDxNTFVcxRkflsrewoULMXr0aERHR6NOnTpYvnw5lEolVq1aVeA2Op0OQ4YMQVxcHKpUqWLFaImIiIgKZ/YYawcPHkRERIQFQyGxk0klCPNzx82HGbYOpUjurjIEeilsHQaR1biIZFxLsRzn08Q0xhpnBc1x6dIlXLlyBRkZGRg6dKhV961Wq/HHH39gxowZxmVSqRSdO3fG8ePHC9xu9uzZCAwMxMiRI3HkyJFC96FSqaBSqYyPU1NTAQAajQYajaaUR0BERERiUdz7BrMTa+3btzd3U6ICVfRT4vbjTLuvoKhUTgmJRHyVLSRepankUmlKPnaiSqt76v96SKQla0MhN29SETFWrNn5r1uLEtOx5uf06dMYPXo0zp8/b1xmSKwdPnwYzz//PNavX4+ePXuWWQyPHj2CTqfL06MhKCgIV65cyXebo0ePYuXKlTh79myx9jFv3jzExcXlWb5nzx4olaw2JyIiouLJzMws1nrFTqx9/fXXAIA+ffrAy8vL+Lg4oqKiir0uiZurixShfu6487h4b2BbcHWRooKvu63DILKq0iScJqz7s1T7fvPHiyXe5quopmbtS86KNacm5llBL168iOeeew5SqRSTJ0/GlStXsHPnTuPzbdu2Rfny5bFx48YyTayVVFpaGoYOHYoVK1agfPnyxdpmxowZiImJMT5OTU1FWFgYunbtCm9v77IKlYiIiJyMoeq9KMVOrA0fPhwSiQQtW7aEl5eX8XFhBEGARCJhYo1KpFI5Jf5NyoReb+tI8lepnFKUA5yTuIkl4STOijXxJJtEdKh5xMbGAgD++OMPVKtWDXFxcSaJNYlEglatWuH06dNlGkf58uUhk8mQkJBgsjwhIQHBwcF51r9x4wbi4+PRo0cP4zL9/98guLi44OrVq6hatarJNgqFAgpF3uEa5HI55HK5JQ6DiIiIRKC49w3FTqytWrUKEokEISEhJo+JLM1NLkOwtzvuJWfZOpQ8XGQShPqxWo3ERyqVQCaVmNVNe+mgRiXeRqXVIWbjXwCABX3rws3VOjPwimWShqfZ65cYZUHMY6z9+uuv6Nu3L6pVq1bgOpUqVcKuXbvKNA5XV1c0adIE+/fvR+/evQHkJMr279+PiRMn5lm/Vq1aJl1XAeDdd99FWloaFi9ejLCwsDKNl4iIiKgoJapYK+wxkSVFlFfifkqW3VUXVPRTQi4TR+UOUW4uMvMSa+aOd2bc3kVa6jaKw0UmEeUXRuKqWBPPseaWlpaGwMDAQtfJysqCTlfyMRFLKiYmBsOGDUPTpk3RvHlzLFq0CBkZGYiOjgaQM4RIaGgo5s2bBzc3N9SrV89ke19fXwDIs5yIiIjIFsyevGDEiBGoX78+Jk+ebMl4iAAASlcXBHq5ISE129ahGMmkElQqx0GPSbzkMilUGuctb3IVadJcTLkmEQ+xhrCwsDyVX7mdOXMmT7fKsjBgwAA8fPgQM2fOxIMHD9CwYUPs2rXLOKHBnTt3IBVJ93MiIiJyfGbftXz//fdITEy0ZCxEJiLK21cSK9TPHa4uvNEn8XL2ak25SK9vVqyJQ/fu3bFnzx7s27cv3+d/+OEHnDhxwtg9s6xNnDgRt2/fhkqlwsmTJ9GiRQvjc4cOHcKaNWsK3HbNmjXYunVr2QdJREREVAxmf4qoWrUq7t+/b8lYiEx4uclR3ivv4MO2IJWC1WokenInH9hfjOOrAYCYUk1irlh7++23UaFCBbz44osYPXo0fv/9dwDAsmXLMHToUAwePBgREREms2kSERERUdFK1RX0ww8/xN27dxEaGmrJmIiMKvt74FGaytZhINjbHW5WGOOJyJ45fcWakx9fQcRUsSamY80tICAAv/76K4YOHYqVK1calxsmDGjRogXWrVsHHx8fW4VIRERE5JDMTqz17dsXBw8eROvWrfHWW2+hWbNmCAoKynfg50qVKpUqSBIvH6Ucfh6uSMpQ2ywGicT+uqUS2YKzd4VWOPnxFURM3SNFdKj5qlKlCo4dO4azZ8/ixIkTePLkCby9vdGiRQs0a9bM1uEREREROSSzE2tVqlSBRCKBIAiYNGlSgetJJBJotVpzd0OECH+lTRNrQd5uULqafakQOQ1nH9xfrBVrYko2ibli7WkNGzZEw4YNbR0GERERkVMwO1sQFRWVb3UakaX5eyrg7S5HapbGJvsP92e1GhHg/Ikn8U5eYOsIrEfMebXZs2dDqVTitddeg0KR//ilv/76K3799VfMnDnTytEREREROS6zE2uFzdZEZGkR/kr89W+K1ffr7+kKLze51fdLZI+cvSuos1fkFURMVVyCqKZqMDVr1ixIJBJs2bIFW7duRUBAQJ51Dh06hNmzZzOxRkRERFQC7N9GDiHASwGpBMhS60q0nUqre+r/ekikJds+2NutROsTOTOnT6w5+fEVRER5NVEda36qV6+OEydOoEWLFti2bRvq1Klj65CIiIiIHB4Ta+QQJBIJRqz9vVRtvPnjRbO2i/+wW6n2S+Qs5DLn7v4v1oo1MVVxiak6Lz+DBw9GzZo1ER0djTZt2mDDhg3o2rWrrcMiIiIicmilSqylpaXh888/x759+3Dv3j2oVKo860gkEty4caM0uyEiIjvgKpNCInHeqh+xVqyJKK8mpkMt0IABA1CpUiX07t0b3bt3x+LFi/Hqq6/aOiwiIiIih2V2Yu3hw4do3bo1bty4AW9vb6SmpsLHxwdqtRpZWVkAgAoVKkAu5/hUZBmXZkeatZ1Go8Hu3XsQGdmV70eiUpBIJJDLpFBr9bYOxeJkMglkUueuyCuImJJNzpoULqlWrVrh5MmT6NatGyZOnIi///4bCxcutHVYRERERA7J7K/nZ82ahRs3buDrr79GUlISAGDy5MnIyMjAyZMn0bx5c0RERODiRfO63xHlpnR1MftHITN/eyL6j7NWdSlE2g0UEFuySVQHW6iIiAgcP34cnTp1wpIlS9CrVy+kpaXZOiwiIiIih2P2J4kdO3agU6dOeOWVVyCRmH7L36xZM+zcuRPx8fGIi4srdZBERGQfFM6aWJM753EVh5jGWBNXErFo3t7e2LlzJ0aPHo1t27Zh8eLFtg6JiIiIyOGY/Uni/v37aNSokfGxTCYzdgEFAD8/P7zwwgv44YcfShchERHZDYWLzNYhlAlnPS4ig/DwcPj6+uZZLpPJsHz5csyfPx96vfN18yYiIiIqa2b3c/Px8YFGozE+9vPzw7///muyjre3NxISEsyPjoiI7IqzdgV11uMqDjFVcYnoUPO4detWoc+/+eabeOWVV5CdnW2liIiIiIicg9mJtSpVqiA+Pt74uFGjRti7dy8eP34Mf39/ZGVl4ZdffkGlSpUsEScREdkBNyftMukm4oo1MSWbxJRENEdQUJCtQyAiIiJyOGYn1rp27YpPP/0UmZmZUCqVGDt2LPr164cGDRqgVatWOHPmDOLj4zFnzhxLxktERDbkrF0mxTzGGjmnO3fuAABCQ0Mhk8mMj4uDX4oSERERFZ/ZibVx48ahTp06xsTaSy+9hPnz5+ODDz7Ajz/+CHd3d8TExGDq1KmWjJeIiGzIWRNQzjopA4lXREQEJBIJLl++jBo1ahgfF0UikUCr1VohQiIiIiLnYHZiLSQkBAMGDDBZ9uabb+KNN97Ao0ePEBgYWKwbOCIichzO2mXSTe6cx0XiFRUVBYlEAh8fH5PHRERERGRZZifWCiKTyThGBxGRk3J1kUIqBZxp8kCJBHCVsWKNnMuaNWsKfUxERERElsFPEkREVCLOVrWWkyxkJY8YsGCLiIiIiCyt2BVrVapUMWsHEokEN27cMGtbIiKyP26uMmSqdbYOw2LcRd4NlLkmIiIiIiLzFTuxptfrzRqbQ+Dc9kRETsXZKtacdabT4hJTFZeIDjVft27dwuLFi3Hu3Dncu3cPGo0mzzr8QpSIiIioZIqdWIuPjy/DMIiIyFG4OdnMoO6uznU8RPnZtWsXevfuDbVaDblcjsDAQLi45L0N5BeiRERERCVj8ckLiIjIubm7OleFl9hnBJWKqGRNzLNiTps2DTKZDBs2bEDfvn0hlTKhTERERGQJvKsiIqIScbauoGJPrIkp1STivBr+/vtvDB48GC+//DKTakREREQWVOyKta+//hoA0KdPH3h5eRkfF0dUVFTJIyMiIrvkbBVrYp+8QEyZNREdah7BwcFwc3OzdRhERERETqfYibXhw4dDIpGgZcuW8PLyMj4ujCAIkEgkTKwRETkRhYsUUimg19s6EssQe2JNTF1BxXSsuQ0ePBgbNmxAdnY2E2xEREREFlTsxNqqVasgkUgQEhICAFi9enWZBUVERPZLIpHAzUWGTLXO1qGUmkIuhVQq3mQLIK5kk5iONbdZs2bh3LlziIyMxNy5c9GgQQN4enraOiwiIiIih1eiirWnDRs2zNKxEBGRg3B3dY7EmtLJurWaQ0x5RRHn1SCXyzFp0iQMHDgQ7dq1K3A9iUQCrVZrxcjImaRma+ClcBH1RCFERCQ+nBWUiIhKzFnGWRP7xAWAuGbKFHPF2oYNGzBkyBDo9XpUqVIFISEhcHHhbSBZzun4JxjwxXGM71ANUyJr2jocIiIiq7HIHZVer0dCQgI0Gk2+z1eqVMkSuyEiIjuhlDvHB3Klq3McR2nISlGyptKUvGpRpdU99X89JNKSt6EwMyFammN1dLNnz4aPjw927dqFZs2a2TocckJfHr4JvQB8d/I2E2tERCQqpfpE8e233+KTTz7BpUuXoNPlf2PMLgVERM7HWSrW2BUUkJWiimvCuj9Lte83f7xo1nZfRTU1azuZ1KzNnMKtW7cQHR3NpBqVmfKergCAYa0jbBsIERGRlZmdWPvkk08wbdo0yOVytGvXjl0KiIhExFkSUs5yHKUhFVGyScxdQcPCwgr8EpTIEv5NygIAhPq62zgSIiIi6zI7E/bZZ58hNDQUv/32GypWrGjJmIiIyM65y2WQSABBsHUkpePOMdZK1T1y6aBGJd5GpdUhZuNfAIAFfevCzdXV7P2XlJi7go4ePRqffvop5s6di3Llytk6HHJCd/8/sZaYpsKTDDXKeVjv2iYiIrIlsxNrDx8+xNixY5lUIyISIalUAne5Y88MqpBL4SLmvoH/z6UUySZzxzozbu8iLXUbJSHmxFq/fv1w7NgxtGnTBu+++y4aNGgAb2/vfNfl2LhUUnq9gH+TcxJr83dfRaVySvRoUMHGUREREVmH2Ym1GjVqICkpyZKxEBGRA3F3dezEGruB5hBT90gXMfV7zaVKlSqQSCQQBAFRUVEFrsexcckcjzJUUGv1AIAALwU0Or2NIyIiIrIesxNrkydPxhtvvIHbt28jPDzckjEREZED8FC44HG62tZhmI0zguYQU7JJRIeaR1RUFCQiSqKSdRnGVwvxccPxGZ1sHA0REZF1mf2pYtiw/2PvvuOjru8/gL++t3PZ80JCSAhTZIYkCIIQDOJCcTH0J4iKrRZH0yqoLWptBapSWhd14KoIWhWtIkICAWUlELbMBAKEXPa+jFu/P44EQi7J7ZXXsw8fJXff+94n+d4l3+/73mMuSktLMW7cODz22GNdlhRcd911Ni+QiIg8k7dnfPkzsAYAEIt7TrBF2oMjax999JG7l0A+rLW/Wlyo0s0rISIicj27ripqa2tRU1ODxYsXd7kdp1AREfkebw9MKeXeHRh0FGkP6jsm6UFBRCJXapsIGsqJoERE1PPYfFW0ePFivPLKK4iMjMSsWbPQq1cvSCSOu8h666238Oqrr0KtVmPEiBF44403kJqaanbbr7/+Gq+88gpOnToFrVaLAQMG4A9/+APuv/9+h62HiIja8/bAlLcHBh2lJw1w6Ellr0SuVFStAQBEBcox8987UVihQdYfJsJfzt+zRETk+2z+a7dq1SoMHDgQubm5CAgIcOSasHbtWmRkZGDlypUYM2YMVqxYgalTp+L48eOIiorqsH1YWBief/55DB48GDKZDN9//z3mzZuHqKgoTJ061aFrIyIiE7lEDIlYgE5vdPdSrCYWCVBIGWQBelYWV0/6XidPngxBEPDxxx+jd+/emDx5skWPEwQBWVlZTl4d+ZrWjLW+Ef74Ys85VGm0KKzQYEiM+TYxREREvsTmwFpVVRVmzZrl8KAaACxfvhzz58/HvHnzAAArV67EDz/8gFWrVmHRokUdtp80aVK7r5988kl8/PHH+OWXXxhYIyJyogC5BNUarbuXYTU/mZiN3C/qKX3HBAGQ9KCy1+zsbAiCAI1G0/a1Jfi+IFu09ljrHapEfLg/qjTVKKxoYGCNiIh6BJvPpocNG4bi4mJHrgUA0NLSgr179yI9Pb3tNpFIhPT0dOzcubPbxxuNRmRlZeH48eMcmkBE5GTeOlkzgOVJbaQ9JItLIhb1qKCRwWCAXq/HwIED27625D/2xSVbPHBtAh4a3xf9owKQEG4aYHCmQuPmVREREbmGzVcWzz//PGbNmoW8vDwkJSU5bEHl5eXQ6/VQqVTtblepVDh27Finj6upqUFsbCyam5shFovx9ttvY8qUKWa3bW5uRnNzc9vXtbW1AACtVgut1vsyL6hrrceUx9b38Ni6n58YMOp1Dt+v0aC/7N8Ghz+HQszXzeUEow4Gg2uey9nHtjNiidgpx5yvIyLgvjHxbf+OD/cHABRWNLhrOURERC5lVynolClTMG7cONx///0YMWIEgoLMp3vPmTPH5gVaKjAwEPv370d9fT2ysrKQkZGBxMTEDmWiALBkyRK89NJLHW7fsmULlEqOCfdVmzZtcvcSyEl4bH1Psx5o/RPVWHgABgfPSThSABxx7C7JQs4+tp3RAFh/1An71XhHVs6DDz6I6dOn47bbbut0m++//x5ff/01Vq1a5cKVka9JiDCdSxcyY42IiHoImwNrDzzwAARBgNFoxAcffACgY18Oo9EIQRCsCqxFRERALBajpKSk3e0lJSWIjo7u9HEikQj9+/cHAIwcORJHjx7FkiVLzAbWnn32WWRkZLR9XVtbi7i4OKSlpSE8PNzitZJ30Gq12LRpE6ZMmQKpVOru5ZAD8di6X7NWj535FQ7fr1inB3IOAQD84kdAIXPs8R2TGAY/Ly1jdYY9ZypR3+SizDEnH9vORAbJcXVMsMP325r17uk++ugjJCQkdBlYO3DgAD7++GMG1sgqxTWNKKltRp8wJcL8ZcxYIyKiHsfmq4oPP/zQketoI5PJMHr0aGRlZWH69OkATH1BsrKysGDBAov3YzAY2pV7Xk4ul0Mul3e4XSqV8uLch/H4+i4eW/eRSqWQyKTQO3gyqGC49EGNIBJBEDsuCCYSAYFKRY/qt9UduVyGBhdVNDrz2HZFLpM55feEL/3uaWpqgkTCgDNZ54eDxfjrD0cxbUQM3pg9CgkXA2sXaprQpNVDIXVRWioREZGb2Hz2NHfuXEeuo52MjAzMnTsXycnJSE1NxYoVK9DQ0NA2JXTOnDmIjY3FkiVLAJhKO5OTk9GvXz80Nzdj/fr1+PTTT/HOO+84bY1ERGQSIJegxosmgyplEgbVriAT+/5kUJnE97/H7nT2ujcajTh37hx+/PFHxMTEuHhV5AuigxSIC/UDAIQqpQhUSFDXpMO5Sg0GqALdvDoiIiLn8siPJWfOnImysjIsXrwYarUaI0eOxIYNG9oGGpw9exYi0aUT5IaGBjz22GM4f/48/Pz8MHjwYPznP//BzJkz3fUtEBH1GP4y7wqscSJoR/IeEHTqCd/jlUSi9pNQX3zxRbz44oudbm80GrFw4UIXrIx8ycMTEvHwhEQYjabMZUEQkBDuj0NFNThTwcAaERH5Po+9uliwYEGnpZ/Z2dntvv7rX/+Kv/71ry5YFRERXcnbAlXetl5XkEt8v1SrJ2asXXfddW2BtW3btqFPnz5ISEjosJ1YLEZYWBgmT56M+fPnu3iV5CsuD+L2CVfiUFEN+6wREVGPYPHVhUgkgkgkwq+//oqBAwd2+BS0M4IgQKdzTUNkIiJyvQCFdwWq/BlY60Au9f2gU08IHl7p8g8iRSIR5s2bh8WLF7tvQdRjJISbJoOeYWCNiIh6AIuvLlo/9VQqle2+JiKins1f7l0BC2asddQTyiR7wvfYFYPB4O4lkA+qbdLiphU/o3eoHz57eAwkF/s1XpoMqnHn8oiIiFzC4quLK8svr/yaiIh6JrlEDKlEBK3O8y/cxWIBfjLvCgS6gq9ncwkCA2uX27dvH/bt24eamhoEBwdj1KhRGDVqlLuXRV7ofGUjiqob0ajVtwXVACA1IQwvTBuCwdFBblwdERGRazj0Y3udTodDhw4BAIYOHepTI+iJiKhzAXIJqnQt7l5Gt5itZp6vB53kEjGz7AHk5uZi/vz5bedqRqOx7ecybNgwvP/++0hOTnbnEsnLFFU3AgB6X5wI2iohwh/zIvq6Y0lEREQuZ9UVRkFBAbKzszF+/HgMHDiw3X3ff/89HnroIZSXlwMAQkND8fbbb2PGjBmOWy0REXmkQIUEVQ2eH1jzlzGwZo5IJEAmEaHFC7IObdETesh1Jy8vD2lpadBoNLj++usxYcIEqFQqlJSUYNu2bdi8eTPS0tLw888/Y+TIke5eLnmJ81WmUs/YEL9utiQiIvJdVl1hvP/++1i2bBkKCgra3X7q1CnMmDEDTU1NiI+Ph7+/P44ePYr77rsPAwYMYHkBEZGP85aBAIFeNmjBlRRSsc8G1hQ+XupqiWeffRZarRY//fQTpkyZ0uH+n376CdOmTcOiRYuwYcMGN6yQvFFRlfmMNQA4UVKHY+o6DIsNRt8If1cvrUfTG/TIK81DmaYMkcpIJEUlQSyy7vegwWDEz6fKMTo+lNneRETdsOoj3F9++QUjR45EfHx8u9v/+c9/oqmpCb/73e9w+vRpHD58GF999RX0ej3efPNNhy6YiIg8j7ecdHvLOt1B4cNZXX4y3/3eLLVjxw7cc889ZoNqADB16lTcfffd2LFjh4tXRt7s/MXAmrmMteUbT+CJz/ch+3ipq5fVo2UWZmLqV1Px4E8PYuHPC/HgTw9i6ldTkVmYadV+Vm0/jbmrcrBk/VEnrZSIyHdYdaZ5+vRppKamdrh9w4YNkMlkeOWVV9pumz59OiZMmICff/7Z/lUSEZFH85aAVQAz1jrlJ/XdrC5fH85gCYlE0uGD0Sv17dsXYjF/VmS51h5rsaHKDvcN6x2MlIRQhCplrl5Wj5VZmImM7AyUaEra3V6qKUVGdobFwTWDwYj/7CoEAGw+Vgqj0ejwtRIR+RKrAmtlZWWIiIhod1tlZSXy8/MxZswYBAYGtrtv1KhRKCoqsn+VRETk0cQiAUoPn7Ypl4ogFTNzqTMKHw6scRIsMG7cOOzevbvLbXbt2oXx48e7aEXkC1p7rJkrBf1dWn98+dtxmD4q1tXL6pH0Bj2W5iyFER2DYK23LctZBr1B3+2+dhVU4EyF6dgW1zS1/ZuIiMyz6gpDKpWioqKi3W179+4FALNTpPz92U+BiKin8PRsMG/JqnMXnw6s+fD3ZqlXX30Ve/fuxZ/+9CdoNO0vkjUaDZ577jns27cPf//73920QvI2Dc06VGm0AIBYM4E1cq280rwOmWqXM8IItUaNvNK8bve1Oudsu6935ld0siUREQFWDi8YOHAgsrKy2t22ceNGCIKAcePGddj+woUL6NWrl30rJCIirxAgl6AUze5eRqc4uKBrnp5xaA9fDhpa6rXXXsPw4cOxZMkSvPPOOxg1alTbVNB9+/ahuroaEyZMwKuvvtrucYIg4IMPPnDTqsmTtZaBBikkCFJIO92uWaeHVCSCSCS4amk9UpmmzCHb1Wi0+OmIGgAwZYgKm34twY78ctw7po/dayQi8lVWXWXcdddd+NOf/oTf/va3eOyxx3DixAm8++67CAgIwI033thh++3bt6N///4OWywREXkuz89Y6/zCj3w3+CSXiiDmBT0++uijtn9XVVVh8+bNHbbZtm0btm3b1u42BtaoM60TQc31VwMAo9GI65dvxenyBmx7Og1xYea3I8eIVEY6ZLtgpRT/e3w8Nh8rRXJ8GDb9WoJdBRUwGo0QBP4uJSIyx6qroKeeegpr167Fu+++i/feew+A6Y/m8uXLO5R97tmzB6dOncJvfvMbx62WiIg8lqeXWvrLfTNw5ChikQC5VIRmrcHdS3EoloGanD592t1LIB/TVX81wBSUFQkCjEbgTEUDA2tOlhSVBJVShVJNqdk+awIEqJQqJEUldbuvwdFBGBwdhGadHgqpCOX1LThZWo+BqsBuH0tE1BNZdRWkVCqxfft2/OMf/8CuXbsQHh6Oe+65B9OmTeuwbV5eHm6//XbcdtttDlssERF5Lj+pGGKRAL3B86aHiUSAv8yzA3+eQCkT+15gzYdLXK3R3URQ8m6NLXp8d6AINw/rhcAuyjId6XxrxlpI5/3VEsKVOFVajzMVGkwY4JJl9VhikRiLUhchIzsDAoR2wTUBpkyzhakLIRZ1/jvxyqw0uUSMlIQw/HyyHDvzKxhYIyLqhNVXGQEBAfjzn//c7XaPPPIIHnnkEZsWRURE3kcQBAQoJKi52MzakyhlEvb3sYCfVIIqeN7xs4eSAVXqAf745QH8cKgY5yob8cepg1zynDcN64WoIAWG9ArqdJv4cFNFS2F5g0vW1NOlx6dj+aTlWJqztN0gA5VShYWpC5Een97l45/9+hCadQb8Lq0f+keZgmjX9o9AtUbr8VnpRETuxN+QRETkMP4yzwys8YLAMr44wMAXvyd7fPbZZ/joo4+wf/9+1NbWIigoCKNGjcIDDzyAe++9193LIxsdLa4FAAyJ6TzI5Wgj40IwMi6ky20Swk3ln2cqNF1uR46THp+OtLg05JXmoUxThkhlJJKikrrMVAOAmkYtvt5XhBadAQ+MS2i7/TfXJeK3E/s5edVERN6NVxpEROQwnjp5k4E1y/hiEIqloCZ6vR4zZszAunXrYDQaoVAoEBMTg5KSEmRmZiIrKwtfffUVvvzyS4hEIncvl6y0/skJ2H26EqP6hLh7Ke20ZaxVMGPNlcQiMVKiU6x6TJBCgi9/MxZZx0oxvHdw2+0cWEBE1D2eORERkcN4agDL0yeWegpfDEIpObwAAPCvf/0L33zzDa699lps374dGo0Gp0+fhkajwY4dOzB+/HisW7cOb7zxhruXSjZQSMWYODASQS7qr9as02P9oWIcPF8No7HzvpoJrYG1Sg0MHth/01kqG1pQ1+R52dtdEQQBI+JCkDFloNlgmqZFh6LqRjesjIjI8zGwRkREDuPvqYE1D12Xp/G1fmRyqQgSMU91AODjjz/GwIEDkZWVhbFjx7a775prrkFmZiYGDhyIDz/80E0r7Ln0Bj1y1blYX7Aeuepc6A16m/bz4ndHcOOKbdh3tsrBK+zofFUjHvssD7Pf3dXldjEhCkhEAlp0Bqhrm5y+Lk9Qo9Hiur9vwTWvZOG1n457ZHsEa327vwgjXtqIP6877O6lEBF5JN86gyYiIreSSUSQS0UeNVlSIhagYNaSRcQi08+qSWvbhb2n8cXSVludOHECCxYsgFRqPqNJKpVi2rRpePPNN128sp4tszDTbKP5RamLum00DwBavQEz/70TyQlhOFRUg2PqOhxX12FUn1BnLhtavQFJfULgJxN3WSooEYsQF6bE6fIGnKloQEwXE0R9xZHiGtQ36wAAb245hY93nsHD4xPx4PgEl01stdYL3x5Gs86AR65LRGJkQIf7+0UGQKs3oqiqscPkUCIiYsYaERE5mKdlrTFbzTpKue8Eo3wtA88eMpkMDQ1d97lqaGiATCZz0YooszATGdkZ7YJqAFCqKUVGdgYyCzO73ce+s9XIO1uN/+4939YX62RpvVPWe7nB0UH4+rFr8dnD13S7bfzFAQaFPWSAQUGZ6X02ICoAg1SBqGvS4R+ZJzDh71vwdvYpaFp0bl5hezWNWqzdcw5rcs+hqpPsuiG9grD16UnY8NQEBtWIiMxgYI2IiBwq0MMCWeyvZh1/HwpG+dL3Yq9Ro0bhiy++wIULF8zeX1xcjC+++AJJSUkuXlnPpDfosTRnKYzo2Hes9bZlOcu6LQvdeqIUADC+fwQGqQIBACdK6hy8Wvu09VnrIYE1hVSMq3oFYerV0fjxyQl4Y/YoJEb6o1qjxd83HMeEZVvw/s8FHpMZ/O3+IjRpDRikCkRSJ8MvRCIB8eH+DKoREXWCgTUiInIoT8tYY3DFOr5UPulL2Xf2ysjIQEVFBZKTk/H6669jz549OHfuHPbs2YPXXnsNo0ePRmVlJTIyMty91B4hrzSvQ6ba5YwwQq1RI680r8v9bD1RBgCYODASA1SmEr5TLshY62pgwZUuZaz1jMmgd4/ujR+fnIA/Th0EkUjAtBEx2PjUdXj9nhHoE6ZERUML/vrDUVz39y34+WSZW9dqNBqxevdZAMCs1DiLAmfWHHsiop6CgTUiInIoT8sQC/Sw9Xg6TwuM2oNB1UumTZuG1157DeXl5XjmmWcwZswYJCQkYMyYMXjmmWdQXl6O1157DbfeeqtL1vPWW28hISEBCoUCY8aMQU5OTqfbvvfee5gwYQJCQ0MRGhqK9PT0Lrf3BmUaywIqXW1XXt+Mw0W1AIAJAyPQP8qUsVZc0+T0iZSz39uF8cs2Y0d+ebfbtmasnekhGWvmSMQi3DW6N7L+MBFL7xyG2BA/VDS0IC5U6dZ1HThv6ssnl4hwx6jYLretbdLikU/2YOySzWjWeUa2HRGRp+AZJxEROZSnBTN8KVDkCr6SsWYaxMDPDy+XkZGB6dOn47PPPsP+/ftRW1uLoKAgjBo1Cvfeey8SExNdso61a9ciIyMDK1euxJgxY7BixQpMnToVx48fR1RUVIfts7OzMXv2bIwbNw4KhQLLli3DDTfcgCNHjiA2tutggKeKVEbavV1rttPVMUGIClQAAFRBcpTUNuNkaT2SnDjAoLBCg+KaJov6GI6IC8G7949GYqS/09bjKQwGUzaXSGQ+80sqFmFWah/ckRSLvWeqkBBx6Wey9Mdj6BfpjztGxbpsmvHnF7PVbhnWCyHKrvsrBsolyDtbhfL6Fuw/W40xieGuWCIRkVfg1QYRETmUWCRAKRND0+L+T7TlUhGkLrpA8RUKqRgSsQCd3rvLfZTdTCvsqRITE/HnP//ZrWtYvnw55s+fj3nz5gEAVq5ciR9++AGrVq3CokWLOmz/2Weftfv6/fffx1dffYWsrCzMmTPHJWt2tKSoJKiUKpRqSs32WRMgQKVUISmq8553W49fKgNtNSAqECW1zThV4rzAWovOAHVtEwAg1oIpn2H+MtxwdbRT1uJpjpfU4Y63t2NkXAjWPDK20+3kEjHG9Y9o+/pkSR3+vS0fRiNwdUwwhsQEOX2tdU1a/O+gqefirNQ+3W4vCAKuSQzH9weLsbOggoE1IqLL8GqDiIgczlOyxDxlHd7GF35uvvA9+KKWlhbs3bsX6enpbbeJRCKkp6dj586dFu1Do9FAq9UiLCzMWct0OrFIjEWppiCigPYB4NavF6YuhFhkPoPUYDBi20lTGWa7wNrFPmvOHGCgrmmC0QjIJSJEBHCK7OUKyhrQpDWgWWew6nGxoX5YeONgzE6Nw6Bof+Sqc7G+YD1y1bndDrCw1XcHLkDToke/SH+kJFgWhB3XzxQM3JFf4ZQ1ERF5K551EhGRw/nLJSira3b3MhDA4IpNlDIxajTO7dHkbAyseaby8nLo9XqoVKp2t6tUKhw7dsyifSxcuBAxMTHtgnOXa25uRnPzpd8/tbWmPmRarRZaree8rifGTMTfJ/wdr+59FaWa0rbbo5RR+OPoP2JizMRO13u4qBaVDS3wl4sxLCagbbvEi4MCTpTUOu17PVNu+nnGhiig0+ksekzumSrkna1GSkJop5MnfcHkgWHIfGo8NC16q37+UgF4aFwfZJ3Lwg1f/b7d6yFSEYVnUp7G9XHXO3Stq3cXAgBmJve2+DimxJsy6fadrUJtQxP8fKR1ABFRZyz9Xc6zTiIicjhPCWgxuGIbTzl+9vDnBZ9PWrp0KdasWYPs7GwoFAqz2yxZsgQvvfRSh9s3btwIpdK9zeLNWSBdgDP+Z1BnrEOgEIgESQKaDzVj/aH1nT5m43kBgBiJSi02/bSh7fayWgCQ4FBhOdav7/zx9thVanpumbbe4uf4okCE7SUi3BBrgLqPddlc3ur0Puu2P9JyBJ9rPu9we1ljKZ7++WnMVs7G1bKrHbK2c/XAkQsSiAUj/MuOYP36IxY9zmgEQmRiVLcAK/+7EYNCvLtlABFRdzQaywbveP+ZMxEReRx/uWcENQI8bJCCt/CFgKQvfA++KCIiAmKxGCUlJe1uLykpQXR01324XnvtNSxduhSZmZkYPnx4p9s9++yzyMjIaPu6trYWcXFxuOGGGxAU5PzeVa7w6fs5AKpxz4SrcXNKXNvt1Rot/nVkC6paBFx3/Q1OCZKfzDoF5BdgxIA+uPnmIRY9Rn+wGOHHy5F+VSRuGtoz+q1ZQ2/Q41/f/cv8nRcrhTdjMzJuzOi0PNgaf/7uVwDncdPQXphxe+fvJXOyGw9h3YFiGCL74+YpA+xeCxGRJ2vNeu8OzzqJiMjh/GUSCILp0213UnpIgM/beHvGmkgE+El57D2RTCbD6NGjkZWVhenTpwMADAYDsrKysGDBgk4f9/e//x1/+9vf8NNPPyE5ObnL55DL5ZDL5R1ul0qlkEqldq3fE9Q2abHvXA0AIG1wdLvvKTJYishAOcrqmlFY1YyRcd0PF7BWcW0LAKBPuL/FP887R/fBnaO7b5DvzYxGI57570HEhSnx0Pi+VgX396v3tyv/NKdEU4JDVYeQEp1i1zobmnX4/qAaAHDfNQlWvyeuHRCJdQeKsftMlU+8n4iIumLp7znvPnMmIiKPJBIJ8JO6dzIoJ4LaTi4RQSwSoDd4Z5mPn1QCkYgTQT1VRkYG5s6di+TkZKSmpmLFihVoaGhomxI6Z84cxMbGYsmSJQCAZcuWYfHixVi9ejUSEhKgVpuCAgEBAQgICHDb99HqcFEN3tmaj/gwJZ65cbDTn29XfgX0BiP6RfojLqxjaevv0wdCLhEhLtTxQTUAKKo2lcX0dtL+vVVpXTO+3HseYpGA307sZ9VjyzRlFm13pOS83YG18vpmDIkJQnldM65JtH4AyNh+pmmgB8/XoK5Ji0AFg2tERAysERGRU/jLJW4NrLEU0HaCIMBfLkFto+c0ereGt2fc+bqZM2eirKwMixcvhlqtxsiRI7Fhw4a2gQZnz56FSHQpKP7OO++gpaUFd999d7v9vPDCC3jxxRdduXSzSmqb8MPBYoT5y/Bk+gDIJc7NlpwyRIX1T0xAlabF7P33jnFuZtj5qkYAQGyIdYE1nd6AC9VNiAqSQ+GDGaX5pfUAgLhQP8gk1n2oE6mM7H4jAB9tq8CMq3RQ2tHmID7cH1/8ZizqmrQQBOs/gOgdqkSfMCXOVmqQe6YSkwerun8QEZGP45knERE5hb9cjLI6Nz4/+6vZRSkTe21gzVN6/LmbVqvFzTffDIVCga+//rrTcobWoFVLSwt++OEHiMXO//ktWLCg09LP7Ozsdl+fOXPG6euxx8SBkVAFyVFS24zMX0txy/BeTn0+QRAwJMY9veJ0egPUNU0ATAEWa0x6LRvnqxrxzWPjMKpPqDOW51b55Q0AgH6R1mdRJkUlQaVUoVRTCiM6yRTWheBMkQoLvzqEf80aaVNQ7HL2ZJqN6xeOs5Ua7MyvYGCNiAgAa2SIiMgp7PlE3THPz+CKPbw564vZiiarV6/G5s2b8fDDD3fZI0Qmk2H+/PnYuHEjVq9e7cIV+gaJWIQZyaYBAmtyz7p5NUCzTo8dp8rxRe45h++7pK4ZOoMRUrGAqMCOfey60lo6Wlhh2YQ1b1NQZspYS4z0t/qxYpEYi1IXAQAEtA+YCRf/97vhf4BEJMb/DlzAqu1nbFrj9lPlqKhvtumxl2stB92RX2H3voiIfAEDa0RE5BTuzhhjcMU+3vzz8+a1O9KXX36JhIQE3H777d1uO23aNPTr1w9r1qxxwcp8T2tg7eeT5ThX6bzA0drcs8hYux878ss73UbTrMe97+/GM18dhKZF59DnL7pYBhoT4md1H8OEcFPA6UxFg0PX5Cnyy2zPWAOA9Ph0LJ+0HFHKqHa3q5QqLJ+0HL9NmY7nb7kKAPDK+qPYVWBdUKuxRY/f/mcvrlmShWNqy6bcdWZsoimwdlxdh7om78xsJiJyJJ55EhGRU7h7IifLAe3jrRlrggAofbB/ky3y8vJwyy23WLz9pEmT8MMPPzhxRb4rLkyJ8f0j8Mupcny55xwybhjklOf5/mAxfj5ZjiExQRjXL8LsNqH+MoyMC0FEgBx1Tfb147pS/6gArPy/JOgN1j82/mJgzfcz1mwfqJEen460uDTkleahTFOGSGUkkqKSIBaZfqc9MC4BB85VY93+C1iwOg/fPz4B0cEKi/atrm1CYoQ/KjUtGBgVaPMaASAqSIGPH0zFyN4hHF5ARAQG1oiIyEmkYhFkEhFadDZcgdlJLBac3kDc1ymk3jkZ1E8m5kTQiyoqKhAdHW3x9iqVChUVLO2y1azUOPxyqhxf7DmPJ64fAIkTphI/cf0ADI0NRvpVXfe1Wve7ax3+3AAQ5i/DjUNt6yEXH27qyeaLGWtNWj2Kqk3ZfLaUgl5OLBJ3OvlTEAQsuXM4jqnrcExdh5Vb8/HibVdbtN++Ef74dsF4VDW0OOR35MSBlg1cICLqCRhYIyIip/GXi90SWHN3GaovEAQBSpkYdU2OLSVzNm/NtHMGpVKJmpoai7evq6uDUmldQ3q6ZMoQFUKVUqhrm7DtZJlTmrqnJIQhJSHM4ft1hdbAmi9mrJ0ub4DRCAT7SRHuL3Pqc/nJxPj3/aOxOucs/mhDZmSok9dHRNQTsccaERE5jZ/UPUEODi5wDG/sVeaNa3aWxMRE7Nq1y+Ltd+7ciX79+jlxRb5NLhHjrqTeAIDPcxw/OMBaRqMRNQ6e7PvDwWL8eKgYlQ0tVj+2tRS0sqHF4etyt4KL/dUSI/3tntZpifhwfzx701WQWpgVmXO60uE/c6PRiH9sOoF7Vu5AWZ39AxGIiLwZA2tEROQ07upzxsCaY3hjkIoZa5fccMMN2Lt3LzZv3tzttlu2bMGePXtwww03uGBlvmtWqmmIweZjpSitbXLovldknsCWY6UWZQEfLqrBiJc24tY3fnboGl796Rge/SwPJ0rqrH5sgFyCiADTJNGzPpa1ln+xv5qtgwvsodUbsGT9URwuMp+d2qTVY/4nezDmlUy7hxZcThAEbPq1BLlnqqwepEBE5GsYWCMiIqfxc1OAy5HNunsybxwAwaDqJY8//jgUCgVmzZqF7OzsTrfbunUrZs6cCaVSiccff9x1C/RB/aMCkRwfCr3BiC/3nnfYfs9VarAi8yTmf7IHTTp9t9tHBytQ26TD+apGh04GTYoPxag+IegTZlvJcIKP9lm7NLjAvv5qtvhn5kn8e1sBHv1sL5q0HV8bPx4uRk2jFuH+cgywc2jBlR65LhFL7hyG1L7eWZ5MROQovPIgIiKncVeAy10BPV/jbdlfgsD+epeLiYnB+++/j/vvvx/XX389rr32WqSlpaF3b1O5YlFREbKysrBjxw4IgoD//Oc/6NXLtsb0dMnMlDjsKazCF3vO4dGJ/RzSKH7riTIApsBWkAVTGCMC5Ajzl6GyoQUFZQ0YGhts9xoAYPmMkXY9Pj7cH3sKq3C20rcy1grKL5aCRrg+Y23+hERsOV6KxycPgMLMROTWsuSZKXEQO3iwy/RRsQ7dHxGRt+LZJxEROY3SzEm+S56XgTWH8JOKIRIBBtfPn7CJab2cCHq52bNnIzQ0FL/73e/wyy+/4JdffmnrAWU0mia+JiYm4q233sLUqVPduVSfccvwXvjrD0eRGOGP2iYtQpT2N4tvDaxZM4mxf1QAck5X4kRJncMCa/Zqy1gr962MtbRBUYgMkGNwtGMzwiwRrJTifwvGm/3dd6q0HjmnKyESgBnJcS5fGxFRZ/QGPfJK81CmKUOkMhJJUUkQi7z3/J2BNSIichqRSIBCKjZbnuIsUonI4obO1DXTZFAJ6r1kMqg39oRzhRtvvBEnT57E5s2bsWPHDqjVagBAdHR0WxabSMT3jKMoZRJsXzTZYRmfLToDdpwqB9B5YM3cBcqAi4G1k6X1DllHk1YPqVhkV9ZTfISpVNLXJoP+fspAtz7/5UG14ppGnC5rwLj+EVibexYAMHlwFKKDFU557tPlDdh6vBSDooMwtl+4U56DiHxLZmEmluYsRYmmpO02lVKFRamLkB6f7saV2Y5noERE5FR+MtcG1pit5lgBcm8KrPHYd0YkEiE9PR3p6d55wuptHFlGvbewCg0tekQEyDCkV1CH+zu7QBkT/CCAYJwscUxg7YNfTuMfm05gztgELJ42xKZ9tGasnfaxHmue4lRpPWb+eydadAZ8+ehY/Pdin7/ZqX2c9pxrc89h5dZ83D26NwNrRNStzMJMZGRnwAhju9tLNaXIyM7A8knLvTK4xsAaERE5lZ9UjCoXPx85jjcFKpmx1pFOp8Pq1auRm5sLQRAwZswYzJw5ExIJf1aucL5Kg9K6ZiT1CbV5H61loNcNiOxQ7tfVBcp3miWQBP4fTpbaNmjgSkXVjdAZjAiwI4A9UBWIH54Yj/hw1zf5d5bSuiaIBAHh/rK2Mmt3iQ9XIjHSH7lnqnDPOztR16xDr2CFVSXE1hrbLxwrt+ZjZ34FjEaj238GROS59AY9luYs7fA3CwCMMEKAgGU5y5AWl+Z1ZaHM+yciIqdydWCGgwscy5uCVZwG255Go8HYsWMxb948vPXWW3jzzTcxZ84cjB8/Ho2Nje5ens/L/LUEE/6+BYu+OtjWz84W21r7qw1qHxzp7gIFAOSq/+FsZb1DsoaLqkyvmdhQP5v3oZCKcXVMsNcNRunK21vykfzXTLz603F3LwVSsQhv3ZuEqEA56ppNmcb3JMdB4sT2CCkJoZCIBBRVN+JcJX+vEFHn8krz2mVXX8kII9QaNfJK81y4KsdgYI2IiJzK1YEuZqw5lldlrHnRWl3h1Vdfxd69ezFo0CAsXboUS5cuxeDBg5Gbm4vXX3/d3cvzeSl9w6CQiBERIEetjeXUpbVN+LW4FoIAjO8f0e6+7i5QAEAkrYHI7zTyy+wvBz1fZeqL1jvUMRlwvqK2SQtBAPqEecbPJSpIgXf+LwkSkQCpWMCM5N5OfT6lTIJRfUIAADvyy536XETk3co0ZQ7dzpP4zsdFRETkkVwdWPOmQJA38JdJIAiAHQk3LiGXipyaleGNvv76a/Tq1Qu5ubnw9zeV3j322GMYPHgw/vvf/+JPf/qTm1fo24L9pNixaDJC/W2fCrrtpClQMSw2GOEB8nb3WXrhIUjqcLKkHlfH2D4Z1Gg0oqj6YsZaiO0ZawCw5Xgpso6W4JrEcNw6PMaufXmC5TNG4pU7hnnU78jR8WH46tFx0BmMLgmEjk0MR+6ZKuzIr8AsJ/ZzIyLvFqm0rCzd0u08iceegb711ltISEiAQqHAmDFjkJOT0+m27733HiZMmIDQ0FCEhoYiPT29y+2JiMh1XJ1BpmDGmkOJRIJXZAF6U8mqq+Tn5+O2225rC6oBQEBAAG677Tbk5+e7cWU9hz1BNeBSfzVzPbIsvfAw6gJxsrTOrnVUNLSgSWuAIAC9QuybLrn/bDX+s+sstp/ynewmhVTscW0IRsSFYHS87b39rDG2nymbcmdBhV1lz0Tk25KikqBSqiDAfC9GAQKildFIikpy8crs55GBtbVr1yIjIwMvvPAC8vLyMGLECEydOhWlpaVmt8/Ozsbs2bOxZcsW7Ny5E3FxcbjhhhtQVFTk4pUTEdGVpGIRxGLXNDMWiQC5xCP/tHk1pRcErfzZX60DjUaDXr16dbhdpVJBo9G4YUU9V2ldE45cqLHqMXqDET+f7DywZskFSqAkAnpNX5ywczJoa3+1qEA55BL7AkjX9o/AgrT+mHp1tF37Ic8xqk8IZBIRyuqaHVJ2TES+SSwSY1HqIgDo8Ler9euFqQu9bnAB4KGBteXLl2P+/PmYN28ehgwZgpUrV0KpVGLVqlVmt//ss8/w2GOPYeTIkRg8eDDef/99GAwGZGVluXjlRERkjqsynhQSMSeSOYE3lNd6wxqpZ/rpiBrjlmzGs18fsupxh4pqUK3RIlAhwci4kA73W3KBMrvf4wBEOFVqX7Dj/MXAmiPKClP7huGPUwdh0qAou/flbllHSzBj5U68k92zM0AVUjGSL2bH7cyvcPNqiMiTpcenY/mk5YhStv8boFKqsHzScqTHp7tpZfbxuI93W1pasHfvXjz77LNtt4lEIqSnp2Pnzp0W7UOj0UCr1SIsLMzs/c3NzWhubm77ura2FgCg1Wqh1WrtWD15otZjymPre3hsvYdcZESd3vLm3UaD/rJ/G2C08LEysYivByeQi4wWH4Pu2HpsuyMTGd1y7D399Xb48GF88cUXHW4DgC+//NJs2daMGTNcsraeYnR8KAQBOHi+Bkcu1Fjc6ywmRIHFtw5Bo1bfaf/A1guUpTlL2w0yUClVWJi6EGNUE5EcWYv+UQF2fQ9F1aYMR3v7q/maIxdqkXOmEn3CPWNwgTuNTQzHjvwK7MivwP1jE9y9HCLyYOnx6UiLS0NeaR7KNGWIVEYiKSrJKzPVWnlcYK28vBx6vR4qlard7SqVCseOHbNoHwsXLkRMTAzS081HO5csWYKXXnqpw+1btmyBUsk/jL5q06ZN7l4COQmPre9p1gOtf6IaCw/AYOHfWQ2AooPOWhU5gq3Htju7ChyzH2t5eknlV199ha+++qrdba3BtFmzZnW4XRAEBtYcLCJAjilDVFh/SI21uefwl9stC6xFBSrw4Pi+3W7X3QXK2H7hdq0fuFQK2jvUMYG1C9WNOFPegKt6Bdndh86dCi6WPSZG+nezpe8b1z8cr28CdhVUwGAwQiRi9jgRdU4sEiMlOsXdy3AYjwus2Wvp0qVYs2YNsrOzoVCYb6767LPPIiMjo+3r2tpaxMXFIS0tDeHh9p98kGfRarXYtGkTpkyZAqlU6u7lkAPx2HqPc5Ua5FtRiiTW6YEcU9mUX/wIKGSWHd+ECH8kRPACx9FadHrsOOWY8h5bj22X+xQJGD8gwi1lwK1Z757ohRdecPcS6KJZKX2w/pAa3+wrwnM3X+XwISvOvkBpLQWNdVBg7ZFP9+BwUS3en5OM9CGq7h/gofLLGgAA/SLtywj0BcN7h0ApE6NKo8UxdR2GxAS5e0lERC7jcYG1iIgIiMVilJSUtLu9pKQE0dFdNzl97bXXsHTpUmRmZmL48OGdbieXyyGXyzvcLpVKeXHuw3h8fRePrefz95NDEDdZvL1guBQgEUQiCGLL/lz5+8n5WnACqVQKiUwKvd7+aW+2HtuuKBUSyGTuyXrx5NcbA2ueY3z/CMSG+KGouhE/Hi7GHaN6d7n93sJK5Jc2YOKgSKiC7JvCubewCht/VeOq6CBMHxVr0z6Kqh3XYw0A4sP9cbioFmcqGhyyP3cwGo1tGWv9mLEGqViElIQwbD1Rhp0FFQysEVGP4nHDC2QyGUaPHt1u8EDrIIKxY8d2+ri///3vePnll7FhwwYkJye7YqlERGQhhZ1T5Cx+HhcNSeiJlB78s+VEUPJ0IpGAmSlxAIDPc851u/2anHN45quDeG+b/TXOB85V499bC7DhsNqmxxuNxksZaw7qsZZwsSdZYYVnl1J3paS2GQ0teohFAvqE+V5gTW/QI1edi/UF65GrzoX+sv6YnbltRAweGJdgdtgGEZEv88gz0YyMDMydOxfJyclITU3FihUr0NDQgHnz5gEA5syZg9jYWCxZsgQAsGzZMixevBirV69GQkIC1GrTiUNAQAACApiaTUTkbnKpaz7HUbjoeXoif7kEdU2OGTTgaH6cCEpe4J7k3liReQI5pytRUFaPxC7KB4fEBGFkaQjSBts/OTM5IRRzxsYjJcH8UC9LfD7/Gpyv0iAuzDGBtfhwUyDKmzPWWrPV+oQpIZP41t+ezMJMswMxFqUu6nJi312je+Ou0V1nYxIR+SKPDKzNnDkTZWVlWLx4MdRqNUaOHIkNGza0DTQ4e/YsRKJLf8DeeecdtLS04O677263nxdeeAEvvviiK5dORERmyCUiCAJgZgChQ7kqM64n8uTgldKD1+ZON998s9WPEQQBP/zwgxNWQ72C/TBpUBQ2HyvF2txzePbmqzrddt61fTHv2u4HF1hieO8QDO8dYvPjBUHAsN7BGNbbsqELlki4GFjz5oy1/HJTUDDRx/p6ZhZmIiM7A0a0/4NdqilFRnYGlk9a3mVwzdcUlNXjtY3HMaJ3CH4zsZ+7l0NEHsojA2sAsGDBAixYsMDsfdnZ2e2+PnPmjPMXRERENhMEAXKJGE3a7ktJbCWViDiFzIk8OXjlyWtzpw0bNlj9GHcMgOhJZqbEYfOxUnyVdx5/uGGQz2U6Waq1FPR8lQYtOoNX/hxaB/L0i/Kd6hi9QY+lOUs7BNUAwAgjBAhYlrMMaXFpbVNnr9Ss02Pf2WqIRYJdWZKeoqCsAesPqfHzyXLMSu2DYD/P7atJRO7jsYE1IiLyLQqpyKmBNbkXXph5E6XUc08ZPDmbzp1Onz7t7iXQFSYPjkJkoBxldc3IOlqCm4b16rDN7oIKXBUThCCF4y7g65t1OFVaj3B/GeLCrBtAsKugAoeLajA6PhSj+oQ6ZD2RgXL4ScVo1OpRVN2Ivl6Y9VXggxlreaV57co/r2SEEWqNGnmleZ1OoV29+yxe+t+vuG5gJD55MNVZS3Uqo9HY9iFD+hAVxiaG4+XpQxlUI6JOee5ZMhER+RS5RAxA67T9c3CBc3lq8EosFi6+tuhK8fHx7l4CXUEqFuHu0b3xTnY+1uSe6xBYa2jW4f8+2A2DEfhlYRp6BTump9nL//sVa/ecwxPXD0DGlIFWPXbjkRKs2n4aj1yX6LDAmiAIiA9X4pi6DmcqGrwzsHaxx1pXvfK8TZmmzO7trkkMR0SAHL3snGbrLjmnK/Hid0fw/txkxFwc1vH5I9e4eVVE5On48T4REbmEswcYMGPNuWQSEcRizysT9GNAlbzMzGTTdNBtJ8twvqp9j7FdBRXQ6o2IDfFDtAMDEwNUpuDPqdI6qx87NDYItw7vhVEOnvTY1met3PsGGDRdzLQDgH6R3hcU7EykMtLu7QZHByL3+eux7O7hjlqWS+j0BizfdAKz3t2JX4tr8dpPxztsYzQaUejFAzeIyHmYsUZERC7h7MAXA2vO5ycVo17vWZNB2V+NvE1ChD+euH4ARsWFdMhI23rClAk0cWCkQ/vdDVAFAgBOltRb/dg7k3rjzqTuJz3qDXrkleahTFOGSGUkkqKSOu3DBQDxEaaS1DNeOMDgdHkDjEYg2E+KMH+Zu5fjMElRSVApVSjVlJrtsyZAgEqpQlJUUqf78MY+jecqNXhq7X7sLawCANyV1Bsv3X51u20q6psx76NcnCqtx/aFkxHqQ8ediOzHwBoREbmEs8v15MxccjqlTIz6Js8KrDFjjbxRZ+WYlwfWHGnAxQb7p8sbnDIsILMwE0tzlrbrz6VSqrAodVGnEyTjw1ong3pfBlB4gAwv3XY1mrR6rwwkdUYsEmNR6iJkZGdAgNAuuCbA9H0uTF3YZcC0ldFoRFF1I3qHWtfTz9W+O3ABz399CHXNOgTKJfjrHUNx+8jYDtuF+cug0xuhadHjk52FeDJ9gBtWS0Seih/vExGRSzBjzft5YhCLvfXInfQGPXLVuVhfsB656lzoDbYPaDlT3oDCCg2kYgFj+4U7cJVAr2AFAuQS6AzWlbJp9QYU1zRCb+iYvdQqszATGdkZHZrel2pKkZGdgczCTLOPa50MWuiFGWtRgQrMHZeA30zs5+6lOFx6fDqWT1qOKGVUu9tVShWWT1reaaD0cmV1zUj5WxYmv77VqUOL7FHfrMMfvjiAJz7fh7pmHZL6hGD9kxPMBtUAUybeo5NMx/ujHaehafGsD5mIyL2YsUZERC7h6AwJV++fPDOI5alDFcj32ZKldbmS2iZ8vOMMapu0+Ov0YW3ZasnxYfCXO/YUXRAE9I8KwP5z1ThZWt9WGtqdgrIGTF2xDREBcuz5U8fvSW/QY2nOUrNlg0YYIUDAspxlSItL65DlFH9xYEFdsw4GgxEike9kfnm79Ph0pMWlWVXae7mIABnEIqBFZ0BeYRXG9Y9w8oqtc+BcNZ5csw9nKjQQCcCCyQPwxOT+kIi7Po+4aWg04sOVKKzQYE3OOTw4vq+LVkxEno5XIURE5BJOD6x1c0JM9vPEIBZ7rJE72JqldblqjRZvZ+djTc45lNU1XyoDHeTYMtBWreWgJ0osH2DQOlxBFSQ3e39eaV6Hn8HljDBCrVEjrzSvw329ghTYv3gKcp9P97qg2pZjpTh4vhrNOs/MxnIEsUiMlOgU3Jx4M1KiUywOqgGmQO7YRFPW5c6CCmct0WoGgxHvZOfjrnd24EyFBjHBCqx5ZCwypgzsNqgGABKxCI9clwgAeO/nArToDM5eMhF5CV6FEBGRS0jFIoiddPEkCCwFdQWPLAV1cu8+oit1l6UFAMtylnVbFjooOhAPje+LN2aPglImxs58UwDC0f3VWrVOBj1ZavkAg9bJl7EhfmbvL9OUWbQfc9uJRAJClN7XAN5oNGLB6jzc9uZ2nKv0vjJWVxnXz5SltiPfMwJrTVo9/u+D3Vi24Rh0BiNuGdYLPz55HVL7hlm1n7uSeiMyUI7imiZ8u7/ISaslIm/DqxAiInIZZ2WtScUin2og7ak8rRRULhV5XaYLeT97srSu9Odbh+CmYb2w/1w1GrV6RAXKMTjasjJNa7WWf56yYjLo+SpTYK2zBvSRSsuCgJZu5w3qm3UYGhsMVZAcfS4OYKCOWvsEHjhXjfpm9/cjU0jFiA5WwE8qxt/vGo437x2FYKXUpv08dLEEdOXWfBi66D9IRD0HA2tEROQyzgqssb+aa4hFgkf9rD0t0Ec9gz1ZWp25fBqosz4kaC0FLSivh1ZvWQlb0cXAWmyo+Yy1pKgkqJSqtomRVxIgIFoZjaSoJLP3bzisxgMf5uDfW/MtWo8nCFRIsfY3Y7H7uXSP+n3oaWJC5IiNLgIC9uH5H9fZNdjDUf5y+1D88MR4zEiJs+t9dt+YPghUSJBf1oCNv3YeZCeinoN/DYiIyGWc1QeNFzeu40l91jyxNJV8n6OztMrqmvHutgIAwHVOKgMFgJhgPyhlYmj1Rosncbb2WOvdSWBNLBJjUeoiAOgQXGv9emHqwk77c5XWNSH7eBn2FFZZtB7yDpmFmZj61VTUhr4Bv9g12FzzEtLWTrGo96Aj7cgvx5/XHUZjiymoFyCXIDEywO79BiqkmDM2HgDwztZ8GI3MWiPq6XglQkRELuO0jDUOLnAZT+ppppDyuJPr2ZuldaXWPmYAMN6J0xNFIqEta+1UqWUDDLrrsQaYJkgun7QcUcqodrerlCosn7S8ywmp4/pF4JU7huF3af0tWo8n0LP0r0udDfaoai7D7y0c7OEITVo9/vjFAXy6qxDvZJ9y+P7nXdsXcokIB85Vt/VHJKKei2ekRETkMs4KrHFwget4UjBL7kFBPuo57M3SutLIuBD87Y6heGP2KIT6O7eZf/+oQMglIlQ0tHS7bWOLHuX1pu3iOumx1io9Ph0/3fUTVo1+DstKy7Fq9HPYcNeGLoNqpvUE4N4xfTAyLsR0Q50a2LLE9P8e6sGPcnHt0s3YcqzU3UvxOF0N9jC9NYwWDfZwBIVUjGV3D8c1iWH47aR+Dt9/RIAcM1PiAJiy1oioZ/Ocs2MiIvJ5zsoskzJjzWU8qa+ZJ62FehZ7srTMuW9MPKaNiHHkEs168bYh+PUvN+K+MfHdbtuarRYglyDIT9Lt9mKRGClhV+HmBg1Swq6yOLDYTp0a2LrUowNrp0rrUVTdiABF9z+Tnqa7wR4ALB7s4QgTBkRizSNjoZQ551jNn5AIsUjA9lPlnBBLFtMb9MhV52J9wXrkqnM9ov8g2Y9/EYiIyGU4vMD7yT0oY82Tsueo50mPT0daXBrySvNQpilDpDISSVFJtgWUXCRQYfkUxNb+arEhfl03eq9TXwqEFR9o//8AEBht+q8TB89X45i6DmP6hqH7cJ97NbbocaHGFHBMjOBE0CtZOrCjsFqNlM5fEnY5X6WB0QjEhXWdZekIcWFKLLlzGMb0DXPJ85H3yyzMxNKcpe0C0CqlCotSF1n9gQx5FgbWiIjIZZyVWcaMNdfxpCwxT1oL9UxikRgp0SnuXoZTtGasdTa4oM2eD01ZZpf73xOX/j1xEZD2bKcPf//HncgvyEfw5P6ID7t4sWlFYM6VTpc3wGgEQpRShDm5bNcbWTqwQ4Jgpzy/Tm/AU2v245i6Dm/cOwppg6K6f5CdZiTHOf05yDe09h+8slS6VFOKjOwMm7KdyXMwsEZERC7DjDXv5yn97MQigQFVIhss/O9BHDhfjbfvS+pyQuL5qouDC7oLrCXPAwbdZPp38QFTUG3av4BeI0y3dRMUu0O/EWnyVcD2y260IjDnSgXl9QBM2WpdZvH1UK2DPUo1peb7rMGUnTNt4LVOef53svOxp7AKAXIJ+jtg+qe1KhtanBJwbdEZoGnRIUTJYK5HqFObPlBInmdx0L+r/oNGGCFAwLKcZUiLS/PorGfqHM9IiYjIZaRi51yIcCqo68jEIog84MftSSWpRN7k1+JaHFPX4URJfZfbFVVZmLEWGA3EjDT91xpM6zXi0m3dXHiqB8zGLc1/wyu9V5oCcoDp/x/ZavoveV6335OrFJQ1AECXAcmerLvBHgIELEpd1BY4MBodN2F1/7lqrMg6CQD4y+1Xu7Q0s0mrx2Of7cXYJVlQ1zQ5dN/NOj0e/c9e3PveblRruh86Qi5gQy/I7voPGmF0af9BcjxmrBERkctInRSRcVbAjjoSBAFyiRiNLe5ttsuJoES2eSp9AIxGICk+tMvt/nL71Xh4Ql9EBsqduh5VbDyOGMtgbAgCegWabmwNzHmY/DJTMLIfA2udah3sYa6P1MLUhUiPT4feYMR7PxfgyIVa/GvWSLuz/xqadfj92v3QG4y4ZXgv3DEq1t5vwyoKqRjldS1o1hmQfbwUs1L7OGS/TVo9Hvl0L7adKINcIsKJknqk9g1zyL7JtSztP2jpduR5GFgjIiKXEYkESMQCdHrHfUotEgESZqy5lFwi8oDAGo85kS2uv0pl0XYhSpn1pWeB0abSTSt6osWHm4YAFFY0wIgAePLHJJcy1ji4oCvdDfY4XV6P1zceh1ZvxIzk3pgwwLLebJ356w9Hcbq8Ab2CFXhl+jC3lOkunjYEErGAwdFBDtmfpkWHhz/egx35FfCTivHB3GQG1dzJziEtlvYftHQ7T6A36L1qeI+zMbBGREQuJROLoNM7LijDPluuZ8oW07p1DZwISh7Dhn47Pisw2up+aL1D/SASgIYWPSqFcIRbGZhzFaPRiIK2jLXOA2u82DTparBH/6hALLrpKgTKJRjfP8Ku59l4RI3Pc85CEIDXZ4xAsNLyybeONDTWcQMZ6pt1ePDDXOScqYS/TIwP56XCYDTi92v3Y4AqAI9N6u+w5yIL2Tmkpbv+gwIEqJQqJEUlOWrFTsXpph0xsEZERC4llYgAB2Y7MbDmep7Q34yloOQxWvvtDLrJIwNCV9LqDcj8tQQnS+vxu7T+EIs6Zveoa5rw7235SIwMwP3XxDt1PXKJGDEhfjhf1YjTzQEI95BBBVcqqW1GQ4seYpGAPmHmA2u82LTcQ+P72r2P0romLPr6EABg/oREjOtnX5DOUS5UNyJUKYOfzPq/U7VNWjywKgd5Z6sRKJfgowdTMTo+FN/uL8I3+4qQmhDGwJo72DmkpbX/YEZ2BgQI7YJrrf0IF6Yu9IogPKebmuf+M2MiIupRHB0IY2DN9TyhDNMT1kDkjUSCgN9/sR/LN53A2UqN2W1Oldbjw+1n8NH20y5ZU8LFctAzFebX4wlas9X6hCnNTqJuvdi8skF568VmZmGmS9bpjWoatdh+qtyqxxiNRjz95UFUNrTgql5B+MMNA520Ouss33gc1/19C9bknrX6sdWaFvzf+7uRd7YawX5SfDZ/DEZf7IWY1CcUT08dhAWTGVRzCzuHtACX+g9GKaPa3a5SqrwmGNXddFMAWJazDHqDe9uFuAMz1oiIyKUcPWiAE0FdzxOyxTxhDdSD2dlvx53EIgH9IgNw5EItTpbUoW9Ex+yr6GA5fjMxEUEK15TV9QlXAqdMfdbs5qTS3PwuykC7u9gUIGBZzjKkxaV5RUaKw1hwLM5XaXDPyp2o1mjx45MTkGDm9WjOJzsLsfViU/9/zhrpMX8TVMEK6AxGvLetAP93TbzFH/5VNpiCar8W1yLMX4ZPH0rF1TGXykvjwpT4XRqDat6uu/6Dns6a6aadlYL7Kl6NEBGRSzk6w0zCiaAuZy5boyeugXqwPR8C7040/dfaZ+d/T1y6bc+H7l1fNwaqTNM3T5bWm72/f1Qgnr3pKpddyCeEKwE4KGOttTS3NfDpIPltgws6TgS15mKzR7HgWMQE+yEh3B+NWj3++OUB6A3dDzc6WVKHV9YfBQA8e9PgttezJ7grqTciA+W4UNOEb/dfsOgxZXXNmPXuTvxaXIuIADk+n39Nu6AaeRgbhrRcrrX/4M2JNyMlOsVrgmoAp5t2hWelRETkUiwF9X6eUIbpCWugHix5HvDIVtN/0/5lum3avy7dljzPvevrRv8oU3DoZEmdm1dicvlkUE81/7pEvDcnGdNHxna4jxebthOJBLx6z3AEyCXYU1iF938u6PYxm46WoFlnwHUDIzF3XILzF2kFhVTc1j9u5dZ8GLoJFJbUNmHWuztxoqQeUYFyrHnkGgyKNh8oVNc04acjauw7W+XwdZMVWoe0eGhWsjP54nRTR2EpKBERuZTETKNse7AU1PXcnS0mEQsQOfh1RGQVc6Werf12vMCA1sBaJxlrx9S1CPGTISpQ7pL3WmuPtdPlDTAajRAEK5/TBaW5sSF+iA3xM3sfLzYvY8Ox6B2qxOJbh+CZrw7i9Y0nkDY4qssstMcm9Uf/yACMjAux/rXiAveN6YO3tpzCqdJ6bDpagqlXd/7aMxiN0OqNiAlWYPX8a7oshV2TexYrMk9iRnJvjOoT6oylE3XJ16abOhIDa0RE5FKODsqwFNT1pGIRRCLAYHDP87s7sEfk7VqDFqdK66E3GDtMBn3ooz0oqm7EV4+Oa2ue7kx9wpQIlEvQJ0yJRq0eSpmVlyh7PjSVHF6utUQXMJVtOXHaKC82L2PjsbgnuTc2HFFj87FSZHyxH988dm2XGek3dBGscrdAhRT3XxOPt7Pz8XZ2Pm4Youo0ANgr2A+r54+B0Wjqo9aV1vft8RLzAXEiZ/O06aYnSmuwV52H4IBGt/erY2CNiIhcytEZawysuYdMLEaTm6Y+eUqTaiIAdvfbcYe4i5Mtm3UGnK/StJViAoBOb4C6tsm0Xaj5DC1H85OJcfDFG2zPPkqeBwy6yfTv4gOmQM60f12a3mfnsTlXqcG3+4swJCYIkwerOtzvaRebbmXjsRAEAUvvHIYbVmzD4aJavLH5FDKmXJr0WaPR4qXvj2DhjYOhClI4+7uw27xr++KDX07jwLlq7CyowLh+EW33FVY04Ji6ri2TrXdo1wG1Vm29EUvqYDAYmblNbtE63XRpztJ2vSVVShUWpi502XTTzMJM/Onnv6JBX9FuDYtSF7llwioDa0RE5FJSB2cbsRTUPWQSEZq07gqs8ZiTB2ntt+NFWieDHi2uxcmS+naBteKaJugNRsjEIkQEyF22JrtK+pxcmnvgfDVe23gCSX1CzAbWAM+52HQ7O45FVJACL98+FI9/vg9vbTmF9KuiMLx3CADgL9//iq/zinC6vAFfPzrOI0tALxcZKMeM5Dh8uqsQ72TntwXW1DVNmPHvnSivb8H7c5ORNijK4n0mhCshE4ugadGjqLqx2ww3Imdx93TTzMJMZGRndMgQLtWUIiM7A8snLXf571wG1oiIyKWkIkeXgjLI4g7uLMdkKSiR/QaqTIG1E6V1SB9yKVhUVN0IAIgJUTAj5iJVkAJ3jopF3y76XwHuv9j0BdNGxOCnI2p8f7AYGV8cwPePj4dCKsajk/rhVFk9Ft86xOODaq0euS4Rq3PO4ueT5ThcVIOhscGICpTj2n4ROHyhBkOtnPwpEYvQL8r0vj2uruuZgbU6tancOHmeTZmoeoOe708HaZ1u6mp6gx5Lc5aaLbs3wggBApblLENaXJpLjy0Da0RE5FKOLt10dGkpWcadmYKcBEtkv9YBBqeu6NdUVGUKrFlanuYoPx4qxj8yT2B0fCiW3Dnc9h05oTQ3JSEMKQlhFm3rrotNj2TjsXj59qHYfboSp0rr8frG43j+liHoHxWAdY95fqba5eLClJg2vBfW7b+Ad7Lz8dZ9SRenoI5AfZMOwUqp1fvsLCBuETuDUh6hTm3q4TfoJqu/h8zCTLMZpe4qHXQ7L3095JXmtTuGVzLCCLVGjbzSPJf+LuaZKRERuZRULIIjz4tZCuoezFgj8m79oy72a7piMuj5i4G1ziZgOosRwImSehxT19m3o9bSXC+6UPRZNh6LUH8Zlt01DADw3s+nsbvA1EPJm4JqrX47qR8A4IdDxThT3gDAVIptS1ANuNRn7YQt75PWoFTr1NYepLV08MqATGvpYGZhpptW5kZe+noo05Q5dDtH4ZkpERG53JUT6GwlEoGlSm7izj5nDKYS2W+g6mLGWmk9DIZLJTVF1RoAQG8XDS5oldo3DJ88mIp/zRrl0uftjtFoREFZPbR6N41B7qEmD1ZhRnJvAEDumUo3r8Z2g6ODkH6VqY/aD4eK7d7foJ44GbRODVzYb/qv+IDptuIDl27rJjDUXekgACzLWQa9mwYykXUi/CK63whApDLSyStpj6WgRETkcjKxCDq9/ScwLAl0H3f+7JmxRmS/PmFK9Iv0R98If9S36BCkMGXQtGWsuTiwFhEgx3UDI6HTG1Cj0UIiFiAWCZCITP/vrmylktpmTH59KxRSEQ6/OJV9PV3ohWlXI9RfhqQ+oe5eil2W3jUcWUdLcOvwGLv3NSjaFFjLL62HTm/o/vVYp74UeLo8KNXK3LAJJ7G5v9meD02ZVZf73xOX/j1xUZcDZDy1dNAtLns9lJ3MQSSAUwe2o3/r/da+HtxQTqrTJMCgDYYgqTFbASNAgEqpQlJUkkvW04qBNSIicjlHZaw5aj9kPbeWgvLClshuErEIWX+Y1OH21uEFru6x1nrRvfd8IV5dfwF6TV9cXlzTGmCTikUX/7818CaCRCzg8/nXIMYJ5av5ZabMoJhgv54XVHNzDyZ/uQTP3nSVy5/X0SIC5JiZ0sch+4oN8YOfVIxGrR5nKjTof7FXYqfsDEo5il39zZLnmXqqAaag4P+eAKb9yzRtFuj2temRpYNuem/9+r9/YsiJtwEArflc/Xc/B+y++IW1rwc7et7Z6uMdZ9FcMg1+vf8DAUK7TEQBpuuChakLXT6UgoE1IiJyOamDgjIMsLiP1MFDKKzBjDUi5zAYjLhQ7fqMtSsvupXxgEEbjOaSadDVDQUA6AxG6AxGNOu6LsnUG4xYk3sWY/qGdx90sEDBxcBaYmTXE0F9khsumqlrIpGAgaoAHDhfgxMldd2/xu0MSjlCa3+zK0sxW/ubLZ+0vOvgmrksql4jgJiRFj2/pSWBLi0ddMN7a8PhYvz54NWIly3Bm/cmQSg+ANXWZ/Csbj6efmAGwpQyj3+fn6vUYNOvJTAYh+Lpka/gkxP/7BCsXZi60C3DKBhYIyIil5OKHBMY6XHZAx7EXcEt8cWsFSJyDKPRCE2LHv5yCUrrmqHVGyERCVAFyl3y/J1ddIuktfDr/Rn+OvbvuDYmDTq9ETqDAXqDEVq9EXqD6WvT7UaEB8gAAK+sP4oPfjmNCQMi8MmDqXaXkOaXmRrOJ0baH6Sjnsfm8scuDFQFtgXWbh7Wq+uN7QxK2au7/mYCBCzLWYa0uDSnZRglRSVB5ReB0sZyM6sABAAqv0iXlw66WvpVKnzavz/G9A1H1MD+EAUpgK3AQX0C1p4Px6MXB210y43lxZ/sPAODERjfPwJzRozBfcNudvj7y1YMrBERkcs5KjAiYYDFbdyVLci+ekSOszO/Ao9+thfxYUp8u2B82+CC6GCFSz646OqiGxcvut888Dpu7T/FooslvUGPkQPKEXriCAb2GQydXg+pxL7LndZS0H49JWPNg3py2csZQS1r2FX+eJkrv48BqhD0DvXzir+HDu9vFhhtKle04jUoFomxaMzzyMjOgACYLx0c85zFr43Vu8/i7exTePu+JAzvHWLxOtzx3tp2ogxjEsMgl4ghEYvwyYNjzJ6Dr809i99OTLTsgwg3lRc3NOuwJvccAODB8QkATMfWU/riMbBGREQuJ5M4JiDmDSeVvkoQBEjEAnR6cxfEzsMyUPJJbuq3ExkoR7VGC72+DjnFOdhQcAJiZSViQka75PkdedHdLogRDnxxAdj6zb+sDmJcqaCnZax5SE8uezkqqGXP89tV/njZfsx9Hy/OWoT0+P5dPNIMG4JS9nJ4f7PAaJtef+nx6Vg+abnZn6U1pYM6vQHPfXMIflIxAi8OfLGYC99bWr0BS388hg9+OY05Y+Pxl9tNJfXtgmqB0WgZ/wwafo7AmQoNdp+uxDWJ4d3v3E3lxV/lnUddkw59I/wxaWCUU57DHgysERGRy4kdVArKkkD3ctR0V2u4s7cbkdO4qZdVQrgSL8zU4z+n/oGHNl7qb1am+BaZhc86PQDhqItuRwUxrtTYom8b5pAY4cKMNXcODfCAnlz2ctbrwVKOKn90+PdhY1DKHp7U3yw9Ph1pcWnIO5OJsl+/RuSQO5GUkG5VFuOW46bfRUqZGLHWDktx4Hurq2zM4ppGLFi9D3sLqwAACqkYRqOxYzZaYDRk6c9jbO0hnMk5i7W55ywLrLmhvNhgMOKj7WcAAHPHxkPkgef/DKwREZHLOaqEk0EW95JJRNC0uDqwxow1IkfJPr8Z/zj4pw4X7hVNZS4JQDjioru7IAaMwCu7l9rUw+l0uSlbLUQpRZi/zKrH2sWdQwPc3JPLXp7Q08sRmZiWfh8TYyfZXe7sTElRSQhXRKGyqayTkm8B0UqVy/qbiUVipCROBRKn2vT4tblnAQB3je4NmUSEFp0BJbVNiAuzYIqyg95bXWVjyppH4Km1+1HZ0IJAhQSv3TMCU6/u+nfIrJQ4fJ5zFusPFePFaVcjWGllJp4LbD1ZhoLyBgTKJbg7Oc7dyzGLZ6dERORyjgqOcHiBe7kjyMVSUPIZdWrgwn7Tf5f322m9rbUXj5N0G5ACsCxnGfQG5wXPk6KSoFKq2vocXUmAgGhldJcX3d0FMSAAZY0lyCvNs3p9BeUXJ4JG+Ns9BIFcw5qglrM4IhPT0u/jzZ0brV6fK52paMT5UzfAaDQCV7zPjUYAMGJh6kK3NZy3RkltEzYfKwUAzEiOw+nyBtz25i+Y+2EOmrSu+ZCxNYvxytdGqaYUv8/+PR78chUqG1pwdUwQvn98fLdBNQAY3jsYg6MD0awzYN3+IusW5KLy4g8vZqvdkxyHALlnBpJ5dkpERC4ncVCmmdQDU8F7ErcE1hhMJV+x50Pg3Ymm/1r77PzviUu37fnQqU/vCQEIsUiMRamLAKBDcK2tqXg3F92WBjF2nDlt9fryS00Za/1c0V/NzYFWs9zQk6uDOjWwZYnF37+je3rpDXrkqnOxvmA9ctW5FgWaHZGJaen6TpRfsGg7d3n/5wLo6oaiP34HlbJ9XyyjLhiKynmY2Huym1Znnf/uPQ+DEUhJCEX/qACEKqWoaGhBtUaLU6X11u3MhvdWdx+GGI2AXPU/zErpja8eHYf4cMvK1wVBwKwUUxbY5zlnLwZBLdRaXmzr7wgL3t/5ZfXYdqIMggA8MC7BtudxAc8M9xERkU9zVCkoe6y5lzuyx6TMWCNf4eZeVg5vKm4je5uKWxrEWLenFr9LMViV6dyWseaKwJonDg1wQ0+uDqwsi3VkTy9bByC0ZmKWakrNBkEECFB1U/5o6fdxX/JQi7Zzh9LaJny115QB9dykGUjqM7+tL1iwLAxPfFSLsnotvj94AXeM6u3m1XbNYDDiiz2miZQzLpYihihlePf+0egTpkR4gNy6Hdrw3uruwxBBAARpDe66tgUKqXUZgNNHxeKVH4/hmLoOh4pqrJt2ag8L3t8J4f5Y+X+j8WtxLfqEW1By6yYMrBERkcs5qoSTpaDu5Y7sMfbVI5/h5l5WHtlUvJNm3F3pLogBANCF4PR5FVbnnMWcsQkWryu/rDWw5oLBBT4wNMATOCKoBdg3OKA1EzMjOwMChHb7sDQTMykqCSq/CJQ2lnfSmQxQ+UVibGzX03LdadX2M2jRGzA6PhQpCWEA0K6n3IPXnsKrPx3Hv7cWYPrIWI8ut951ugKFFRoEyCW4ZXivtttH9Ql12Rqc+WFIiFKGm4ZG49v9F7Am95zrAmsWEIsE3Dg0GjcO9ezfgbwiISIil+PwAt8glbj+589SUN/w1ltvISEhAQqFAmPGjEFOTk6X23/55ZcYPHgwFAoFhg0bhvXr17topb6rNQBxZd+jVpb0N3MksUiMlOgU3Jx4M1KiUyzuudRdOakAAdPjHgUgwusbT6CyocWi/RqNRpwp1wBwUSloYLQpqBoz8lIwrTXQGjPS+sCalSWUHsWOslhHlBc7ov9gayZm1BXljyqlyqKhIGKRGIvGPI/WV3HH70PAwjHPeWxvstomLT7bVQgA+O3Efma3+b8x8VDKxDimrsPPJ8tduTyrrc01ZavdNjIGSpn53KQfDxXj/Z8LnLYGZ38YMvNiOeix4lrrykGt5Yll7w7As1MiInI5RwXWJCL+GXMndwS5OLzA+61duxYZGRl44YUXkJeXhxEjRmDq1KkoLS01u/2OHTswe/ZsPPTQQ9i3bx+mT5+O6dOn4/Dhwy5euRO5oZdVawBCAHBl/MDSAISn6C6I8WL6bFzVKwg1jVq8vvF41zu7GJAS6kuQ8/z1+OGJ8Yj34PKjTrWWWHnjRaqd/QfTw4Zi+fDHESVvn02kkodi+fDHkR7WdfmkQ/oP1qmRLo3AT+P+jlUJM7CstByrEmZgw7hlSJdGWHRcuntdV5cPxnPfHMLJkrpu9+Vqq3efRV2zDv2jAnD94MvWf1nAN1gpbQvmvLvNeQEpe9VotPjxsOl4tfYiu1LumUo8+lkelv54DEeLa52yjqSoJKjESgidBL0EoxHRYqXNH4aMTQzHt7+7Fl89Os652YMWvr91egPufHs7/pV1Eg3NOuetx0FYCkpERC4nEYsgCK0ToezYD3usuZU7+p25Y2ACOdby5csxf/58zJs3DwCwcuVK/PDDD1i1ahUWLVrUYft//vOfuPHGG/H0008DAF5++WVs2rQJb775JlauXOnStTuNm3pZtV64L8z+C1pQ1Xa7pf3NPEl35aQvThuCme/uwuqcs5id2gdDY4PN7+iynj/KwGhcHdPJds7kCUMD3Mnestg9HyJ961KkAchTyFEmFiNSr0dS01mIj+0HJpZ3+X5zSMndxZ55YgBtxY9bXjP9B1jcM6/tdX0mE2W/fo3IIXciKSEdYpEY923ahe2nKjAyLgQDVIEWrdkVmnV6rPrFNCzkkesSIbr8XO2KnloPje+LT3YW4pdT5ThcVNP5+9KN1u0vQovOgMHRgRjWyfqS40Mx9WoVfjpSgqf/ewDfPHatw89XxCIxFiX/ERm7/wIB7T8PEQBAELAw+Y82fxgiCAJGxIXYv9DuWPj+zjpWiryz1ThTocEj1yU6f1128sjA2ltvvYVXX30VarUaI0aMwBtvvIHU1FSz2x45cgSLFy/G3r17UVhYiH/84x946qmnXLtgIiKymlgkQKe3PbImEqH9yRq5nKsz1gSBwVRv19LSgr179+LZZy9dUIpEIqSnp2Pnzp1mH7Nz505kZGS0u23q1KlYt26d2e2bm5vR3Nzc9nVtrSl7QKvVQqvV2vkd+Jg6NSYKIXjc/0n8cuwH3Cn/EQWRs/Bw6myIBRG0lee8LrgzMnwkEG76t0FvgEFvAAAkxQXhlmHR+OGQGi98exifP5xiPitDp4MUgFanA9z1elGEA+P/aPq3NWuoUwP1pkwrQX0QEgC683kw6i5mewSovON4KsJN/wGXjkfk1UDk1Ze26ernMuL/gH5TAACj1AchWf976G7+BwzRw2EATD+HLh4fKrOsb1aoLLTz3ymXrUG4bA3G6OGm+7tZw5VGxk0G4kzTM1tf1/0j/bH9VAWOXaiBVus5x/WrvedRWtcMVZAct1wd1f5ndMX7SxUgxU1Xq/D9ITX+vfUUlt8z3G3rNsdoNOLz3aaS1ntGx0Kn6zxzavEtg7GroAKHi2qxcstJ/HaiY4NBn+w6i0Gq6/D3Ca/i1b2volRzKcs7SqnCH0f/ERPjrnfI3zlNiw7NOgNClTK799WBhe/v8YmheP3uYWjU6iGGAVqtwfFrsYClP0+PC6y1lgesXLkSY8aMwYoVKzB16lQcP34cUVFRHbbXaDRITEzEPffcg9///vduWDEREdlCKhZBp+9+bH1nWAbqfq7OHpOKRR7d3Ji6V15eDr1eD5VK1e52lUqFY8eOmX2MWq02u71abb6UasmSJXjppZc63L5x40YolV5Y0udEg4q/xmD1OjwA4AEA0AFoWAV8uAoAcCx6Oo73utNt63O0VCmwSSTG3rPVePmTDUiONH24I9dWQ6GtBgAEa85gFIBv/rsa+w07MCTEiIiQEDRLQ9y2bku1Hs/LSdZfuj7yxuMZrDmDSQC2b9+OGmWRDY+vwyQAv+TXoaa49fFd78dgNCDcIEWl0AKjmb85gtGIMKMM6j1qrBe67/doyxos0VwiABBjx5HTWG/Mt3t/jmAwAiv2iwEIuCZUg8yNG8y+vw5v+gw1yu0AgNH6EHyPCPxwsBhJkvMIs3LApjNVNgP5pWJIBMCv5DDWr++6BcGtsQI+OyXGiqyTkJUdQ7SD/uQcqhTw/nExpIIRC0fosUCxAOWSXYi98AmKYuYgQnoNmg81Y/0h+/uPbi8R8G2hCGOjjLgjwbnBrO7e3xIAgQDWrz/o1HV0RaPRWLSdxwXWrC0PSElJQUqKKcHW3P1EROSZxHZmHjFzyf3EIgFikQC9wYlNbi/DMlCyxLPPPtsuw622thZxcXG44YYbEBQU5MaVeaC6JGjrH8fZSg3e/fI7LJO+h6PJL6P/8HEAgH4BKvTzhgwnK9SEFWB55ilsLFHiD7Ouhb9cAtG2ZRD//Gq77WbUfoAZAFAP6Ps+DcN197plvVa5eDwB81lSXnk869TQR9Xh2lF32pZtV3wAOA5ce+21l0rNLOB3ohnP7PlbpyV3i1KewfUDb3XqGrrT62w11hTkoMrgh5tvnuiw/dpj468lKN11AEEKCV68fzICOnl/jTq3qu3fEyY8jQPSYegfFYDbU+MQqPCsEMVtN2pxoKgGE/pHdLvtTUYjzn+6D1tPluPHynCsuTPV7vNdALheq0f+2gMYEBWAOVMGmD5krEuGaF8gDKPmOjQTVXG8DF8U7EO1JAQ33ZTq3A80O3l/G41Gy5+3Tg3Rvo8d/nNo1Zr13h2PetXaUh5gC5YI9Cytx5TH1vfw2Ho3MfQw6s2n1Bsvm7RlNBjMbieCwGPvAcQwWJV5aMmx7YxEEHncMfe09Xi6iIgIiMVilJS0bwxeUlKC6GjzJ8TR0dFWbS+XyyGXd0x5kEqlkEqlNq7cR4XFAWFxiIsx4PBaU0aAos9oSPsku3lhzvPIxP74b94FlNc342iJBmP7hQOpDwNXXQySXOz5c2T0X7G3pQ/SBkcirk8ixN7w2rl4PAEAEtNlnqR3kmmqqLcKiwOu/xNsHqER2huYuAjS0N6AFcfwxqtnQRIQgaU5S9sNMlApo63vP2jjGrpzVWwIAKCkrhkNWiNCnFG2ZwWj0Yj3fjGVTd4/Nh6hAX6mO8y8vy7vqSUOjMYKDw74hkulmBxkeerZ0ruH44bl27D/XA3+k3MeD0+wvyRUKpXivTkpEIuESwEne98bnbj+qmiseeQapCaEOb/lipnvoayuGTPf3YnZKX3w4Pi+3QcmmyqAn1+F+KpbL/3+cyBLzxs8KrBmS3mALTorEdiyZQtLBHzYpk2b3L0EchIeW9/TrAda/0Q1Fh6AwcxZgwbA+iOuXBU5giXHtjMaABcOOWNVtrO0RIBMZDIZRo8ejaysLEyfPh0AYDAYkJWVhQULFph9zNixY5GVldWuh+6mTZswduxYF6y4Z5BJRPjdpH7ATiAhwrfPhRVSMd6YPQqqIAWigxWmGwOjO2Q6XD16Aq725oAUmdgxGKRtcMCvX6DsxwxE3rQcSUNmWN8c3knDSQIVUsSG+KGouhEnSuqR2jfM4c9hjZOl9ThwvhoyiQgPjOt76Q4z7y/0GuHxAd+GZh385daHS3oF++G5W67Cs18fwmsbjyP9KhUSIvyt3k/28VLknK7E01MHQRAESFyUtS8Ri3BNYrhLnsuc1bvPoqCsAT8cKsZ8Lxha0MqjAmuu0lmJQFpaGsLD3fciIufQarXYtGkTpkyZwk+qfQyPrXc7WlyLkpoms/eJdXogxxRB8YsfAYWs4/GNDJK7Z1obtXPwfDUq61ss3t6SY9uZmFA/DPSgyWeA5SUCdElGRgbmzp2L5ORkpKamYsWKFWhoaGhrAzJnzhzExsZiyZIlAIAnn3wSEydOxOuvv45bbrkFa9aswZ49e/Duu++689vwOTePGwXIFkEI7OXupTidSybfuVtPnyzqIGKRGCnxaUDyE0B8GmDjxEVnGagKuBhYq3N7YG2gKhCZGRNx8Hw1IgOtb5SmNxjx0xE1/rv3PN6+LwkKqXt/1g98mIMWnQF/u2OY1dNKZ6XE4fuDF7D9VAWe+eog1sy/xqrsr10FFfjNp3vRrDMgIdwfM1Icn4lliWadHi06AwIVrrnOatbp8ekuU9bjvGsTOt+wTm36DzBlQV7+/4D5YK6TeVRgzZbyAFuwRKBn4vH1XTy23kkuk0EQmy8DFAyXTj4EkQiCuOOfK5lUxuPuARRyGYRGy5vbWnJsO+Mn97xj7mnr8QYzZ85EWVkZFi9eDLVajZEjR2LDhg1tFQtnz56F6LLhJOPGjcPq1avxpz/9Cc899xwGDBiAdevWYejQoe76FnyTk7JqPN2OU+UQiYRLGRqB0ahKycDxcikSA5oQFaRw7wJt1UOPp1N48M9yYHQgthwvw4mSOncvBQDQLzIA/SIDOt+gi4CvwWjEy9//iuKaJqzbV4RZqX2cuNKuldY2Yf+5augNxnZBQr1Bj7zSPJRpyhCpjERSVJLZDEZBELD0zuGYumIbck5X4rPdhbh/bIJFz73/XDUe+igXzToDJg+OwvRRsY76tqyyevdZ/P2nY5hzTTwybhjkkuf84WAxyutNE2VvHtbFhzx7PgS2Lm1/2/+euPTviYtc/p71qMCaLeUBRETkneweXiDm8AJPIHPhQAEOL/AdCxYs6PTcLjs7u8Nt99xzD+655x4nr4p6mq/zziPjiwPoG+GPDU9NgFwiBgKj8Yn8Xvxj9QncM1qHV++xodl8ndp04Zc8jxlj5FSDLmZxH1e7N7BWrWmxrMdbF0FKqViEJ64fgOLqRqQPUZndxlWighTY+ez1yD1dCdXF4HpmYaaZnnsqLEpdZLbnXlyYEgtvHIwXvjuCJT8ew6RBUYgL67rU/mhxLeauykFDix5jE8Px9n1JkEncc+4T5CdBtUaLL/acx5PpAx0yhKErRqMRH24/AwCYMzah63O+5HnAoJtM/zbTt88dv3c97gw1IyMD7733Hj7++GMcPXoUjz76aIfygMuHG7S0tGD//v3Yv38/WlpaUFRUhP379+PUqVPu+haIiMgCUjsDY5wK6hlcecInd9PJJZFXqFMDW5ZcKo+hbk0ZokKvYAUmDIiATn9p9mN+WT0AoF9UF5k3XalTm7IpeCzsojfokavOxfqC9chV50JvsHxQTk/R2h7hREkdjEbXTOi+0vkqDVJfycITn+9Di87yDHZzZqf2QcYNgxARYH0pqaNFBMhx08WsqczCTGRkZ7QLqgFAqaYUGdkZyCzMNLuP+6+JR0pCKCQiAafLG7p8vvyyetz/wW7UNGqR1CcE789Ndms57JQhKoQqpVDXNmHbiTKnP9/ewiocKqqBXCLC7O6yFQOjTT36YkZeCqa19u2LGemWwJpHZawB1pcHXLhwAaNGjWr7+rXXXsNrr72GiRMnmv3Ek4iIPIPdGWsiBlk8gSuzyNz1qS2RV2gN5gy6iVlSFgpUSJH1h4lQytpfEhWUmwJriTY0HCfHsDY7qKfqHxUAQQCqNFqU1TcjKtD1pctbjpWiRWdARUOzT/ydbtEZ2n0feoMeS3OWwoiOgUsjjBAgYFnOMqTFpXUoCxWJBCyfMRJyiajLsvJzlRr83/u7UV7fgiG9gvDhvFSbBic4klwixp1JvfHBL6exJvcs0gZHOfX5WrPVpo+MRZi/eyfc2sLjAmuAdeUBCQkJbovOExGR7ewNyLAU1DO48iSapaBE5GiXB9X0Bj32luzF6cZfIFb6Iz5ivOU78sBm2t6qNTvoykBGa3bQ8knLGVy7SCEVIyHcH6fLG3BCXe+WwNr9YxMwqk8oBAeelm09UYZ3sk/hmRsHI6lPqON2bIHffLoHDS16LL51CIbGBiOvNK9DptrljDBCrVEjrzQPKdEpHe7vrvyzpLYJ972/G8U1TegfFYBPH0pFsJ9n9G+dmRKHD345jayjpSita3La66uouhEbjph+f84bn2Ddgz1kUItHBtaIiMj3sceab3BlYM0XPgkncigGcxzmkwP/w4p9r0IrVEGkApQAHtv2HZ61NEPKA5tpeyN7soN6qluG9UKVpsWtWT7WTs3szvcHLmBXQSXe3VqAlfePdui+u3KhuhHZJ8pgNAIBFzPGyjSWlUFasl3mryXY9GsJlt41DIIgoKK+Gfe9vxtnKzWIC/PDfx4ag3APKINtNVAViKQ+Icg7W42v9hbh0Un9nPI8n+w8A73BiLGJ4RgcHWTdgz1kuAgDa0RE5BZSO0s5WQrqGVw1vEAkYsYaUQcM5jhEZmEmXt3/HIwALv/IpsyaDCkPbKbtjezNDuqJ/jjVNRMbr9TYokddk9Ypk3MfuS4RX+49j59+VeN0eQP6uqgs+797z8NoBK5JDEPCxeeMVEZa9NjutlPXNOGxz/LQojfguoGRGD8gAnNW5eBUaT2igxRY/fA1iA72vCnEs1L6IO9sNdbmnsVvJyZCcGRqIgBNiw5rcs4BAOZdm+DQfbsSz1CJiMgtxHZmnDl7OhFZxlWBNQbViMxIngc8stX037R/mW6b9q9LtyXPc+/6vEBrhhSADqVsrVlTy3KWdd843wObaXsjR2YHkXN9seccxi/bgn9sOuHwfQ9QBWLy4CgYjcD7PxcAcP4wC4PBiLW5pgDPrJRLzfOTopKgUqogwPx5pwAB0cpoJEUldbn/6GAFnpoyAL+5LhGTB0dh/sd7cORCLcL9ZfjPw2O6LRl1l1uG94K/TIwzFRrsPl3p8P1/s68INY1axIX54fqr3DsN1h7MWCMiIrewd6qnvVNFyTFEIgESsdBuop4zuCqAR+RVzJV6tgZzyCLMkPIsjsoO6mkaW/Q4VVqPobFBDs8oMkenN+C9nwvQojcgIsA5JaiPXJeIzcdK8d+95zF6yHm8ffB1pw6z2J5fjqLqRgQqJLhx6KXfq2KRGItSFyEjOwMChHZlyq3BtoWpCy0qTX5sUv+2fz84PgEF5Q345MFU9Ld1ArEL+MsluG1kDD7POYe1uedwTWK4w/ZtNBrx0cWhBXPHJnj1h+Y8SyUiIrewN7DmzX98fY0rep+xvxoROYNTMqQ8pJm2N3JUdlBPotMbMOIvGzHtzV9QVN3okuf84VAxzlc1ItxfhnuS45zyHGP6hmFE72Do/Q7ihV3PdAiAtw6zyCzMdMjzrbmYrXbHqFgopO2DZOnx6Vg+aTmilO0nY6qUKpuHadw4tBe2PTMJQ2Ks7CnmBq0ZfOsPFaNGo3XYflv0Btw2IgaJkf6YkeKc15GrMGONiIjcQiIWQRAAWwc729ujjRxHLhFD0+zYkgxzz0FEXWAwxyZOyZDykGba3siR2UE9hUQsQt9wf5TVN6Okthm9Q51bUmg0GrFyq6k884FxCR2CUI4iCAIenpCARbmL0KEBIhw7zKKyoQWbjpgCdzM7CfCkx6cjLS4NeaV5KNOUIVIZiaSoJLue9/KpxJ5seO9gDI4OxDF1HdbtL8LccQkO2a9cIsbj1w/Agsn9XZJp6Uy8KiEiIrexNetMJDKVIJJnkDNjjcj9WoM5DKxZhRlSnscZ2UG+7uvHxiHvz1MwOj7U6c+17WQ5jhbXQikT4/6x8U59rsjICxBJazoE1VpdXqptj2/2FaFFb8DQ2CBcHdP5hFOxSIyU6BTcnHgzUqJTekyAVxAEzLoYcPw85yyMtn4qDkCrN+CtLafwdd75dvv3dt4RIiUiIp8kEYmg01uf6SRmtppHcUXQyxXBOyLqeZgh5ZmckR3ky/zlrrusX5mdD8BUHhiidE5/tVaVTeUWbWfPMAuj0Yi1uWcBADMvG1pA7U0fFYtvD1zAnaNiYTACtrY6/mrvebz603EE+0mRNigKof7OfQ25CgNrRETkNhKxANjQqkHKbDWP4oqgFwNrROQsrRlSS3OWdmiOvjB1ITOk3KQ1O4g8x4Fz1dhZUAGJSMDDE/o6/flcMcxi37lqnCiph0Iqwm0jYmzej68LUcrwzWPX2r2fu0f3xg+HinFnUixClFIHrMwzMLBGRERuY+sAAw4u8Cyu6H/GHmtE5EzMkCJvVqPR4vdf7MeZ8gZsypjotPOklVtN2Wq3jYxBTIifU57jcq2l2p1N7hUgQKVU2VWq/cXFoQU3D+uFYD/fCfR4ik2/luDjHWfwwQPJkEvEkIhF+PShMe5elsMxsEZERG4jEduWhWTr48g5XJKxJuUxJyLnYoYUeasAhQQ78svRpDWgsKIBiZEBDn+OgrJ6bDiiBgD8dmI/h+/fnNZS7d9n/x5GI3B5Ky5HlGrXN+vw3YELAICZTppu6mvqmrT47sAF9ApWYPJgVafbldY24YXvjuDHw6bXzMc7zuCR61zzunEHnqUSEZHb2JqxZuvjyDlcEfSSMZhKRERkllgkYEBUIADgREmdU57jvZ8LYDQC1w+OwkBVoFOew5z0+HT8Y9I/oBSFtbvdEcMsNC06TBseg6GxQUjtG9b9Awif7irE898cxltb8s3ebzAY8dnuQly/fCt+PKyGWCTgtxP74f5rEly7UBdjxhoREbmNxMbOp7Y+jpzD2WWaUomIU2CJiIi6MFAViENFNThRUo8bhzp239WaFnydVwQA+I2LstUulx6fjkn3TcK+sn1tpdrDw0dCLrWvdDMqUIFldw+HwWD0icmUrnB3Um98t/8CbhoaDYPB2O787FRpHZ79+hByz1QBAEb0DsaSO4djSEyQu5brMgysERGR20hsnO4pZfaSRxGLBEjEAnR628evd0XBwQVERERdGhRtKv887oSMtf8dLEazzoCregUhJSHU4fu3hEQsaSvVrmpoQdpr2zAzpQ9+OynR7g/4+OGd5aKCFNjw1HXtbmvW6fH2lny8nX0KWr0RSpkYf7xhEOaOS+gxfZEZWCMiIrfh8ALfIZeIodPrnLNvKZuHExERdWXAxfLME+qOgTW9QW/XYI7ZKXHoFaSAWCR4RGbXf/eex4WaJmw4osbjk/vbtI/1h4rRO9QPw2KDPeJ78lY5pyvx7NcHkV/WAACYPDgKL08filgXDLfwJAysERGR29ha0im1MdONnEcuFaGh2Un7ZsYaERFRlwZdDKydLm9As07flsWVWZiJpTlL203WVClVWJS6yOL+ZBKxCOlDOm9U72oPje+L6GAFwgNkbdlmmhYdvs4rwj3JvbvNYGvW6fH8N4dQpdFi9cNjMK5/hCuW7VMaW/SY9d4uHDhXDQCICJDjxduG4JZhvXpkoJKBNSJyO02LbVkuWq0OzXrT46VG63+BK2X8FehutpaCitljzeMonNhnTcGMNSIioi71ClYgUC5BXbMOp8sbMDg6CJmF5L5/7AAAQQJJREFUmcjIzoAR7Vs1lGpKkZGdYVHzf6PR8/qPiUQCpo2IaXfbxzsKsWzDMbyTnY8nrx+AO5NiO50iX9ekw8SBkdh3rppDC2y0cmt+W1BtdmocFt14FYKV9vW882a8qiQitxuy+Cc7Hi3BMzmbbXrkmaW32PG85Ai2Z6x51gkeOXcyqMIFU0eJiIi8mSAIGBgdiL2FVThRUo8BUf5YmrO0Q1ANAIwwQoCAZTnLkBaX1mlZaE2jFtPf2o5pw3thweQBkHlwBnlkoBxRgXIUVTfima8O4p2t+XgqfQCmDY/p0EMtIkCOFbNGQac3dBp8o679dmI/yCQipPYNQ0oCg5N8FRERkduwx5rvcGZWmbOnjhIREfmCgZf1WcsrzWtX/nklI4xQa9TIK83rdJv/HbiA0+UN2PhrCaQeXi1w9+je2PZMGp6/+SqE+ctwurwBT67Zj5v++TN+OqKG0dgxwMigmu38ZGL8Lq0/g2oXMWONiNzu179MtfoxeYVV+L8PcgAAb84ahslDYrp5BHkiW09oeCLkeZw5uZMZa0RERN0bpLo0GXSIpsyix5R1sd2M5DiEKmWQSUQeVw5qjkIqxvzrEjF7TB98+MtpvPtzAY6X1OE3n+7FiN7B+MMNg2AwGtEr2A+DogPdvVzyIQysEZHb2dLrTG+49KmTAFN/J47K9j62Zqx5+qemPZEzM9ac2b+NiIjIV7RlrJXUIVIZadFjutpOJhHhluG9HLI2VwqQS/D49QNw/9h4vLutAB9uP4MD52swZ1UOxCIBeoMRH85LQdqgKHcvlXwEPwImIq/UqNW3/dtoBDSXfU3eg6WgvsNZgTWZRMSgORERkQUGXszCOlupweCQ4VApVRBg/m+oAAHRymgkRSW5cokuFaKU4ZkbB+PnhWl48Nq+kElE0BuMCFFKMTYx3N3Lcxu9QY9cdS7WF6xHrjoXegOvo+zFjDUi8jrNOj30+vZ9Ehpb9AiQ81eat5GIRRAEU3DUGlIbp4mS84hFAqQSEbQ6g0P36ydjthoREZElIgLkWHTTYPSN8IdULMGi1EXIyM6AAKHdEIPWYNvC1IVmBxfUNmlxzzs7cdvIGMyfkAixyIi80jyUacoQqYxEUlRSpwMPPFFEgByLpw3B/Ov64ss955GSENZjJ45nFmZiac7Sdv33VEoVFqUu6nZCLHWOV6FE5HVazFy4t+gdezFPriMWCdDpLY+siURgBpOH8pOKHR5YYxkoERGR5X47sV/bv9Pj07F80nKzgZSFqQs7DaR8u/8CjpfU4Zt9RRjY9zSW5S7ziUBMr2A/PHH9AHcvw20yCzORkZ3RYVJsqaYUGdkZWD5pudcdU0/BwBoReZ3L+6u13WZFYIY8i1Qsgk5veQq6hNlqHkshFaG20bH79JPxeBMREdkqPT4daXFpFmecGY1GrN59FgCQMuQ8/rB1GQMxPkBv0GNpztIOxxIwTYgVIGBZzjKkxaV5VTaip2BgjYi8jrlsJcZavJe1fdZs7ctGzufnhLIKOTPWiIiILFbTqEXO6UpoWnS4fWQsAEAsEiMlOsWixx88X4OjxbWQSYDdtasYiPEReaV57bIOr2SEEWqNGnmleRa/VugSXooSkdeRSzr+6uLFt/eSiK37UyQ1c/zJMzijXwl7rBEREVnuZEkd5n+yB0t/PGbT4z/PMWWrjR1Sg7LG0k63uzwQQ56vTFPm0O2oPV6dEJHXkUvEEIvbZy0pefHttazNQONEUM/ljCCYM7LgiIiIfNUAVSCG9ArC2MRw6KzsQVzfrMN3By4AAEYnWlbcxkCMd4hURjp0O2qPpaBE5JWuzIzhxbf3koitC5RxIqjncsb7kO9tIiIiywX7SbH+yQk2Pfa7/RegadEjMdIf18RH4r3j3T+GgRjvkBSVBJVShVJNqdnyXgECVEoVkqKS3LA678erEyLySiKhfTBGYBKT15JaWQpqbSCOXMfRQTC5VMQJsERERC7SWgZ6b2ofjFaNhkqpggDzf4cFCIhWRjMQ4yXEIjEWpS4CgA7HtPXrhakL2S/PRgysEZHXMRiMaGzRtbutocXyqZLkWawtBZUysOaxRCIBcqnjTi2YrUZERGQbnd6Aivpmi7c/dL4Gh4pqIBOLcGdSbwZifFB6fDqWT1qOKGVUu9tVShUnvNqJpaBE5HVK6pqg07dPYT5fpcHg6CA3rYjsYXXGGktBPZqfVIxmrXU9XTrjjGEIREREvu6nI2o8vnofRseH4vNHrrHoMZ/nmrLVpg6NRpi/DMClQMzSnKXtJkqqlCosTF3IQIwXSo9PR1pcGvJK81CmKUOkMhJJUUkMkNqJgTUi8ir1zTocV9d1uP18ZSPClDJEBSncsCqyh7WlnSwF9Wx+MjGqNVqH7ItDSYiIiKzXK1iBFr0BJ0o6njOb09Csw7f7igAAs1Pj2t3HQIzvEYvESIlOcfcyfAoDa0TkNSobWnCoqKZDtlqrQ0U1GKQ3oHeo0sUrI3tYO+WTGWuezZHlm0oZT1OIiIis1T8qAIIAVDS0oLy+GREB8i63/9+BC2ho0SMhXImxieEd7mcghqhrvDohIo+nNxhxsqQOeYVV0Oo6LzEzGoFjxXU4cK4aTVr2XPMW1k75ZMaaZ3NkMIw91oiIiKynlEnQJ8z0QfMJM5UeV5KIRYgN8cPs1D4QOBGMyGr8KJiIPFpJbRNOltRbFSgrq2tGpaYFfcP90SdMyamCHs7aQJm1gThyLT8Hlm86cl9EREQ9yUBVIAorNDhRUodx/SO63Pbu0b1xx6hYaPWO6ZFK1NPw6oSIPFJVQwtyz1Ti0Pkam7LP9HojTpXWY2dBBdQ1TTAazZePkvtZPbyAGWsezVF90SRiATIJT1OIiIhsMUgVCAA4XlJv0fZikcChQUQ24hkrEXmUhmYd9p+rxt7CKtQ4oAF6Y4seh4tqsPt0JSobWhywQnI0ibU91hhY82hSscghx4hloERERLYbGG0KrHU1wEDTosOPh4qZqUZkJwbWiMgj6C5OLtpVUIHyumaH77++SYe8wir2X/NAErEI1rTzYCmo53NEnzUOLiAiIrLdQFUAAFOPtc4qN74/WIxHP8vDrHd3uXJpRD6HVydE5HbVmhbsKqjE2QoNnF2xWVbXjJ0FFbhQ3ejcJyKrSCwsBxWLBPbM8wKOKAdlfzUiIiLbJUYEQCISUNesQ3FNk9lt9AYjIgPlSL9K5eLVEfkWfhxMRG51rtLUVNWVLdD0eiN+vVCLmkYtBqkCGajxAFKRAEsKf1kG6h0cERRzVK82IiKinkgmEaFvhD9OltbjeEkdYkL8OmwzO7UP7h7dGzo9exET2YMZa0TkNqdK63Fc7dqg2uWKqhpxsKgGegNPJtzN0ow1CctAvYIjgmIMrBEREdmntc/ayS76rEnFImaJE9mJVyhE5HJGoxHH1LU4U97g7qWgvK4Z+89VsWmrm1maiSZlxppXUErtT4jnST4REZF92iaDqttPBm1s0WPLsVJ+uEzkICwFJSKX0uoNOHKh1ikDCmxV1aDFnjNVGBEXzIbpbmLpQAJLM9vINTQtOrO3G2FEcydDQpp1+sv+bYAg6ridWCxAbzB2un++T4mIiLrXNsDgioy19YeK8YcvD2BM3zCs/c1YdyyNyKfwzJSIXKa8vhnHius6TOXs7AK8K5ZcnHdHLr2UEdPQrMPugkr0jwpA71A/CNaMqSS7WZqxJmE/PI8yZPFPdj3+D18dselxZ5beYtfzEhER9QRjEyPw3YJr0T8qoN3tn+ecBQBcNzDSHcsi8jkMrBGR09U1aXGqtB4V9S1m7//d5/vs2r+tF+fvz0lu97XeYMRxdR2KqhvRPyoAEQFyu9ZFlpNamIkmkzBjjYiIiMgSwUophitD2t12oqQOewqrIBYJuGd0b/csjMjHMLBGRE5T26TFmfIGlNZ6TtmnJeqbdNh/thrBSikSwv0RGcgAm7NZ2juNGWue5de/TLXpcVqtFj/9tBFTp94AqVTq4FURERFRZ1qz1dKvikJUkMLNqyHyDQysEZHD1Wi0KCjvPEPtSm/NHmX1czTr9Mj48iAA4PW7roZCJrN6H92p0WhxQFONAIUEiRGmABtLRJ3D0t5plma2kWvY2utMKxghF5seL3XAoAMiIiIyb/upcvx4uBij40Nx09Be+DqvCAAwO7WPm1dG5Dt4NktEDtPYoseJkjqUWTmY4PJeZ7aQS0R276Mr9U06HDxfg0CFBIOjgxCsZIaNNTprQH85nc7QrtdeZz30tHqDRftjc3siIiIi4FBRDf6z6yxqG3UQIKCmUYvYED9MGMD+akSOwisPInKIak0L9p2rhl7vu2O765p02FNYiUHRgegdqnT3cryGOxrcs7k9ERERETA2MRyPTuqH1IQwvLM1HwAwKyUOYrbXIHIYj62peeutt5CQkACFQoExY8YgJyeny+2//PJLDB48GAqFAsOGDcP69etdtFIiAoAzFRqfDqq1MhqBgrIGdy+DiIiIiKhbI+JCsPDGwYgLUyLndKVpaEFynLuXReRTPDJjbe3atcjIyMDKlSsxZswYrFixAlOnTsXx48cRFRXVYfsdO3Zg9uzZWLJkCW699VasXr0a06dPR15eHoYOHeqG74Co50kIV6K2UYsWncHdS3EqkQjod8XIcuoaG9wTERERudeai0MLJg+OQnQwhxYQOZJHBtaWL1+O+fPnY968eQCAlStX4ocffsCqVauwaNGiDtv/85//xI033oinn34aAPDyyy9j06ZNePPNN7Fy5UqXrp2opwpRyjC2XzjOVzXiQnUjGlv03T/oost7a1n8mE56cFnDmr5sErGAXsF+iA9XQuHEfm6+iA3uiYiIiNynuKYR7/9yGgAwO5XZakSO5nFXKi0tLdi7dy+effbZtttEIhHS09Oxc+dOs4/ZuXMnMjIy2t02depUrFu3zuz2zc3NaG6+1Fy9trYWgCk7QqvV2vkdkKdpPaY8tq7RO1iG2CAp6pp0KK9vRnl9CzTNXTeb/93n++16Tlt6cAHAe/eN7PJ+uVSMsAAZwv3lCFNKIRIJAAzQan07K89T8L3ru3zp2PrC90BERL7toY/2tP174sCOFWBEZB+PC6yVl5dDr9dDpVK1u12lUuHYsWNmH6NWq81ur1arzW6/ZMkSvPTSSx1u37JlC5RKNiT3VZs2bXL3EqhT7vlVpCnY0/X9AKoA5LtkNdQZvnd9ly8cW41G4+4lEBERdenpqYPw4Me5+Ov0oRxaQOQEHhdYc4Vnn322XYZbbW0t4uLikJaWhvDwcDeujJxBq9Vi06ZNmDJlCvs0eahJ6V1ntHVGq9Vh8+bNmDx5sk2lgraWKJJr8L3ru3zp2LZmvRMREXmqtMFROPHXmyAVe+zsQiKv5nFXlRERERCLxSgpKWl3e0lJCaKjo80+Jjo62qrt5XI55HJ5h9ulUqnXn+BT53h8PVewjcdFq9VCLgaC/RU8tj6M713f5QvH1tvXT0REPQODakTO43HvLplMhtGjRyMrK6vtNoPBgKysLIwdO9bsY8aOHdtue8BUXtLZ9kRERERERERERPbyuIw1AMjIyMDcuXORnJyM1NRUrFixAg0NDW1TQufMmYPY2FgsWbIEAPDkk09i4sSJeP3113HLLbdgzZo12LNnD9599113fhtEREREREREROTDPDKwNnPmTJSVlWHx4sVQq9UYOXIkNmzY0Dag4OzZsxCJLiXbjRs3DqtXr8af/vQnPPfccxgwYADWrVuHoUOHuutbICIiIiIiIiIiH+eRgTUAWLBgARYsWGD2vuzs7A633XPPPbjnnnucvCoiIiIiIiIiIiITj+uxRkRERERERERE5A0YWCMiIiIiIiIiIrIBA2tEREREREREREQ2YGCNiIiIiIiIiIjIBgysERERERERERER2YCBNSIiIiIiIiIiIhswsEZERERERERERGQDBtaIiIiIiIiIiIhswMAaERERERERERGRDRhYIyIiIiIiIiIisgEDa0RERETkEpWVlbjvvvsQFBSEkJAQPPTQQ6ivr+9y+8cffxyDBg2Cn58f+vTpgyeeeAI1NTUuXDURERFR5xhYIyIiIiKXuO+++3DkyBFs2rQJ33//PbZt24ZHHnmk0+0vXLiACxcu4LXXXsPhw4fx0UcfYcOGDXjooYdcuGoiIiKizkncvQAiIiIi8n1Hjx7Fhg0bkJubi+TkZADAG2+8gZtvvhmvvfYaYmJiOjxm6NCh+Oqrr9q+7tevH/72t7/h//7v/6DT6SCR8FSWiIiI3ItnIwCMRiMAoK6uDlKp1M2rIUfTarXQaDSora3l8fUxPLa+jcfXd/nSsa2trQVw6VyCOrdz506EhIS0BdUAID09HSKRCLt378Ydd9xh0X5qamoQFBTUaVCtubkZzc3N7bYHTGWlWq3Wju+AiIiIepK6ujoA3Z/nMbAGoKKiAgDQt29fN6+EiIiIvFFdXR2Cg4PdvQyPplarERUV1e42iUSCsLAwqNVqi/ZRXl6Ol19+ucvy0SVLluCll17qcDvP84iIiMgW3Z3nMbAGICwsDABw9uxZnhT7oNraWsTFxeHcuXMICgpy93LIgXhsfRuPr+/ypWNrNBpRV1dntoyxp1i0aBGWLVvW5TZHjx61+3lqa2txyy23YMiQIXjxxRc73e7ZZ59FRkZG29cGgwGVlZUIDw+HIAh2r4OIiIh6BkvP8xhYAyASmWY4BAcHe/0JPnUuKCiIx9dH8dj6Nh5f3+Urx7anfyj3hz/8AQ888ECX2yQmJiI6OhqlpaXtbtfpdKisrER0dHSXj6+rq8ONN96IwMBAfPPNN12WEMvlcsjl8na3hYSEdLl/IiIiInMsOc9jYI2IiIiIbBYZGYnIyMhutxs7diyqq6uxd+9ejB49GgCwefNmGAwGjBkzptPH1dbWYurUqZDL5fjuu++gUCgctnYiIiIie4ncvQAiIiIi8n1XXXUVbrzxRsyfPx85OTnYvn07FixYgFmzZrWVWBQVFWHw4MHIyckBYAqq3XDDDWhoaMAHH3yA2tpaqNVqqNVq6PV6d347RERERACYsQbAVDLwwgsvdCgbIN/A4+u7eGx9G4+v7+Kx7bk+++wzLFiwANdffz1EIhHuuusu/Otf/2q7X6vV4vjx49BoNACAvLw87N69GwDQv3//dvs6ffo0EhISXLZ2IiIiInMEI+fDExEREREREblcQkICnnrqKTz11FPuXgoR2YiloERERERERGSTBx54ANOnT2/3tSAIEAQBMpkM/fv3x1/+8hfodLq2bYxGI959912MGTMGAQEBCAkJQXJyMlasWNGWseoMgiBg3bp1Ttu/LXJzc/HII4+4exlEZAcG1oiIiIiIiMhhbrzxRhQXF+PkyZP4wx/+gBdffBGvvvpq2/33338/nnrqKdx+++3YsmUL9u/fjz//+c/49ttvsXHjRjeu3HVaWloAmAbAKJVKN6+GiOzBwBoRERERERE5jFwuR3R0NOLj4/Hoo48iPT0d3333HQDgiy++wGeffYbPP/8czz33HFJSUpCQkIDbb78dmzdvRlpaWqf7PXLkCG699VYEBQUhMDAQEyZMQH5+PgBT5teUKVMQERGB4OBgTJw4EXl5eW2Pbe3JeMcdd0AQhHY9Gr/99lskJSVBoVAgMTERL730UrsMu2PHjmH8+PFQKBQYMmQIMjMzO2S/HTp0CJMnT4afnx/Cw8PxyCOPoL6+vu3+1sy+v/3tb4iJicGgQYPa1rVixYq27aqrq/Hwww8jMjISQUFBmDx5Mg4cONB2/4EDB5CWlobAwEAEBQVh9OjR2LNnj+UHh4gcjoE1IiIiIiIicho/P7+2DK3PPvsMgwYNwu23395hO0EQEBwcbHYfRUVFuO666yCXy7F582bs3bsXDz74YFsArK6uDnPnzsUvv/yCXbt2YcCAAbj55ptRV1cHwBR4A4APP/wQxcXFbV///PPPmDNnDp588kn8+uuv+Pe//42PPvoIf/vb3wAAer0e06dPh1KpxO7du/Huu+/i+eefb7e2hoYGTJ06FaGhocjNzcWXX36JzMxMLFiwoN12WVlZOH78ODZt2oTvv//e7Pd5zz33oLS0FD/++CP27t2LpKQkXH/99aisrAQA3Hfffejduzdyc3Oxd+9eLFq0CFKptPuDQEROw6mgRFbKzs7GpEmT3L0McjKj0YjPP/8cr7/+Ov785z+36x1CRERERN0zGo3IysrCTz/9hMcffxwAcPLkybZsLWu89dZbCA4Oxpo1a9oCSQMHDmy7f/Lkye22f/fddxESEoKtW7fi1ltvRWRkJAAgJCQE0dHRbdu99NJLWLRoEebOnQsASExMxMsvv4xnnnkGL7zwAjZt2oT8/HxkZ2e3Pe5vf/sbpkyZ0raP1atXo6mpCZ988gn8/f0BAG+++SamTZuGZcuWQaVSAQD8/f3x/vvvQyaTmf0ef/nlF+Tk5KC0tLRtcvZrr72GdevW4b///S8eeeQRnD17Fk8//TQGDx4MABgwYIDVP0sicixmrBFZIDs7GzNnzoRMJsOcOXNw6NAhdy+JnGTLli2YMWMG/Pz8MHfuXDQ3N6OxsdHdyyIiIiLyGt9//z0CAgKgUChw0003YebMmXjxxRcBmIJttti/fz8mTJjQaXZWSUkJ5s+fjwEDBiA4OBhBQUGor6/H2bNnu9zvgQMH8Je//AUBAQFt/82fPx/FxcXQaDQ4fvw44uLi2gXjUlNT2+3j6NGjGDFiRFtQDQCuvfZaGAwGHD9+vO22YcOGdRpUa11LfX09wsPD263n9OnTbSWvGRkZePjhh5Geno6lS5e23U5E7sOMNaJOnDp1Ch9++CE++OADlJaWol+/fnjooYcwZcoUxMbGunt55EBlZWX461//iq+++goXLlxAYmIiHnroIaSlpWHUqFHtenCQ++zevRvbtm1DU1MTgoODkZCQgNtuuw1GoxGCILh7eeSFjEYjTp48ib59+7KMhojIgdLS0vDOO+9AJpMhJiYGEsmly86BAwfi2LFjVu/Tz8+vy/vnzp2LiooK/POf/0R8fDzkcjnGjh3bVoLamfr6erz00ku48847O9ynUCisXmdXLg+8dbaWXr16ITs7u8N9ISEhAIAXX3wR9957L3744Qf8+OOPeOGFF7BmzRrccccdDl0rEVmOgTWiy1RWVmLVqlX44IMP2j5d6tevH15//XUMGTIEgwYN4tQeH7R161a88cYbiImJwTvvvIPx48cjISGh25Mfcj61Wo13330X77//PoqLixEREYGamhpIpVLExMRgzJgxbeUVRJbKysrCe++9h127dsFoNCIkJASPPvoo7r33XgQFBTFYS0RkJ39/f/Tv39/sfffeey9mzZqFb7/9tkOfNaPRiNraWrN91oYPH46PP/4YWq3W7Ich27dvx9tvv42bb74ZAHDu3DmUl5e320YqlUKv17e7LSkpCcePH+90vYMGDcK5c+dQUlLSds7R2p+t1VVXXYWPPvoIDQ0NbeeP27dvh0gksqrsNSkpCWq1GhKJpMsPdgcOHIiBAwfi97//PWbPno0PP/yQgTUiN2IpKPVoranohw4dwqhRoxAZGYnFixejT58+ePrppyGXyxEYGIjp06dj1KhRbUE1W1PYyTNcefxSU1MxcuRI+Pv7Y+zYsbj66qsZVPMAv/zyC2bMmIHly5dj5MiRWL58OT766CPk5+fj2LFjWLFiBY8TWezEiRN48sknERkZiSlTpmDv3r0YPnw4hgwZgjNnzuCPf/wj/v3vf7t7mUREPm/GjBmYOXMmZs+ejVdeeQV79uxBYWEhvv/+e6Snp2PLli1mH7dgwQLU1tZi1qxZ2LNnD06ePIlPP/207cPwAQMG4NNPP8XRo0exe/du3HfffR2y3BISEpCVlQW1Wo2qqioAwOLFi/HJJ5/gpZdewpEjR3D06FGsWbMGf/rTnwAAU6ZMQb9+/TB37lwcPHgQ27dvb7uv9UOY++67DwqFAnPnzsXhw4exZcsWPP7447j//vut+gAwPT0dY8eOxfTp07Fx40acOXMGO3bswPPPP489e/agsbERCxYsQHZ2NgoLC7F9+3bk5ubiqquusu4gEJFDMbBGPVZNTU3bH8OKigooFAosXLgQ33zzDVatWoVly5YhLS0N+/fvR1ZWFgC0TR1iJoN3OXr0KH788UccOnQIv/76K5qbm9vdHx0djRtuuAEnT57Etm3b2m43GAw4c+YMvv76a+zcubPDJ5zkPIcOHcJjjz2Gffv24cUXX8S///1vPP7445g6dSp69eqFXr16YerUqQgICHD3UskLfPnllxg8eDDeeOMN3HTTTXjvvffw3//+F2vXrsWPP/6INWvWQKPRICsrC01NTfwdT0TkRIIgYPXq1Vi+fDnWrVuHiRMnYvjw4XjxxRdx++23Y+rUqWYfFx4ejs2bN6O+vh4TJ07E6NGj8d5777Vlr33wwQeoqqpCUlIS7r//fjzxxBOIiopqt4/XX38dmzZtQlxcHEaNGgUAmDp1Kr7//nts3LgRKSkpuOaaa/CPf/wD8fHxAACxWIx169ahvr4eKSkpePjhh9umgraWiiqVSvz000+orKxEyv+3d+dhXZR7H8ff82MTFyA4iAqiqYgLxwVSEQm1UlmCUtNQSOW48NjRrGOaHj2V5V5ZaWoJkWFqWs+TRIgI+iiJG0qlIGDmkrKJiICYrPfzB89vktQ6edyi7+u6ui6b38wwM/dv5mI+3Pf37tWLp556ikcffZT33nvvd1+brVu34uPjQ1hYGB07diQ4OJgzZ87g4OCAiYkJRUVFjBkzho4dOzJy5Ej8/PyYN2/e7/o5QojbS1PS9Ub8iRw/fpy1a9dy4MABGjVqhIuLC+Hh4XTu3Jm8vDzs7OzqFRSNiopiwoQJTJw4UXoy/MFkZWXx4YcfEhsbS2lpKVeuXKG0tBQTExOGDRtGSEgIQUFB+vq7du1i8ODBPPHEEyxcuJC8vDx27dpFYmIiKSkpPP3006xevVqvbyFuj5MnT1JbW4uTkxNmZmaYmJgAMGnSJCIjI1m3bh0hISH6+sZw07ieEL/GOKTz9OnT+Pn5cf78eQ4dOsSDDz5Yb70LFy7w0EMP0blzZz799NMbDkESQgghjFJSUvD29ubEiRO0b9/+Xh+OEOIekxprosErLS0lKiqKiIgIMjMzsbW1pWnTpvz000/Ex8dz6NAhFi9ejLe3N/DzMEFN0/D398fa2podO3Zw9uxZWrduLbV37mNXrlxh5cqVrF+/niNHjmBvb4+XlxcuLi60atUKCwsL1q9fz2effcbnn3/Otm3beOSRRzAxMaFz58707duXr776iry8PI4ePUpZWRl9+vTh/fffJywsTIqb3yanTp3igw8+4Msvv+TKlStcvXoVOzs7nn/+eSZOnMi5c+f4+OOP6d69O8OHDwfqeg8aDIZ6gVpeXh4HDhygqqqKESNG3KvTEfcx47O6bdu2+Pj4EBERQWpq6nXBWkxMDBcuXKBv375YW1vr3zchhBAC4IsvvqBp06a4uLhw4sQJpk2bRr9+/SRUE0IAEqyJBu7o0aOEhISQnp6Ol5cXy5Ytw93dHVdXV0xMTBgzZgzbtm3jk08+oXfv3pibm9cLzVq0aMHjjz/O+vXrSUpKIiwsTIK1+1hSUhIvvfQSNjY2LFu2jN69e9OxY0f+8pe/6OtMnjyZV199lddee41//vOfvPHGGwwYMAAbGxuefPJJvv76a7Kzs5k5cyZhYWG0atVK31ba/j9z8eJFFi9erA/b8PT0xMnJCSsrK8rKyigsLKSyspJvv/0WAC8vLxo1alQv5KiurubQoUPs37+fpKQkvvvuO8rKyujdu7c+ZEP8eVRUVGBhYfGr69TU1GBiYoK/vz8RERGsW7eOkSNHkpeXR3p6OgkJCaxZswYTExNsbW05fPgwf/3rX+v1XhZCCPHnVlZWxksvvcSPP/7IX/7yFx577DHeeuute31YQoj7hARrokHZsWMHqamp/O1vf6N58+a0aNECDw8PfvjhByZNmsSYMWPqrT9jxgyOHTvG4cOHOXPmDC4uLtftMzg4mPXr1xMXF0dYWJj0YrhPpKWl8fHHH7NgwQK9zlb//v1p164dlZWV+Pr60qlTJ339a4cQPvvssxQWFrJ69Wo2btzIgAEDsLCwwMfHBxsbGx566CG9dkZVVZXeU0pCtVtXU1PDsmXLePPNNwkICGDy5Mn06tULe3t7gHrh2dWrV6mqqtKLCl/LxMSEf/zjH+zfv5+OHTvi7OzMvn372Lp1K5MnT76r5yTujeLiYrZs2cKxY8coKSlhypQpdOvW7aa9zIzL+vfvT8+ePYmPj+eVV17h8OHDJCcnc/nyZTw8PHB0dGTu3LmUlZUxf/58Zs+efbdPTQghxH1qzJgx171HCCGEkSQE4g/v+++/Z/r06bRq1YpBgwaxbt06ysrKALC3t+fhhx+mqqqKo0ePUl5eDqAXr3d2dqaqqorLly9jZWV1w/37+PjQpk0bvv76a9LT04G6EEDcW/Pnz2fFihVs27YNqGsTa2trAgICOHfu3HUTTpiYmOjDCJs3b05oaCjNmzcnMTGRjIwMANq1a4ePjw/79u3jiy++uG47ces+/vhjFi5cyOjRo4mNjcXf318P1WpqajAYDPow7G7dugHw7bffUlFRoQcjNTU1aJrGiy++SFpaGllZWaxcuZLGjRvz6aef3psTE3fNjh078PX1pWXLlsyYMYP169cTGRnJZ599BnDTP3pomkZtbS02NjY89thjGAwGXn/9dbKzs5kxYwZnz54lNTWVTZs2ERcXh5WVFQsXLrzprHRCCCGEEEJcS4I18YdUUlLC22+/TZcuXXB1dSU6Ohpvb28iIiKIjo6mTZs2+kv6Qw89RNeuXYmPj+f06dMA+tChvLw88vLycHBwuG7WIKNmzZoxfPhwCgsL9RBH3DvGnmchISFomsbGjRuBn2spPf300wBs27aNmpoaTE1v3DG3c+fODBgwQJ/GHOra+oknnqC0tJSUlBTg5i/r4t9XUlLC5s2bsbS0ZNasWUBdEGq8R43BpbEN7e3t6dGjBydPntRnaTUO5wMYNmwYPXr0AKB169b06tWLr7/+miNHjtzN0xJ30aeffsqoUaPIyspi6tSprFmzhm3btnH16lWeffbZG26jlNK/Y8b72M/PDysrK7p06cL333/Pv/71LxwdHamtrcXCwoJ+/foxfvx4ysvL2b59+3UzCAshhBBCCPFL8sYo/nAWLVrEAw88wPTp03F2dmbJkiV88cUXvP/++4wfPx4PDw9MTU31l3QXFxf69+9PVlYWGRkZlJeXk5GRwfLly3nqqaews7Nj3rx5+vo3mijXWBg9Pj6e6upqCVvuIeO1HzBgAF27diUuLo7c3Fy9/Xr16kW3bt3Yu3cvqampwI17GDZp0gQPDw8AfvzxR5RSmJqa4uXlhaOjI7t37+b7778HbvydEP++0tJStm/fTtu2bXFzcwPq2vFmQ2ubNWtGUFAQlZWVrF+//obrVFdXo5TCzs6OwMBAAL766itA2qshuLYNMzIyCAsLw9bWlqioKBYtWsSwYcPo1q0b5ubmtGzZ8ob70DRN/47l5OQA4O3tTY8ePTh27BhpaWnAz8OQKysrAfTnQmZmJhYWFtJDWQghhBBC/CpJB8QfhnFIn52dHSYmJgwcOJANGzbw4osv4u3tja2t7Q23s7S0xNvbm6ZNm/Lee+/xwgsvMHz4cJ5//nlKSkqoqKjgueee44033gC44cu+h4cH7u7uHDx4kP379wM/95wSt09SUhLvv/8+cPPhtpqm6YHKoEGDqKys5Msvv9S3MTMzY+TIkRQXF7N9+3Z9m18yMzPTey5eWz/N2dmZIUOGkJGRwcGDB2/7Of4ZXb16FRsbGzp27EhRUdFvrm9qakpISAiWlpZER0dz4MABvbea8XthDM+zs7OJiYkB6gI5uHF7i/vb5cuXycjIoKCggIqKinptuHXrVioqKnj55Zd55JFHMDU1pba2lsrKSj2Au9Hz+MKFCyQnJ7NkyRKeeOIJtmzZgqmpKb6+vgD6EFLjPoyTFRj3ZZy4RP6QIoQQQgghfo38tijuSydOnGDp0qVMmTKF999/n3379ulD+gIDA+nQoQOpqan1eqYZFRYWkpiYqNdDA+jevTuenp7s2bOH6Oho3NzciIuL48iRIyxZsoSCggJeeuklpk+fTkFBAVC/x4SpqSnBwcGUl5frQw/lZev2uLZG3uDBg1m1ahWVlZW/en2NbRMQEICZmRmffPIJ8HOgMmzYMDRNIzExkbKysuu+I8ZwxszMDEDvqQJ1QWxgYCBXr15ly5Yt173ki9/P0tISpRR5eXn/Vr266upqXFxcmDFjBlBXMDgiIoLy8nIMBgMFBQWkpKSwYMECRo8ezcmTJ/noo4+YOnXqnT4VcZtt2rQJf39/3N3dCQgIoEuXLgQGBnLs2DF9HWPNzNzcXH2ZwWDQZ3G+evXqdd+rmJgYQkJCGDFiBLNnz+b8+fN6cObr64u9vT2bNm0Cfh6KnJOTQ0REBNOmTcPZ2ZmJEyfe0XMXQgghhBANg8wKKu4bpaWlfPjhh0RGRpKZmYmlpSWVlZXU1NRgY2PDV199haenJy1btuSRRx5h9erVxMbGEhISQklJCcePH+fgwYMkJiYSFxeHj4+PXsC+Xbt2eHp6kpiYyJIlS5g2bRpQ1zNh8uTJ9O7dm3nz5vH2229z4cIFli5dioODQ71Z5vz9/Xnrrbdo3779TWefE/+ekpISPvnkE1auXElWVhZ2dnYMHDiQIUOG0L17998MX4xBl5eXF3369GHPnj0cO3aMLl26oJSiU6dODBw4kD179pCSkoKvr6/eZsZaXeXl5fzP//wPjRo14rHHHqu3/x49euDt7a0PCRP/mVatWmFvb09qaipnz57FxsbmV9c3hujPP/88tra2PP/884SHh/P222/TuHFjzM3NOX36NPn5+Xh5ebFixQr8/f3vwpmI2+HKlSts2rSJpUuXcuLECdzc3PD09MTKyooHHniA4uJizp07R5cuXQAICgrSJytp3749jRs3BiA7O5vU1FTMzMxwcnLi4YcfZtCgQQBcvHiRpKQkZs2axYQJE3jwwQf1n+/m5oaPjw///d//zZYtW2jTpg27du0iISGB5ORkHBwcWLx4MT179rz7F0cIIYQQQvzxKCHusfz8fNW/f3+laZqytLRUjzzyiFqyZInaunWrOn78uJo6darSNE2NHTtWFRYWKqWUiouLUyYmJqpPnz5q48aNauzYscrJyUlpmqbatGmjXnnlFXX27FmllFI1NTVKKaUSEhKUvb29CgwMVD/++GO9z5RS6ty5c2rgwIFK0zT16KOPqpMnT97lK9HwVVdXq8rKSr2tPD091fLly9Xu3btVUVHRr25bW1uramtr9f83tt2CBQuUpmnq5Zdfrrc8MjJSaZqmnnvuOX37a7333ntK0zQ1bNgw9dNPP922cxQ39tZbbylN09Srr75a7767VnV1tVKq7l6MjIxUFRUVSimlDh8+rMLDw9XgwYOVt7e38vb2VtOmTVPffPPN3Tp8cRsY78GoqChlZ2enOnfurFavXq2ysrL0tlaq/nPZuE1oaKiytLRUmqYpg8GgDAaD0jSt3n8tWrRQr732Wr3trt1nVVWV/h1bu3atMjU1VY6OjsrR0VFpmqY6dOigFi9e/JvPIiGEEEIIIa4lwZq45y5duqSaNm2qLC0tVUREhCouLq73YnXs2DHVsWNH1aFDB3XlyhWllFJlZWXK09NTf6GytrZW48ePV4cOHbrpz8nNzVVBQUHqgQceULt27brhOoWFhcrPz09pmqbeeOMNVVlZeXtP9k8oOTlZhYSEKE3TVGRkpFJKqWnTpilN09T8+fN/9/4qKytVTk6OunTpklKqLnSxtbVVrq6u+kuzUnXtbW1trf7617+qixcvKqWUKioqUomJiSo4OFhZWFiooUOHqoKCAqXU9S/i4vbKy8tTTZs2Ve3bt1c7duxQStVd8xuFbJMnT1b9+vVT33///XWfnT9//o4fq7g9Ll++rD+zjffXnj17lKZpysfHR//jh1FNTc11z1zjPV1cXKy+/PJL9be//U3Nnj1bzZs3T61YsUIlJSWptLQ0FR4erpo0aaJsbGxUdna2vr+qqqp697bx3ydPnlQODg7KwcFBTZkyRR05cuTOXAQhhBBCCNHgSbAm7gsvvPCC0jRNffDBB0qp+j0WfvrpJ+Xo6Kj8/f3r9WqYPXu20jRNjRkz5rr9/fJlymjZsmXKYDCo11577bpeSsYXuPz8fD1sEbfm5MmTaubMmcrBwUFpmqZcXFzUM888oxITE5VSSu3du1dpmqYCAwPrhWFK1V3/9PR0VVJSUm/5uXPnVHx8vJo5c6YaMGCA2rJli/5ZUFCQ0jRN7d69Wyn188vzqFGj9JD0888/V6GhocrJyUnZ2dmpKVOmqKysrHrriztr1qxZymAwqK5du+rX3qi4uFglJSWpwMBApWmaWrBgwXXbSzv9MWzYsEH17t1btW7dWh08eLDeZ8b2/eqrr5RSdc/dX/ZGVarujye/dn/+MpCtqalREyZMUJqmqXffffeG6/zSL7+DQgghhBBC3AqpsSbuC8OGDeOdd94hLi6OSZMmYTAYKC0t5bvvvmPZsmXk5uby6quv1isiHxgYyPLly/VJCqqqqjAxMcFgMGBqalpv8gEjT09PXFxc2Lp1K6NGjaJDhw76Z8a6Xg4ODnf4bBumkpISoqKiiIqKIiMjA4DRo0fz8MMP06dPH1xcXGjSpAkADz30ED169CAlJYW0tDR69erFgQMHOHz4MDExMeTn57No0SL8/f2pqalh48aNfPTRR+zdu5eKigo8PT1p166dXjctICCA2NhYNmzYgI+PD0opNE0jJCSETz/9lFmzZlFbW4u1tTXPPPMM//Vf/6XXbwKZRfJueeWVV7h48SIRERH07duXoKAgevbsSWFhISdPniQ5OZnKykpeeeUVvQ7itaSd7l+7d+9m9erVxMTEUFFRgbu7O6NGjar3PD1//jxZWVl4eHjg7e0NUK+eYk1NDWfOnCEtLY2UlBT27NlDbGwsLVq00O9p43PdYDBQW1tLdXU1pqamGAwGmjVrhsFg0Pf5W3UwXV1db/dlEEIIIYQQf0KaulH6IMRdVl1djbu7Ozk5OaxatQozMzNiY2NJSkoiJycHZ2dn7O3tsbKyYv78+fTt25fa2loCAgJISEhg//799O7dWy9Mf62LFy9iMBiwsbGhqKiIsLAwdu7cSXJyMu7u7vfojBuO6OhooqOj2blzJ40aNcLLy4vMzEzy8vI4cOAAvXr10tc1Pm40TWPx4sX885//ZOjQodjZ2REfH09OTg6tW7dm7NixzJgxg2bNmgHwj3/8g//93//lmWeeYfz48VhbW+v70zSNU6dOMXDgQCoqKjh+/Li+3aVLl+jVqxddu3Zl8uTJDBky5C5fHfFLxcXFxMTEsGbNGtLS0tA0jUaNGtG4cWOCgoL4+9//jpub270+TPFvevvtt1m2bBk5OTl06NCBRx99lIEDB+Lu7k7btm31iSgAvvvuO3r27Em3bt349ttvr5sE5t133yUiIoKsrCzMzMyoqKjg9ddfZ86cOXqABj/P6nvttoWFhfj4+JCdnc2hQ4fk2S6EEEIIIe4aCdbEfWPhwoXMnTuXli1bkpeXR9OmTRkxYgTBwcE0a9aM6OhoIiMjeeCBB0hISKBHjx4sW7aMF198keeee4533nlH31dpaSnZ2dns27ePXbt24evry8SJE9E0jR9++IHWrVtjbm5+7062AenatSsAQ4cOxdPTk0GDBrFkyRJeffVV5syZw+uvv05lZeV11zs7O5uuXbtSW1tLs2bNCA4OZsKECfWCOGNQevXqVRo1alRvOdTv7TJ+/Hg++ugjoqOjCQ0N1UM3mcH1/lRUVERFRQU//PADjRs3lhlY/wCM9xSg31eTJk0iMjKS4cOH8+6779KkSRM9+P6ly5cv4+joiI2NDSkpKTg5OaHqSlJgMBhYtGgRa9euZenSpbRq1Yq+ffvi4uJCZmbmDfdXXV3NqVOn2LdvH2+++SY//PAD8+fP54UXXqh3rEIIIYQQQtxJEqyJ+0ZmZiZubm5YW1uzevVqnn766evWmTlzJm+++SbPPvss7733Hunp6QwZMgSDwcCRI0fIy8vj0KFD7Ny5k6SkJHJzc7G3t2fVqlUMHTpUApY7ICcnh9LSUlxcXPQeJZmZmXTt2pVWrVpx7ty5m27r5+dHQkIC27ZtY/Dgwfry6upqTExM6r0YK6X0oO3a5cZlGzZsYN68eSxZsoQnn3zy9p+ouG0k7PzjOX78OI6Ojvpw7qqqKszMzPjmm2/w8PCgS5cu+rD8a1VVVQFgZmZGQUEBISEhHDhwgOjoaIYOHUptbS2apunDPK+9t318fNizZw/ffPMN3bt3B2Dz5s0kJiZiYmLCxYsX9aGj9vb2TJ8+nbCwMGxtbe/CFRFCCCGEEKKOvNmI+0bnzp0ZMGAAlZWVtGnTBoCrV69SW1urDyEMDQ0FIDExEQA3NzcGDhxITk4O48aNIzg4mHHjxrFlyxb8/f05fPgwBQUFDB8+XF7k7xBHR0c6d+6s17Wrra3V2zI3N5eUlBTg515m1xo5ciQAcXFxQF2gBmBqanpdbxNN02643NiuwcHBZGdnS6j2ByD34h9DcnIyISEhPPjggwwaNIiAgADmzJkD1AVlAD179sTT05Njx47Vq3d55swZvvjiC1577TViYmIAaNKkCd7e3pSXl+vPcIPBoN/TmqZRU1NDeXk5UHdPA3z44Yf6MdnY2LB27Vq2b99Oeno6zZs3JyIigjNnzjB9+nQJ1YQQQgghxF0nbzfivjJq1CiuXLnCxo0bAbCwsNB7M0BdgXwrKyvatGlDcXExAP379wcgNjaWNm3aEBsby6VLl1izZg09e/a8NyfyJ3Nt7TTjv409DiMiIm66nZ+fH1ZWVuzYsYOcnJybTjrxa4zfDQlrhPjPnThxgtmzZ9OiRQsGDBjA3r176datG66urhw6dIhFixaxadMm4OdaZyNGjABg+fLlHD16lIULFxIaGsqIESNYunQpp06dAqBp06Y89thjODg4sHnzZtLS0oC650d1dTVKKUxMTPReccbJBVJTU/XjGzx4MNnZ2cTFxbFv3z5iY2MZN26cHvQJIYQQQghxt8lQUHFfycvLw9XVlbZt2xIfH4+jo6P+WWlpKVOmTOGTTz7hX//6F/PmzQPgwoUL7Nu3j8GDB2NhYXGvDl38P+Nwrvz8fDp27Eh1dTWXL1++afAVGhrKhg0bWLduHSEhITJMUIh7ZP/+/Xh5eQHw5JNPEhgYSPfu3Wnfvj3W1tZs2LCBsLAwfH19iYmJ0ScUOH36NG5ubtTU1GBubk5ZWRkeHh6Eh4cTGhparz6iUoo5c+awePFifH19effdd3FxcdE/r62tJTs7my+//JLFixfj6urKqlWrcHd3l7ppQgghhBDiviTBmrjvBAcHs3nzZj777DOGDx9Oeno6hw8fZsOGDSQlJfH000+zdu1amXzgPmZ8ATa25ebNm3nqqaduOGtrXFwcgYGBhISEsG7dunt0xEKI3NxcRo4cycmTJ4mKisLX17fe50VFRbRv3x4nJyd92KfxXg8ICCA+Pp6QkBDWrFmDpaWlvl1NTU29IZ8XL17kmWeeIT4+ngcffJDx48fTtWtXcnJyOHv2LElJSZw4cYI+ffrw8ssv62GfEEIIIYQQ9yPpFiLuO6NGjQLggw8+YMaMGQQHBxMWFkZaWhpz587ljTfewNzc/HcPGRR3j3GImLGGWmRk5E3X9fHxoV27duzcuZOjR4/W214Icfc0b94cX19f8vPzr5uIoKamhn379lFRUcG4cePqLQcYPXo0UDck29LSksrKSr1m4i8nHLG1teXzzz9nzpw5VFVVMXfuXJ566ilmzpzJO++8g4WFBatWrSIuLk5CNSGEEEIIcd+THmvivlNaWoqzszOlpaWYmpoyaNAgJk+ezOOPP36vD038Tj/99BOurq6cO3eOCxcuYGtre8PhXBMmTCAqKoq4uDj8/Pzu0dEKIQ4cOMCjjz7KwIEDWbt2LWZmZqSmprJz506WLVuGiYkJb775Jj179qRPnz76/VxSUoKrqyvFxcVcuHCBZs2a3fRnXPsMyM/PJy8vj+PHj2NhYYGXlxfNmze/W6crhBBCCCHEf0yCNXFfWrFiBebm5owdO7ZefR7xx2GslTZ16lRWrlzJ8uXLmTJlil6X6VrGF3GpkSfE7WG8z35vzcJLly4xevRokpOTGTduHLm5uezcuZPS0lLc3Nzo0qUL8fHxlJWVsWjRIp577jl92KcxII+KimLcuHE3vNeFEEIIIYRoaCRYE0LcEcZ6anv27MHHx4dOnTpx7NgxKUAuxB2Un5/P6NGjcXR0vKWahbW1tURERDB58mQAnJ2dGTduHOPHj6d169ZUVlayc+dOZs2aRUZGBps2bWLYsGEAJCYmMmTIEB5++GF2794tE5EIIYQQQog/BQnWhBB3nJOTE7m5uRQUFGBvb3+vD0eIBqukpISWLVtib29PYmIiHTt2/NWAy/grwLVhd0ZGBoMHD8bW1pbdu3dja2sLUG/ykZUrVzJ16lRGjBjBpk2bgLpQzs3NjaysLH788UecnJwkXBNCCCGEEA2e/LYrhLhjjIXNk5OTqa2tlVBNiDvM2tqa8PBwzp49S2Ji4m+ur2maHqoVFBRw+fJlXF1d8fHx4fTp02zfvh2oG1pqYmJCbW0tNTU1dOrUCQsLCy5cuEBpaSlQN3FBQEAAABEREfr+hRBCCCGEaMgkWBNC3DHG3i3t2rW7x0cixJ/H8OHDAdi+fftv9hgrKipi7969LF26lEmTJhEZGYmpqSlPPPEE5eXlJCcnU1VVpddKMxgMmJiYkJ6eTkVFBZ06dcLKyoqqqioAxowZw9SpUwkNDQUkWBNCCCGEEA2fDAUVQgghGpDq6mo8PDzIyclh69at9O7d+7qAraamhpSUFN555x1SUlIoLCzE1dWVJUuWEBQUxKlTp/D19cXMzIzPP/+cTp06AZCbm0tCQgJz5szB3Nyc9evX069fv3t1qkIIIYQQQtxz0mNNCCGEaEBMTU0ZOXIkFy9eJCEhAbi+55ix11l6ejqjRo0iOzubzMxMgoKCAGjVqhV+fn5kZWWRkJDA0aNHWb58OeHh4fz973/H1NSUuXPnSqgmhBBCCCH+9KTHmhBCCNHAZGZm4ubmRr9+/YiLi6NZs2b6Z8aZeS9fvkzTpk3rLa+pqdGHfe7YsYPHH38cW1tblFLk5+fTpk0bxo8fT3h4uNRMFEIIIYQQAumxJoQQQjQ4nTt3ZsCAAaSmprJ3716gbtZOqOu9ppSiSZMmQN3Q0draWjRN00M1gE6dOtG+fXvOnz/P0KFDOXToEKdOnWLu3LkSqgkhhBBCCPH/JFgTQgghGqBRo0ZRUVHBtm3b9GXXhmvG4aFKKQwGA7/swN6iRQvi4uKoqqpi5cqVuLu7372DF0IIIYQQ4g9ChoIKIYQQDVBeXh6urq60bduW+Ph4HB0d9c8KCws5ePAgKSkpuLq6Mnbs2N+cQVQIIYQQQghxPfkNWgghhGiAWrZsib+/P+np6Rw8eBCA5ORkFixYQHBwMMOHD2fx4sXs3LkTQEI1IYQQQgghboH0WBNCCCEaqJiYGIYOHYqXlxctW7Zk165dFBUVYW1tTXBwMBMnTpQhnkIIIYQQQvwHJFgTQgghGqjS0lKcnZ0pLS3F1NQUPz8/wsPD8ff3v9eHJoQQQgghRIMgwZoQQgjRgK1YsQJzc3PGjh1Lo0aN7vXhCCGEEEII0aBIsCaEEEIIIYQQQgghxC2QSsVCCCGEEEIIIYQQQtwCCdaEEEIIIYQQQgghhLgFEqwJIYQQQgghhBBCCHELJFgTQgghhBBCCCGEEOIWSLAmhBBCCCGEEEIIIcQtkGBNCCGEEEIIIYQQQohbIMGaEEIIIYQQQgghhBC3QII1IYQQQgghhBBCCCFugQRrQgghhBBCCCGEEELcAgnWhBBCCCGEEEIIIYS4BRKsCSGEEEIIIYQQQghxCyRYE0IIIYQQQgghhBDiFvwf7hH3s4ajYlwAAAAASUVORK5CYII=",
      "text/plain": [
       "<Figure size 1500x600 with 2 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "all_results = [results_BERT[1:], results_tf[1:], \n",
    "               results_CG[1:], results_LB[1:]]\n",
    "\n",
    "result_x_ticks = ['','BERT','TF-IDF', 'CG','L-BFGS-B']\n",
    "\n",
    "\n",
    "fig, axs = plt.subplots(1,2, figsize=(15, 6))\n",
    "# plot violin plot\n",
    "axs[0].violinplot(all_results,\n",
    "                  showmeans=True,\n",
    "                  showmedians=False)\n",
    "axs[0].set_title('Cosine Similarity Results distribution')\n",
    "axs[0].set_ylabel('Similarity', fontsize=14)\n",
    "axs[0].set_xticks(range(len(all_results)+1))\n",
    "axs[0].set_xticklabels(result_x_ticks, rotation=20, fontsize=14)\n",
    "axs[0].grid()\n",
    "\n",
    "axs[1].plot(sent_uncons_CG[0], '-.', label='Target patent')\n",
    "axs[1].plot(sent_uncons_CG[result_sort_CG[-1]],'+', label='The least similar patent')\n",
    "axs[1].plot(sent_uncons_CG[result_sort_CG[1]],'o', label='The most similar patent')\n",
    "axs[1].set_title('Patent IPC scores by Conjugate Gradien')\n",
    "axs[1].set_ylabel('IPC optimize scores', fontsize=14)\n",
    "axs[1].set_xticks([]) \n",
    "axs[1].set_xlabel('IPC categories')\n",
    "axs[1].grid()\n",
    "axs[1].legend()\n",
    "# plt.savefig('similarity_range_biomedical.jpg', dpi=700)"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "python_tf",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.18"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
